Solving Kids' Cancer UK

England & Wales · Charity number 1135601

Details

Other names	NEUROBLASTOMA CHILDREN'S CANCER ALLIANCE, NEUROBLASTOMA CHILDREN'S CANCER ALLIANCE UK, SOLVING KIDS' CANCER EUROPE
Status	Registered
Legal form	Charitable company
Company number	07208648
Registered	2010-04-20
Register	View on the Charity Commission register

Contact

Address	Solving Kids Cancer Salisbury House 29 Finsbury Circus London EC2M 7AQ
Phone	02072840800
Email	gemma.wadsley@solvingkidscancer.org.uk
Website	www.solvingkidscancer.org.uk

Activities

Objects: 1. TO ADVANCE THE UNDERSTANDING AND TREATMENT OF CANCER IN CHILDREN THROUGH THE GREATER AWARENESS, PROVISION OF EQUIPMENT, ACCESS TO TREATMENT PROTOCOLS IN HOSPITALS AND MEDICAL CENTRES AND CLINICAL RESEARCH AIMED AT IMPROVED DIAGNOSIS AND TREATMENT ANYWHERE IN THE WORLD.2. TO ADVANCE THE EDUCATION, RELIEVE THE SICKNESS AND THE POVERTY OF PERSONS LIVING ANYWHERE IN THE WORLD THROUGH THE PROVISION OF EQUIPMENT, FINANCIAL ASSISTANCE AND BY ANY OTHER CHARITABLE MEANS THAT THE DIRECTORS IN THEIR ABSOLUTE DISCRETION THINK FIT.

Activities: We help children access potentially life-saving treatment, whilst supporting research that not only aims to introduce new treatments but also bring existing internationally available options here to the UK. We support parents by sharing the most current resources available for neuroblastoma treatments and providing access to other parents who want to share their knowledge and experiences.

Downloaded from opencharities.uk/ew/1135601

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People, The General Public/mankind

Geography

- **Area of benefit:** ANYWHERE IN THE WORLD
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£2,937,893	£2,232,606	£13,439,433	20
2024-03-31	£2,476,390	£3,226,862	£12,909,236	19
2023-03-31	£2,991,524	£1,884,851	£13,333,320	18
2022-03-31	£3,579,609	£2,105,215	£12,367,643	15
2021-03-31	£2,297,271	£2,309,712	£10,590,757	12

Trustees

Name	Role	Appointed
Alexandra May Austin Lane		2020-09-14
Cameron Miller		2025-09-15
Carl Cavers		2024-09-16
DAVID FRANCOIS COULON		2017-08-22
Dr Aine McCarthy		2021-07-20
Helen Duffy		2025-09-15
Ioannis Topsakalidis		2024-09-16
Nick Bird		2016-04-04
Stewart Alan Leaver		2024-09-16

Downloaded from opencharities.uk/ew/1135601

Solving Kids' Cancer UK

England & Wales - Charity number 1135601

Accounts



Annual report and accounts 2024/2025



Maya

Who's on our cover?

Maya was diagnosed with high-risk, stage 4 neuroblastoma at just three years old. Her family fundraised and accessed the Bivalent Vaccine trial in New York in the hope that Maya would remain cancer free, but she sadly relapsed in July 2023. By April 2024, after receiving BIT salvage therapy in the UK, Maya showed 'no evidence of disease'.

However, just three months later new areas of disease were found. Once her disease stabilised with chemotherapy, Maya was enrolled onto the MiNivAn trial in Southampton and scans midway through showed 'no evidence of disease'.

Maya has now completed the trial and is awaiting re-assessment scans after which her treating team will decide upon any next steps. Maya is very creative and loves music, singing, and dancing.

Our vision

Solving Kids' Cancer UK's vision is a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.

Our mission

Helping those affected by neuroblastoma, an often aggressive and deadly childhood cancer, by:

- Initiating and funding best-in-class clinical research
- Providing hope, information and support to families throughout their cancer journey
- Raising awareness of childhood cancer, advocating and campaigning for positive change.

Contents

03 Our year
04 An introduction from our Chair of Trustees
06 Welcome from our Chief Executive Officer
08 Strategy
10 Research
12 Support
14 Awareness
16 Your support and events
20 Achievements and performance 2024-25
22 Future plans
23 Structure, governance and management
26 Legal and administrative details
27 Finances
32 Independent auditor's report
35 Financial statements and notes
60 Thank yous

Our year





Our vision is a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.

Every two weeks a child in the UK with neuroblastoma dies. Help us to change this outcome.

We are a small but mighty parent-led charity with children firmly at our heart. We are striving for better outcomes for children and families affected by neuroblastoma, both now and in the future. In every conversation, we amplify their voices and ensure their needs are at the heart of all we do.

We will not stop until children with neuroblastoma, in the UK and beyond, have access to the treatment they need, when they need it, and as close to home as possible.

We do this through our mission of helping those affected by neuroblastoma, an often aggressive and deadly childhood cancer, by:

- Initiating and funding best-in-class clinical research.
- Providing hope, information and support to families throughout their cancer journey.
- Raising awareness of childhood cancer, advocating and campaigning for positive change.

Over the last year, we have:

- Refreshed our research strategy which aims to accelerate access to innovative clinical approaches by strengthening existing trial infrastructure, enabling transatlantic collaboration, and fast-tracking promising research into frontline treatment.
- Held our first hybrid Neuroblastoma Parent Symposium since 2019 bringing together clinicians, researchers and parents to connect, gain peer support and hear directly from leading experts.
- Appointed the charity's first ever Chief Nurse, Dr. Helen Pearson, an appointment that will strengthen our commitment to patient-centred care, integrating nursing insight into every aspect of our work.
- Brought together leading scientific experts from Europe and North America to foster transatlantic collaboration and discuss shared objectives.
- Formally launched our coaching programmes for parents of children post treatment as well as parents in bereavement.
- Held a parliamentary reception to launch our Kids Get Cancer Too campaign to shine a light on the unique challenges faced by children with cancer.
- Officially convened IMPACCT (Initiative for Multi-stakeholder Partnership to Accelerate Children's Cancer Trials) to bring experts from across research and healthcare together to identify and resolve the root causes of delays for children in treatment.
- Launched our first Development Board to strengthen fundraising and expand our reach through professional and personal networks.
- Welcomed many of our supporters and families to our in-person Christmas Concert with very special performances from the amazing Louis Moorhouse, Ella Henderson and the London Show Choir.
- Reached more families of children diagnosed with neuroblastoma at an earlier point, providing 31 Big Love Fund grants to families and 36 Care & Connect Support Bags to children.
- Welcomed Joining Against Cancer in Kids into Solving Kids' Cancer UK as a named fund, continuing the amazing work of its trustees and supporters.

Welcome

An introduction from our Chair of Trustees

As we reflect on another year of Solving Kids' Cancer UK's work, I'm reminded of the strength and resilience of the community that binds us—families, clinicians, researchers, and supporters—all walking this incredibly difficult path together. At the heart of it all are the children diagnosed with neuroblastoma. And at their side, our charity, driven by an urgent need to do more, do better, and move faster in the face of this relentless disease.

In March, we held our first in-person parent symposium since the pandemic. For many, it was their first experience of this unique gathering. The sense of connection—among families brought together by the most devastating of circumstances—was as strong as ever. The event has evolved beyond sharing treatment options and clinical research updates. It now reflects the broader needs of families, with sessions on long-term effects, follow-up care, and survivorship. Hearing directly from people who have lived through neuroblastoma brought a powerful and moving mix of honesty, hope, and perspective.

We also hosted an international scientific meeting as part of the symposium, bringing together leading researchers to advance transatlantic collaboration—a core component of our newly refreshed research strategy. For us, it's not enough to fund research. What matters to Solving Kids' Cancer UK is delivering tangible impact and benefit for children. That's why we remain committed to supporting clinical trials, even when the path is slower, more complex, and comes with real risk of failure. This commitment underpins our work leading the IMPACCT initiative alongside Professor Pam Kearns, which is showing promising progress toward improving how clinical trials are delivered in the UK.

Our support for families continues to adapt to the changing needs of our community. The introduction of DFMO in the UK through a company-led access scheme has altered the family support landscape. Today, families tend to explore options abroad only after exhausting those available here, or to access CAR T-cell therapy in Rome based on emerging evidence.

Still, the need for expert, compassionate support and guidance as families navigate the horror and complexities of a neuroblastoma diagnosis remains as profound as ever. Our team—many with their own personal experience—continues to walk alongside families with empathy and understanding.

On a personal note, in June I was honoured to receive an MBE for services to paediatric oncology patients and research advocacy. Yet even as I reflect on that recognition, I am acutely aware that the needs of children and families affected by neuroblastoma are as urgent now as they were when I heard that word for the very first time.

It is right that we look back on our achievements. But more than that, we must continue to look forward—towards the work still to be done. That is where our community needs our focus to be, and your kind and generous support will help us to ensure that it is.

Nick Bird MBE
Chair of the Board of Trustees



NICK BIRD MBE



Accelerating research. Driving change. Unlocking hope for children with cancer.

Welcome from our Chief Executive Officer

As we reflect on the past year at Solving Kids' Cancer UK, I am filled with immense pride and gratitude for the incredible strides we have made together.

This year has been marked by significant achievements and milestones that have brought us closer to our vision of a future where no child dies of neuroblastoma or suffers due to the treatment they receive.



One of the highlights of this year was celebrating Nick Bird's well-deserved recognition with an MBE for his outstanding contributions to our cause. Nick's dedication and leadership as Chair of the Board of Trustees have been instrumental in driving our mission forward, and this honour is a testament to his unwavering commitment to the children and families we serve. We are immensely proud of Nick who continues to honour the memory of his precious son, Adam, through every effort he makes to improve future outcomes.

We have refreshed our research strategy this year to accelerate access to innovative clinical approaches. By strengthening existing trial infrastructure, enabling transatlantic collaboration, and fast-tracking promising research into frontline treatment, we are steadfast in our commitment to expanding and enhancing therapeutic options for children with high-risk neuroblastoma.

This year also saw the official launch of IMPACCT (Initiative for Multi-stakeholder Partnership to Accelerate Children's Cancer Trials), chaired by Professor Pam Kearns. IMPACCT aims to address one of the biggest barriers in childhood cancer treatment: the slow and complex process of delivering clinical trials.

By bringing together experts from across research and healthcare, we are developing practical solutions to help more children access innovative treatments faster.

We were thrilled to host our first in-person Neuroblastoma Parent Symposium since 2019. This hybrid event brought together families, clinicians, and researchers, providing a vital opportunity for connection, peer support, and learning from leading experts. The energy and enthusiasm at the symposium were palpable, and it was heartwarming to see our community come together once again.

Our advocacy efforts reached new heights with the parliamentary reception for our Kids Get Cancer Too campaign. This event shone a light on the unique challenges faced by children with cancer and emphasised the urgent need for accelerated clinical research. It was inspiring to see families, clinicians, charities, politicians, and healthcare leaders come together to champion this cause.

As we look to the future, we remain steadfast in our vision to see a world where no child dies from neuroblastoma or suffers due to the treatment they receive. With your continued support, we will make this a reality. As ever, thank you for being a part of our journey.




Gail Jackson
Chief Executive Officer



Our impact

Invested £6.4 million in clinical trials

directly and through funding partners over the last 10 years.



Supported over 1,000 families

affected by neuroblastoma through our dedicated Family Support services.





Connected 370 families at our Neuroblastoma Parent Symposium,

providing support and information to those in treatment, survivorship and bereavement.



Funded a Neuroblastoma Clinical Trials Coordinator –

the only dedicated role of its kind.



Continued to advocate for change

including our efforts to ensure that every child in the UK who may benefit from the relapse-prevention drug DFMO can access it as quickly as possible.

Solving Kids' Cancer UK

Strategic plan 2022–2027

We are fighting for a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.

Our strategy

To underpin the delivery of our five-year strategy, our work is guided by an internal implementation plan centred around three key enablers and a clear focus on our vision and values.

Sustainable
We will ensure our charity remains financially robust to deliver against our strategic objectives, securing the funds required.

Good governance
We will continue to build a strong culture of compliance, transparency and continuous improvement at all levels of the organisation.

Impact
We will measure and showcase the impact of our work and demonstrate return on investment to our supporters.

Our values

Caring

We care passionately about children with neuroblastoma, their families, and all those who care for them, including our staff, volunteers and supporters.

Transparent

We are open and honest about all that we do and how we do it.

Collaborative

Relationships are at the heart of our work – from the children and families we work with, to the individuals, organisations and networks that are involved in their care.

Inclusive

Our services are developed to ensure they meet needs and we aim to make them accessible to all.

Determined

We lead with tenacity and are unfaltering in our drive to help, support and fight for children with cancer.

Hopeful

We have a strong sense of optimism and hope is at the heart of all that we do.

Our three pillars





Our work is driven by three key pillars

Research

Accelerate clinical trial development

We will focus on the development of new treatments by investing in clinical research and working with valued partners for maximum impact.

Prioritise the needs of children

We will engage with families to identify areas of unmet need, challenging experts to find solutions and work together to deliver maximum impact through the research we fund.

Foster collaboration

We will build and strengthen international partnerships to share expertise, best practice and resource, whilst building knowledge.

Support

Reach ALL families

Every family of a child diagnosed with neuroblastoma in the UK will have access to our support service from the point of diagnosis.

Broaden range of support

We will develop and expand our support offer in line with what families tell us they need.

Inform and support decision-making

We will ensure families have access to the most current and scientifically robust data from around the world and support their decision to access the best treatment possible.

Awareness

Research advocacy

We will amplify the voice of the children and parents, seeking to advance science and understanding of the disease alongside patient-centric research.

Patient advocacy

We will champion the needs of individual children and their families, providing parent-led support around decision-making to improve treatment outcomes.

Awareness and campaigning

We will raise the profile and support the treatment needs of children with neuroblastoma and other childhood cancers with the general public, government and public bodies.

Solving Kids' Cancer UK Research

Driving breakthroughs in neuroblastoma research

We are committed to advancing pioneering clinical and near-clinical research that delivers more targeted, more effective treatments for children with neuroblastoma.

Our research strategy is shaped by the families directly impacted by this disease and guided by our expert Scientific Advisory Board. Together, we prioritise areas of greatest unmet medical need and invest in cutting-edge science that seeks to expand the UK's clinical trial landscape. By doing so, we aim to bring innovative therapies closer to home for more children and their families.



This work has never been more urgent. Neuroblastoma continues to be one of the leading causes of cancer-related death in children. Through strategic investment and collaboration, we are accelerating the path towards new hope and better outcomes.

2024/25 summary

Increasing access to novel therapies: a MIGHTY consortium and two clinical trials
Over the past year, we have made important progress in laying the groundwork for two new clinical trials for children in the UK, despite significant delays caused by difficulties in accessing essential investigational drugs from pharmaceutical companies.

While the two clinical trials TACTIC and MINT have not yet launched, the need remains, and so does our determination. We are working closely with our partners, trial leads, and sponsors to overcome these challenges.

Refreshing our research strategy
Over the past year, we have taken time to reflect, reviewing our achievements, recognising recurring barriers, and acknowledging the realities of limited resources. Our refreshed strategy aims to accelerate access to innovative clinical approaches by strengthening existing trial infrastructure, enabling transatlantic collaboration, and fast-tracking promising research into frontline treatment.

With limited resources, we're focusing on high-impact, smaller-scale projects that deliver tangible progress, while remaining agile and responsive to emerging opportunities and partnerships.

Scientific meeting at the Neuroblastoma Parent Symposium: bridging continents, aligning goals
Fostering transatlantic collaboration has been a core component of our research strategy since 2017. As part of the 2025 Neuroblastoma Parent Symposium, we convened a meeting of leading scientific experts from Europe and North America — including representatives from the leading paediatric oncology organisations, SIOPEN in Europe and COG in the US — to discuss key transatlantic objectives. The meeting outcomes will directly inform our research implementation plan for the next three years, with a focus on advancing our second strategic goal: enabling transatlantic collaboration through targeted, high-impact projects that we hope will benefit children now and create a legacy for generations to come.

Amplifying patient and parent perspectives in European projects: ALADDIN and MONALISA
Over the past year, we have been an active patient partner in ALADDIN and MONALISA, two European-funded research initiatives addressing unmet needs in paediatric oncology.

ALADDIN is an educational programme designed to enhance stakeholders' understanding of strategy and regulatory science in order to accelerate paediatric oncology drug development. The initiative aims to build expertise and foster genuine multi-stakeholder collaboration. Alongside expert-led teaching and interactive online sessions, the programme has, for the first time, developed a comprehensive online portal with a range of educational resources.

MONALISA seeks to establish liquid biopsies, non-invasive tests like blood tests, as a standard procedure for monitoring neuroblastoma recurrence and progression.



Train-loving Teddy had just turned three and become a big brother to baby Rupert when, after multiple trips to the GP for fevers and discomfort, and several visits to A&E for pain in his sides, he was diagnosed with stage four high-risk neuroblastoma.

After his diagnosis, Teddy faced 18 months of intensive treatment, which included high-dose chemotherapy, stem cell transplants, radiotherapy, and immunotherapy. This frontline treatment was delivered through the SIOPEN High-Risk Neuroblastoma 2 Trial, a critical study aimed at evaluating the effectiveness of current standard therapies across Europe, while exploring new approaches in induction chemotherapy, high-dose chemotherapy, and radiotherapy. The trial's UK sites were co-funded by Solving Kids' Cancer UK and Neuroblastoma UK, ensuring that children in the UK have access to the same standard of care and new approaches available to children across Europe.

In January 2024, Teddy completed his frontline treatment, and post-treatment scans confirmed that he had achieved a complete response, with his medical team declaring there to be 'no evidence of active disease'. After a year of accessing a maintenance option at Penn State Children's Hospital, Teddy has now finished treatment and is being closely monitored by his UK treating team, while enjoying being back at school and spending time with his family.

For the first time in neuroblastoma research, the MONALISA study is also capturing families' experiences of disease monitoring using Observer Reported Outcomes (ObsROs). Through a custom app, the realities of disease monitoring will be assessed, helping to shape more compassionate and responsive care.

As a patient organisation, we play a critical role in ensuring that the perspectives of children and families are amplified in every discussion and embedded throughout the research process. By bringing lived experience and advocacy expertise to the table, we help make research outcomes more relevant, responsive, and reflective of the real-world needs of patients and their families.

Partnerships driving impact for children
We operate through a strong collaborative model, uniting diverse stakeholders to drive progress for children with neuroblastoma. Over the past year, we have deepened existing partnerships and forged new ones, all aligned with our research agenda to address the most pressing unmet needs facing children with this disease.

Despite delays and challenges, the ACTION (Advancing Clinical Trial Implementation and Optimisation in Neuroblastoma) consortium - which awarded nearly $2 million to the MIGHTY (Molecular and Immunologic Guided High-Risk Neuroblastoma Therapy) consortium and the associated TACTIC clinical trial in March 2024 - remains united and committed. For charities like ours, delays in clinical research are especially difficult, as we must balance long-term investment with the urgent need to demonstrate progress and impact for the children and families we serve. Progress is hard-won and often slow, but it is possible, and it is exactly what children and their families urgently need.

2025/26 goals

- Strategic review of support to Cancer Research Clinical Trials Unit (CRCTU, Birmingham) to enhance and expand neuroblastoma research
- Strengthen and enhance BEACON2 (a multi-arm, multi-stage platform trial) by increasing therapeutic options for children with relapsed or refractory disease
- Facilitate steps towards development of a transatlantic common induction protocol for high-risk neuroblastoma
- Explore innovative strategies to enhance and expedite the development of SIOPEN High-risk Neuroblastoma 3, Europe's next frontline study for children diagnosed with high-risk neuroblastoma
- Successfully complete and pass the AMRC (Association of Medical Research Charities) audit to maintain our commitment to research excellence, transparency, and best practice.

Solving Kids' Cancer UK
Support

At Solving Kids' Cancer UK, our dedicated Family Support team provides hope, information, and support to families throughout their journey with neuroblastoma.

Built on hope, our service places children at the heart of everything we do. Our Family Support team has personal experience and truly understands what it means to be a parent of a child with neuroblastoma.

They offer tailored support and impartial information and guidance based on the unique needs of each family, helping to ease the practical, financial, and emotional burdens and pressures that a neuroblastoma diagnosis brings.

By presenting unbiased information to support decision-making, our Family Support team and Chief Nurse expertly guide families through the complexities of parental decision-making, including repeated treatment decisions.

2024/25 summary

Introducing our Chief Nurse
In November 2024, Solving Kids' Cancer UK appointed its first-ever Chief Nurse, Dr. Helen Pearson — a ground-breaking move rooted in our commitment to elevating clinical expertise and enhancing patient-centred care. With over 17 years of experience in paediatric oncology across the NHS and private sector, Helen holds a Master's in Advanced Practice in Cancer Care, a post-graduate diploma in Children's Advanced Nurse Practitioner, and is a Doctor of Philosophy in Health Sciences. Helen was the first paediatric oncology nurse to receive a National Institute for Health and Care Research fellowship where she led the REDMAPP study into treatment decision-making for relapsed and refractory neuroblastoma and co-designed with parents an intervention to support parents in making these decisions. She brings to the charity a unique blend of clinical insight, research leadership, and deep empathy. Helen's appointment will strengthen our advocacy, integrate nursing perspectives into research strategy, and ensure that every family's journey is navigated with compassion, clarity and best-practice care at the heart of our work.


DR. HELEN PEARSON

Neuroblastoma Parent Symposium
This year, we were proud to deliver a hybrid symposium that brought together neuroblastoma families both in person and online. The event offered a vital opportunity for families to connect, gain peer support, and hear directly from leading experts about the latest developments in neuroblastoma research. In addition, participants took part in a range of thoughtfully curated workshops designed to offer emotional and practical support.

A standout moment of the symposium was the survivor-led session, which provided an empowering platform for five remarkable neuroblastoma survivors to share their lived experiences. Through open and honest storytelling, they offered inspiration and practical insight into navigating life after cancer, addressing the physical and emotional challenges they have faced.



Coaching Programme
With in-house trained coaches, we formally launched and delivered our patient-driven, compassionate cancer coaching programmes—a series of online group sessions for parents of children diagnosed with neuroblastoma following the end of treatment, as well as for those experiencing bereavement—focusing on parental wellbeing and life after cancer.

"After losing my daughter 2 years ago it has been difficult to make progress in my life. To meet people on the course that genuinely understood my situation was a game changer for me and the activities that I have been introduced to will hopefully mean I can make long-term changes for the better. I felt that the charity is invested in me not just for the duration of the course but long term which is very reassuring."

Coaching Programme participant



Dulcie was just five years old when she was diagnosed with stage 4 high-risk neuroblastoma in December 2021. She immediately began frontline treatment, which included chemotherapy and an 11-hour surgery to remove a 1.2 kg tumour. Unfortunately, scans showed that frontline treatment hadn't worked as hoped, and her cancer had not only increased in intensity but had also spread. With her cancer now classified as relapsed, Dulcie's family turned to clinical trials as the next step in her treatment journey.

Dulcie was enrolled onto two clinical trials, including the MiNivAn trial, co-funded by Solving Kids' Cancer UK, which aims to improve outcomes for children with relapsed or refractory neuroblastoma. After completing the MiNivAn trial, Dulcie's reassessment scans brought amazing news – she had almost beaten cancer, with only one small spot left in her femur. She was finally eligible for high-dose chemotherapy and a stem cell transplant, which began in April 2024.

By February 2025, after completing antibody treatment with Cis Retinoic Acid, Dulcie's end-of-treatment scans showed 'no evidence of disease'. In March 2025, after three years of intense treatment, Dulcie finally rang The End of Treatment Bell.

"Vicky and Donna from SKC's Family Support team were like a breath of fresh air, helping me to understand what was being said to me, advising me to stay away from Google (we are all guilty of it) but also encouraging me to also do my own research by asking the right questions. SKC was there every step of the way, holding our hands and answering our questions and concerns. We couldn't have done this journey without them."

Debbie, Mum to Dulcie

Parent/patient advocacy
We continue to have a core role as parent/patient advocates through active engagement with emerging clinical trials and research developments.

This year, we presented the parent perspective at key scientific national and international meetings. By staying closely connected to the research community, we help ensure that families are informed and empowered to support parental decision-making.

Post-treatment service
Parents tell us that life after treatment can be a lonely, overwhelming, and isolating time, full of worries and uncertainties. Developments in our post-treatment service include our recently launched Connected After Cancer: Peer-to-Peer Drop-Ins for parents of children after neuroblastoma treatment.

"While our treatment centre is excellent, I do feel once frontline treatment finished, we were just left to fend for ourselves and it was a very strange and scary feeling, especially when we had relied so heavily on the hospital staff throughout treatment." – Post-treatment parent attendee

Care and Connect Bags
Our Care and Connect Family Support Bags have been gifted to 36 more families this year, bringing much needed comfort and smiles at a time of need.

"We have immense gratitude for the huge support bag that arrived last week for Gitty! You guys are really incredibly amazing!! Gitty was very excited with all her new toys, they will come to very good use whilst we need to entertain her throughout this journey!"

Parent to Gitty

Big Love Fund
During 2024/25, it has been our privilege to support more children, young people, and their families through the award of 31 Big Love Fund grants.

2025/26 goals

- Enhance and expand the current coaching programme, exploring the feasibility of scaling it to other rare childhood cancer types
- Develop an enhanced post-treatment offering as part of our support service
- Work to enable equitable access to support services for all children, young people and families affected by neuroblastoma
- Develop a low / intermediate-risk support offering and related implementation plan
- Undertake key projects to advance our strategy

Solving Kids' Cancer UK
Awareness





Solving Kids' Cancer UK is committed to raising awareness of the realities of childhood cancer and advocating for the change children urgently need. Our awareness and advocacy work go hand in hand – amplifying the voices of children and families, influencing national policy, and building our reputation as a trusted leader to transform outcomes for children with cancer.

Kids Get Cancer Too campaign
In 2024, our Kids Get Cancer Too campaign became a cornerstone of our awareness efforts, shining a national spotlight on the unique challenges faced by children with cancer. The campaign focused on the urgent need to accelerate clinical research to find kinder, more effective treatments.

The campaign launched with our very own manifesto, outlining the key priorities for a step change in children's cancer clinical research. In May 2024, we held our inaugural parliamentary reception at the House of Lords to showcase the manifesto and its important messages. True to our ethos of putting children and families at the heart of what we do, over 40 children, parents and family members attended to share their experiences and perspectives with politicians and healthcare leaders.

During Childhood Cancer Awareness Month in September, families across the UK united under the campaign banner to raise awareness and call for meaningful change.

Positioning ourselves as policy leaders
In 2024–25, we deepened our engagement with policymakers to ensure that the voices of children with cancer and their families are heard at the highest levels.

We attended both the Labour and Conservative party conferences for the first time, meeting MPs and sector leaders to champion the needs of children and young people with cancer. This proved useful to hear first-hand perspectives on national health issues, and to champion the needs of children and young people with cancer within these conversations.

In December, we submitted a detailed response to the NHS 10-Year Health Plan consultation, calling for a dedicated focus on childhood cancer. Our recommendations included recognising the unique needs of children and young people, investing in child-specific clinical trials, and embedding family-centred care across the NHS. In February 2025, we were named as charity members of the Children and Young People Cancer Government Taskforce, where we continue to advocate for these priorities as part of the upcoming National Cancer Plan.

We also proudly supported the progression of the Rare Cancers Bill, working alongside other charities and parliamentarians to ensure that children with rare cancers are not left behind. Our involvement will continue into next year as we help shape the Bill's development and implementation.

Making an IMPACCT
In 2024–25, we officially convened IMPACCT – the Initiative for Multi-stakeholder Partnership to Accelerate Children's Cancer Trials, chaired by Professor Pam Kearns. IMPACCT addresses one of the biggest barriers in childhood cancer treatment: the slow and complex process of delivering clinical trials.

In its first year, the initiative brought together experts from across research and healthcare to identify the root causes of delays. Three key areas have been prioritised: pharmacy processes, hospital costing and capability decisions, and workforce capacity. Through focused working groups, we are developing practical solutions to ultimately help more children access innovative treatments faster.

With strong engagement across the sector, IMPACCT is now moving into its next phase: detailed analysis and implementation of solutions that will make a tangible difference to trial delivery and accessibility.

2025/26 goals

- Engage with and influence the National Cancer Plan, amplifying the needs of children and young people with cancer
- Support the progression of the Rare Cancers Bill through Parliament
- Further develop the activities of the IMPACCT working groups:
  - Conduct a comprehensive survey of the paediatric oncology research workforce
  - Convene a UK forum for knowledge exchange between the Children and Young People Clinical Trials Units and Research & Development experts
  - Review IMPACCT's progress and priorities against the evolving landscape
  - Engage politicians and policy makers in IMPACCT and work together to develop effective solutions
- Take a deep dive into the equity of access to children's cancer trials
- Develop a pilot patient expert training and mentoring scheme for parents and young people



Annabel was a happy, fun-loving four-year-old when she began complaining of back pain. After multiple visits to the GP and A&E, her family received the devastating diagnosis: stage 4 high-risk neuroblastoma.

Over the next 15 months, Annabel braved intensive treatment, including surgery, chemotherapy, stem cell transplant, proton therapy, and immunotherapy. Despite this, her parents, Mike and Libby, knew there was still a high risk of relapse. They began exploring additional options to help prevent the cancer from returning.

Around this time, a promising new relapse-prevention drug called DFMO was approved in the United States. Rather than uproot their lives to access it abroad, Mike and Libby hoped the drug would become available in the UK through a proposed Expanded Access Programme. Unsure whether this would be available in time for Annabel, they contacted their local MP, Mark Ferguson, to explain their situation and the urgent need for the programme to open. Mark Ferguson raised the question of DFMO access in Prime Minister's Questions and Annabel's family were delighted to receive PM Kier Starmer's best wishes. This exchange led to a meeting between the family, Health Minister Karyn Smith, and members of Solving Kids' Cancer UK, where Mike shared their experience and the importance of timely access to treatment.

Thankfully for Annabel, the programme opened in time, and she continues to receive DMFO in the UK. Whilst the drug is still in the process of being considered for full approval and use in standard of care, Solving Kids' Cancer UK are continuing our advocacy efforts so that every child who may benefit can do so, as rapidly as possible.

Your support

Over the last year, we have been incredibly grateful for the support we have received from our community and event fundraisers, as well as the ongoing generosity and commitment of our corporate supporters.

Some standout moments from the year include:



British Racing Greats

September 2024 marked the return of British Racing Greats, a unique charity track event celebrating the greatest racing games ever made, all in support of Solving Kids' Cancer UK and SpecialEffect.

Held at the historic Goodwood Motor Circuit, the day included a thrilling mix of activities – from passenger rides and skid pan experiences to pit stop challenges. Throughout the day, famous cars from racing game history took to the circuit for parades and demonstrations, entertaining both gaming and car enthusiasts alike.

This incredible event was made possible by the generosity of so many individuals and companies, raising an amazing £50,000 which was equally shared between the two charities.





Halloween Walk

In October, our fantastic team of 40 fundraisers took part in the Ultra Challenge Series Halloween Walk. Dressed in their best Halloween costumes – from spooky witches to cheerful pumpkins – the group tackled the 10km and 25km routes across London, all in support of families affected by neuroblastoma.

Thanks to this dedicated team and the generous people who donated, an incredible £25,060 was raised to help fund life-saving neuroblastoma research, support families, and bring hope to children living with cancer.

BBC Radio 4 appeal

In 2024, we were proud to be selected to broadcast a charity appeal on BBC Radio 4. The appeal was presented by actress Natalie Cassidy and aired in September. During the appeal, Natalie shared Arianna's story, who was diagnosed with stage 4 high-risk neuroblastoma at just five years old. Natalie's daughter and Arianna are best friends, so she has seen first-hand the impact neuroblastoma has had on Arianna and her family, as well as the invaluable support they have received from Solving Kids' Cancer UK.

Thanks to the generous support of BBC Radio 4 listeners, the appeal raised £19,000 towards vital neuroblastoma research and support.





800-mile challenge

In 2024, Rebecca took on the ultimate challenge – cycling, running, and walking 800 miles over 50 days in memory of Oscar, who passed away from high-risk neuroblastoma in 2018 at just three years old. Rebecca completed her epic challenge with the Snowdon Marathon on October 26th, just in time for Oscar's 10th birthday in November.

Through her determination, she raised an incredible £800 for children and families facing neuroblastoma.

Children's comedy afternoon

In January 2025, the Carpenter family, who were supported by Solving Kids' Cancer UK after their son, Alec, was diagnosed with neuroblastoma at just 19 weeks old, hosted a family-friendly comedy fundraiser. The afternoon was packed with laughter and entertainment as some of the country's top kid comedians took to the stage. Thanks to the generous support of attendees, the event raised over £2,700, helping to provide vital support for other families facing neuroblastoma.















Events

Neuroblastoma Parent Symposium

In March 2025, we were thrilled to host our first in-person Neuroblastoma Parent Symposium since 2019. Held as a hybrid event, it brought together families, professionals, and experts from around the world, with sessions live-streamed to ensure the event was accessible to all.

It was a weekend of information, hope, and connection – giving families affected by neuroblastoma the chance to engage with those who treat and care for them. From expert-led sessions on the latest treatments and research to inspiring stories from adult neuroblastoma survivors, the event offered something meaningful for all, leaving everyone feeling truly empowered.

Designed for the whole family, the symposium also featured fun activities for children, including goody bags from Jude and the Book Factory and gifts kindly donated by Julius Baer International Ltd employees.

We are grateful for the support from Children with Cancer UK, United Therapeutics, Norgine, The National Lottery Community Fund, Recordati Rare Diseases, The Hospital Saturday Fund, and Y-mAbs Therapeutics, Inc. in making this event possible.

Christmas Concert

On 16 December 2024, our Christmas Concert returned to Holy Trinity Church, Sloane Square, London, for a magical evening filled with hope, inspiration, and incredible festive performances. Hosted by Eastenders' actress, Kellie Bright, the concert raised over £35,000 for children and families affected by neuroblastoma.

We were delighted to be joined by some extraordinary guests, including the brilliant London Show Choir and talented musician Louis Moorhouse, a neuroblastoma survivor whose story of resilience is truly inspiring. And of course, Father Christmas made a special appearance, taking time out of his busy schedule to hand out presents to all the children.

One of the evening's highlights was undoubtedly our special guest, double Brit Award nominee and gifted singer-songwriter Ella Henderson, who performed some of her hit singles. Made possible through the generous support of Evamore Music and the Cancer Awareness Trust, Ella also performed beautifully alongside Louis Moorhouse, before ending the evening with a heartwarming sing-along with the children.

We were also honoured to present our Hero Awards to individuals in the neuroblastoma community, celebrating those whose extraordinary efforts have made a meaningful difference to families facing childhood cancer.

A special thanks to our friends at Cancer Awareness Trust for their support with our event, and to our wonderful supporters Miniclip, Lioncroft Foundation, and Brandler Galleries.

Family fun day

Held on 15 June 2024, our Family Fun Day at Knebworth House brought together over 40 families for a day to remember. The event was designed as a space where families could meet, form connections, and create lasting memories – all while enjoying a wide range of activities for children of all ages. From exciting ball pits, face painting, and a giant inflatable slide to creative arts and crafts and a mobile petting zoo, there was something for everyone to enjoy.

Thank you to Miniclip and Flix Interactive for supporting this event.



Achievements & performance 2024–2025

The third year of our 2022-2027 strategy has been packed with developments and achievements across all our pillars - Research, Support and Awareness. Alongside this we have maintained a lean and highly effective infrastructure to ensure our teams can focus on driving our strategy.

Solving Kids' Cancer UK





Research

- Refreshed our Research Strategy which aims to accelerate access to innovative clinical approaches by strengthening existing trial infrastructure, enabling transatlantic collaboration, and fast-tracking promising research into frontline treatment.
- Worked to drive the implementation of the MIGHTY and MINT projects that we are supporting financially, and are keen to see move into recruitment.
- Brought together leading scientific experts from Europe and North America to foster transatlantic collaboration and discuss shared objectives.
- Amplified patient and parent perspectives in European projects: ALADDIN and MONALISA.
- Worked closely with several international non-profit organisations to identify areas of synergy and help inform neuroblastoma-specific research strategies. These include Children with Cancer UK, Villa Joep, Neuroblastoma Australia and LifeArc.

Support

- Introduced the charity's first ever Chief Nurse, Dr. Helen Pearson.
- Held our first hybrid Neuroblastoma Parent Symposium since 2019, bringing together clinicians, researchers and parents to connect, gain peer support and hear directly from leading experts.
- Formally launched our coaching programmes for parents of children post treatment as well as parents in bereavement.
- Began to develop our post-treatment service with peer-to-peer drop-in sessions for parents.
- Provided 31 Big Love Fund pastoral grants and 36 Care and Connect Bags to families.

Awareness

- Held a parliamentary reception to launch our Kids Get Cancer Too campaign to shine a light on the unique challenges faced by children with cancer.
- Worked to further our awareness agenda and position ourselves as policy leaders by becoming members of the Children and Young People Cancer Government Taskforce and by supporting the progression of the Rare Cancers Bill.
- Officially convened IMPACCT to bring experts from across research and healthcare together to identify and resolve the root causes of delays for children in treatment.

Inspire public support for the charity

- Raised £1,116,822 of undesignated income, 11% growth on prior year.
- Launched three-year major charity partnership with Julius Baer International Ltd.
- Launched our Development Board—a strategic milestone designed to strengthen our fundraising efforts and expand support across professional and personal networks.
- Welcomed many of our supporters and families to our Christmas Concert with very special performances from the amazing neuroblastoma survivor, Louis Moorhouse, twice Brit award nominee, Ella Henderson, and the London Show Choir.
- Secured GamesAid funding of £18,000 for a ninth year running.

Strong governance and infrastructure

- Further developed our website providing all our stakeholders with a more user-friendly digital way into the organisation.
- Moved funds to a banking platform to enable significant increases in our interest income through active management of our cash reserves.
- On boarded three new trustees to further enhance the skills and experience of our trustee board.

Future plans

The 2022 – 2027 organisational strategy is hugely ambitious, and we are working hard to deliver it for the benefit of all our beneficiaries. We are continuing to grow our networks, partnerships and relationships to help drive our huge programme of very exciting work over the next year across all pillars.

Over the next year, we will:

- Focus on the development of new and existing research programmes to help deliver treatment options for children in the UK, including strengthening and enhancing the BEACON2 trial to increase therapeutic options for children with relapsed and refractory disease and exploring innovative strategies to enhance and expedite the development of SIOPEN HRNBL3, Europe's next frontline study for children diagnosed with high-risk neuroblastoma.



- Facilitate steps towards development of a transatlantic common induction protocol for high-risk neuroblastoma.
- Actively advocate for the needs of children and young people with cancer including engaging with and influencing the National Cancer Plan, the Children and Young People's Cancer Taskforce and supporting the progression of the Rare Cancers Bill through Parliament.
- Further develop the activities of the IMPACCT working groups to include conducting a comprehensive survey of the paediatric oncology research workforce, convene a UK forum for knowledge exchange between the Clinical Trials Units and research and development experts and engaging politicians and policy makers in IMPACCT and working together to develop effective solutions.



- Enhance and expand the coaching programme, including assessing scalability to other rare childhood cancers.
- Develop our support service to enhance the support we provide to families post treatment and those with children diagnosed with low/intermediate-risk disease.
- Continue to grow and strengthen our fundraising pipeline by expanding corporate partnerships, developing an individual giving programme, and advancing our Named Funds to offer families a supported way to raise funds in their child's name for the charity's core work.

Structure, governance and management

Governing document

The trustees, who are also Directors for the purposes of company law, present their report and the financial statements of the company for the year ended 31 March 2025.

The charity is controlled by its governing document, the Articles of Association, and constitutes an incorporated registered charity. The charity was incorporated on 30 March 2010 at Companies House, was entered in the Register of Charities on 20 April 2010 and is administered by the trustees. At their discretion, the trustees may spend all or part of the capital of the charity in furthering its Objects, in the following ways:

i. To raise funds. The trustees must not undertake any substantial permanent trading activity and must comply with any relevant statutory regulations.

ii. To buy, take on a lease or in exchange, hire or otherwise acquire property and to maintain and equip it for use.

iii. To sell, lease or otherwise dispose of all or any part of property belonging to the charity.

iv. To borrow money and to charge the whole or any part of the property belonging to the charity as security for repayment of the money borrowed.

Aims and objects

The charity's objects ("Objects") are specifically restricted to the following:

- To advance the understanding and treatment of cancer in children through the greater awareness, provision of equipment, access to treatment protocols in hospitals and medical centres and clinical research aimed at improved diagnosis and treatment anywhere in the world.
- To advance the education, relieve the sickness and the poverty of persons living anywhere in the world through the provision of equipment, financial assistance and by any other charitable means that the trustees in their absolute discretion think fit.

Public benefit

The trustees give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the Objects and due consideration to the relevant guidance issued by the Charity Commission. The trustees will continue to ensure that the principal activities of the charity are to provide public benefit.

Board of Trustees

Solving Kids' Cancer UK is governed by the Board of Trustees, chaired by Nick Bird MBE. The trustees determine the charity's strategic direction and oversee progress against objectives. The Board is responsible for governance and for upholding the charity's values. The charity must have at least three trustees. The day-to-day running of the charity is the responsibility of the Chief Executive Officer.

The Board of Trustees supports the principles of good governance set out in the Charity Governance Code (see www.charitygovernancecode.org) and also the continuous improvement model which the Code promotes.

The Board of Trustees receives periodic technical briefings on neuroblastoma research, has joint sessions with the Chair of the Scientific Advisory Board and attends the annual Neuroblastoma Parent Symposium and other relevant conferences/meetings.

The Board of Trustees has formal board meetings six times during the year. In accordance with the charity's Articles of Association, trustees must undertake to attend meetings regularly and any trustee failing to do so may be duly removed from their position.

The quorum necessary for the transaction of trustee business at an ordinary meeting is three trustees or two thirds of all trustees, whichever is greater. The trustees agree that the nominated Chair has the casting vote for decisions where there is equal weighting.

The Board selects new trustees based upon their empathy with the Objects of the charity, skills and experience to help provide the appropriate level of governance and oversight for the charity to be effective, coupled with their ability to commit the necessary time for Board meetings and other key events.

Structure, governance and management Continued

In 2024, we welcomed three new trustees: Carl Cavers OBE, a leader in the gaming industry who has greatly supported us over the years as a Patron; Stewart Leaver, a business director who, after receiving support during his daughter's neuroblastoma diagnosis, now gives back to the charity after Jossie sadly passed away in November 2019; and Ioannis Topsakalidis, an energy sector executive whose daughter, Jasmine, passed away in December 2019 after two years of treatment for neuroblastoma. Since joining the Board, Ioannis has shared, "I am truly humbled and honoured to be a part of this amazing organisation and believe there are so many more things we can do to help children and families in dire need".

We are delighted to welcome our three new trustees and are greatly appreciative of the dedication and experience they bring to the Board.



Carl Cavers



Stewart Leaver



Ioannis Topsakalidis

Trustee induction procedures include completing relevant training and working with staff and existing trustees to understand the organisation and develop internal relationships, to include one-to-one meetings with the CEO, Chair of the Board, trustees and members of the Leadership team. The induction also covers governance processes, strategic planning and finance, so that new trustees are equipped with relevant knowledge about the organisation and its priorities. New trustees are provided with a Role Description and Person Specification and Board Code of Conduct.

Scientific Advisory Board

Solving Kids' Cancer UK's Scientific Advisory Board (SAB) is an independent panel of leading experts providing strategic guidance and scientific oversight to support the charity's research mission.

The SAB plays a crucial role in shaping research priorities and ensuring the integrity of our rigorous, AMRC-accredited grant award process. Their recommendations are communicated to the Board of Trustees through our research team, helping to inform funding decisions and drive progress toward better outcomes for children with neuroblastoma.

The SAB has been central to the recent refresh of our research strategy, providing expert guidance through thorough evaluation combined with forward-thinking discussions and collaborative brainstorming. They helped us critically assess past achievements and ongoing challenges, ensuring our updated approach remains ambitious yet pragmatic. Their insights have been vital in shaping a focused strategy that maximises the impact of limited resources by prioritising projects that strengthen transatlantic collaboration and alignment, enhance existing infrastructure, and accelerate clinical innovation for children with high-risk neuroblastoma.

The trustees extend sincere thanks to every SAB member for their dedication to advancing the charity's research mission - improving outcomes for children with neuroblastoma in the UK and beyond. Special thanks go to Professor Andy Pearson, Chair of the SAB, for his outstanding expertise, tireless commitment, and unwavering passion for helping children affected by neuroblastoma. His leadership and enthusiastic support have been instrumental in the work and progress of Solving Kids' Cancer UK.

Staff remuneration

All salaries, including that of the Chief Executive, are based upon an assessment of the employment market, the skill levels required, the size and financial performance of the charity and the salary levels required to obtain and retain the services of the best staff.

Equity, diversity and inclusion

Solving Kids' Cancer UK has a strong, caring ethos and is firmly committed to equity, diversity, and inclusion (EDI), which is integral to our five-year strategy and values.

We are committed to embedding principles of equity, diversity, and inclusion, ensuring that our operations, activities, and services are designed and open for everyone to be included, and to fostering culture, behaviours, and practices in support of social justice.

EDI is fundamental to achieving our charity objectives to reach and be there for all families affected by neuroblastoma, and for the health and wellbeing of all those we work with and exist for. We want everyone to feel included and believe in the importance of reflecting different perspectives, experiences, and skills, including from those with lived experience of neuroblastoma, within our staff, board, and volunteer teams.

We are not EDI experts, we do not have all the answers, and we will not always get it right - but this can't and won't hold us back. We are committed to learning, to listening and to creating safe spaces for difficult conversations that will inspire and lead to positive and lasting change.

Safeguarding

Our work and practice is underpinned by safeguarding principles with the aim of protecting children and young people and enhancing their welfare. Solving Kids' Cancer UK always works in accordance with legislation, statutory guidance, and best safeguarding practices. Solving Kids' Cancer UK has robust safeguarding policies and procedures in place and all staff and trustees receive dedicated safeguarding training upon induction with regular updates as required.

All hiring managers are required to access Safer Recruitment training to ensure that our recruitment processes are robust, with an emphasis on ensuring the safety and welfare of the children and families we support. All staff and trustees are required to have a basic DBS check and clearance before commencing their role with Solving Kids' Cancer UK, and this is extended to any volunteer or service provider that may have regular direct interaction with the children and families we support.

The charity reviews and revises safeguarding policies and procedures at regular intervals, at least annually, and has a designated safeguarding lead within the leadership team and a trustee with designated safeguarding oversight.

Volunteers

In 2025, Solving Kids' Cancer UK launched its inaugural Development Board—a strategic milestone designed to strengthen our fundraising efforts and expand support across professional and personal networks. Comprising business leaders and individuals personally affected by neuroblastoma, the volunteer board is uniquely positioned to leverage both corporate and lived cancer experiences. By blending deep empathy with leadership insight, the Board will champion innovative fundraising campaigns and community engagement, ensuring vital funds continue flowing into lifesaving childhood cancer research and family support services.



The trustees are extremely grateful for the considerable contribution made by all of the charity's volunteers and fundraisers in support of children with neuroblastoma, including our Patrons, our Parent Involvement Forum members and all those who lend their time, expertise and resources in furtherance of our charitable objectives. We couldn't do all we do without wonderful volunteers.

From the amazing London Show Choir at our Christmas Concert, to the clinicians, advocates and young survivors at our Symposium, and to everyone else who has helped us this year, we thank you from the bottoms of our hearts - we are all a part of Team SKC.

During the year, volunteers supporting the charity collectively contributed over 2,300 hours and we are hugely grateful to them all.

Our legal and administrative details





Registered charity name
Solving Kids' Cancer UK

Charity registration number
1135601 (England and Wales)
SC045094 (Scotland)

Company registration number
07208648

Registered office
Unit 02-03 Salisbury House,
29 Finsbury Circus
London EC2M 7AQ

Trustees
The trustees who served the company during the period were as follows:

Nick Bird (Chair of the Board of Trustees)
Joseph Tabone (to 15th Sept 2025)
Cameron Miller (from 15th Sept 2025)
Helen Duffy (from 15th Sept 2025)
Matthew White (Equity, Diversity and Inclusion Lead)
David Coulon (Treasurer)
Alexandra Lane
Dr Áine McCarthy
Carl Cavers (from 16th Sept 2024)
Stewart Leaver (from 16th Sept 2024)
Ioannis Topsakalidis (from 16th Sept 2024)

Company Secretary
Claire Hislop (from 24th June 2025)
Gemma Wadsley (until 24th June 2025)

Chief Executive Officer
Gail Jackson

Leadership team
Susan McGregor-Ogden (Head of Finance from 9th July 2025)
Claire Hislop (Operations Director)
Danielle Russell (Head of Fundraising and Engagement)
Gemma Wadsley (Director of Strategic Finance – to 9th July 2025)
Leona Knox (Head of Research)
Vicky Inglis (Head of Family Support Service)
Emily Hall (Public Affairs and Advocacy Lead)

Patrons
Carl Cavers (to 16th Sept 2024)
Kellie Bright
Rob Brydon

Auditors
Moore Kingston Smith LLP (from 15th September 2025)
Chartered Accountants and Business Advisers
10 Orange Street, Haymarket,
London WC2H 7DQ

Shipleys LLP (to 6th May 2025)
Chartered Accountants & Statutory Auditor
10 Orange Street, Haymarket
London WC2H 7DQ

Bankers
National Westminster Bank
Church Road Branch
London NW4 4DS

Investment managers
CCLA Investment Management Limited
1 Angel Lane
London EC4R 3AB

Solicitors
Withers
20 Old Bailey
London EC4M 7AN

Our finances

Overview

Over the past year, our financial strategy has evolved following the approval of DFMO as a maintenance treatment in the UK. This significant milestone now allows us to support more children closer to home, with fewer families feeling compelled to seek treatment abroad. Our undesignated income is made up firstly of donations from the general public, which we are hugely grateful for, supported by investment income on our funds held.

Our finances remain tightly controlled with lean expenditure across the organisation.

We are presenting an undesignated surplus for the year of £220,050 which will increase our reserves position to 10 months and enable future investment in our strategy ahead of wider sustainable income growth.

Overall, we are presenting a surplus of £530,197, largely due to a number of grants and transfers into the charity. This includes £380,000 transferred from Joining Against Cancer in Kids, who joined us as a Named Fund this year — these funds will support Research and Family Support projects over the coming years. This also includes a grant from Children with Cancer UK, which will help further our research aims.

Income

Our total income for the year was £2,937,893 (2024: £2,476,390). This comprises £1,116,822 undesignated funds (2024: £1,003,793); £874,698 designated funds (2024: £1,285,522) and £946,373 restricted funds (2024: £187,075).

Our undesignated income is made up of donations and investment income, which supports all our charity's internal activities. This includes our family support provision – offering pastoral care and grants to support families and providing evidence-based, impartial information to support parents in their choice of treatment options for their child, and to access treatments and clinical trials if they are not available in the UK. It also includes our internal research team and infrastructure, all our fundraising activities and our operational running and governance costs. Most of the remainder of our income relates to designated family funds which the Board has designated in the name of a child to support treatment options for that individual child, and income restricted to our research activities.

Overall income has increased largely as a result of funds transferred in and improved return on cash balances through the introduction of an online platform which allows maximisation of interest income while maintaining low credit risk.

Expenditure

Expenditure decreased this year to £2,232,606 (2024: £3,226,862). This largely related to the prior year including a large number of Research commitments whereas this year, there has been a focus on implementation and management of these grants. Therefore, overall Charitable expenditure was lower at £1,888,285 (2024: £2,884,684). Children's treatment costs were largely flat at £648,321 (2024: £639,537) whilst Family Support spend, which includes grants to families, was up again at £216,087 (2024: £176,402). This reflects the overall shift with families requiring support in the UK and for living costs whilst in treatment, with thankfully fewer families needing to travel abroad. Fundraising costs were flat at £344,321 (2024: £342,178) as we continue to manage spend effectively whilst driving fundraising growth.

Within these costs, we keep our support spend as lean as possible and this remains flat on the prior year at £404,183 (2024: £406,009).

Investments

Given the nature of the organisation, supporting very young children and their families, our investment objectives are primarily to invest in an ethically sound manner to protect the value of the charity's assets against inflation, and provide modest returns through a combination of income distribution and capital growth. In addition to being mindful of the nature of investments made on behalf of the charity, the trustees' appetite for risk is also influenced by the significant amount of funds that are designated for future purposes. The COIF Charities Ethical Investment Fund aims to provide a long-term gross return of 5% per annum net of inflation. Within this, the fund aims to deliver a consistent annual distribution of income and operate with a level of volatility (risk) that is no greater than 75% of the volatility of the UK equity market. The return performance for the year was -1.46% given the market volatility at the end of the year, with a three-year figure of +2.99% and the last five years at +8.58%, which is consistent with our aims.

Our finances

Continued

Following a volatile investment year, we are reporting an investment loss of £163,965 (2024: £345,776 gain). This was largely caused by the volatility in the market at the year end. Since purchase, the investment has given capital growth of £1,201,199.

Reserves policy

The trustees have adopted a reserves policy which they consider appropriate to ensure the continued ability of the charity to meet its objectives.

General funds are set aside to meet future costs to support our families and deliver our strategy. At the financial year-end, general funds were £1,068,709 (2024: £848,659).

General free reserves (undesignated funds excluding fixed assets) were £1,063,781 and represent 10.3 months' undesignated expenditure (based on the 2026 budget).

Free reserves are calculated as follows:

	2025
	£
Total funds of the charity	13,439,433
Less: Restricted funds	(2,550,050)
Less: Designated funds	(9,820,674)
Less: Fixed assets held for charity use	(4,928)
	£1,063,781

The reserves policy states that six to nine months of essential running costs should be covered to meet its obligations in the short-term (£616,550 - £924,825) based upon the 2026 budget. This is based on an assessment of the organisational risk approach and funding model. This year, we are above the top end of the range.

As part of our five-year strategy, we have a focus on long-term income sustainability and whilst in the short term we have benefited from the impact of high interest rates, longer term we need to further drive our undesignated fundraising to enable long-term sustainable growth.

We are forecasting a deficit in the 2026 budget as we invest ahead of this income growth and this will reduce our reserves back close to the target range.

This robust financial plan, alongside the need for caution given the continued challenging nature of the external environment for all charities, means that the trustees are comfortable with the current reserves level and longer-term policy.

Designated funds are largely set aside for the treatment of specific children with neuroblastoma and are not available for the general running of the charity, or any projects which do not directly relate to the treatment of that child. At the financial year-end, the charity held designated reserves of £9,820,674 (2024: £9,996,527). In the event of a child's death, the funds will be available to the family to support funeral and related costs and then the balance will be released from designated children's funds after a period of a year. Following the end of a successful course of treatment, and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of five years so that they are available for that child should they suffer a relapse and require further treatment or pastoral support, a situation which is sadly common for neuroblastoma patients. This policy resulted in £592,795 (2024: £84,627) transferring from designated children's funds within the year, 70% transferred to the designated Solving Kids' Cancer UK Research Fund; 10% to the designated Solving Kids' Cancer UK Children's Reserve Fund; and 20% to undesignated reserves.

Restricted Reserves are funds which can only be used for particular restricted purposes within the objects of the charity and arise when specified by the donor, or when funds are raised for particular restricted purposes.

At the financial year-end, the charity held restricted reserves of £2,550,050 (2024: £2,064,050), of which £1,215,548 (2024: £1,177,426) relates to funds being held on behalf of families who were previously supported by Families Against Neuroblastoma.

Supporters of the charity are kindly advised that, although the charity may appear to hold substantial reserves, 83% of these funds are either designated or restricted. They are committed specifically to funding treatment and support for children and families, as well as advancing research.

Risk management

The charity's trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks. The trustees have overall responsibility for ensuring that the charity has an appropriate system of controls, financial and otherwise. They are responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the charity or for publication is reliable and reviewed at every trustee meeting; and
- the charity complies with relevant laws and regulations.

The risk register is a live document which is reviewed in detail every six months by the Board and Leadership team, and we run a full risk register alongside a current risks and issues register to enable focus on the current key risks for the charity.

Risk categories include:

Governance
Covers risk of non-delivery of strategy, Board skills and capabilities, and effective decision-making and reporting.

Controls in place to manage these risks include a clear strategy underpinned by annual plans, a balanced and involved Board that has clear terms of reference and considers its effectiveness and undertakes training as appropriate. The Board requests and receives regular reporting from executive management.

People
Covers risk of loss of key staff and poor structure.

Controls in place to manage these risks include strong oversight by the CEO and senior managers, clear roles and responsibilities and strong HR processes. As staff numbers are small, this is a key risk which is closely monitored.

Finance
Covers all financial risks around effectiveness of our business model, level of reserves, management of investments and effective insurance.

Controls in place to manage these risks include annual budgeting and forecasting processes with regular reporting of our financial position to trustees. We have a clear reserves policy and hold general reserves to manage any changes in cash flow. We have an investment policy and investment managers who report on performance regularly.

Compliance
Covers all risks relating to non-compliance of required regulations including data protection, health and safety, employment and financial.

Controls in place to manage these risks include effective policies, staff training and awareness and effective advisors.

Operational, legal and physical
Covers risk of not being able to meet demands for family support and quality of support provided; risk of lack of funds due to expenditure exceeding income; health and safety risks and other operational risks including employment risks and disaster recovery.

Controls in place to manage these risks include ensuring the team has appropriate support to deliver in their roles and we are continuously considering current and future demand. Budgets and reserves are effectively managed to ensure funding is maintained. We have policies in place which are well understood and adhered to around health and safety, disaster recovery, employment policies and other areas of compliance.

Environmental / external factors
Covers reputational risk and relevant external risks such as economic conditions and Brexit.

Controls in place to manage these risks include effective communications policies and resource and ongoing monitoring of relevant external plans with action plans as required.

Our finances

Continued

Grant-making policy

The Board of Trustees makes two types of grants. Firstly, small grants to assist children living with neuroblastoma. Families who wish to apply either self-refer, hear about the charity from their child's oncologist, or contact the charity's Family Support Team. Grants are also offered in the form of a hardship fund for families struggling to meet their necessary costs due to the effects of having a child in treatment for neuroblastoma.

The second type is research grants. We engage in two distinct research funding mechanisms: a regular competitive funding call, and also ad-hoc exceptional funding requests. All research grants are awarded in line with the principles laid out by the Association of Medical Research Charities (AMRC). Each application will be subject to rigorous scientific review guided by the charity's Scientific Advisory Board (SAB) and the nature of any grant made will depend on funds available through Solving Kids' Cancer UK's own reserves, or those made available through strategic collaborative partnerships.

Investment policy and objectives

The Deed of Trust allows the charity to deposit or invest funds in any manner, but only after obtaining advice from financial experts as deemed necessary by the trustees, and with due consideration to the suitability of investments and the need for diversification. The charity aims to follow the COIF Ethical Fund Policy; excluding investments in companies involved in, for example, nuclear weapons, landmines, production of abortifacients, and other disqualifying criteria where there is a significant involvement (>10% of turnover).

Fundraising approach and policy

As a cause-related charity, we recognise that the service we offer for children and families affected by neuroblastoma and the advances in research we invest in, would not be possible without the generous support and passion our supporters, and families' supporters provide. We receive very little public funding for our work, relying on the generous support of the neuroblastoma community and general public.

We are registered with the regulatory body for fundraising in the UK, the Fundraising Regulator. As members of the scheme, we follow their Code of Fundraising Practice and comply with the key principles embodied in The Code. Many of our families raise funds for us at a local level and we ensure that they have all the information they need to comply with our policies and procedures.

It is hugely important to us that our supporters trust us and are well looked after:

- We ensure that we never put undue pressure on members of the public when raising funds.
- We are open and honest and approach our fundraising activities respectfully and considerately.
- We ensure that we comply with the wishes of our donors and comply with all general data protection laws.
- We respect the rights, dignity and privacy of our supporters and beneficiaries.
- We are accountable to our supporters and take this responsibility seriously.

We review all of our fundraising campaigns to ensure they fully comply with The Code and our fundraising activities are discussed regularly at Board meetings, to help ensure that our fundraising practices reflect and reinforce our values. Whether we're fundraising ourselves or working with families, organisations or volunteers, it's just as important.

We currently raise funds in a variety of ways, including regular and individual giving programmes, challenge events, Solving Kids' Cancer UK run and third party events, corporate partnerships, direct cash donations, raffles, sponsored events and Charity of the Year partnerships. We are performing well against our five-year fundraising strategy, which is building upon our strong stewardship approach to develop existing income streams and develop new ones.

Within the year, we achieved an undesignated income of £1,116,822 with 31% coming from Corporates, Trusts, Third Party Events and Major Gifts, 23% from Community and Events and 43% coming through investment income. Our performance reflects our strong and evolving strategy.

We take the protection of the personal data of all our supporters and donors extremely seriously, and constantly review and monitor our fundraising policies and procedures to ensure we deliver 'best practice'. We do not engage professional fundraisers to raise money on our behalf. We use our CRM system to further protect and manage our supporter data.

We welcome feedback on our fundraising activities at any time and strive to listen and learn from this feedback. During the year, we recorded one complaint. We have a robust complaints policy. If a complaint about our fundraising activities is unable to be resolved through our complaints procedure, members of the public are advised to raise it with the Fundraising Regulator.

Trustees' responsibilities statement

The trustees (who are also the Directors of Solving Kids' Cancer UK for the purposes of company law) are responsible for preparing the trustees Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the trustees to prepare financial statements for each financial year. Under that law, the trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the income and expenditure of the company for that period.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in operation.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of the persons who is a trustee at the date of approval of this report confirms that:

- so far as each trustee is aware, there is no relevant audit information of which the company's auditor is unaware; and
- each trustee has taken all steps that they ought to have taken as a trustee to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Registered office:
Signed on behalf of the Board of Trustees
Unit 02-03 Salisbury House,
29 Finsbury Circus,
London EC2M 7AQ



David Coulon
Trustee and Treasurer
1 October 2025

Independent auditor's report

Independent auditor's report to the trustees and members of Solving Kids' Cancer UK

Opinion

We have audited the financial statements of Solving Kids' Cancer UK ("the charitable company") for the year ended 31 March 2025 which comprise the Statement of Financial Activities (incorporating the Income and Expenditure Account), the Balance Sheet, the Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2025 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and trustees Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Solving Kids' Cancer UK's ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the trustees' Annual Report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- The directors' report included within the Trustees' Annual Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees Annual Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006, and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the trustees' report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditors under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The extent to which the audit was considered capable of detecting irregularities including fraud

- We obtained an understanding of the charitable company's activities, controls and laws and regulations and assessed the susceptibility of the charitable company's financial statements to material misstatement from irregularities, including fraud.

Independent auditor's report

Continued

- We determined that the laws and regulations that are most significant to the charitable company are the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)), Companies Act 2006, Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, the Fundraising Regulations and the charitable company's Articles of Association.
- Based on this understanding we designed our audit procedures to detecting irregularities, including fraud. Testing undertaken included making enquiries on the management and those charged with governance; journal entry testing; review of bank letters, investments reports, trustee board minutes and the Articles of Association; review of transactions for any undisclosed related party transactions; reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations. These procedures were designed to provide reasonable assurance that the financial statements were free from fraud or error.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control. .
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Tim Hardy (Senior Statutory Auditor)
1 October 2025
For and on behalf of Moore Kingston Smith LLP
Chartered Accountants & Statutory Auditor
10 Orange Street, Haymarket, London WC2H 7DQ

Statement of financial activities

(Incorporating the income and expenditure account) year ended 31 March 2025

	Note	General funds undesignated £	General funds designated £	Restricted funds £	Total funds 2025 £	Total funds 2024 £
INCOME						
Donations	2	**630,256**	**874,697**	**889,394**	**2,394,347**	2,096,627
Trading activities	3	**2,222**	**1**	**100**	**2,323**	49,140
Investment income	4	**484,344**	**-**	**56,879**	**541,223**	330,623
TOTAL INCOME		**1,116,822**	**874,698**	**946,373**	**2,937,893**	2,476,390
EXPENDITURE ON:						
Raising funds	5	**(328,495)**	**(6,406)**	**(9,420)**	**(344,321)**	(342,178)
Charitable activities	6	**(689,347)**	**(747,842)**	**(451,096)**	**(1,888,285)**	(2,884,684)
TOTAL EXPENDITURE		**(1,017,842)**	**(754,248)**	**(460,516)**	**(2,232,606)**	(3,226,862)
NET INCOME / (EXPENDITURE) BEFORE NET (LOSSES) /GAINS ON INVESTMENTS		**98,980**	**120,450**	**485,857**	**705,287**	(750,472)
Net (losses) / gains on investments	13	**–**	**(163,965)**	**–**	**(163,965)**	345,776
Other (losses) / gains		**(14,958)**	**3,833**	**–**	**(11,125)**	(19,388)
NET INCOME / (EXPENDITURE)		**84,022**	**(39,682)**	**485,857**	**530,197**	(424,084)
Transfer between funds	20,21,22	**136,028**	**(136,171)**	**143**	**–**	**–**
NET MOVEMENT IN FUNDS		**220,050**	**(175,853)**	**486,000**	**530,197**	(424,084)
RECONCILIATION OF FUNDS						
Total funds brought forward		**848,659**	**9,996,527**	**2,064,050**	**12,909,236**	13,333,320
TOTAL FUNDS CARRIED FORWARD		**1,068,709**	**9,820,674**	**2,550,050**	**13,439,433**	12,909,236

The Statement of financial activities includes all gains and losses in the year. All of the above amounts relate to continuing activities.
The notes on pages 38-59 form part of these financial statements.

Balance sheet

Year ended 31 March 2025

	Note	2025 £	2025 £	2024 £	2024 £
FIXED ASSETS					
Tangible assets	12		**4,928**		6,722
Investments	13		**4,776,466**		3,865,164
			4,781,394		3,871,886
CURRENT ASSETS					
Debtors	14	**119,948**		228,021	
Current investments		**5,173,463**		-	
Cash at bank and in hand		**5,614,252**		11,396,820	
		10,907,663		11,624,841	
CREDITORS					
Amounts falling due within one year	15	**(1,117,455)**		(1,205,625)	
NET CURRENT ASSETS			**9,790,208**		10,419,216
TOTAL ASSETS LESS CURRENT LIABILITIES			**14,571,602**		14,291,102
CREDITORS:					
Amounts falling due after one year	16		**(1,132,169)**		(1,381,866)
NET ASSETS			**13,439,433**		12,909,236
FUNDS OF THE CHARITY					
Restricted funds	20		**2,550,050**		2,064,050
Designated funds	21		**9,820,674**		9,996,527
Undesignated funds	22		**1,068,709**		848,659
TOTAL CHARITY FUNDS			**13,439,433**		12,909,236

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. These financial statements were approved by the members of the committee and authorised for issue on 1 October 2025 and are signed on their behalf by:



David Coulon, Trustee
Company registration number: 07208648

The notes on pages 38-59 form part of these financial statements.

Statement of cash flows

Year ended 31 March 2025

	Note	2025 £	2024 £
CASH FLOWS FROM OPERATING ACTIVITIES			
Net income / (expenditure)		**530,197**	(424,084)
Adjustments for:			
Depreciation		**2,730**	6,007
Losses / (gains) on investments		**163,965**	(345,776)
Dividends and interest from investments		**(541,223)**	(330,623)
Loss on sale of fixed assets		**-**	72
Decrease / (increase) in debtors		**107,973**	(131,672)
(Decrease) / increase in creditors		**(337,867)**	1,007,047
Net cash used in operating activities		**(74,225)**	(219,029)
CASH FLOWS FROM INVESTING ACTIVITIES			
Dividends and interest from investments		**541,323**	335,195
Purchase of property, plant and equipment		**(936)**	(3,825)
Deposit in current investments		**(5,173,463)**	-
Deposit in fixed asset investments		**(1,075,267)**	-
Net cash used in investing activities		**(5,708,343)**	331,370
CHANGE IN CASH AND CASH EQUIVALENTS	28	**(5,782,568)**	112,341
CASH AND CASH EQUIVALENTS AT START OF YEAR	28	**11,396,820**	11,284,479
CASH AND CASH EQUIVALENTS AT END OF YEAR	28	**5,614,252**	11,396,820
CASH AND CASH EQUIVALENTS			
Cash at bank and in hand		**2,300,978**	9,303,453
Deposits (less than 3 months)		**3,313,274**	2,093,367
CASH AT BANK AND IN HAND PER BALANCE SHEET		**5,614,252**	11,396,820

The notes on pages 38-59 form part of these financial statements.

Notes to the financial statements

1. Accounting policies

General information
Solving Kids' Cancer UK is a private company limited by guarantee incorporated in England under the Companies Act. The address of the registered office is Unit 02-03 Salisbury House, 29 Finsbury Circus, London EC2M 7AQ. The objectives of the charity are set out on [page 23].

Basis of preparation
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Solving Kids' Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policies.

The functional currency of the charity is considered to be pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling.

The amounts in the financial statements are presented to the nearest £, unless otherwise stated.

Preparation of the financial statements on a going concern basis
The financial statements of the charity have been prepared on the going concern basis. There are no material uncertainties about the charity's ability to continue. The trustees consider that the going concern basis is appropriate having considered a period of at least twelve months from approval of these financial statements. The trustees have prepared budgets and cash flow forecasts for that period which support the going concern assumption.

Fund accounting
Undesignated funds are available to spend on activities that further any of the purposes of charity.

Designated funds are funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose.

Restricted funds are donations which the donor has specified are to be solely used for particular restricted purposes within the objects of the charity.

Income
Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that those conditions will be fulfilled in the reporting period.

100% of any donation made to an individual appeal or journey is designated for the particular purpose of funding treatment not freely available on the NHS (prior year - 90% of any donation made to an individual appeal or journey was designated, with the remaining 10% retained within undesignated general funds.)

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income from Government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred. In respect of the Coronavirus Job Retention Scheme grant; all conditions, with respect to the eligible costs being claimed, need to be met.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due. This is normally upon notification by our investment advisor of the dividend yield of the investment portfolio.

Expenditure and irrecoverable VAT
Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis.

Expenditure is classified under the following activity headings:

- Costs of raising funds comprise the costs of attracting donations and fundraising.
- Expenditure on charitable activities includes the cost incurred by the charity in the delivery of activities and services for its beneficiaries.

Grants payable are payments made to third parties in the furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the grant. Grant awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include staff, premises, legal and professional, finance, depreciation and governance costs. These costs have been allocated between cost of raising funds and expenditure on charitable activities on the basis of an estimate of the proportion of time spent by staff on those activities.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Tangible fixed assets
Fixed assets are capitalised at cost and are depreciated over their estimated useful economic lives on a straight line basis as follows:
Equipment – 25% on straight line basis.

Fixed asset investments
Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. Fixed asset investments include long term deposits with maturity of more than 12 months from the date of acquisition or opening of the deposit or similar account.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

.

Notes to the financial statements Continued

Debtors
Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand
Current investments includes cash and short term deposits with a maturity of more than three months from the date of acquisition or opening of the deposit or similar account.

Current investments
Current investments includes cash and short term deposits with a maturity of more than three months from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions
Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably.

Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments
The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases
The charity classifies the lease of the office space as an operating lease as the title remains with the lessor. Rental charges are charged on a straight line basis over the term of the lease.

Pension costs
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Differences between contributions payable in the year and the contributions actually paid are shown as either accruals or prepayments on the balance sheet.

2. Donations

	Undesignated funds	Designated funds	Restricted funds	Total funds 2025
	£	£	£	£
Donations	**593,396**	**874,697**	**889,394**	**2,357,487**
Donated services	**36,860**	**-**	**-**	**36,860**
Government grants	**-**	**-**	**-**	**-**
	630,256	**874,697**	**889,394**	**2,394,347**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Donations	657,671	1,259,095	44,713	1,961,479
Donated services	48,500	-	-	48,500
Government grants	-	-	86,648	86,648
	706,171	1,259,095	131,361	2,096,627

The charity benefits greatly from the involvement and enthusiastic support of its many volunteers. In accordance with FRS 102 and Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the financial statements.

During the year, the charity received donated services relating to legal services and support for the Neuroblastoma Parent Global Symposium.
The value of these services to the charity is estimated at £36,860 and £nil respectively (2024: £38,500 and £10,000 respectively). The estimated value of these services is recognised within income as a donation with an equivalent expense through the Statement of Financial Activities.

Income from Government grants comprises grants received under the UK Government COVID Medical Research Charity Support Fund of £nil (2024: £86,648) to provide support to UK Research in funding. The charity has not benefited from any other kinds of government assistance during the current or prior year.

3. Other trading activities

	Undesignated funds	Designated funds	Restricted funds	Total funds 2025
	£	£	£	£
Fundraising events	**2,222**	**1**	**100**	**2,323**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Fundraising events	22,563	26,427	150	49,140

Notes to the financial statements Continued

4. Investment income

	Undesignated funds	Designated funds	Restricted funds	Total funds 2025
	£	£	£	£
Income from investments	**109,232**	**-**	**-**	**109,232**
Deposit account interest	**375,112**	**-**	**56,879**	**431,991**
	484,344	**-**	**56,879**	**541,223**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Income from investments	108,084	-	-	108,084
Deposit account interest	166,975	-	55,564	222,539
	275,059	-	55,564	330,623

5. Cost of raising funds

	Undesignated funds	Designated funds	Restricted funds	Total funds 2025
	£	£	£	£
Cost of raising funds	**233,315**	**6,406**	**9,420**	**249,141**
Support costs	**95,180**	**-**	**-**	**95,180**
	328,495	**6,406**	**9,420**	**344,321**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Cost of raising funds	215,334	17,207	1,053	233,594
Support costs	108,584	-	-	108,584
	323,918	17,207	1,053	342,178

6. Costs of charitable activities

	Activities undertaken directly	Grant funding activities	Support costs	Total funds 2025
	£	£	£	£
Support	**304,574**	**864,408**	**119,580**	**1,288,562**
Research	**140,062**	**134,552**	**99,925**	**374,539**
Awareness	**135,686**	**-**	**89,498**	**225,184**
	580,322	**998,960**	**309,003**	**1,888,285**

	Activities undertaken directly	Grant funding activities	Support costs	Total funds 2024
	£	£	£	£
Support	221,888	815,939	119,853	1,157,680
Research	153,089	1,262,051	92,022	1,507,162
Awareness	134,291	-	85,551	219,842
	509,268	2,077,990	297,426	2,884,684

Expenditure on charitable activities was £1,888,285 (2024: £2,884,684) of which £689,347 was undesignated (2024: £777,113), £747,842 was designated (2024: £1,972,911) and £451,096 was restricted (2024: £134,660).

Notes to the financial statements Continued

7. Analysis of support costs

Support costs are allocated based on the proportion of time spent by staff on those activities.

	Support	Research	Awareness	Fundraising activities	Total funds 2025
	£	£	£	£	£
Staff costs	**70,067**	**58,550**	**52,439**	**55,770**	**236,826**
Premises	**22,938**	**19,167**	**17,167**	**18,257**	**77,529**
Legal and professional	**6,641**	**5,549**	**4,970**	**5,286**	**22,446**
Finance costs	**1,680**	**1,404**	**1,258**	**1,338**	**5,680**
Depreciation	**808**	**675**	**604**	**643**	**2,730**
Governance costs	**17,446**	**14,580**	**13,060**	**13,886**	**58,972**
	119,580	**99,925**	**89,498**	**95,180**	**404,183**

	Support	Research	Awareness	Fundraising activities	Total funds 2024
	£	£	£	£	£
Staff costs	63,519	48,769	45,340	57,547	215,175
Premises	32,491	24,946	23,192	29,436	110,065
Legal and professional	3,458	2,655	2,468	3,133	11,714
Finance costs	774	594	552	701	2,621
Depreciation	1,773	1,362	1,266	1,606	6,007
Governance costs	17,838	13,696	12,733	16,160	60,427
	119,853	92,022	85,551	108,583	406,009

8. Governance costs

	2025	2024
	£	£
Auditor's remuneration	**13,824**	13,000
Legal and professional	**36,860**	39,828
Staff costs	**8,288**	7,599
	58,972	60,427

9. Analysis of grants

	2025	2024
	£	£
Children's treatment	**648,321**	639,537
Family support	**216,087**	176,402
Research		
University of Birmingham	**-**	626,321
University of Southampton	**-**	159,827
St Jude Hospital	**-**	469,129
Hospital Vall d'Hebron, Barcelona	**(42,625)**	-
Boston Children's Hospital	**(97,112)**	-
Neuroblastoma UK	**125,000**	-
Gustave Roussy Hospital, Paris	**75,894**	-
Children's Hospital of Philadelphia	**41,787**	-
University College London	**17,881**	-
Harvard University	**9,230**	-
REDMAPP	**2,600**	2,500
Other grants	**1,897**	4,274
	998,960	2,077,990

Children's treatment grants are made towards the medical costs of the children suffering from neuroblastoma. The grants are paid directly to the hospitals providing the treatment.

Family Support Grants are those made towards providing essential support services to families affected by high-risk childhood cancers. These grants are paid directly to affected families and organisations as appropriate or as directed.

Grants are made towards medical research for potential future life-saving treatments made possible through the constantly evolving world of burgeoning laboratory, pre-clinical and clinical research. These grants are paid directly to the institutions and are institutions working internationally which reflects the specialist and global nature of the research we fund.

When a grant has been awarded for research work that can now no longer be completed, the grant will be formally withdrawn, and funds previously committed will be released.

Notes to the financial statements Continued

10. Staff costs and emoluments

	2025	2024
	£	£
Wages and salaries	**741,558**	676,290
Social security costs	**60,178**	58,664
Pension costs – defined contribution	**26,848**	24,871
	828,584	759,825

Pension costs are allocated to activities in proportion to the related staffing costs and are allocated between undesignated, designated and restricted funds on the basis of each employee's activities.

The charity paid redundancy costs of £7,392 during the year (2024: £nil).

Particulars of employees: The average head count of employees during the year was 20 (2024: 19). The average number of full-time equivalent employees during the year is analysed as follows:

	2025	2024
	No.	No.
Charitable activities	**7**	8
Fundraising	**4**	3
Support	**4**	4
	15	15

The number of employees whose remuneration for the year fell within the following bands, were:

	2025	2024
	No.	No.
£60,000 to £69,999	**1**	1
£80,000 to £89,999	**1**	1

No higher paid staff were accruing benefits under a pension scheme (2024: None).

11. Net income Net income is stated after charging:

	2025	2024
	£	£
Auditor's remuneration		
Audit	**13,824**	13,000
Depreciation	**2,730**	6,007
Operating leases – offices	**1,580**	6,925

12. Tangible fixed assets

	Equipment
	£
Cost	
At 1 April 2024	**27,842**
Additions	**936**
At 31 March 2025	**28,778**
DEPRECIATION	
At 1 April 2024	**21,120**
Charge for the year	**2,730**
At 31 March 2025	**23,850**
NET BOOK VALUE	
At 31 March 2025	**4,928**
At 31 March 2024	**6,722**

Notes to the financial statements Continued

13. Investments

Analysis of investments as at 31 March 2025	Designated funds 2025	Designated funds 2024
	£	£
UK listed investments	**3,701,199**	3,865,164
Cash on deposit	**1,075,267**	-
	4,776,466	3,865,164

Movement in market value – UK listed investments	2025	2024
	£	£
Market Value at 1 April 2024	**3,865,164**	3,519,388
Net gain / (loss) on revaluation	**(163,965)**	345,776
Market value at 31 March 2025	**3,701,199**	3,865,164
Historical cost at 31 March 2025	**2,500,000**	2,500,000

All investments are carried at their fair value. Holdings in investment funds, unit trusts and open-ended investment companies are at the bid price. The basis of fair value for quoted investments is equivalent to the market value, using the bid price. Asset sales and purchases are recognised at the date of trade at cost (that is their transaction value).

The following investments were material in the context of the investment portfolio:

COIF Charities Ethical Investment Fund - £3,701,199 (2024: £3,865,164).

The main form of financial risk faced by the charity is that of volatility in investment markets due to wider economic conditions and variability of investment returns. This risk is mitigated by obtaining advice from a financial expert on the charity's investment portfolio.

14. Debtors

	2025	2024
	£	£
Other debtors	**8**	16,620
Prepayments and accrued income	**119,940**	211,401
	119,948	228,021

15. Creditors

Amounts falling due within a year	2025	2024
	£	£
Trade creditors	**2,695**	2,328
Accruals and deferred income	**372,657**	154,103
Grant commitments (note 17)	**440,822**	501,136
Funds held as agent (note 18)	**301,281**	548,058
	1,117,455	1,205,625

16. Creditors

Amounts falling due after more than one year	2025	2024
	£	£
Grant commitments (note 17)	**1,132,169**	1,381,866

Grant commitments of £nil are due in more than five years (2024: £153,976).

17. Grant commitments

	2025	2024
	£	£
Grant commitments brought forward	**1,883,002**	801,007
New commitments during the year	**274,289**	1,273,444
Reversal of unused commitments during the year	**(139,737)**	-
Payments made in the year	**(444,563)**	(191,449)
Grant commitments carried forward	**1,572,991**	1,883,002
Commitments at 31 March 2025 are payable as follows:		
Within one year	**440,822**	501,136
After more than one year	**1,132,169**	1,381,866
Grant commitments carried forward	**1,572,991**	1,883,002

Notes to the financial statements Continued

18. Funds held as agent

	2025	2024
	£	£
Funds held as agent brought forward	**548,058**	621,542
Funds received during the year	**155,505**	56,637
Funds transferred to SKC UK	**(195,122)**	-
Payments made	**(207,160)**	(130,121)
Funds held as agent carried forward	**301,281**	548,058

The charity has received funds as agent in its role as administrator of the Request for Applications (RFA) process and also of the research project for the prospective identification of children with "ultra-high-risk" (UHR) neuroblastoma.

The Merryn Lacy Trust and the charity Joining Against Cancer in Kids (J-A-C-K) have both been closed and their funds transferred to Solving Kids' Cancer UK. Therefore, funds held of £50,331 from The Merryn Lacy Trust and £144,791 from J-A-C-K have been transferred to Solving Kids' Cancer UK's grant commitments.

At the year end, the charity held £301,281 (2024: £548,058) and this has been included in creditors in Note 15. £301,281 was held on behalf of Zoe4Life (2024: £361,698), £nil on behalf of The Merryn Lacy Trust (2024: £143,292) and £nil on behalf of Joining Against Cancer in Kids (J-A-C-K) (2024: £43,068).

19. Commitments under operating leases

At 31 March 2025 the company had total minimum lease payments under non-cancellable operating leases as set out below.

Land and buildings	2025	2024
	£	£
Operating leases which expire:		
Within 1 year	-	1,484
Within 2 to 5 years	-	-
	-	1,484

20. Restricted funds

	Balance at 1 April 2024	Income	Expenditure	Transfers	Balance at 31 March 2025
	£	£	£	£	£
Families Against Neuroblastoma (FAN)	**872,988**	**43,445**	**(18,757)**	-	**897,676**
FAN Emergency Relapse Fund	**304,438**	**13,434**	-	-	**317,872**
CE Discretionary Fund	-	**500**	-	-	**500**
Restricted research funds	**42,018**	**125,728**	**(125,027)**	-	**42,719**
Other funds	**257,051**	**36,873**	**(4,083)**		**289,841**
Joining Against Cancer in Kids	**25,640**	-	-	-	**25,640**
Sunni Mae Fund	**84,365**	-	-	-	**84,365**
Merryn Lacy Fund	**100,570**	-	**43,188**	-	**143,758**
Lottery funding	**2,819**	**10,000**	**(12,819)**	-	-
Rupert's Revenge Trust Fund	**148,891**	-	-	-	**148,891**
ALADDIN	**7,160**	**49,862**	**(57,022)**	-	-
Isla Caton Fund	**209,306**	**63**	**(2)**	-	**209,367**
Ireland	**8,804**	-	-	-	**8,804**
MONALISA	-	**14,202**	**(14,202)**	-	-
Joining Against Cancer in Kids transfer fund	-	**525,266**	**(144,792)**	**143**	**380,617**
Parent Symposium Fund	-	**127,000**	**(127,000)**	-	-
	2,064,050	**946,373**	**(460,516)**	**143**	**2,550,050**

Notes to the financial statements Continued

20. Restricted funds (continued)

	Balance at 1 April 2023	Income	Expenditure	Transfers	Balance at 31 March 2024
	£	£	£	£	£
Families Against Neuroblastoma (FAN)	938,184	41,819	(35,965)	(71,050)	872,988
FAN Emergency Relapse Fund	290,693	13,745	(71,050)	71,050	304,438
HK Fund	5,919	-	(5,919)	-	-
CE Discretionary Fund	238	-	(238)	-	-
Restricted research funds	46,590	792	(5,364)	-	42,018
Other funds	150,634	117,479	(11,062)	-	257,051
Joining Against Cancer in Kids	27,180	-	(1,540)	-	25,640
Sunni Mae Fund	84,365	-	-	-	84,365
Merryn Lacy Fund	100,570	-	-	-	100,570
Lottery funding	6,139	-	(3,320)	-	2,819
Rupert's Revenge Trust Fund	148,169	735	(13)	-	148,891
ALADDIN	7,160	-	-	-	7,160
Isla Caton Fund	206,847	2,505	(46)	-	209,306
Ireland	-	10,000	(1,196)	-	8,804
	2,012,688	187,075	(135,713)	-	2,064,050

Restricted funds can only be used for particular restricted purposes within the objects of the charity as specified by the donor or when funds are raised for particular restricted purposes.

Families Against Neuroblastoma (FAN)/ FAN Emergency Relapse Fund There are 9 funds transferred from Families Against Neuroblastoma (FAN) and held for the sole use of individual children for access to treatment and welfare / pastoral issues. Treatments are limited to those that are consistent with Solving Kids' Cancer UK Clinical Trial Policy.

A further two donations from FAN were received to be used solely to support children with relapsed neuroblastoma with no access to other funds to pay for treatment that is not freely available on the NHS.

CE Discretionary Fund was established through an individual donation made to the charity to provide the Chief Executive with a means to fund initiatives in support of the effective working of the organisation, but for which no other budget existed.

Restricted research funds is a restricted fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research.

Other Funds represent funds created by families in memoriam specifically for research and advocacy projects.

Joining Against Cancer in Kids is a restricted fund which has been provided by Joining Against Cancer in Kids to support the costs incurred by families when participating in neuroblastoma trials/treatment being conducted at The Memorial Sloan Kettering Cancer Centre, New York or Hospital Saint Joan de Déu Barcelona.

Sunni Mae Fund is restricted to support the development and operational running of a Solving Kids' Cancer UK's presence in Ireland and / or provide wider support to Irish families affected by Neuroblastoma. Alternatively, the fund can be used to support a future research funding call in which The Sunni Mae Trust will be acknowledged as a named collaborative funding partner.

Merryn Lacy Fund represents funds donated by the trust which are restricted to Research.

Lottery funding represents a National Lottery Awards For All grant restricted to our family support Life after Cancer Programme.

Rupert's Revenge Trust Fund represents restricted funds for Research

ALADDIN represents a European funding grant for the delivery of a multi-stakeholder educational programme on regulatory science in paediatric cancer drug development.

Isla Caton Fund represents funds transferred and raised for pioneering research in memory of beautiful Isla who loved to sing and dance.

Ireland represented funds provided to the charity from a donor specifically to support the registration of the charity in Ireland to enable wider support of families in Ireland.

MONALISA represents a European funding grant which reimburses Solving Kids' Cancer UK for staff time and expenses incurred in a patient advocate role.

Joining Against Cancer in Kids Transfer Fund is restricted to vital investment in neuroblastoma research and support for families.

Parent Symposium Fund consists of donations expressly restricted for the purpose of supporting the Neuroblastoma Parent Symposium held in March 2025.

Notes to the financial statements Continued

21. Designated funds

	Balance at 1 April 2024	Income	Expenditure	Transfers	Net losses on investments	Other gains and losses	Balance at 31 March 2025
	£	£	£	£	£	£	£
Designated Funds	**7,825,789**	**861,674**	**(817,507)**	**(610,265)**	**-**	**-**	**7,259,691**
Solving Kids' Cancer Children's Reserve Fund	**601,157**	**-**	**(41,474)**	**79,642**	**-**	**-**	**639,325**
Solving Kids' Cancer Research Fund	**183,912**	**13,024**	**104,733**	**414,957**	**-**	**3,833**	**720,459**
Family Support Fund	**1,399**	**-**	**-**	**(1,399)**	**-**	**-**	**-**
Covid-19 Fund	**143**	**-**	**-**	**(143)**	**-**	**-**	**-**
Big Love and pastoral Funds	**18,963**	**-**	**-**	**(18,963)**	**-**	**-**	**-**
Investment Reserve	**1,365,164**	**-**	**-**	**-**	**(163,965)**	**-**	**1,201,199**
	9,996,527	**874,698**	**(754,248)**	**(136,171)**	**(163,965)**	**3,833**	**9,820,674**

21. Designated funds Continued

	Balance at 1 April 2023	Income	Expenditure	Transfers	Net gains on investments	Other gains and losses	Balance at 31 March 2024
	£	£	£	£	£	£	£
Designated Funds	7,385,497	1,196,884	(671,965)	(84,627)	-	-	7,825,789
Solving Kids' Cancer Children's Reserve Fund	619,431	-	(26,737)	8,463	-	-	601,157
Solving Kids' Cancer Research Fund	1,310,972	88,300	(1,277,757)	59,238	-	3,159	183,912
Family Support Fund	1,399	-	-	-	-	-	1,399
Covid-19 Fund	143	-	-	-	-	,-	143
Big Love and pastoral Funds	23,821	338	(13,659)	8,463	-	-	18,963
Investment Reserve	1,019,388	-	-	-	345,776	-	1,365,164
	10,360,651	1,285,522	(1,990,118)	(8,463)	345,776	3,159	9,996,527

Designated funds are funds which have been allocated by the trustees out of undesignated general funds to specific appeals for the treatment of children with neuroblastoma. In the event of a child's death, the funds will be released from designated funds. Following the end of a successful course of treatment, and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of 5 years so that they are available for that child should they suffer a relapse and require further treatment, a situation which is common for neuroblastoma patients. During the year, this policy resulted in transfers of £592,795 (2024: £84,627) with 70% transferred to the designated Solving Kids' Cancer Research Fund, 10% to the designated Solving Kids' Cancer Children's Reserve Fund and 20% to undesignated reserves. An additional £17,470 of non-child specific designated reserves were transferred to undesignated reserves

Solving Kids' Cancer Children's Reserve Fund is money designated to;
(1) support families who are fundraising for treatment who may require additional financial support to be able to meet the deadlines for enrolment on a particular clinical trial, and

(2) support children who are receiving treatment abroad but for whom additional unanticipated medical expenses are incurred. During the year £79,642 was transferred from Designated funds (2024: £8,463).
(3) provide pastoral funding to families through SKC UK grant programmes (currently would include Big Love Fund and Clinical Trial travel).
(4) Any spend specifically approved by the Board which directly benefits families looking to access treatment.

Solving Kids' Cancer Research Fund is a designated fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research. During the year, £414,957 was transferred from Designated Funds (2024: £59,238).

Family Support Fund is designated to the activities of the family support team. During the year £1,399 (2024: £nil) was transferred to the Solving Kids' Cancer Children's Reserve Fund.

COVID-19 fund is designated to the granting of funds to families of children with Neuroblastoma who have suffered a loss of income or increase in costs as a result of the diagnosis. It is initially for those affected by the need to shield during COVID-19. £143 was transferred to the J-A-C-K restricted fund during the year.

Big Love and pastoral Funds is designated to the granting of pastoral funds to support a child or young person's physical or emotional welfare and to support families in bereavement. During the year £nil was transferred from Designated funds (2024: £8,463) and £18,963 (2024: £nil) was transferred to the Solving Kids' Cancer Children's Reserve Fund.

Investment Reserve represents the movement in fair value on investments since acquisition.

22. Undesignated funds

	Balance at 1 April 2024	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2025
	£	£	£	£	£	£
Undesignated funds	**848,659**	**1,116,822**	**(1,017,842)**	**136,028**	**(14,958)**	**1,068,709**

	Balance at 1 April 2023	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2024
	£	£	£	£	£	£
Undesignated funds	959,981	1,003,793	(1,101,031)	8,463	(22,547)	848,659

23. Analysis of net assets between funds

Fund balances at 31 March 2025 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2025
	£	£	£	£
Tangible fixed assets	**4,928**	-	-	**4,928**
Investments	-	**4,776,466**	-	**4,776,466**
Cash at bank and in hand	**1,378,930**	**1,385,223**	**2,850,099**	**5,614,252**
Current investments	-	**5,173,463**	-	**5,173,463**
Other net current (liabilities)/assets	**(315,149)**	**(520,704)**	**(161,654)**	**(997,507)**
Creditors falling due in more than one year	-	**(993,774)**	**(138,395)**	**(1,132,169)**
	1,068,709	**9,820,674**	**2,550,050**	**13,439,433**

Fund balances at 31 March 2024 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Tangible fixed assets	6,722	-	-	6,722
Investments	-	3,865,164	-	3,865,164
Cash at bank and in hand	1,289,255	7,868,586	2,238,979	11,396,820
Other net current (liabilities)/assets	(447,318)	(432,352)	(97,934)	(977,604)
Creditors falling due in more than one year	-	(1,304,871)	(76,995)	(1,381,866)
	848,659	9,996,527	2,064,050	12,909,236

24. Company limited by guarantee

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is £10.

25. Taxation

The charity is exempt from tax on income and gains to the extent that these are applied to its charitable objects.

Notes to the financial statements Continued

26. Related party transactions

The key management personnel of the charity for the year comprised the trustees, Chief Executive and the Heads of Departments. The total employee benefits of the key management personnel were £392,937 (2024: £382,764).

The trustees did not receive any remuneration or other benefits during the year (2024: £nil). Two trustees received reimbursement of expenses during the year of £1,216 relating to travel and subsistence (2024: one trustee, £569).

During the year, the charity paid £nil (2024: £600) to Yassine Rhardoud, the husband of member of key management Claire Hislop, for moving and refurbishment costs associated with the move to the new office.

The total donations received from 3 trustees (2024: 2) during the year amounted to £990 (2024: £2,688).

27. Financial instruments

Financial assets measured at fair value through statement of financial activities:

	2025	2024
	£	£
Investments	**3,701,199**	3,865,164

The income, expense, gains and losses in respect of all financial instruments are summarised below:

	2025	2024
	£	£
Net gain / (loss) on revaluation of investments	**(163,965)**	345,776
Investment income	**109,232**	108,084

For further details about risks arising from financial instruments and the measurement basis see note 13.

28. Analysis of changes in debt

	At 1 April 2024	**Cash flows**	**At 31 March 2025**
	£	**£**	**£**
Net cash			
Cash at bank and in hand	**9,303,453**	**(7,002,475)**	**2,300,978**
Cash equivalents	**2,093,367**	**1,219,907**	**3,313,274**
	11,396,820	**(5,782,568)**	**5,614,252**

28. Analysis of changes in debt Continued

	At 1 April 2023	**Cash flows**	**At 31 March 2024**
		£	**£**
Net Cash			
Cash at bank and in hand	9,292,711	10,742	9,303,453
Cash equivalents	1,991,768	101,599	2,093,367
	11,284,479	112,341	11,396,820

29. Comparatives for the statement of financial activities

	Undesignated funds	**Designated funds**	**Restricted funds**	**Total funds 2024**
	£	**£**	**£**	**£**
INCOME			-	
Donations	706,171	1,259,095	131,361	2,096,627
Trading activities	22,563	26,427	150	49,140
Investment income	275,059	-	55,564	330,623
TOTAL INCOME	**1,003,793**	**1,285,522**	**187,075**	**2,476,390**
EXPENDITURE				
Raising funds	(323,918)	(17,207)	(1,053)	(342,178)
Charitable activities	(777,113)	(1,972,911)	(134,660)	(2,884,684)
TOTAL EXPENDITURE	**(1,101,031)**	**(1,990,118)**	**(135,713)**	**(3,226,862)**
NET (EXPENDITURE) / INCOME BEFORE GAINS ON INVESTMENTS	(97,238)	(704,596)	51,362	(750,472)
Net gains on investments	–	345,776	–	345,776
Other (losses) / gains	(22,547)	3,159	–	(19,388)
NET (EXPENDITURE) / INCOME	(119,785)	(355,661)	51,362	(424,084)
Transfer between funds	8,463	(8,463)	–	–
NET MOVEMENT IN FUNDS	(111,322)	(364,124)	51,362	(424,084)
RECONCILIATION OF FUNDS				
Total funds brought forward	959,981	10,360,651	2,012,688	13,333,320
TOTAL FUNDS CARRIED FORWARD	**848,659**	**9,996,527**	**2,064,050**	**12,909,236**

Thank You

We want to say a heartfelt thanks to the following companies, people, charities, foundations and trusts for their wonderful support.

Companies

A&O Shearman
Brandler Galleries
Burnt Peach
DHL
EasyJet
Eton House School
Flix Interactive
Google
Irish Solicitors Bar Association
Julius Baer International Ltd
Keel Toys
Laser Quest
Lioncroft Foundation
Miniclip
Norgine
Privacy Culture Limited
Recordati Rare Diseases
Ritter Sport
Scamp and Dude
Sharp IT
Sumo Digital
Sumo Group PLC
United Therapeutics
Workspace
Y-mAbs Therapeutics Inc.

Patron & champions

Carl Cavers OBE (to September 2024, when appointed as Trustee)
Demie Risby
Kellie Bright
Rob Brydon

Parent Involvement forum

Carrie Wright
Catherine Morais
Claire Bailey
Claire Donnelly
Debbie O'Kelly
Garrett Fitzgerald
Kate Dixon
Leeanne Brennan
Mandy Berriman
Mark Bell
Naomi Bentham
Naomi Shefford-Thomas
Sam Anstey
Stewart Leaver

Development Board (founded in 2025)

Abigail Solieri
Carl Cavers OBE
Cassie Leaver
Garrett Fitzgerald
Marina Nikoloska
Padmesh Thuraisingham
Patrick Harney

Individuals

Adam Webb
Adelaide Lane
Dr Aditi Vedi
Alan Hooks
Alan Pearson
Dr Assunta Albanese
Becky Parris
Cameron Miller
Charlotte Wint
Chris Lee
Christina Haralambous
Clare and Chris Andrew
Clare Hayles
Cliona O'Tuama
Clive Jones MP
Cormac Owens
Darren Mills
Dr Ella Henderson
Emma Potter
Evie Baldwin
Fabio Benidio
Dr Francesca del Bufalo
Gavin Lindberg
Georgina Arquati
Graham Cooper
Grace White
Dr Gudrun Schleiermacher
Hannah Cohen
Helen Duffy
Iulia Thuraisingham
Jason Newell
Jason Pickering
Prof John Anderson
Katie Andrew
Kato Kossaridou
Prof Kelly Goldsmith
Kevin Doyle
Kim Leadbeater MP
Kira Noble
Lauren Stebbing
Libby Marks
Prof Lieve Tytgat
Liliana Jackson
Louis Moorhouse
Louise Bellamy
Dr Lynley Marshall
Maddy Meeson
Mark Ferguson MP
Mike Ashmore
Mike Zatyka
Molly Treves
Monique King
Natalie Cassidy
Dr Naureen Rizvi
Nick Streeter
Nicholas Jackson
Prof Pamela Kearns
Dr Paula Adkin
Pippa Collins
Polly Ord
Dr Ramya Ramanujachar
Richard Hage
Robson O'Reardon
Dr Rochelle Bagatell
Ruben Hage
Dr Sally George
Dr Scott Arthur MP
Shirley Hepworth
Tom Becker
Tom Donegan
Tony Colville

Charities, foundations & trusts

Anti Cancer Fund
Band of Parents
Cancer Awareness Trust / Cancer Platform
Children with Cancer UK
The Evan Foundation
GamesAid
The Hospital Saturday Fund
Joseph's Smile
Jude and the Book Factory
Kindred Foundation
Life After Cancer
National Lottery Community Fund
Neuroblastoma UK
Rupert's Revenge
Solving Kids' Cancer US
SpecialEffect
St. George's Society of New York
We Can Kick It
Zoe4Life

Family & named funds

ForeverSIX Fund
Hannah's Heroes Fund
J-A-C-K Fund
Kitty Belle's Fund
Oscar Knox Fund
Poppy's Hope and Happiness Fund
Smiles for Stanley Fund
The Alfie's Wishes Fund
The Isla Caton Fund

Hero Awards 2024 recipients

Arron and Lucy Mellon-Jameson, Jude and the Book Factory
Emma Rees and Katy Yeandle, Joseph's Smile
Helen Pearson
Jenna Pentney, Natalie Cassidy and Rachel Wells and Tessa Farmer
Rebekah Chance
Dr Sam Behjati
Sarah Garratt

Scientific Advisory Board members

Prof Andy Pearson (Chair)
Dr John Maris (Vice-Chair)
Dr Julia Glade-Bender
Dr Julie Park
Dr Juliet Gray
Dr Lucas Moreno
Dr Meredith Irwin
Prof Michel Zwaan
Dr Steve Dubois

Solving Kids' Cancer UK

We need your help...

Solving Kids' Cancer UK is a registered charity. We receive very little public funding for our work. Thanks to supporters and philanthropic partnerships, we've made progress over the years. But there is still so much more to do to ensure a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.

The support you give will make a difference to the lives of children and families affected by childhood cancer. For more information on how you can support and to donate:

Visit: solvingkidscancer.org.uk
Call: 020 7284 0800
Email: fundraising@solvingkidscancer.org.uk

Or donate directly here:

Solving Kids' Cancer UK is a registered charity in England and Wales (1135601) and in Scotland (SC045094). It is a company limited by guarantee in England and Wales (7208648). The charity and company currently operate as Solving Kids' Cancer UK.

Solving Kids' Cancer UK
Unit 02-03, Salisbury House, 29 Finsbury Circus, London EC2M 7AQ
Email: info@solvingkidscancer.org.uk
Telephone: 020 7284 0800

@SKC_UK
SolvingKidsCancer365
skc365
Solving Kids' Cancer UK
skcuk.bsky.social

Registered with FUNDRAISING REGULATOR

Solving Kids' Cancer UK

England & Wales - Charity number 1135601

Accounts

Solving Kids' Cancer UK



Annual Report & Accounts 2023/2024



Alec

WHO'S ON OUR COVER?
At just 19 weeks old, Alec was diagnosed with intermediate risk neuroblastoma. After four rounds of chemotherapy and surgery to remove his primary tumour Alec had no evidence of disease in February 2017.

Alec has struggled with late effects caused by treatment, 3 corrective surgeries with one more due and Horner Syndrome which has affected his temperature control from the nerve damage, muscle weakness and trauma.

In May 2024 Alec celebrated being in remission for over seven years.

Our vision

Solving Kids' Cancer UK's vision is a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.

Our mission

Helping those affected by neuroblastoma, an often aggressive and deadly childhood cancer, by:

- Initiating and funding best-in-class clinical research
- Providing hope, information and support to families throughout their cancer journey
- Raising awareness of childhood cancer, advocating and campaigning for positive change.

Contents

03 Our year
04 Introduction from our Chair of Trustees
06 Welcome from our Chief Executive Officer
08 Strategic Plan 2022-2027
10 Research
12 Support
14 Awareness
16 Your support
19 Events
20 Achievements & performance 2023-24
22 Future plans
23 Structure, governance & management
26 Our legal & administrative details
27 Our finances
32 Independent auditor's report
35 Financial statements and notes
60 Thank you

Our year





Every two weeks a child in the UK with neuroblastoma dies. Help us to change this outcome.

We are a small but mighty parent-led charity with children firmly at our heart. We are striving for better outcomes for children and families affected by neuroblastoma, both now and in the future. In every conversation, we amplify their voice and ensure their needs are at the heart of all we do.

We will not stop until children with neuroblastoma, in the UK and beyond, have access to the treatments they need, when they need it, as close to home as possible.

Over the last year, we have:

- Delivered the second year of our ambitious strategy, introducing our new brand and strengthening our networks and infrastructure.
- Launched our public affairs strategy through the Unlocking Hope campaign.
- Extended funding for the MiNivAn clinical trial, maintaining treatment options for children in the UK and funded a new molecular radiotherapy trial to open afterwards (MINT) for children who currently have no well-defined therapeutic options.
- Welcomed over 360 participants from 29 countries to our fourth Neuroblastoma Parent Global Symposium, including a new psychosocial programme of seminars and peer support sessions.
- Delivered our first co-facilitated post treatment and bereavement coaching programmes alongside Life After Cancer and devised and began to roll out our first SKC-run coaching programme for parents.
- Reached more families of children diagnosed with neuroblastoma at an earlier point, providing 47 Big Love Fund grants to families and 49 Care & Connect Support Bags to children.
- We were supported by some amazing partners, individuals and organisations to enable events including our Carol Concert, our charity film premiere, the ISBA Solicitors Ball and in partnership with SpecialEffect the wonderful British Racing Greats event.
- Funded five Research Grants including concluding the $2m ACTION grant call for an innovative approach to accelerating clinical trials and evaluating novel therapies, renewed our Senior Neuroblastoma Clinical Trials Coordinator role at the Clinical Trials Unit in Birmingham and supported the BIOPORTAL project to improve neuroblastoma understanding.

Welcome

Introduction from our Chair of Trustees

Welcome to our annual report for 2023/24, showcasing Solving Kids' Cancer UK's unwavering commitment to children and families affected by neuroblastoma. In these pages you'll read about the work we've been doing over the past twelve months to directly improve the lives of children with neuroblastoma and their families and learn more about our aims for the forthcoming year.

Our efforts are guided by our strategy, as outlined on pages 8 and 9, with impact measured by how effectively we deliver against objectives in our three strategic pillars. We serve the needs of individual children through our unique support service, and work on behalf of all children in our research, advocacy and awareness initiatives. Central to such endeavours is our newly-developed policy and public affairs work, which is gathering momentum as we address the barriers holding back delivery of clinical trials for children with cancer in the UK that are critical to improving survival and quality of life.

Underpinning everything Solving Kids' Cancer UK does is governance, finance, operations, and fundraising. Areas often less visible, but nonetheless vital to ensuring effective delivery of services in support of our mission.

Our Trustees are committed volunteers dedicating their time to set strategic direction, provide governance and oversight of all activities, and assess performance against aims and objectives. The Board's role is to provide the best possible stewardship to maintain the charity's continued good health and sustainability. I'm delighted we've appointed several new Trustees to join us over the coming year, to bring new skills and fresh perspectives.

Finance and operations are critical to the smooth running of the organisation and play a pivotal role in delivering for children and families. An example being our research collaborations with multiple funding partners and participating research institutions, requiring expert management of agreements and money flows without which we simply couldn't fund clinical trials for children.

Similarly, in 2025 we plan to hold our first in-person conference since 2019. This will be a hybrid event to maintain the reach of our virtual symposium while allowing families who can attend to benefit from the unique peer support provided by such a setting.

Ultimately, everything the charity seeks to achieve depends on our fundraising efforts, and on the generosity of those who support us. The landscape remains a challenging one. There is no shortage of worthy charities, including those with links to neuroblastoma. Solving Kids' Cancer UK belongs to the community it serves, and our primary task is to deliver for children and families. But we must also translate that delivery into ongoing and increased support. We're incredibly grateful to everyone who helped us over the last year; our corporate partners, patrons, donors, supporters and all who volunteered their time. Our hope for a better future for every child with neuroblastoma drives us forward. It is only through your support that we can turn that hope into reality.

Nick Bird
Chair of the Board of Trustees



NICK BIRD



Accelerating research. Driving change. Unlocking hope for children with cancer.

Welcome from our Chief Executive Officer

As we close the chapter on another busy year at Solving Kids' Cancer UK, I am proud to share this year's Annual Report with you and showcase the impact we've made together.

Our research initiatives have seen groundbreaking advancements. We successfully concluded the ACTION grant call, bringing together international partners to award a $2 million grant for an innovative approach to accelerating clinical trials and evaluating novel therapies. We renewed funding for the Senior Neuroblastoma Clinical Trials Coordinator at the Clinical Trials Unit in Birmingham. This role has been pivotal in accelerating neuroblastoma trials availability for children. Extending funding for the MiNivAn clinical trial and supporting the BIOPORTAL project to improve neuroblastoma understanding are significant strides in our quest to find better treatments. These efforts are not just milestones; they represent hope and new possibilities for children who currently have limited treatment options.

Support for families remains at the heart of our mission. This year, we delivered our first post-treatment and bereavement coaching programmes and provided crucial pastoral grants and Care and Connect Bags to families in need. Our Neuroblastoma Parent Global Symposium introduced a new psychosocial programme, offering seminars and peer support that empower families and survivors. The stories shared on our new "Stories of Hope" page are a testament to the strength and resilience of those we support.

Our advocacy efforts have gained momentum with the launch of the Unlocking Hope campaign, which has significantly increased our presence in Westminster and Parliament. We continue to lead in research advocacy, working with clinical trial steering groups and international research networks to push for advancements in paediatric cancer treatment options.

We are proud of the growth in public support and awareness. Our new charity brand film, launched at the iconic Mayfair Hotel, has helped raise awareness and attract new supporters. Events like the British Racing Greats fundraiser and our Christmas Carol Concert brought our community together, showcasing the incredible spirit of our supporters.

Behind these achievements is a robust infrastructure and dedicated governance. We launched a new website, enhanced our Customer Relationship Management (CRM) system, and moved into new office premises, thanks to corporate support.

None of this would be possible without the tireless efforts of our supporters. Whether running, canoeing, head-shaving, or carol singing, every effort makes a profound difference. Special thanks to our Patron, Carl Cavers, and the Sumo Group team for their unwavering support and a huge welcome to new celebrity Patron, Kellie Bright.

As we look to the future, we are inspired by the children and families we serve and motivated by the generosity of our supporters. We remain steadfast in our mission: to see a world where no child dies from neuroblastoma or suffers due to the treatment they receive. With your continued support, we will make this vision a reality.

Thank you for being a part of our journey.

Gail Jackson
Chief Executive Officer



Our impact

£5.2 million invested in childhood cancer clinical trial development.



Supported more than **1,000 families** affected by neuroblastoma.



Supported over **55 families** to access **life saving treatments** and clinical trials in the UK and abroad.

Facilitated a **landmark collaboration** between the Children's Oncology Group in North America and the SIOPEN research network in Europe.

Formally challenged the decision by the National Institute for Health and Care Excellence not to approve anti-GD2 immunotherapy for children with neuroblastoma in the UK, paving the way for it to become part of frontline treatment.

Funded first ever **dedicated** neuroblastoma **Clinical Trials Coordinator** In the UK.



Hosted the award-winning Neuroblastoma Parent Global Symposium, welcoming more than **1,660 participants** from over **50 countries.**



Co-authored **the first paediatric oncology advocate-only manuscript** to be published in the esteemed Journal of Clinical Oncology.

Solving Kids' Cancer UK

Strategic plan 2022-2027

We are fighting for a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive

Our strategy

To underpin the delivery of our five-year strategy, our work will be guided by an internal implementation plan centred around three key enablers and a clear focus on our vision and values.

Sustainable
We will ensure our charity remains financially robust to deliver against our strategic objectives, securing the funds required.

Good governance
We will continue to build a strong culture of compliance, transparency and continuous improvement at all levels of the organisation.

Impact
We will measure and showcase the impact of our work and demonstrate return on investment to our supporters.

Our values

Caring

We care passionately about children with neuroblastoma, their families, and all those who care for them, including our staff, volunteers and supporters.

Transparent

We are open and honest about all that we do and how we do it.

Collaborative

Relationships are at the heart of our work – from the children and families we work with, to the individuals, organisations and networks that are involved in their care.

Inclusive

Our services are developed to ensure they meet needs and we aim to make them accessible to all.

Determined

We lead with tenacity and are unfaltering in our drive to help, support and fight for children with cancer.

Hopeful

We have a strong sense of optimism and hope is at the heart of all that we do.

Our three pillars





Our work is driven by three key pillars

Research

Accelerate clinical trial development

We will focus on the development of new treatments by investing in clinical research and working with valued partners for maximum impact.

Prioritise the needs of children

We will engage with families to identify areas of unmet need, challenging experts to find solutions and work together to deliver maximum impact through the research we fund.

Foster collaboration

We will build and strengthen international partnerships to share expertise, best practice and resource, whilst building knowledge.

Support

Reach ALL families

Every family of a child diagnosed with neuroblastoma in the UK will have access to our support service from the point of diagnosis.

Broaden range of support

We will develop and expand our support offer in line with what families tell us they need.

Inform and support decision-making

We will ensure families have access to the most current and scientifically robust data from around the world and support their decision to access the best treatment possible.

Awareness

Research advocacy

We will amplify the voice of the children and parents, seeking to advance science and understanding of the disease alongside patient-centric research.

Patient advocacy

We will champion the needs of individual children and their families, providing parent-led support around decision-making to improve treatment outcomes.

Awareness and campaigning

We will raise the profile and support the treatment needs of children with neuroblastoma and other childhood cancers with the general public, government and public bodies.

Solving Kids' Cancer UK Research





We drive and invest in pioneering clinical research, focused on finding treatments that are more effective and less toxic.

Our research mission is led by parents of children affected by neuroblastoma alongside our expert Scientific Advisory Board, ensuring we are focusing on unmet needs and investing in the most cutting-edge research to increase the UK's clinical trial footprint, allowing more children to access innovative therapies closer to home. This is an urgent and vital need, as neuroblastoma remains one of the leading causes of death from cancer in children.

2023/24 summary

Funding Boost to Help Clinical Trial Delivery
In January 2024, we renewed funding for the Senior Neuroblastoma Clinical Trials Coordinator at the Cancer Research Clinical Trials Unit in Birmingham. Initially funded in 2018, this role has been pivotal in accelerating neuroblastoma trials availability for children, enabling new trials to begin setup even before funding is secured, by supporting with grant applications and development of documentation for regulatory submission and trial setup. The partnership has enhanced our understanding of the trial landscape, informing our new External Affairs Strategy to expedite clinical trials for childhood cancer in the UK. Extending the funding for a further three years ensures the continuation of vital work to advance neuroblastoma trials, critical to improving treatments for children.

Extending Hope for Families
The MiNivAn trial, funded by Solving Kids' Cancer UK and partner organisations since 2018, is an international study testing a combination of immunotherapy and specialised radiotherapy for high-risk neuroblastoma that has recurred or resisted standard treatments. Led by Dr Juliet Gray at University Hospital Southampton, the trial met its recruitment target by the end of 2023, benefiting numerous children in the UK. Early analysis shows some encouraging responses, although further data is needed to fully assess treatment effectiveness. Given the limited options for relapsed and refractory high-risk neuroblastoma, the MiNivAn trial offers families a crucial opportunity to access innovative therapies for their children. In recognition of its importance, Solving Kids' Cancer UK and partner organisations have committed an additional £295,207 to extend the trial, to enable a better understanding of treatment effectiveness and how best to develop it further. To ensure the continuation of these promising findings, we have funded a further trial investigating specialised radiotherapy, led by Drs Sally George and Daniel Morgenstern, which aims to open in the UK and Canada in 2025.

Ambitious New Plan for Transatlantic Clinical Trials
The ACTION Consortium, a collective force of five non-profits brought together by Solving Kids' Cancer UK (SKC) and dedicated to Advancing Clinical Trial Implementation and Optimisation in Neuroblastoma, has concluded its first grant call. A high-caliber proposal has been selected to receive $2 million for an innovative approach to accelerating clinical trials and evaluating novel therapies. The winning application unites a distinguished team of neuroblastoma clinicians and translational researchers to address the urgent need for a multinational, intercontinental network for early-phase clinical trials, integrating biological data with clinical outcomes. This collaboration paves the way for addressing rare patient groups defined by biological features in future studies. The potential impact on the field, and most importantly, for children with neuroblastoma, could be profound.



Kayla was diagnosed with high-risk neuroblastoma in May 2021, when she was three years old. This began when Kayla experienced ongoing pain in her legs, which led the family to A&E where multiple investigative scans confirmed their worst fears, Kayla had cancer.

In the months after her diagnosis, Kayla bravely took on the grueling treatment, involving chemotherapy, surgery, stem cell transplant, radiotherapy and immunotherapy. Despite this, her family was devastated when scans in November 2022 showed the cancer had progressed. With limited options available at this stage, Kayla was put on a new treatment plan to manage her disease as best as possible.

At the start of 2024, thanks to the funding extension for the MiNivAn trial at University Hospital Southampton, Kayla was able to access a novel combination of therapies to try and treat her disease. The MiNivAn study is an innovative trial that is investigating a new combination of immunotherapy and specialised radiotherapy. Kayla is one of the children who will benefit from the trial extension, giving her and her family the all-important hope that they need.

"Trials are so important for these children. There really aren't enough trials out there unfortunately, so options can become very limited. We are so very lucky that this is available." - Stacey, Kayla's mum.

Advocacy in Action at the Advances in Neuroblastoma Research Congress
In May 2023, we were proud to be a Gold Sponsor of the Advances in Neuroblastoma Research (ANR) conference in Amsterdam, in partnership with our friends at Solving Kids' Cancer US. This biennial event was an opportunity for the global neuroblastoma research community to come together, share knowledge, exchange ideas, establish new partnerships and generate new hypotheses.

For the first time in the history of the conference, advocates were invited to be part of the main agenda, a recognition of the important perspective they bring to the table and tenacious work done to build relationships with the scientific and medical community. We were proud to see our Chair of Board of Trustees, Nick Bird, share his views on the role of advocates in improving the survival of children with neuroblastoma.

We also hosted a patient advocate-led symposium to stimulate discussions on moving the field forward to improve outcomes for all children with high-risk neuroblastoma. This included articulating a vision for neuroblastoma therapy extending beyond what is right around the corner and considering the paradigm shifts that are needed to turn a broad vision into reality. A manuscript is in preparation summarising the themes of the discussion.

2024/25 goals

- Support the launch of new clinical trials TACTIC and MINT to improve access to novel therapies for children with neuroblastoma.
- Refine our research strategy based on experience to date and ensuring optimal value for money.
- Host a scientific meeting alongside an in-person/ hybrid parent conference to further strategic research goals.
- Deliver patient-partner commitments in European grants, amplifying the voice of children (ALADDIN, MONALISA).
- Build on existing collaborative partnerships to fund and advance research benefiting children with neuroblastoma.

Solving Kids' Cancer UK
Support





A diagnosis of neuroblastoma can be overwhelming and life-changing for the entire family. Our unique Family Support Service is dedicated to the neuroblastoma patient and parent community in the UK. The team blends personal experience and acquired knowledge, as parents of children affected by neuroblastoma, with professional skills and experience.

We carefully tailor the support given based on the bespoke needs of the family to help ease practical, financial and emotional burdens and pressures that a neuroblastoma diagnosis brings. We also help to expertly guide families through often difficult, complex and fraught decision-making processes.

Our service is built upon hope and places children at the heart of all we do. It focusses on the here and now, easing the immediate burdens and pressures that a neuroblastoma diagnosis brings.

2023/24 summary

Coaching programme
This year we undertook the pilot Post Treatment and Bereavement Coaching Programmes with Life After Cancer and all those that took part said it had a positive impact on their wellbeing.

Solving Kids' Cancer provides support once you have finished treatment that is 100% tailored to your experience as a neuroblastoma parent. Doing their workshop meant I could meet other parents and explore my own identify after being a mum of a child who had cancer for 2 years. We spoke about things like fear of relapse and finding purpose and it made me feel much less alone. It's amazing that SKC continue to support parents and recognise that ending treatment is a really difficult time and not the "relief" that many think it is." Parent attendee.

Now, with in-house trained coaches we are preparing to launch our SKC coaching programme. The aim is to ensure that as many parents as possible have access, if they wish, to this support – either in post treatment or bereavement.

Care and Connect Bags
This year, the Care and Connect Family Support Bags have directly supported 49 families and their children in their time of need. For some, this is their first point of contact with our charity.

"The Care and Connect bag was such a lovely gesture and really made us smile during a difficult time. It made us feel like people were looking out for us and supporting us. The items in the bag were really practical and useful but also really great quality so it felt like a special treat to use them. We were so grateful for the bag, as a family it really perked us up to receive the bag and see all the goodies inside." Neuroblastoma family.

Big Love Fund
During 2023/24, we have awarded 47 grants through the Big Love Fund – this includes families in bereavement.

Neuroblastoma Parent Global Symposium
We were so proud to deliver a new psycho-social programme of seminars and interactive sessions at our Neuroblastoma Parents Global Symposium. Themes around supportive care were discussed, with an emphasis on mental and physical wellbeing of families and children affected by cancer.

Clinical experts shared information and offered intervention strategies.

"The peer support session was great. I also liked how there were parallel sessions running, and we had an opportunity to send questions during the session which were then addressed at the end."

Stories of Hope
We listen to our parent community. We know the value of hope to families facing their toughest challenge and helping to provide hope to families is a central part of Solving Kids' Cancer UK's mission. In 2023, we introduced a new area on our website called Stories of Hope.

Among the incredibly sad stories, there are also stories of hope, which we are pleased to be able to share and celebrate with you. The stories featured, shared with permission, are of children and young people who have been diagnosed with neuroblastoma, have completed treatment and are now in remission and doing the things they enjoy most in life.

"I find social media a bit hard sometimes with all the bad news, so just wanted to say I love the stories of hope on your website."

2024/25 goals

- Deliver a hybrid conference to enable neuroblastoma families the option to come together in-person for peer support, hear about the latest developments in neuroblastoma research and take part in psycho-social workshops, whilst also providing access to the conference remotely to ensure we are able to reach all families.
- Officially launch SKC's bespoke coaching programme for neuroblastoma parents.
- As Advocates, ensure continuous engagement with new trials and developments within the research landscape such as DFMO and CAR-T.
- Present unbiased information to support parental decision-making by working closely with Clinicians and maintaining and building strong networks in the global research landscape.



Alice was diagnosed with high-risk neuroblastoma in April 2022, when she was eight years old.

For 14 months, Alice endured grueling treatment for neuroblastoma including taking part in two clinical trials at the Sant Joan de Déu Barcelona Hospital. When end of treatment scans confirmed Alice was clear of disease in June 2023, the family flew out to New York in July for Alice to start the bivalent vaccine clinical trial with the aim of keeping her cancer away.

Alice is now a ten-year-old bubbly, bright, beautiful, and brave young lady. She loves to spend her time singing, running and keeping family and friends entertained. Alice says, "I'm back in normal life and I love it!"

Alice's mum and dad, Dylan and Norah, were supported by Solving Kids' Cancer UK to navigate the treatment landscape and make crucial decisions at an already difficult time.

"We found out about Solving Kids' Cancer UK through our early research into neuroblastoma. They had lots of very useful information available, such as the recordings of the Neuroblastoma Parent Global Symposium. Initially, the most beneficial support we received from SKC UK was sharing impartial and easy-to-understand information about pathways available in Europe for neuroblastoma patients. They were helpful in sharing advice and information on different treatment types and the associated trials that were being conducted. This helped our family with some very difficult decision-making and provided comfort and hope that we were not alone in facing the challenges of neuroblastoma." Dylan, dad to Alice.

Solving Kids' Cancer UK
Awareness





In order to drive long-term change and improvement to the lives of children with cancer, we are committed to raising the profile of childhood cancer, and tackling systemic challenges that stand in the way of progress. Through strategic partnerships across the sector, we are amplifying the voices of children and families, driving action amongst experts, and influencing key decision-makers to facilitate national change.

Unlocking Hope
To mark the end of Childhood Cancer Awareness month, last October we launched the Unlocking Hope campaign, publishing our first-ever public affairs strategy. In our strategy, we set out a mission to accelerate clinical research into children's cancers in the UK. Currently, there are numerous barriers and bottlenecks in the UK healthcare system that are hindering the progress of clinical trials, and ultimately limiting the progress we can make for children with cancer. By developing this new strategy and creating the new role of Public Affairs & Advocacy Lead, we have paved strong foundations for our campaigning and influencing work, to drive real change and bring real impact for children and families.

Building our relationships with parliament
With a strategy established to steer our campaigning efforts, we began our parliamentary engagement activities to establish new relationships that will help to champion our cause in Westminster and beyond. In August 2023, we were pleased to support a debate on Neuroblastoma Treatment, called by former MP, Peter Gibson, thanks to our friends at the Luke Bell Foundation. The debate involved constructive conversation about ways to tackle the harsh reality faced by children diagnosed with neuroblastoma, and recognition of SKC UK's efforts to drive this issue forward. In December 2023, we secured several MP meetings to raise awareness of our mission, bringing new connections in parliament and better awareness of SKC UK amongst key influential figures.

The vehicle to drive change
In addition to garnering political support for our mission to accelerate clinical research for children's cancers, we have put a focused effort on what we can achieve in collaboration with the research and healthcare communities to facilitate change. As a research funder and patient organisation, SKC UK has developed strong relationships with stakeholders across the whole childhood cancer sector. To bring about impactful change for children with cancer, we are using our position to convene a new multistakeholder initiative with a focus on accelerating clinical research in the UK. The initiative will be fast-paced and solution-driven, with the intention to develop actionable steps that can be implemented in collaboration with key decision-makers in government. In early 2024, we recruited Pam Kearns, Professor of Clinical Paediatric Oncology, as an independent Chair for the initiative, and aim to formally establish the group by the start of 2025.

Putting children at the heart of research
Alongside our strategic efforts to reshape the landscape for future trials, we continue our commitment to engaging in current research, to ensure that the needs of children and families are put at the front and centre of progress. This year, our research team has participated in several Trial Steering Committees, bringing patient perspective into conversations that shape trial setup and delivery.



In April 2021, just after her sixth birthday, Eden was diagnosed with high-risk neuroblastoma after weeks of suffering with leg pain and fevers. X-rays, MRIs, and CT scans confirmed the awful news that Eden had cancer, and within hours she began treatment, which started with chemotherapy.

Being diagnosed at the height of the COVID-19 pandemic caused complications and delays, but thankfully Eden completed frontline therapy, with her end of treatment scans showing she was in remission in November 2022. Following this, in December 2022, Eden enrolled on a clinical trial for an experimental relapse-prevention therapy in New York, which she will continue on until late 2024.

In July 2023, Eden's family featured in our campaign with the Daily Express - Back Britain to Beat Childhood Cancer - proudly holding up a letter to the former Health Secretary, Steve Barclay, signed by 15 families, urging for change. Eden's family bravely shared their experience of travelling abroad to access the Bivalent Vaccine trial in New York to demonstrate the need to make more clinical research available for families here in the UK.

Since then, Eden's parents, Jen and Lee, have shown continuous support for Solving Kids' Cancer UK's campaigning efforts, including our Unlocking Hope campaign, helping us to pave the way for change.

We have also strengthened the position of advocates in numerous international research networks, including the European Neuroblastoma Research Network (SIOPEN), where our Head of Research Leona Knox participated in the Annual Meeting in Ljubljana, focusing on expanding the SIOPEN advocate network across all European countries.

Paving the way for future advocates
Research advocacy is a nuanced field, but one that brings important benefit to the patient community. An important element is ensuring that advocate involvement is sustained long into the future, so that the progress made so far can continue for future generations of children. SKC UK is committed to expanding our work to support this, and at this year's Neuroblastoma Parent Global Symposium, we held a dedicated session on Research Advocacy. This was aimed as an introduction for parents interested in becoming involved in advocacy activities, and we look forward to building on this in the coming year, to strengthen the support available for future advocates.

2024/25 Goals

- Launch Solving Kids' Cancer UK's manifesto for children's cancer research.
- Host our first parliamentary reception.
- Attend first major political Party Conferences and develop a strong parliamentary network in the new government.
- Convene and coordinate a UK multistakeholder initiative to drive forward our aim to accelerate clinical research into children's cancers.
- Develop a pilot advocate mentoring scheme for parents and young people.



Your Support

Over the last year, we have been humbled by the support we have received from our community and event fundraisers and the ongoing support we have received from our corporate supporters. Highlights from the year include:



British Racing Greats

In May 2023, Solving Kids' Cancer UK alongside SpecialEffect had the honour of being charity beneficiaries of a first-of-its-kind unique charity track event celebrating the greatest racing games ever made. Held at Donington Park Circuit, the amazing day was brought together by the generosity of so many individuals and companies and hosted by Ben Collins (The original, The Stig) with special guest, Jodie Kidd. An incredible £100,000 was raised and split between the two charities.

The Irish Solicitors Bar Association, London – Autumn Ball

Our friends at The Irish Solicitors Bar Association, London held their Autumn Ball at Claridge's in aid of Solving Kids' Cancer UK. Our Head of Research, Leona Knox, spoke at the event sharing her personal story of her son's passing from neuroblastoma at the age of five and the urgent need for more childhood cancer research and support. The ball raised over £24,000 for Solving Kids' Cancer UK.

Sumo Group

We are proud to continue our ongoing charity partnership with Sumo Group, a collaboration that has significantly advanced our mission. Through a variety of joint initiatives and fundraising efforts, Sumo Group has demonstrated an unwavering commitment to supporting our cause. Their continued generous contributions to our Care & Connect Support Bags, their support with making our first charity film and introductions to their networks have been invaluable. Together, we are making strides towards a better future for children with childhood cancer.

Swimming Challenge

For Childhood Cancer Awareness Month in September 2023, Jonathan took on a 40km (1600 lengths) swimming challenge in memory of his daughter Bella, who he tragically lost to high-risk neuroblastoma on her sixth birthday. He raised an incredible £21,844 for children with neuroblastoma and to support more research

Fundraising walk in memory of friend

Eleven-year-olds Jessie, Gabriella and Phoebe wanted to raise money in memory of their best friend, Kitty, who devastatingly passed away in 2022 after being diagnosed with neuroblastoma. The girls organised and walked more than 25 miles in one day.

At times the terrain was very hilly, and the weather was treacherous, but they never complained once! The girls raised over £4,000 for SSolving Kids' Cancer UK. Jessie, Gabriella and Phoebe were awarded hero awards at our annual Carol Concert for their amazing fundraising for their friend'.





Family Fun Day

On 8th July 2023, we hosted our annual Family Fun Day at the picturesque Knebworth House, bringing together over 40 families for a delightful and child-friendly event. The day was filled with a variety of activities catering to all ages and interests, helping families to foster new connections and ensuring everyone had a wonderful time.

Families enjoyed various activities, from ball pits, face painting to arts and crafts. We Can Kick It led football games outside, while an indoor gaming room provided additional entertainment. Guests were treated to a delicious BBQ lunch and refreshing treats from an ice-cream van, rounding off a truly memorable day for all.

Thank you to Flix Interactive for supporting this event.
















Events

Neuroblastoma Parent Global Symposium 2023

On 3rd November 2023, we held our fourth Neuroblastoma Parent Global Symposium (NPGS) in partnership with Solving Kids' Cancer US. The award-winning global event aims to inform and empower families affected by neuroblastoma, connecting them with those who work to treat, help and support them. The event welcomed over 360 participants who heard from world-leading scientific and clinical experts working to push boundaries in the treatment of neuroblastoma, as they provided updates on the latest cutting-edge research. It also included Q&A sessions with experts and virtual conversation rooms on specific topics where families could come together for peer support.

We are grateful for the support from Recordati Rare Diseases, Y-mAbs Therapeutics Inc, United Therapeutics Oncology, Sanofi, US WorldMeds and GRC World Forums in making this event possible.

Film Premiere

Thanks to our incredible corporate partner, Sumo Group, SKC UK were proud to officially launch our new charity film to showcase our work and impact. The film premiere was held at the iconic Mayfair Hotel in London with guests including existing and new supporters of the charity, clinicians and researchers and most importantly, many of the families who appeared in the film. Our guest speakers included our Head of Family Support, Vicky Inglis; Head of Research, Leona Knox; and Trustee, Alex Lane, all of whom shared their candid personal experiences to a very moved audience.

Christmas Carol Concert

On 5 December 2023, we packed out Holy Trinity Church, Sloane Square, London for our sold-out Christmas Carol Concert and raised over £25,000 for children and families affected by neuroblastoma.

We had a range of performers including the renowned London Show Choir and the cast and crew of EastEnders. We also presented our special Hero Awards to those in the community who made a real difference in 2023.

One of the highlights was undoubtedly a performance from the incredible Louis Moorhouse and fellow blind musician, Sirine Jahangir. Louis was diagnosed with stage 4 neuroblastoma when he was 18 months old. He had a primary tumour on his adrenal gland and another tumour in his nasal cavity.

The tumour in his nasal cavity crushed his optic nerve leaving him permanently blind and the toxic side effects of treatment also left Louis partially deaf too. Despite having difficulties as a result of neuroblastoma, this incredible young man has not let this hold him back.

After getting his first keyboard, aged eight, he has recently finished university with a degree in music production and is enjoying his work as a mixing engineer.

It was an absolute privilege to have Louis perform at the concert, and we're so grateful to him and Sirine for being a part of it.

Thank you to Miniclip, Laser Quest, PitStop Productions and Anglo Stainless for supporting this event.



Achievements & performance

The second year of our 2022-2027 strategy has been even busier and we have achieved so much across all three of our pillars - Research, Support and Awareness. Alongside this we have maintained a lean and highly effective infrastructure to ensure our teams can focus on driving our strategy.

Solving Kids' Cancer UK





Research

- Successful conclusion of ACTION grant call, brand new clinical trial (TACTIC) and international data platform (MIGHTY) funded.
- Extended funding for MiNivAn clinical trial maintaining this treatment option for children in the UK, and a new molecular radiotherapy trial to open afterwards (MINT) for children who currently have no well-defined therapeutic options.
- Extended funding for the Senior Trials Coordinator in Birmingham and gaining on-the-ground insight to inform our new multistakeholder Partnership approach to accelerating Children's Cancer Trials (IMPACCT).
- Co-funded BIOPORTAL to ensure UK inclusion in pan-European virtual biobank to improve understanding of neuroblastoma.
- Supported, attended and contributed to major international meetings (Advances in Neuroblastoma Research Congress, Amsterdam; Neuroblastoma Drug Development Strategy, Boston)

Support

- Delivered our first post treatment and bereavement coaching programmes.
- Provided 47 Big Love Fund pastoral grants and 49 Care and Connect Bags.
- Delivered a new psychosocial programme of seminars and interactive peer support sessions at our Neuroblastoma Parent Global Symposium, whilst facilitating and moderating key sessions.
- Actively engaged with clinicians and researchers through attendance at SIOPE, REDMAPP and PanCare.

Awareness

- Launched our first-ever public affairs strategy through the Unlocking Hope campaign.
- Increased our presence in Westminster/ parliament through policy engagement efforts (MP meetings, debates etc.)
- Led on the development of UK multistakeholder initiative to accelerate clinical research for children's cancers.
- Continued research advocacy through involvement in clinical trial steering groups and international research networks.
- Increased effort to educate and support future advocates.

Inspire public support for the Charity

- Raised £1,003k of unrestricted income, 32% growth on prior year.
- Launched our new charity brand film at the iconic Mayfair Hotel, welcoming existing supporters, clinicians and families and welcoming new supporters. The event and film will help us to raise greater awareness of the needs of children and their families facing a neuroblastoma diagnosis and broaden our reach to attract new supporters to our cause.
- Launched our new Solving Kids' Cancer UK brand.
- Alongside our partner charity SpecialEffect, delivered the British Racing Greats fundraising event hosted by Jodie Kidd and the Stig, raising over £50k for each charity.
- Welcomed many of our supporters and families to our in-person Christmas Carol Concert with very special performances from the amazing Louis Moorhouse and Sirine Jahangir, the Eastenders Choir and the London Show Choir.
- Secured GamesAid funding for an eighth year running.

Strong governance and infrastructure

- Launched our new website including our 'Stories of Hope' section, providing all our stakeholders with a more user-friendly digital way into the organisation.
- Further developed and embedded our Customer Relationship Management (CRM) system to ensure we can support all our families, research initiatives and donors in the best way for them.
- Following Board review, began our open recruitment process for new Trustees to join our hugely committed and expert Board.
- Thanks to corporate support we have been able to move into new office premises to provide a hub for the organisation's activities and reduce costs.

Future plans

The 2022 – 2027 organisational strategy is hugely ambitious, and we have made a very strong start over the last two years. This year, we will continue to build on these efforts, growing our networks, relationships and activity to deliver a huge programme of very exciting work over the next year across all pillars, and most notably drive a real step change in our advocacy work.

Over the next year we will:

- Continue to effectively and passionately advocate for children and families affected by neuroblastoma and work in partnership with the global neuroblastoma clinical and research communities, to help facilitate more effective and less toxic treatment options for children in the UK.

- Deliver our first-ever Hybrid Neuroblastoma Parent Conference, bringing together the research and clinical community to host scientific meetings and families to come together for peer support, hear about the latest developments in neuroblastoma research and take part in psychosocial workshops.

- Launch Solving Kids' Cancer UK's manifesto for children's cancer research to include the hosting of our first ever parliamentary reception bringing together MP's, families, the clinician and research community and supporters.

- Convene and coordinate a UK multistakeholder initiative to drive forward our aim to accelerate clinical research into children's cancers.

- Formally launch the Solving Kids' Cancer UK coaching programmes, which will be a series of online group sessions for parents of children diagnosed with neuroblastoma following the end of treatment, as well as for those in bereavement, focusing on parental wellbeing and life after cancer.

- Work with our Scientific Advisory Board to refine our existing Research Strategy to enable us to drive progress for children with neuroblastoma as effectively as possible through new research funding opportunities, advocacy efforts and our existing and new research investments.

- Recruit at least two additional Trustee Board members based on analysis of skills and experiences needed in accordance with the charity's five-year strategy.

- Continue to grow and strengthen our fundraising pipeline through expansion of our corporate partnerships, development of an individual giving programme and further development of our Named Funds so that families have a supported way to raise funds in the name of their child that support the core activities of the charity.

Structure, governance & management

Governing document

The Trustees, who are also Directors for the purposes of company law, present their report and the financial statements of the company for the year ended 31 March 2024.

The charity is controlled by its governing document, the Articles of Association, and constitutes an incorporated registered charity. The charity was incorporated on 30 March 2010 at Companies House, was entered in the Register of Charities on 20 April 2010 and is administered by the Trustees. At their discretion, the Trustees may spend all or part of the capital of the charity in furthering its Objects, in the following ways:

i. To raise funds. The Trustees must not undertake any substantial permanent trading activity and must comply with any relevant statutory regulations.
ii. To buy, take on lease or in exchange, hire or otherwise acquire property and to maintain and equip it for use.
iii. To sell, lease or otherwise dispose of all or any part of property belonging to the charity.
iv. To borrow money and to charge the whole or any part of the property belonging to the charity as security for repayment of the money borrowed.

Aims and objects

The charity's objects ("Objects") are specifically restricted to the following:

- To advance the understanding and treatment of cancer in children through the greater awareness, provision of equipment, access to treatment protocols in hospitals and medical centres and clinical research aimed at improved diagnosis and treatment anywhere in the world.

- To advance the education, relieve the sickness and the poverty of persons living anywhere in the world through the provision of equipment, financial assistance and by any other charitable means that the Trustees in their absolute discretion think fit.

Public benefit

The Trustees give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the Objects and due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the principal activities of the charity are to provide public benefit.

Board of Trustees

Solving Kids' Cancer UK is governed by the Board of Trustees, chaired by Nick Bird. The Trustees determine the charity's strategic direction and oversee progress against objectives. It is responsible for governance and for upholding the charity's values. The charity must have at least three Trustees. The day-to-day running of the charity is the responsibility of the Chief Executive Officer.

The Board of Trustees supports the principles of good governance set out in the new Charity Governance Code (see www.charitygovernancecode.org) and also the continuous improvement model which the Code promotes.

The Board of Trustees receives periodic technical briefings on neuroblastoma research, have joint sessions with the Chair of the Scientific Advisory Board and attend the annual Neuroblastoma Parent Global Symposium and other relevant conferences/ meetings.

The Board of Trustees has formal board meetings six times during the year. In accordance with the charity's Articles of Association, Trustees must undertake to attend meetings regularly and any Trustee failing to do so may be duly removed from their position.

The quorum necessary for the transaction of Trustee business at an ordinary meeting is three Trustees or two thirds of all Trustees, whichever is greater. The Trustees agree that the nominated Chair has the casting vote for decisions where there is equal weighting.

The Board selects new Trustees based upon their empathy with the Objects of the charity, skills and experience to help provide the appropriate level of governance and oversight for the charity to be effective, coupled with their ability to commit the necessary time for Board meetings and other key events.

Structure, governance & management Continued

During the year, the Board has reviewed their composition and made the decision to recruit a number of additional Trustees, which is underway. They also updated their Memorandum and Articles to reflect current practice. With the support of the Scientific Advisory Board, the Trustees committed five new research grants in partnership with others.

Trustee induction procedures include completing relevant training and working with staff and existing Trustees to understand the organisation and develop internal relationships, to include one-to-one meetings with the CEO, Chair of the Board, Trustees and members of the Leadership Team. The induction also covers governance processes, strategic planning and finance, so that new Trustees are equipped with relevant knowledge about the organisation and its priorities. New Trustees are provided with a Role Description and Person Specification and Board Code of Conduct.

Scientific Advisory Board

Solving Kids' Cancer UK's Scientific Advisory Board (SAB) is an independent body of experts who are responsible for providing expert guidance and support to help us achieve our research goals, as well as overseeing our robust, Association of Medical Research Charities accredited grant award process. Their advice and recommendations are presented to the Board of Trustees via our research team.

The SAB's insight and expertise has been invaluable again this year running an extremely rigorous grant award process for our ACTION consortium grant call, providing $2 million of partnership funding to a new plan for Transatlantic Clinical Trials. Overall, we made five separate significant grant awards within the year under the SAB expert guidance and have strongly managed and influenced the research programmes within our portfolio through regular monitoring by the SAB.

The Trustees would like to extend their wholehearted gratitude to every member of our Scientific Advisory Board, for their continued dedication to push the charity's research goals forward, for the benefit of children with neuroblastoma in the UK, and internationally. A special thanks goes to the Chair of our Scientific Advisory Board, Professor Andy Pearson, for providing his expertise and continued tireless commitment to help children with neuroblastoma, and for his incredible enthusiasm and support for the work of Solving Kids' Cancer UK.

Staff remuneration

All salaries, including that of the Chief Executive Officer, are based upon an assessment of the employment market, the skill levels required, the size and financial performance of the charity and the salary levels required to obtain the services of the best staff.

Equity, diversity and inclusion

Solving Kids' Cancer UK has a strong, caring ethos and is firmly committed to equity, diversity, and inclusion (EDI), which is integral to our five-year strategy and values.

We are committed to embedding principles of equity, diversity, and inclusion, ensuring that our operations, activities, and services are designed and open for everyone to be included, and to fostering culture, behaviours, and practices in support of social justice.

EDI is fundamental to achieving our charity objectives to reach and be there for all families affected by neuroblastoma, and for the health and wellbeing of all those we work with and exist for. We want everyone to feel included and believe in the importance of reflecting different perspectives, experiences, and skills, including from those with lived experience of neuroblastoma, within our staff, board, and volunteer teams.

We are not EDI experts, we do not have all the answers, and we will not always get it right - but this can't and won't hold us back. We are committed to learning, to listening and to creating safe spaces for difficult conversations that will inspire and lead to positive and lasting change.

Safeguarding

Our work and practice is underpinned by safeguarding principles with the aim of protecting children and young people and enhancing their welfare. Solving Kids' Cancer UK always works in accordance with legislation, statutory guidance, and best safeguarding practices. Solving Kids' Cancer UK has robust safeguarding policies and procedures in place and all staff and Trustees receive dedicated safeguarding training upon induction with regular updates as required.

All hiring managers are required to access Safer Recruitment training to ensure that our recruitment processes are robust, with an emphasis on ensuring the safety and welfare of the children and families we support. All staff and Trustees are required to have a basic DBS check and clearance before commencing their role with Solving Kids' Cancer UK, and this is extended to any volunteer or service provider that may have regular direct interaction with the children and families we support.

The charity reviews and revises safeguarding policies and procedures at regular intervals, at least annually, and has a designated safeguarding lead within the leadership team and a Trustee with designated safeguarding oversight.

Volunteers

The Trustees are extremely grateful for the considerable contribution made by the charity's volunteers and fundraisers in support of children with neuroblastoma, including our Patrons, our Parent Involvement Forum members and all those who lend their time, expertise and resources in furtherance of our charitable objectives.

We couldn't do all we do without wonderful volunteers. From the amazing Louis Moorhouse and Sirine Jahangir performing at our Christmas Carol Concert alongside the brilliant Eastenders choir and the London Show Choir, the amazing volunteers who help run our Family Fun Day and the parents who formed a focus group to develop our coaching programme or facilitated peer support sessions at our Neuroblastoma Parents Global Symposium, and to everyone else who has helped us this year. We are all part of team SKC and we thank every one of you from the bottom of our hearts.

During the year, volunteers supporting the charity collectively contributed over 3,200 hours and we are hugely grateful to them all.



Our legal & administrative details





Registered charity name
Solving Kids' Cancer UK (changed from Solving Kids' Cancer Ltd on 25 August 2023)

Charity registration number
1135601 (England and Wales)
SC045094 (Scotland)

Company registration number
07208648

Registered office (from 1st Sept 2023)
Unit 02-03 Salisbury House,
29 Finsbury Circus
London EC2M 7AQ

(Previous address) Coram Campus
41 Brunswick Square
London WC1N 1AZ

Trustees
The Trustees who served the company during the period were as follows:

Nick Bird (Chair of the Board of Trustees)
Joseph Tabone (Board Policy and Safeguarding Lead)
Matthew White (Equality, Diversity and Inclusion Lead)
David Coulon (Treasurer)
Alexandra Lane
Dr Áine McCarthy
Carl Cavers (from 16th Sept 2024)
Stewart Leaver (from 16th Sept 2024)
Ioannis Topsakalidis (from 16th Sept 2024)

Company Secretary
Gemma Wadsley

Chief Executive Officer
Gail Jackson

Leadership Team
Claire Hislop (Head of Operations)
Danielle Russell (Head of Fundraising and Engagement)
Gemma Wadsley (Director of Strategic Finance)
Leona Knox (Head of Research)
Vicky Inglis (Head of Family Support Service)

Patrons
Carl Cavers
Kellie Bright
Rob Brydon

Auditor's
Shipleys LLP
Chartered Accountants & Statutory Auditor
10 Orange Street, Haymarket
London WC2H 7DQ

Bankers
National Westminster Bank
Church Road Branch
London NW4 4DS

Investment managers
CCLA Investment Management Limited
1 Angel Lane
London EC4R 3AB

Solicitors
Withers
20 Old Bailey
London EC4M 7AN

Our finances

Overview

2023/24 was a very impactful year for us with five large research grants awarded and positive growth to our undesignated income and networks, which has further embedded strength into our income streams for the future. We saw lower designated income as fewer families raised funds for treatment, which potentially reflects the current options available in the UK. Our finances remain tightly controlled with lean expenditure across the organisation.

We had planned for an undesignated deficit for the year to manage our reserves position and enable investment in year two of our strategy ahead of wider income growth, and the undesignated deficit of £111,322 is very much in line with these plans.

Overall, we are presenting a deficit of £424,084, which largely relates to the £1,262,051 of Research commitments in year using previously raised funds.

Income

Our total income for the year was £2,476,390 (2023: £2,991,524). This comprises £1,003,793 undesignated funds (2023: £760,051); £1,285,522 designated funds (2023: £1,614,036) and £187,075 restricted funds (2023: £617,437).

Our undesignated income is made up of voluntary and investment income, which supports all our charity's internal activities. This includes our family support provision – offering pastoral care and grants to support families and providing evidence-based, impartial information to support parents in their choice of treatment options for their child, and to access treatments and clinical trials if they are not available in the UK. It also includes our internal research team and infrastructure, all our fundraising activities and our operational running and governance costs. Our designated income of £1,285,522 relates predominantly to funds designated in the name of a child to support treatment options with a full breakdown of our designated and restricted fund income in notes 20 and 21.

Overall income has reduced by £515,134 with this being split across designated family funds and restricted research income offset by undesignated funds which have increased for the year.

Expenditure

Expenditure increased significantly for the year to £3,226,862 (2023: £1,884,851). The growth largely relates to charitable spend which was up £1,320,939 to £2,884,684. The biggest element of this increase is the Research Grants spend totaling £1,262,051 which includes the five large Research grants. Children's treatment costs were just slightly down at £639,537 (2023: £685,390) whilst Family Support spend, which includes grants to families was up at £176,402 (2023 122,200). Fundraising costs were flat at £342,178 (2023: £321,106).

Within these costs, we keep our support spend as lean as possible and this remains flat on the prior year at £406,009 (2023: £395,141).

Investments

Given the nature of the organisation, supporting very young children and their families, our investment objectives are primarily to invest in an ethically sound manner to protect the value of the charity's assets against inflation, and provide modest returns through a combination of income distribution and capital growth. In addition to being mindful of the nature of investments made on behalf of the charity, the Trustees' appetite for risk is also influenced by the significant amount of funds that are designated for future purposes. The COIF Charities Ethical Investment Fund aims to provide a long-term gross return of 5% per annum net of inflation. Within this, the fund aims to deliver a consistent annual distribution of income and operate with a level of volatility (risk) that is no greater than 75% of the volatility of the UK equity market. The actual return performance (not inflation adjusted) for the year was +13.11% given market strength over the past year, with a three-year figure of +7.34% and the last five years at +8.95%, which is consistent with our aims.

Following a stronger investment year, we are reporting an investment gain of £345,776 (2023: £184,680 loss). Since purchase, the investment has given capital growth of £1,365,164.

Our finances

Continued

Reserves policy

The Trustees have adopted a reserves policy which they consider appropriate to ensure the continued ability of the charity to meet its objectives.

General funds are set aside to meet future costs to support our families and deliver our strategy. At the financial year-end, general funds were £848,659 (2023: £959,981).

General free reserves (undesignated funds excluding fixed assets) were £841,937 and represent 8.9 months' undesignated expenditure (based on the 2025 budget).

Free reserves are calculated as follows:

	2024
	£
Total funds of the charity	12,909,236
Less: Restricted funds	(2,064,050)
Less: Designated funds	(9,996,527)
Less: Fixed assets held for charity use	(6,722)
	£841,937

The reserves policy states that six to nine months of essential running costs should be covered to meet its obligations in the short-term (£567,500-£851,250) based upon the 2025 budget. This is based on an assessment of the organisational risk approach and funding model. This year, we are at the top end of the range as per our plan.

As part of our five-year strategy, we agreed investment in service delivery and income generation ahead of income growth, with planned deficits across the first half of the strategy and this year's deficit in year two of our strategy is in line with this plan. We have another smaller deficit forecast for the 2025 budget, which will result in reserves within our agreed range and still towards the higher end of the range.

This robust financial plan, alongside the need for caution given the continued challenging nature of the external environment for all charities, means that the Trustees are comfortable with the current reserves level and longer-term policy.

Designated Funds are predominantly set aside for the treatment of children or our Research or Investment reserves funds and are not available for the day to day running of the charity. At the financial year-end, the charity held designated reserves of £9,996,527 (2023: £10,360,651). In the event of a child's death, the funds will be available to the family to support funeral and related costs and then the balance will be released from designated children's funds after a period of a year. Following the end of a successful course of treatment, and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of five years so that they are available for that child should they suffer a relapse and require further treatment or pastoral support, a situation which is sadly common for neuroblastoma patients. This policy resulted in £84,627 (2023: £280,187) transferring from designated children's funds within the year, 70% transferred to the designated Solving Kids' Cancer UK Research Fund; 10% to the designated Solving Kids' Cancer UK Children's Reserve Fund; 10% to the Pastoral Grant Fund and 10% to undesignated reserves.

Restricted Reserves are funds which can only be used for particular restricted purposes within the objects of the charity and arise when specified by the donor, or when funds are raised for particular restricted purposes. At the financial year-end, the charity held restricted reserves of £2,064,050 (2022: £2,012,688), of which £1,177,426 (2023: £1,228,877) relates to funds being held on behalf of families who were previously supported by Families Against Neuroblastoma.

Supporters of the charity are asked to note that, although the charity appears to hold significant reserves, 77% of these funds are designated or restricted to fund the treatment or support of children and families, and a further 5% is designated or restricted to Research.

Risk management

The charity's Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks. The Trustees have overall responsibility for ensuring that the charity has an appropriate system of controls, financial and otherwise. They are responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the charity or for publication is reliable and reviewed at every Trustee meeting; and
- the charity complies with relevant laws and regulations.

The risk register is a live document which is reviewed in detail every six months by the Board and Leadership Team.

Risk categories include:

Governance
Covers risk of non-delivery of strategy, Board skills & capabilities and effective decision-making and reporting.

Controls in place to manage these risks include a clear strategy underpinned by annual plans, and a balanced and involved Board who have clear terms of reference and consider their effectiveness and undertake training as appropriate. The Board requests and receives regular reporting from executive management.

People
Covers risk of loss of key staff and poor structure.

Controls in place to manage these risks include strong oversight by CEO and senior managers, clear roles and responsibilities and strong HR processes. As staff numbers are small, this is a key risk which is closely monitored.

Finance
Covers all financial risks around effectiveness of our business model, level of reserves, management of investments and effective insurance.

Controls in place to manage these risks include annual budgeting and forecasting processes with regular reporting of our financial position to Trustees. We have a clear reserves policy and hold general reserves to manage any changes in cash flow. We have an investment policy and investment managers who report on performance regularly.

Compliance
Covers all risks relating to non-compliance of required regulations including data protection, health and safety, employment and financial.

Controls in place to manage these risks include effective policies, staff training and awareness and effective advisors.

Operational, legal and physical
Covers risk of not being able to meet demands for family support and quality of support provided; risk of lack of funds due to expenditure exceeding income; health and safety risks and other operational risks including employment risks and disaster recovery.

Controls in place to manage these risks include ensuring the team have appropriate support to deliver in their roles and we are continuously considering current and future demand. Budgets and reserves are effectively managed to ensure funding is maintained. We have policies in place which are well understood and adhered to around health and safety, disaster recovery, employment policies and other areas of compliance.

Environmental / external factors
Covers reputational risk and relevant external risks such as economic conditions and Brexit.

Controls in place to manage these risks include effective communications policies and resource and ongoing monitoring of relevant external plans with action plans as required.

Our finances

Continued

Grant-making policy

The Board of Trustees makes two types of grants. Firstly, small grants to assist children living with neuroblastoma. Families who wish to apply, either self-refer, hear about the charity from their child's oncologist, or contact the charity's Family Support Team. Grants are also offered in the form of a hardship fund for families struggling to meet their necessary costs due to the effects of having a child in treatment for neuroblastoma.

The second type is research grants. We engage in two distinct research funding mechanisms: a regular competitive funding call, and also ad-hoc exceptional funding requests. All research grants are awarded in line with the principles laid out by the Association of Medical Research Charities (AMRC). Each application will be subject to rigorous scientific review guided by the charity's Scientific Advisory Board (SAB) and the nature of any grant made will depend on funds available through Solving Kids' Cancer UK's own reserves, or those made available through strategic collaborative partnerships.

Investment policy and objectives

The Deed of Trust allows the charity to deposit or invest funds in any manner; but to do so only after obtaining such advice from financial experts as the Trustees deem necessary and having regard to the suitability of investments and need for diversification. The charity aims to follow the COIF Ethical Fund Policy; excluding investments in companies involved in, for example, nuclear weapons, landmines, production of abortifacients, and other disqualifying criteria where there is a significant involvement (>10% of turnover).

Fundraising approach and policy

As a cause-related charity, we recognise that the service we offer for children and families affected by neuroblastoma and the advances in research we invest in, would not be possible without the generous support and passion our supporters, and families' supporters provide. We receive very little public funding for our work, relying on the generous support of the neuroblastoma community and general public.

We are registered with the regulatory body for fundraising in the UK, the Fundraising Regulator.

As members of the scheme, we follow their Code of Fundraising Practice and comply with the key principles embodied in The Code. Many of our families raise funds for us at a local level and we ensure that they have all the information they need to comply with our policies and procedures.

It is hugely important to us that our supporters trust us and are well looked after:

- We ensure that we never put undue pressure on members of the public when raising funds.
- We are open and honest and approach our fundraising activities respectfully and considerately.
- We ensure that we comply with the wishes of our donors and comply with all general data protection laws.
- We respect the rights, dignity and privacy of our supporters and beneficiaries.
- We are accountable to our supporters and take this responsibility seriously.

We review all of our fundraising campaigns to ensure they fully comply with The Code and our fundraising activities are discussed regularly at Board meetings, to help ensure that our fundraising practices reflect and reinforce our values. Whether we're fundraising ourselves or working with families, organisations or volunteers, it's just as important.

We currently raise funds in a variety of ways, including regular and individual giving programmes, challenge events, SKC-run and third party events, corporate partnerships, direct cash donations, raffles, sponsored events and Charity of the Year partnerships. We are performing well against our five-year fundraising strategy, which is building upon our strong stewardship approach to develop existing income streams and develop new ones.

Within the year, we achieved an undesignated income of £1,003,793 with 30% coming from Corporates, Trusts, Third Party Events and Major Gifts, 27% from Community and Events and 27% coming through investment income. Our performance reflects our strong and evolving strategy.

We take the protection of the personal data of all our supporters and donors extremely seriously, and constantly review and monitor our fundraising policies and procedures to ensure we deliver 'best practice'. We do not engage professional fundraisers to raise money on our behalf. We use our CRM system to further protect and manage our supporter data.

We welcome feedback on our fundraising activities at any time and strive to listen and learn from this feedback. During the year, we recorded one complaint. We have a robust complaints policy. If a complaint about our fundraising activities is unable to be resolved through our complaint's procedure, members of the public are advised to raise it with the Fundraising Regulator.

Trustees' responsibilities statement

The Trustees (who are also the Directors of Solving Kids' Cancer UK for the purposes of company law) are responsible for preparing the Trustees Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees' to prepare financial statements for each financial year. Under that law, the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the income and expenditure of the company for that period.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of the persons who is a Trustee at the date of approval of this report confirms that:

- so far as each Trustee is aware, there is no relevant audit information of which the company's auditor is unaware; and
- each Trustee has taken all steps that they ought to have taken as a Trustee to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Registered office:
Signed on behalf of the Board of Trustees
Unit 02-03 Salisbury House,
29 Finsbury Circus,
London EC2M 7AQ



David Coulon
Trustee and Treasurer
26th September 2024

Independent Auditor's Report

Independent Auditor's Report to the Trustees and members of Solving Kids' Cancer UK

Opinion

We have audited the financial statements of Solving Kids' Cancer UK ("the charitable company") for the year ended 31 March 2024 which comprise the Statement of Financial Activities (incorporating the Income and Expenditure Account), the Balance Sheet, the Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2024 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and trustees Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions Relating to Going Concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Solving Kids' Cancer UK's ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other Information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on Other Matters Prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the Trustees' Annual Report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- The directors' report included within the Trustees' Annual Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees' Annual Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

We have been appointed as auditor's under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- We obtained an understanding of the charitable company's activities, controls and laws and regulations and assessed the susceptibility of the charitable company's financial statements to material misstatement from irregularities, including fraud.

Independent Auditor's Report

Continued

- We determined that the laws and regulations that are most significant to the charitable company are the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)), Companies Act 2006, Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, the Fundraising Regulations and the charitable company's Articles of Association.
- Based on this understanding we designed our audit procedures to detecting irregularities, including fraud. Testing undertaken included making enquiries on the management and those charged with governance; journal entry testing; review of bank letters, investments reports, trustee board minutes and the Articles of Association; review of transactions for any undisclosed related party transactions; reviewing financial statement disclosures and testing of supporting documentation to assess compliance with applicable laws and regulations. These procedures were designed to provide reasonable assurance that the financial statements were free from fraud or error.

  As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.



Tim Hardy (Senior Statutory Auditor)
26th September 2024
For and on behalf of SHIPLEYS LLP
Chartered Accountants & Statutory Auditor
10 Orange Street, Haymarket, London WC2H 7DQ

Statement of financial activities

(incorporating the income and expenditure account) year ended 31 March 2024

	Note	General Funds Undesignated £	General Funds Designated £	Restricted funds £	Total Funds 2024 £	Total Funds 2023 £
INCOME						
Donations	2	**706,171**	**1,259,095**	**131,361**	**2,096,627**	2,764,305
Trading activities	3	**22,563**	**26,427**	**150**	**49,140**	44,510
Investment income	4	**275,059**	**-**	**55,564**	**330,623**	182,709
TOTAL INCOME		**1,003,793**	**1,285,522**	**187,075**	**2,476,390**	2,991,524
EXPENDITURE ON:						
Raising funds	5	**(323,918)**	**(17,207)**	**(1,053)**	**(342,178)**	(321,106)
Charitable activities	6	**(777,113)**	**(1,972,911)**	**(134,660)**	**(2,884,684)**	(1,563,745)
TOTAL EXPENDITURE		**(1,101,031)**	**(1,990,118)**	**(135,713)**	**(3,226,862)**	(1,884,851)
NET (EXPENDITURE) / INCOME BEFORE GAINS / (LOSSES) ON INVESTMENTS		**(97,238)**	**(704,596)**	**51,362**	**(750,472)**	1,106,673
Net gains / (losses) on investments	13	**–**	**345,776**	**–**	**345,776**	(184,680)
Other (losses) / gains		**(22,547)**	**3,159**	**–**	**(19,388)**	43,684
NET (EXPENDITURE) / INCOME		**(119,785)**	**(355,661)**	**51,362**	**(424,084)**	965,677
Transfer between funds	20,21,22	**8,463**	**(8,463)**	**–**	**–**	**–**
NET MOVEMENT IN FUNDS		**(111,322)**	**(364,124)**	**51,362**	**(424,084)**	965,677
RECONCILIATION OF FUNDS						
Total funds brought forward		**959,981**	**10,360,651**	**2,012,688**	**13,333,320**	12,367,643
TOTAL FUNDS CARRIED FORWARD		**848,659**	**9,996,527**	**2,064,050**	**12,909,236**	13,333,320

The Statement of financial activities includes all gains and losses in the year. All of the above amounts relate to continuing activities.
The notes on pages 38-59 form part of these financial statements.

Balance sheet

Year ended 31 March 2024

	Note	2024 £	2024 £	2023 £	2023 £
FIXED ASSETS					
Tangible assets	12		**6,722**		8,976
Investments	13		**3,865,164**		3,519,388
			3,871,886		3,528,364
CURRENT ASSETS					
Debtors	14	**228,021**		100,921	
Cash at bank and in hand		**11,396,820**		11,284,479	
		11,624,841		11,385,400	
CREDITORS					
Amounts falling due within one year	15	**(1,205,625)**		(1,022,050)	
NET CURRENT ASSETS			**10,419,216**		10,363,350
TOTAL ASSETS LESS CURRENT LIABILITIES			**14,291,102**		13,891,714
CREDITORS:					
Amounts falling due after one year	16		**(1,381,866)**		(558,394)
NET ASSETS			**12,909,236**		13,333,320
FUNDS OF THE CHARITY					
Restricted funds	20		**2,064,050**		2,012,688
Designated funds	21		**9,996,527**		10,360,651
Undesignated funds	22		**848,659**		959,981
TOTAL FUNDS CARRIED FORWARD			**12,909,236**		13,333,320

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. These financial statements were approved by the members of the committee and authorised for issue on 26th September 2024 and are signed on their behalf by:

David Coulon, Trustee
Company registration number: 07208648

The notes on pages 38-59 form part of these financial statements.

Statement of cash flows

Year ended 31 March 2024

	Note	2024 £	2023 £
CASH FLOWS FROM OPERATING ACTIVITIES			
Net income		**(424,084)**	965,677
Adjustments for:			
Depreciation		**6,007**	5,508
Losses / (gains) on investments		**(345,776)**	184,680
Dividends and interest from investments		**(330,623)**	(161,742)
Loss on sale of fixed assets		**72**	-
(Decrease) / increase in debtors		**(131,672)**	119,512
(Decrease) / increase in creditors		**1,007,047**	(101,031)
Net cash provided by operating activities		**(219,029)**	1,012,604
CASH FLOWS FROM INVESTING ACTIVITIES			
Dividends and interest from investments		**335,195**	157,068
Purchase of property, plant and equipment		**(3,825)**	(5,234)
Net cash provided by investing activities	28	**331,370**	151,834
CHANGE IN CASH AND CASH EQUIVALENTS	28	**112,341**	1,164,438
CASH AT START OF YEAR	28	**11,284,479**	10,120,041
CASH AT END OF YEAR		**11,396,820**	11,284,479

The notes on pages 38-59 form part of these financial statements.

Notes to the financial statements

1. Accounting policies

General information
Solving Kids' Cancer UK Ltd is a private company limited by guarantee incorporated in England under the Companies Act. The address of the registered office is Unit 02-03 Salisbury House, 29 Finsbury Circus, London EC2M 7AQ. The objectives of the charity are set out on page 23.

On 25 August 2023, the charitable company changed its name from Solving Kids' Cancer UK Ltd to Solving Kids' Cancer UK.

Basis of preparation
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Solving Kids' Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policies.

The functional currency of the charity is considered to be pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling.

The amounts in the financial statements are presented to the nearest £, unless otherwise stated.

Preparation of the financial statements on a going concern basis
The financial statements of the charity have been prepared on the going concern basis. There are no material uncertainties about the charity's ability to continue. The trustees consider that the going concern basis is appropriate having considered a period of at least twelve months from approval of these financial statements. The trustees have prepared budgets and cash flow forecasts for that period which support the going concern assumption.

Fund accounting
Undesignated funds are available to spend on activities that further any of the purposes of charity.

Designated funds are funds of the charity which the Trustees have decided at their discretion to set aside to use for a specific purpose.

Restricted funds are donations which the donor has specified are to be solely used for particular restricted purposes within the objects of the charity.

Income
Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that those conditions will be fulfilled in the reporting period.

90% of any donation made to an individual appeal or journey is designated for the particular purpose of funding treatment not freely available on the NHS. The remaining 10% is retained within undesignated general funds to cover costs associated with the administration and management of appeals and journeys; including support with fundraising, logistics, and development of relationships as intermediary between families and the medical institutions that provide access to treatments and clinical trials.

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income from Government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred. In respect of the Coronavirus Job Retention Scheme grant; all conditions, with respect to the eligible costs being claimed, need to be met.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due. This is normally upon notification by our investment advisor of the dividend yield of the investment portfolio.

Expenditure and irrecoverable VAT
Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis.

Expenditure is classified under the following activity headings:

- Costs of raising funds comprise the costs of attracting donations and fundraising.
- Expenditure on charitable activities includes the cost incurred by the charity in the delivery of activities and services for its beneficiaries.

Grants payable are payments made to third parties in the furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the grant. Grant awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include staff, premises, legal and professional, finance, depreciation and governance costs. These costs have been allocated between cost of raising funds and expenditure on charitable activities on the basis of an estimate of the proportion of time spent by staff on those activities.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Tangible fixed assets
Fixed assets are capitalised at cost and are depreciated over their estimated useful economic lives on a straight line basis as follows:
Equipment – 25% on straight line basis.

Fixed asset investments
Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

.

Notes to the financial statements Continued

Debtors
Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand
Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions
Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due

Financial instruments
The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases
The charity classifies the lease of the office space as an operating lease as the title remains with the lessor. Rental charges are charged on a straight line basis over the term of the lease

Pension costs
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Differences between contributions payable in the year and the contributions actually paid are shown as either accruals or prepayments on the balance sheet.

2. Donations

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Donations	**657,671**	**1,259,095**	**44,713**	**1,961,479**
Donated services	**48,500**	**-**	**-**	**48,500**
Government grants	**-**	**-**	**86,648**	**86,648**
	706,171	**1,259,095**	**131,361**	**2,096,627**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2023
	£	£	£	£
Donations	533,973	1,602,591	493,919	2,630,483
Donated services	35,071	-	-	35,071
Government grants	-	-	98,751	98,751
	569,044	1,602,591	592,670	2,764,305

The charity benefits greatly from the involvement and enthusiastic support of its many volunteers. In accordance with FRS 102 and Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the financial statements.

During the year, the charity received donated services relating to legal services and support for the Neuroblastoma Parent Global Symposium. The value of these services to the charity is estimated at £38,500 and £10,000 respectively (2023: £25,071 and £10,000 respectively). The estimated value of these services is recognised within income as a donation with an equivalent expense through the Statement of Financial Activities.

Income from Government grants comprises grants received under the UK Government COVID Medical Research Charity Support Fund of £86,648 (2023: £98,751) to provide support to UK Research. The charity has not benefited from any other kinds of government assistance during the current or prior year.

3. Other trading activities

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Fundraising events	**22,563**	**26,427**	**150**	**49,140**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2023
	£	£	£	£
Fundraising events	29,265	11,445	3,800	44,510

Notes to the financial statements Continued

4. Investment income

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Income from investments	**108,084**	**-**	**-**	**108,084**
Deposit account interest	**166,975**	**-**	**55,564**	**222,539**
	275,059	**-**	**55,564**	**330,623**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2023
	£	£	£	£
Income from investments	107,438	-	-	107,438
Deposit account interest	54,304	-	20,967	75,271
	161,742	-	20,967	182,709

5. Cost of raising funds

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Cost of raising funds	**215,334**	**17,207**	**1,053**	**233,594**
Support costs	**108,584**	**-**	**-**	**108,584**
	323,918	**17,207**	**1,053**	**342,178**

	Undesignated funds	Designated funds	Restricted funds	Total funds 2023
	£	£	£	£
Cost of raising funds	188,963	17,978	1,781	208,722
Support costs	112,384	-	-	112,384
	301,347	17,978	1,781	321,106

6. Costs of charitable activities

	Activities undertaken directly	Grant funding activities	Support costs	Total funds 2024
	£	£	£	£
Support	**221,888**	**815,939**	**119,853**	**1,157,680**
Research	**153,089**	**1,262,051**	**92,022**	**1,507,162**
Awareness	**134,291**	**-**	**85,551**	**219,842**
	509,268	**2,077,990**	**297,426**	**2,884,684**

	Activities undertaken directly	Grant funding activities	Support costs	Total funds 2023
	£	£	£	£
Support	181,279	807,590	123,667	1,112,536
Research	135,806	38,765	88,152	262,723
Awareness	117,548	-	70,938	188,486
	434,633	846,355	282,757	1,563,745

Expenditure on charitable activities was £2,884,684 (2023: £1,563,745) of which £777,113 was undesignated (2023: £561,581), £1,972,911 was designated (2023: £755,452) and £134,660 was restricted (2023: £246,712).

Notes to the financial statements Continued

7. Analysis of support costs

Support costs are allocated based on the proportion of time spent by staff on those activities.

	Support	Research	Awareness	Fundraising activities	Total funds 2024
	£	£	£	£	£
Staff costs	**63,519**	**48,769**	**45,340**	**57,547**	**215,175**
Premises	**32,491**	**24,946**	**23,192**	**29,436**	**110,065**
Legal and professional	**3,458**	**2,655**	**2,468**	**3,133**	**11,714**
Finance costs	**774**	**594**	**552**	**701**	**2,621**
Depreciation	**1,773**	**1,362**	**1,266**	**1,606**	**6,007**
Governance costs	**17,838**	**13,696**	**12,733**	**16,160**	**60,427**
	119,853	**92,022**	**85,551**	**108,583**	**406,009**

	Support	Research	Awareness	Fundraising activities	Total funds 2023
	£	£	£	£	£
Staff costs	54,224	38,652	31,104	49,277	173,257
Premises	42,579	30,351	24,424	38,694	136,048
Legal and professional	9,931	7,079	5,697	9,025	31,732
Finance costs	812	579	466	739	2,596
Depreciation	1,724	1,229	989	1,566	5,508
Governance costs	14,397	10,262	8,258	13,083	46,000
	123,667	88,152	70,938	112,384	395,141

8. Governance costs

	2024	2023
	£	£
Auditor's Remuneration	**13,000**	13,000
Legal and professional	**39,828**	26,437
Staff costs	**7,599**	6,563
	60,427	46,000

9. Analysis of grants

	2024	2023
	£	£
Children's treatment	**639,537**	685,390
Family support	**176,402**	122,200
Research		
University of Birmingham	**626,321**	38,378
University of Southampton	**159,827**	-
St Jude Hospital	**469,129**	-
Newcastle University	**-**	(912)
University College London	**-**	(1,001)
Redmapp	**2,500**	-
Travel bursary	**4,274**	2,300
	2,077,990	846,355

Children's treatment grants are made towards the medical costs of the children suffering from neuroblastoma. The grants are paid directly to the hospitals providing the treatment.

Family Support Grants are those made towards providing essential support services to families affected by affected by neuroblastoma. These grants are paid directly to affected families and organisations as appropriate or as directed.

Grants are made towards medical research for potential future life-saving treatments made possible through the constantly evolving world of burgeoning laboratory, pre-clinical and clinical research. These grants are paid directly to the institutions that are working internationally, reflecting the specialist and global nature of the research we fund.

Notes to the financial statements Continued

10. Staff costs and emoluments

	2024	2023
	£	£
Wages and salaries	**676,290**	581,282
Social security costs	**58,664**	55,767
Pension costs – defined contribution	**24,871**	19,280
	759,825	656,329

Pension costs are allocated to activities in proportion to the related staffing costs and are allocated between undesignated, designated and restricted funds on the basis of each employee's activities.

Particulars of employees: The average head count of employees during the year was 19 (2023: 18). The average number of full-time equivalent employees during the year is analysed as follows:

	2024	2023
	No.	No.
Charitable activities	**8**	7
Fundraising	**3**	3
Support	**4**	4
	15	14

The number of employees whose remuneration for the year fell within the following bands, were:

	2024	2023
	No.	No.
£60,000 to £69,999	**1**	-
£80,000 to £89,999	**1**	1

No higher paid staff were accruing benefits under a pension scheme (2023: None).

11. Net income Net income is stated after charging:

	2024	2023
	£	£
Auditor's remuneration		
Audit	**13,000**	13,000
Taxation	**-**	804
Depreciation	**6,007**	5,508
Operating leases – offices	**6,925**	8,593

12. Tangible fixed assets

	Equipment
	£
Cost	
At April 2023	**28,572**
Additions	**3,825**
Disposals	**(4,555)**
At 31 March 2024	**27,842**
DEPRECIATION	
At 1 April 2023	**19,596**
Charge for the year	**6,007**
Disposals	**(4,483)**
At 31 March 2024	**21,120**
NET BOOK VALUE	
At 31 March 2024	**6,722**
At 31 March 2023	**8,976**

Notes to the financial statements Continued

13. Investments

Movement in market value	2024	2023
	£	£
Market Value at 1 April 2023	**3,519,388**	3,704,068
Net gain / (loss) on revaluation	**345,776**	(184,680)
Market value at 31 March 2024	**3,865,164**	3,519,388
Historical cost at 31 March 2024	**2,500,000**	2,500,000

Analysis of investments as at 31 March 2024	Designated funds 2024	Designated funds 2023
	£	£
UK listed investments	**3,865,164**	3,519,388

All investments are carried at their fair value. Holdings in investment funds, unit trusts and open-ended investment companies are at the bid price. The basis of fair value for quoted investments is equivalent to the market value, using the bid price. Asset sales and purchases are recognised at the date of trade at cost (that is their transaction value).

The following investments were material in the context of the investment portfolio:

COIF Charities Ethical Investment Fund - £3,865,164 (2023: £3,519,388).

The main form of financial risk faced by the charity is that of volatility in investment markets due to wider economic conditions and variability of investment returns. This risk is mitigated by obtaining advice from a financial expert on the charity's investment portfolio.

14. Debtors

	2024	2023
	£	£
Other debtors	**16,620**	10,869
Prepayments and accrued income	**211,401**	90,052
	228,021	100,921

15. Creditors

Amounts falling due within a year	2024	2023
	£	£
Trade creditors	**2,328**	247
Other creditors	**-**	8,183
Accruals and deferred income	**154,103**	149,465
Grant commitments (note 17)	**501,136**	242,613
Funds held as agent (note 18)	**548,058**	621,542
	1,205,625	1,022,050

16. Creditors

Amounts falling due after more than one year	2024	2023
	£	£
Grant commitments (note 17)	**1,381,866**	558,394

Grant commitments of £153,976 are due in more than five years (2023: £153,976).

17. Grant commitments

	2024	2023
	£	£
Grant commitments brought forward	**801,007**	969,960
New commitments during the year	**1,262,051**	38,766
Payments made in the year	**(180,056)**	(207,719)
Grant commitments carried forward	**1,883,002**	801,007
Commitments at 31 March 2024 are payable as follows:		
Within one year	**501,136**	242,613
After more than one year	**1,381,866**	558,394
Grant commitments carried forward	**1,883,002**	801,007

Notes to the financial statements Continued

18. Funds held as agent

	2024	2023
	£	£
Funds held as agent brought forward	**621,542**	602,488
Funds received during the year	**56,637**	90,000
Payments made	**(130,121)**	(70,946)
Funds held as agent carried forward	**548,058**	621,542

The charity has received funds as agent in its role as administrator of the Request for Applications (RFA) process and also of the research project for the prospective identification of children with "ultra-high-risk" (UHR) neuroblastoma.

At the year end, the charity held £548,058 (2023: £621,542) and this has been included in creditors in Note 15. £361,698 was held on behalf of Zoe4Life (2023: £392,604), £143,292 on behalf of The Merryn Lacy Trust (2023: £174,198) and £43,068 on behalf of Joining Against Cancer in Kids (J-A-C-K) (2023: £54,740).

19. Commitments under operating leases

At 31 March 2024 the company had total minimum lease payments under non-cancellable operating leases as set out below.

Land and buildings	2024	2023
	£	£
Operating leases which expire:		
Within 1 year	**1,484**	1,619
Within 2 to 5 years	**-**	1,484
	1,484	3,103

20. Restricted funds

	Balance at 1 April 2023	Income	Expenditure	Transfers	Balance at 31 March 2024
	£	£	£	£	£
Families Against Neuroblastoma (FAN)	**938,184**	**41,819**	**(35,965)**	**(71,050)**	**872,988**
FAN Emergency Relapse Fund	**290,693**	**13,745**	**(71,050)**	**71,050**	**304,438**
HK Fund	**5,919**	**-**	**(5,919)**	**-**	**-**
CE Discretionary Fund	**238**	**-**	**(238)**	**-**	**-**
Restricted research funds	**46,590**	**792**	**(5,364)**	**-**	**42,018**
Other funds	**150,634**	**117,479**	**(11,062)**		**257,051**
Joining Against Cancer in Kids	**27,180**	**-**	**(1,540)**	**-**	**25,640**
Sunni Mae Fund	**84,365**	**-**	**-**	**-**	**84,365**
Merryn Lacy Fund	**100,570**	**-**	**-**	**-**	**100,570**
Lottery funding	**6,139**	**-**	**(3,320)**	**-**	**2,819**
Rupert's Revenge Trust Fund	**148,169**	**735**	**(13)**	**-**	**148,891**
ALADDIN	**7,160**	**-**	**-**	**-**	**7,160**
Isla Caton Fund	**206,847**	**2,505**	**(46)**	**-**	**209,306**
Ireland	**-**	**10,000**	**(1,196)**	**-**	**8,804**
	2,012,688	**187,075**	**(135,713)**	**-**	**2,064,050**

Notes to the financial statements Continued

20. Restricted funds (continued)

	Balance at 1 April 2022	Income	Expenditure	Transfers	Balance at 31 March 2023
	£	£	£	£	£
Families Against Neuroblastoma (FAN)	932,614	16,488	(10,918)	-	938,184
FAN Emergency Relapse Fund	286,208	4,485	-	-	290,693
HK Fund	15,842	-	(9,923)		5,919
CE Discretionary Fund	3,782	-	(3,544)	-	238
Restricted research funds	45,534	1,078	(22)	-	46,590
Parent Conference fund	834	28,979	(29,813)		-
Other funds	96,815	55,324	(1,505)	-	150,634
Joining Against Cancer in Kids	27,180	-	-	-	27,180
Sunni Mae Fund	84,365	-	-	-	84,365
Family Support fund	25,000	-	(25,000)	-	-
Support bags	25,000	-	(25,000)	-	-
Merryn Lacy Fund	100,570	-	-	-	100,570
Lottery funding	-	9,660	(3,521)	-	6,139
Rupert's Revenge Trust Fund	-	248,191	(100,022)	-	148,169
ALADDIN	-	46,181	(39,021)		7,160
Isla Caton Fund	-	207,051	(204)		206,847
	1,643,744	617,437	(248,493)	-	2,012,688

Restricted funds

Restricted funds can only be used for particular restricted purposes within the objects of the charity as specified by the donor or when funds are raised for particular restricted purposes.

Families Against Neuroblastoma (FAN)/ FAN Emergency Relapse Fund There are 10 funds transferred from Families Against Neuroblastoma (FAN) and held for the sole use of individual children for access to treatment and welfare / pastoral issues. Treatments are limited to those that are consistent with Solving Kids' Cancer UK Clinical Trial Policy. A further two donations from FAN were received to be used solely to support children with relapsed neuroblastoma with no access to other funds to pay for treatment that is not freely available on the NHS.

HK Fund is restricted for the sole purposes of supporting an individual named child. In accordance with the wishes of the donor, the fund supports the long-term health and welfare related needs of the beneficiary, and is not accessed on a regular basis.

CE Discretionary Fund was established through an individual donation made to the charity to provide the Chief Executive with a means to fund initiatives in support of the effective working of the organisation, but for which no other budget existed.

Restricted research funds is a restricted fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research.

Parent conference fund represents donations towards the annual parent conference.

Other Funds represent funds created by families in memoriam specifically for research and advocacy projects.

Joining Against Cancer in Kids is a restricted fund which has been provided by Joining Against Cancer in Kids to support the costs incurred by families when participating in neuroblastoma trials/treatment being conducted at The Memorial Sloan Kettering Cancer Centre, New York or Hospital Saint Joan de Déu Barcelona.

Sunni Mae Fund is restricted to support the development and operational running of a Solving Kids' Cancer UK's presence in Ireland and / or provide wider support to Irish families affected by Neuroblastoma. Alternatively, the fund can be used to support a future research funding call in which The Sunni Mae Trust will be acknowledged as a named collaborative funding partner.

Family support fund is restricted to the activities of the family support team.

Support bags represents funds donated specifically to create Support bags for all children diagnosed with Neuroblastoma.

Merryn Lacy Fund represents funds donated by the trust which are restricted to Research.

Lottery funding represents a National Lottery Awards For All grant restricted to our family support Life after Cancer Programme.

Rupert's Revenge Trust Fund represents restricted funds of £100,000 towards the Anti-CD47 + anti-GD2 research and £148,169 restricted to Research.

ALADDIN represents a European funding grant for the delivery of a multi-stakeholder educational programme on regulatory science in paediatric cancer drug development.

Isla Caton Fund represents funds transferred and raised for pioneering research in memory of beautiful Isla who loved to sing and dance.

Ireland represented funds provided to the charity from a donor specifically to support the registration of the charity in Ireland to enable wider support of families in Ireland.

Notes to the financial statements Continued

21. Designated funds

	Balance at 1 April 2023	Income	Expenditure	Transfers	Net gains on investments	Other gains and losses	Balance at 31 March 2024
	£	£	£	£	£	£	£
Designated Funds	**7,385,497**	**1,196,884**	**(671,965)**	**(84,627)**	**-**	**-**	**7,825,789**
Solving Kids' Cancer Children's Reserve Fund	**619,431**	**-**	**(26,737)**	**8,463**	**-**	**-**	**601,157**
Solving Kids' Cancer Research Fund	**1,310,972**	**88,300**	**(1,277,757)**	**59,238**	**-**	**3,159**	**183,912**
Family Support Fund	**1,399**	**-**	**-**	**-**	**-**	**-**	**1,399**
Covid-19 Fund	**143**	**-**	**-**	**-**	**-**	**-**	**143**
Big Love and pastoral Funds	**23,821**	**338**	**(13,659)**	**8,463**	**-**	**-**	**18,963**
Investment Reserve	**1,019,388**	**-**	**-**	**-**	**345,776**	**-**	**1,365,164**
	10,360,651	**1,285,522**	**(1,990,118)**	**(8,463)**	**345,776**	**3,159**	**9,996,527**

21. Designated funds Continued

	Balance at 1 April 2022	Income	Expenditure	Transfers	Net losses on investments	Other gains and losses	Balance at 31 March 2023
	£	£	£	£	£	£	£
Designated Funds	6,923,606	1,525,794	(783,716)	(280,187)	-	-	7,385,497
Solving Kids' Cancer Children's Reserve Fund	600,812	-	(9,400)	28,019	-	-	619,431
Solving Kids' Cancer Research Fund	959,004	101,466	61,150	196,130	-	(6,778)	1,310,972
Family Support Fund	29,123	3,000	(30,724)	-	-	-	1,399
Covid-19 Fund	143	-	-	-	-	,-	143
Big Love and pastoral Funds	5,927	615	(10,740)	28,019	-	-	23,821
Designated general	16,839	(16,839)	-	-	-		-
Investment Reserve	1,204,068	-	-	-	(184,680)	-	1,019,388
	9,739,522	1,614,036	(773,430)	(28,019)	(184,680)	(6,778)	10,360,651

Designated funds are funds which have been allocated by the trustees out of undesignated general funds to specific appeals for the treatment of children with neuroblastoma. In the event of a child's death, the funds will be released from designated funds. Following the end of a successful course of treatment, and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of 5 years so that they are available for that child should they suffer a relapse and require further treatment, a situation which is common for neuroblastoma patients. During the year, this policy resulted in transfers of £84,627 (2023: £280,187) with 70% transferred to the designated Solving Kids' Cancer Research Fund, 10% to the designated Solving Kids' Cancer Children's Reserve Fund, 10% to designated pastoral funds and 10% to undesignated reserves.

Solving Kids' Cancer Children's Reserve Fund is money designated to;
(1) support families who are fundraising for treatment who may require additional financial support to be able to meet the deadlines for enrolment on a particular clinical trial.

Notes to the financial statements Continued

(2) support children who are receiving treatment abroad but for whom additional unanticipated medical expenses are incurred. During the year £8,463 was transferred from Designated funds (2023: £28,019).
(3) provide pastoral funding to families through SKC grant programmes (currently includes Big Love Fund and Clinical Trial travel).
(4) any spend specifically approved by the Board which directly benefits families looking to access treatment.

Solving Kids' Cancer Research Fund is a designated fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research. During the year, £59,238 was transferred from Designated Funds (2023: £196,130).

Family Support Fund is designated to the activities of the family support team.

COVID-19 fund is designated to the granting of funds to families of children with Neuroblastoma who have suffered a loss of income or increase in costs as a result of the diagnosis. It was initially for those affected by the need to shield during COVID-19.

Big Love and pastoral Funds is designated to the granting of pastoral funds to support a child or young person's physical or emotional welfare and to support families in bereavement. During the year £8,463 was transferred from Designated funds (2023: £28,019).

Designated general is a general fund to hold designated income prior to allocation against an individual fund for example whilst awaiting gift aid allocation.

Investment Reserve represents the movement in fair value on investments since acquisition.

22. Undesignated funds

	Balance at 1 April 2023	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2024
	£	£	£			£
Undesignated funds	**959,981**	**1,003,793**	**(1,101,031)**	**8,463**	**(22,547)**	**848,659**

	Balance at 1 April 2022	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2023
	£	£	£			£
Undesignated funds	984,377	760,051	(862,928)	28,019	50,462	959,981

23. Analysis of net assets between funds

Fund balances at 31 March 2024 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2024
	£	£	£	£
Tangible fixed assets	**6,722**	-	-	**6,722**
Investments	-	**3,865,164**	-	**3,865,164**
Cash at bank and in hand	**1,289,255**	**7,868,586**	**2,238,979**	**11,396,820**
Other net current (liabilities)/assets	**(447,318)**	**(432,352)**	**(97,934)**	**(977,604)**
Creditors falling due in more than one year	-	**(1,304,871)**	**(76,995)**	**(1,381,866)**
	848,659	**9,996,527**	**2,064,050**	**12,909,236**

Fund balances at 31 March 2023 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2023
	£	£	£	£
Tangible fixed assets	8,976	-	-	8,976
Investments	-	3,519,388	-	3,519,388
Cash at bank and in hand	1,523,780	7,555,004	2,205,695	11,284,479
Other net current (liabilities)/assets	(572,775)	(271,763)	(76,591)	(921,129)
Creditors falling due in more than one year	-	(441,978)	(116,416)	(558,394)
	959,981	10,360,651	2,012,688	13,333,320

24. Company limited by guarantee

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is £10.

25. Taxation

The charity is exempt from tax on income and gains to the extent that these are applied to its charitable objects.

Notes to the financial statements Continued

26. Related party transactions

The key management personnel of the charity for the year comprised the Trustees, Chief Executive Officer and the Heads of Departments. The total employee benefits of the key management personnel were £369,170 (2023: £301,390).

The trustees did not receive any remuneration or other benefits during the year (2023: £nil). One trustee received reimbursement of expenses during the year of £569 relating to travel and subsistence (2023: £854 relating to memberships and subscriptions).

During the year, the charity paid £600 to Yassine Rhardoud, the husband of member of key management Claire Hislop, for moving and refurbishment costs associated with the move to the new office.

The total donations received from 2 trustees (2023: 2) during the year amounted to £2,688 (2023: £1,100).

27. Financial instruments

Financial assets measured at fair value through statement of financial activities:

	2024	2023
	£	£
Investments	**3,865,164**	3,519,388

The income, expense, gains and losses in respect of all financial instruments are summarised below:

	2024	2023
	£	£
Net gain / (loss) on revaluation of investments	**345,776**	(184,680)
Investment income	**108,084**	107,438

For further details about risks arising from financial instruments and the measurement basis see note 13.

28. Analysis of changes in debt

	At 1 April 2023	**Cash flows**	**At 31 March 2024**
	£	**£**	**£**
Net cash			
Cash at bank and in hand	**11,284,479**	**112,341**	**11,396,820**

	At 1 April 2022	**Cash flows**	**At 31 March 2023**
		£	**£**
Net Cash			
Cash at bank and in hand	10,120,041	1,164,438	11,284,479

29. Comparatives for the statement of financial activities

	Undesignated Funds	**Designated Funds**	**Restricted Funds**	**Total Funds 2023**
	£	**£**	**£**	**£**
INCOME			-	
Donations	569,044	1,602,591	592,670	2,764,305
Trading activities	29,265	11,445	3,800	44,510
Investment income	161,742	-	20,967	182,709
TOTAL INCOME	**760,051**	**1,614,036**	**617,437**	**2,991,524**
EXPENDITURE				
Raising funds	(301,347)	(17,978)	(1,781)	(321,106)
Charitable activities	(561,581)	(755,452)	(246,712)	(1,563,745)
TOTAL EXPENDITURE	**(862,928)**	**(773,430)**	**(248,493)**	**(1,884,851)**
NET INCOME / (EXPENDITURE) BEFORE LOSSES ON INVESTMENTS	(102,877)	840,606	368,944	1,106,673
Net losses on investments	–	(184,680)	–	(184,680)
Other gains / (losses)	50,462	(6,778)	–	43,684
NET INCOME	(52,415)	649,148	368,944	965,677
Transfer between funds	28,019	(28,019)	–	–
NET MOVEMENT IN FUNDS	(24,396)	621,129	368,944	965,677
RECONCILIATION OF FUNDS				
Total funds brought forward	984,377	9,739,522	1,643,744	12,367,643
TOTAL FUNDS CARRIED FORWARD	**959,981**	**10,360,651**	**2,012,688**	**13,333,320**

Thank You

We want to say a heartfelt thanks to the following companies, people, schools, charities, foundations and trusts for their wonderful support.

Companies

Allen & Overy LLP
A&O Shearman
Anglo Stainless
Burnt Peach
Flix Interactive
GamesAid
Google
GRC World Forums
Harper Collins
Irish Solicitors Bar Association
iTech Media
Julius Baer International Ltd
Keel Toys
Laser Quest
Marks Sattins
Miniclip
Norgine
OVID Health
Pipeline Technology Centre
Party Ideas
Pitstop Productions
Privacy Culture Limited
Recordati Rare Diseases
Ritter Sport
Sanofi
Scamp and Dude
Sumo Digital
United Therapeutics
Y-mAbs Therapeutics Inc.
We Can Kick It
Workspace
US World Meds
Reach Creative Branding Ltd

Patron & Champions

Kellie Bright
Rob Brydon
Carl Cavers
Demie Risby

Parent Involvement Forum

Naomi Bentham
Leeanne Brennan
Kate Dixon
Claire Donnelly
Garrett Fitzgerald
Stewart Leaver
Naomi Shefford-Thomas
Carrie Wright

Schools

London Oratory School
Eton House School

Ambassadors & individuals

Clare and Chris Andrew
Polly Arber
Mandy Berriman
Mary Boullin
Ashley Byam
Ed Cartledge
Tony Clay
Will Cocker
Adam and Hannah Cohen
Pippa Collins
Graham Cooper
Stephanie Davies
Kevin Doyle
Tom Donegan
Jack Fleming
Gurlaine Kur Garcha
Roger Griffiths
Liam Gurney
Rob Hancock
Ruben Hage
Richard Hage
Christina Haralambous
Patrick Harney
Tom Hartley Jnr
Shirley Hepworth
Sirine Jahangir
Liliana Jackson
Nicholas Jackson
Russell Jackson
Prof Pam Kearns
Adelaide Lane
Stewart and Cassie Leaver
Chris Lee
Kim Leadbeater MP
Gavin Lindberg
Cameron Miller
Darren Mills
Louis Moorhouse
Louise Murphy
Robson O'Reardon
Cliona O'Tuama
Polly Ord
Lara Polati
Jude Sibley
James Speakman
Nick Streeter
Ali Timmons
Iulia and Padmesh Thuraisingham
Ioannis Topsakalidis
Mark Ward
Grace White
Colleen White
Katy Yeandle

EastEnders choir:

Zaraah Abrahams
Isobel Allan
Gareth Ambrose
Delroy Atkinson
Renee Baker
Emma Barton
Joanna Bayliss
Kellie Bright
Natalie Cassidy
Navin Chowdhry
Charlotte Christoforon
Juhaim Rasul Choudhury
Tia Daby
Ellie Dadd
Sarah Edwards Knight
Dee Helier
Margaret Jarvie-Smith
Aaliyah James
Lawrie Jordan
Katy Karger
Sophie Khen Levy
Jaden Ladega
Fiona Martin
Ruth Mandel
Matthew Morrison
Clair Norris
Jacqueline Osborne
Maria Paraskeva
Diane Parish
Emma Perry
Heather Peace
Hannah Pigott
Julia Sawkins
Simon Naylor
Harriet Thorpe
Gilly Taylforth
Lacey Turner
Rudolph Walker
Gillian Wright
Melissa Wright

Charities, foundations & trusts

Anticancer Fund
Band of Parents
Cancer Awareness Trust / Cancer Platform
GamesAid
Joining Against Cancer in Kids (J-A-C-K)
Joseph's Smile
Kindred Foundation
Neuroblastoma UK
Rupert's Revenge
Solving Kids' Cancer US
SpecialEffect
St. George's Society of New York
The Evan Foundation
The Merryn Lacy Trust
Zoe4Life

Family & named funds

Alfie's Wishes
Hannah's Heroes
Oscar Knox Fund
Smiles for Stanley
The Isla Caton Fund

Hero Awards 2023 recipients

Clare Andrew
Andy Biddle, Chris Haigh, Katie Derry, Sarah Gibbon and Roberttown Community
Clare Churchman
Jessie Collins
Jayne Delaney
Gabriella Flynn
Wendy Gardner
Chris Lee
Darren Mills
Phoebe McCluskey
Robson O'Reardon
Leah Walton
We Can Kick It, received by Adrian Conoboy MBE
Wendy Gardner

Scientific Advisory Board Members

Dr Steve Dubois
Dr Julia Glade-Bender
Dr Juliet Gray
Dr Meredith Irwin
Prof John Maris (Vice-Chair)
Dr Lucas Moreno
Dr Julie Park
Prof Andy Pearson (Chair)
Prof Michel Zwaan

Our Patrons



Rob Brydon

Rob, one of the UK's most celebrated performers, joined as our first charity Patron on 2020. He has a personal connection to Solving Kids' Cancer UK, having supported out Trustee, Max White and his family, when their son Felix was diagnosed with neuroblastoma in 2009 at the age of four..



Carl Cavers

Carl is chief executive Officer of Sumo Group and first reached out to Solving Kids' Cancer UK following our call to the gaming community to make a seemingly impossible wish come true for an inspirational young man, Luke. Carl and Sumo Group continue to provide incredible support and opportunities for Solving Kids' Cancer UK. Carl joined the Trustee Board in Sept 2024.



Kellie Bright

Kellie has been a prominent part of the BBC's Eastenders cast for 10 years. After visiting her cousin on the oncology ward at University College Hospital in London, she was introduced to a Solving Kid's Cancer UK member of staff who told her about the charity's work. Kellie rallied 22 of her fellow Eastenders cast members to sing and meet families affected by childhood cancer at our Christmas Carol Concert and we're delighted that she has joined the charity as a Patron.

Solving Kids' Cancer UK

Solving Kids' Cancer UK is a registered charity. We receive very little public funding for our work. Thanks to supporters and philanthropic partnerships we've made progress over the years. But there is still so much more to do to ensure a future where no child dies of childhood cancer neuroblastoma or suffers due to the treatment they receive.

The support you give will make the difference to the lives of children and families affected by childhood cancer. For more information on how you can support and to donate;

Visit: solvingkidscancer.org.uk
Call: 020 7284 0800
Email: fundraising@solvingkidscancer.org.uk

Or donate directly here;

Solving Kids' Cancer UK is a registered charity in England and Wales (1135601) and in Scotland (SCO45094). It is a company limited by guarantee in England and Wales (7208648). The charity and company currently operate as Solving Kids' Cancer UK.

Solving Kids' Cancer UK
Unit 02-03, Salisbury House, 29 Finsbury Circus, London EC2M 7AQ
Email: info@solvingkidscancer.org.uk
Telephone: 020 7284 0800

@SKC_UK
SolvingKidsCancer365
skc365
Solving Kids' Cancer UK

Registered with FUNDRAISING REGULATOR

Solving Kids' Cancer UK

England & Wales - Charity number 1135601

Accounts

Solving Kids' Cancer UK



Annual Report & Accounts 2022/2023



Jessica

WHO IS ON OUR COVER?

In April 2021, Jessica was diagnosed with neuroblastoma and she began standard frontline treatment. The disease did not respond as hoped. Jessica was then enrolled in a clinical trial in Southampton called MiNivAn. This trial is being co-funded by Solving Kids' Cancer UK.

Jessica has now completed all of her treatments and has no evidence of active disease. She has started attending nursery and is enjoying life away from the hospital.

We have supported the family throughout their journey and continue to be there to share their important milestones.

Our vision

Solving Kids' Cancer UK's vision is a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.

Our mission

Helping those affected by neuroblastoma, an often aggressive and deadly childhood cancer, by:

- Initiating and funding best-in-class clinical **research**
- Providing hope, information and **support** to families throughout their cancer journey
- Raising **awareness** of childhood cancer, advocating and campaigning for positive change.

Contents

03 Our year
04 An introduction from our Chair of Trustees
07 Welcome from our Chief Executive Officer
08 Strategic Plan 2022-2027
10 Research
12 Support
14 Awareness
16 Your support
19 Events
20 Achievements & performance 2022-23
22 Future plans
23 Structure, governance & management
26 Our legal & administrative details
27 Our finances
32 Independent auditors report
35 Financial statements and notes
59 Thank you

Our year





Solving Kids' Cancer UK's' vision is a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.

Every two weeks a child in the UK with neuroblastoma dies.
Help us to change this outcome.

We are a small but mighty parent-led charity with children firmly at our heart. We are striving for better outcomes for children and families affected by neuroblastoma, both now and in the future. In every conversation, we amplify their voice and ensure their needs are at the heart of all we do.

We will not stop until children with neuroblastoma, in the UK and beyond, have access to the treatment they need, when they need it, as close to home as possible.

Over the last year, we have:

- Delivered the first year of our **ambitious strategy**, strengthening our team and wider infrastructure.
- Supported over 400 families by providing emotional, practical and financial support which includes 76 families who are new to the charity.
- Formed the **ACTION Consortium**, a group of five charities from across North America and Europe, to launch the largest-ever research grant call dedicated to neuroblastoma at $2 million.
- Led and facilitated the **first cross-party roundtable of MPs in Westminster**, focussed on the challenges faced by neuroblastoma families in accessing novel treatment options.
- Developed a Solving Kids' Cancer UK **Family Support Service-led coaching programme** for families in post-treatment or bereavement.
- Supported 20 families from across the UK and Republic of Ireland to enable them to access treatments and clinical trials not currently available within the NHS.
- Collectively saved families over £150,000 by negotiating treatment costs with instituitons.
- Welcomed over 400 participants from 39 countries to our third **Neuroblastoma Parent Global Symposium**.
- Reached more families of children diagnosed with neuroblastoma at an earlier point, providing **35 Big Love Fund** grants to families and **52 Care & Connect Support Bags** to children.
- We had eight Research Programmes and grants in funding during the year.

Welcome

Introduction from our Chair of Trustees

This year marks 10 years since my son, Adam, died of neuroblastoma. He was diagnosed in 2009, aged five, and spent the next four years in treatment. As I reflect now, some things have changed for the better since then, yet at the same time so much remains the same. For children diagnosed today, survival for high-risk neuroblastoma is still no more than a 50-50 chance.

Evidence of how things have changed is seen in the 'Stories of hope' section of our new website, launched as part of our brand refresh. Here you can read about children, many supported by Solving Kids' Cancer UK, who have completed treatment and are in remission from their cancer.

While there have been improvements for newly diagnosed neuroblastoma, there are few good options for children whose disease is resistant to initial therapy or that later comes back. Research into neuroblastoma is critically underfunded. Clinical trials overwhelmingly depend on charities to initiate and fund them. This year, along with charity partners from Europe and North America, we launched our latest initiative seeking to deliver the most innovative and impactful clinical trial possible for children using our shared funding model. The fact we currently lack the financial firepower to drive more major improvements to benefit children is a source of profound frustration. Clinical trials are costly, complicated and painstakingly slow. It's hard to overstate this and even harder to explain. Yet without clinical trials, we will never provide better treatments for children, regardless of the lab-based research conducted by scientists.

Delivering on our five-year strategy means a renewed and much stronger emphasis on campaigning and advocacy. The lack of focus on childhood cancer, the leading cause of death in children over the age of one, by successive UK governments cannot be allowed to continue. Last year, we participated in a roundtable meeting in Westminster with MPs from the three main political parties, before launching our 'Back Britain to Beat Childhood Cancer' campaign alongside the Daily Express. Our call for direct government investment to enable the UK to lead Europe in a transatlantic clinical trial for children with neuroblastoma could pave the way for accelerated progress across the childhood cancer landscape in the UK.

Our campaign launch was spearheaded by six-year-old Beau from West Yorkshire, who was diagnosed with neuroblastoma in December 2020. Beau and her mum, Shirley, received support from Solving Kids' Cancer UK and, after Beau's neuroblastoma returned, she participated in the MiNivAn trial we are co-funding. Tragically, despite everything, Beau's cancer progressed further and in June, just before her seventh birthday, she died.

Things have changed – yes – but too much remains the same. There is still so much work to do so that one day all children with neuroblastoma survive their disease and go on to lead long and healthy lives. This is the vision that drives us and that we continue to work towards every day. Enabled only by the commitment, kindness, and generosity of everyone who supports us in our mission.

Nick Bird
Chair of the Board of Trustees



NICK BIRD





> **“On the other side of a storm is the strength that comes from having navigated through it.”** Gregory S. Williams

Welcome from our Chief Executive Officer

We have emerged from the multitude of challenges presented by the pandemic and then launched headlong into a fragile economic climate that has affected both our community and our supporters in a host of different ways.

Despite these challenges, the charity has proven itself to be robust and resilient in the face of adversity and, if anything, these challenges have served to make us stronger and more determined than ever before. After all, we are here to support children facing neuroblastoma, one of the most aggressive cancers in its high-risk form. These precious children face unimaginable challenges each and every day – it is from them that we draw our strength and absolute determination to make a real difference.

The charity has now completed the implementation of the first year of our five year strategy and I’m pleased to report that we have delivered against all of the ambitious objectives we set for ourselves; from launching our most aspirational research grant call yet and piloting our new coaching programme for parents/carers, to engaging with political leaders to raise awareness of some of the barriers and challenges families face, we have laid the groundwork and set the pace for change and progress.

After reading this year’s review, I know you will feel, as I do, that the team at Solving Kids’ Cancer UK has once again evidenced their absolute commitment and determination to providing bespoke support to children and families facing neuroblastoma in the here and now while focussing on improving outcomes for children in the future through our dedicated research and advocacy work. I am proud to work alongside this incredible team and am thankful for all that they do every day.

Of course, we couldn’t achieve all of this without the invaluable contribution of the individuals, families and businesses who do their utmost to support our work every day; from running to canoeing, from head-shaving to carol singing. Our supporters are dedicated and creative and each individual effort helps to make such a difference. I am so grateful to all of you who have supported us this year. I would particularly like to thank our Patron, Carl Cavers, for his continued and unwavering support. It is because of Carl that we have the incredible support of the amazing team at Sumo Group who have been such champions of our shared cause – my heartfelt thanks to all of you.

Finally, I would like to say a personal thanks on behalf of myself and our team, to our dedicated Board of Trustees who continue to give their time freely to supporting the charity and providing expert advice and guidance to me as their Chief Executive Officer.

And so, we look to the future from a position of strength, motivated by our generous supporters and inspired by the children and families we support, we simply won’t stop until we achieve our vision of a world where no child dies from the childhood cancer neuroblastoma or suffers due to the treatment they receive.



Gail Jackson
Chief Executive Officer



Solving Kids' Cancer UK

Strategic plan 2022–2027

We are fighting for a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.





Our work is driven by three key pillars

Research

Accelerate clinical trial development

We will focus on the development of new treatments by investing in clinical research and working with valued partners for maximum impact.

Prioritise the needs of children

We will engage with families to identify areas of unmet need, challenging experts to find solutions and work together to deliver maximum impact through the research we fund.

Foster collaboration

We will build and strengthen international partnerships to share expertise, best practice and resource, whilst building knowledge.

Support

Reach ALL families

Every family of a child diagnosed with neuroblastoma in the UK will have access to our support service from the point of diagnosis.

Broaden range of support

We will develop and expand our support offer in line with what families tell us they need.

Inform and support decision-making

We will ensure families have access to the most current and scientifically robust data from around the world and support their decision to access the best treatment possible.

Awareness

Research advocacy

We will amplify the voice of the children and parents, seeking to advance science and understanding of the disease alongside patient-centric research.

Patient advocacy

We will champion the needs of individual children and their families, providing parent-led support around decision-making to improve treatment outcomes.

Awareness and campaigning

We will raise the profile and support the treatment needs of children with neuroblastoma and other childhood cancers with the general public, government and public bodies.

Our strategy

To underpin the delivery of our five-year strategy, our work will be guided by an internal implementation plan centred around three key enablers and a clear focus on our vision and values.

Sustainable

We will ensure our charity remains financially robust to deliver against our strategic objectives, securing the funds required.

Good governance

We will continue to build a strong culture of compliance, transparency and continuous improvement at all levels of the organisation.

Impact

We will measure and showcase the impact of our work and demonstrate return on investment to our supporters.

Our values

Caring

We care passionately about children with neuroblastoma, their families, and all those who care for them, including our staff, volunteers and supporters

Transparent

We are open and honest about all that we do and how we do it.

Collaborative

Relationships are at the heart of our work – from the children and families we work with, to the individuals, organisations and networks that are involved in their care.

Inclusive

Our services are developed to ensure they meet needs and we aim to make them accessible to all.

Determined

We lead with tenacity and are unfaltering in our drive to help, support and fight for children with cancer.

Hopeful

We have a strong sense of optimism and hope is at the heart of all that we do.

Solving Kids' Cancer UK
Research





We drive and invest in pioneering clinical research, focussed on finding treatments that are more effective and less toxic.

Our research mission is led by parents of children affected by neuroblastoma, who have become experts in the field, allowing us to build a portfolio that has children and families at its heart. We are uniquely placed to use our influence, embedded position within the research community and reputation alongside our Association of Medical Research Charities (AMRC)-accredited research funding framework to make a difference for children.

Clinical research brings the all-important hope that families need when facing a childhood cancer diagnosis. By investing in pioneering projects, we are working towards a future with improved outcomes for children with neuroblastoma, as well as bringing more options to the clinic for children who are in need now.

2022/23 summary

ACTION Consortium
– accelerating clinical trials development
We announced our largest-ever award, the international Advancing Clinical Trial Implementation and Optimisation in Neuroblastoma (ACTION) grant call. In collaboration with four like-minded non-profit organisations – Anticancer Fund, Kindred Foundation, The Evan Foundation, and Zoé4Life – we presented this ambitious grant call, valued at $2 million. This is one of the largest dedicated to neuroblastoma research. The focus is on novel treatments for relapsed high-risk neuroblastoma, an area with poor survival and no current standard of care. Our goal with this research grant is to challenge the research community to find better solutions for this underserved part of the neuroblastoma community.

SIOPEN High-Risk Neuroblastoma Study 2 UK sites opening – accelerating clinical trial development
In 2020, we committed to majority fund the UK arm of the latest frontline trial for neuroblastoma, SIOPEN High-Risk Neuroblastoma Study 2, being implemented across Europe. However, opening these complex trials poses challenges due to limited resources in the UK healthcare system. As advocates for affected children and families, we are determined to ensure every child can access all available treatments, including clinical trials. Opening the high-risk 2 trial sites has been a top priority for our research team. We have addressed several barriers through conversations with the Solving Kids' Cancer UK-funded neuroblastoma Senior Trials Coordinator at the Cancer Research Clinical Trials Unit at the University of Birmingham and involvement on the trial steering committee. Over half of the trial sites have now opened. We remain dedicated to this cause, ensuring prompt access to the trial at Principal Treatment Centres and preventing future neuroblastoma trial delays.

ALADDIN – prioritising needs of children and families/fostering collaboration
We are proud to be one of the 13 partners involved in the launch of the brand-new ALADDIN educational programme. Our collective mission is to accelerate the pace of childhood cancer drug development by empowering the current and future generations of researchers through education and knowledge.



Arianna was diagnosed with stage 4 high-risk neuroblastoma in November 2021 and immediately began frontline treatment at Great Ormond Street Hospital. At the end of her induction chemotherapy, scans showed that her disease had reduced significantly, but not enough to move on to the next stage of treatment. At this point, Arianna was accepted onto the MiNivAn trial.

The MiNivAn study is a clinical trial at the University Hospital in Southampton, co-funded by Solving Kids' Cancer UK. The trial is investigating new combinations of specialised radiotherapy and antibody therapies to treat neuroblastoma that has not responded fully to chemotherapy or that comes back after remission.

As a result, Arianna's disease reduced even further which allowed her to progress on the standard treatment pathway as planned. She has now started immunotherapy which will be the final stage of her frontline treatment. Her family continues to admire her strength and confidence throughout this difficult journey, as the 'real-life Wonder Woman'.

As one of the lead patient organisations involved in the project, we're working to ensure that the scientific community is properly informed on the importance of involving patients in research. The programme successfully launched in 2022 after receiving funding through the EU ERASMUS scheme, with several educational activities now underway.

Advances in Neuroblastoma Research
– fostering collaboration
This year we sponsored the 2023 Advances in Neuroblastoma Research meeting (ANR) that took place in Amsterdam. The meeting was attended by over 800 members of the scientific community, as well as patient representatives like ourselves. Of note at this year's event, was that patient advocates appeared on the main agenda for the first time in ANR history, thanks to our active participation alongside other international charities. In the session titled: "How patient advocates can help improve the survival of children with neuroblastoma," Chair of our Scientific Advisory Board (SAB), Professor Andy Pearson, led engaging talks and discussion, including a presentation by Chair of the Board of Trustees, Nick Bird, who shared the learnings from his journey from parent to expert advocate.

Patient Information Forum (PIF) Tick – prioritising needs of children and families
Solving Kids' Cancer UK is now a certified member of the Patient Information Forum (PIF) Tick scheme as a Trusted Information Creator. This scheme is an independently-assessed quality mark for trusted health information. Having this accreditation and the robust process we have developed to achieve this, means we can now be certain that the health information we share is best fulfilling the needs of the children and families that we support.

2023/24 goals

- Complete ACTION Request for Application process in collaboration with our consortium partners.
- Engage in the planning of the next European frontline trial – High-Risk Neuroblastoma Study 3 to drive innovation.
- Facilitate the opening of the TITAN trial for ALK-positive high-risk neuroblastoma across Europe.
- Actively participate in and contribute to the Third Neuroblastoma Drug Development Strategy which will focus on the needs of children.

Solving Kids' Cancer UK
Support





Our unique Family Support Service is dedicated to the neuroblastoma patient and parent community in the UK. The team blends personal experience and acquired knowledge, as parents of children affected by neuroblastoma, with professional skills and experience. They provide expert advice on practical, financial and emotional burdens, as well as helping to guide families through often difficult, complex and fraught decision-making processes. Our service focusses on the here and now, easing the immediate burdens and pressures that a neuroblastoma diagnosis brings.

2022/23 summary

Care & Connect Support Bags
In 2022/23, 52 families received our Care & Connect Support Bags, which have been carefully created for every family with a neuroblastoma diagnosis, based in the UK and in active treatment. Every bag contains specially selected items to support children and families during their hospital stays, as well as items to provide comfort and entertainment.

"Wow, Solving Kids' Cancer UK really understands what oncology families need! We got an amazing box of goodies for all of us today. We've got the dreaded scans next week and a treat like this really helps. Thank you so much!" Laura, Bibi's Mum.

Big Love Fund
Inspired by Luke Wiltshire, who sadly passed away of neuroblastoma in 2021, we launched the Big Love Fund in June 2022. The fund was created for families affected by neuroblastoma, to support children or young people's physical or emotional welfare and families in bereavement with funeral and associated costs. During 2022/23, we gave out 35 grants to families.

Post-treatment support
We truly understand the conflicting emotions parents feel when their child's treatment ends. It can be an overwhelming, isolating time full of worries and uncertainties. Our Family Support team has lived experience of this. We received National Lottery funding to develop our post-treatment support offer, which we recognise as an area of unmet need. In March 2023, we launched a carefully designed, pilot phase Coaching programme in partnership with Life After Cancer, specifically with oncology parents in mind. The aim of the programme has been to increase a parent's physical, mental, emotional and social wellbeing and fulfil their potential after their child's diagnosis, reducing the risk of mental distress.

2023/24 goals

- Expand the Neuroblastoma Parents Global Symposium (NPGS) to include two content tracks, one focussing on the latest developments in neuroblastoma research and the other on psycho-social support for neuroblastoma.
- Participate in the REDMAPP study which is an intervention to support parent treatment decision-making in relapse and refractory neuroblastoma.
- Having been piloted in early 2023, officially launch the Post Treatment programme and design and launch the pilot phase of the Bereavement Coaching programme.
- Further develop our own working knowledge and relationships with institutions offering the most promising, innovative treatments such as CAR-T Cell therapy.



Peter

Peter was diagnosed with neuroblastoma in 2019. After complaining of backache, doctors identified a growth in his thorax pressing on his spinal cord, causing a spinal cord injury and leaving him with no movement in his lower body. After surgery, his parents were given the devastating news that the growth was intermediate-risk neuroblastoma.

Peter completed treatment and was disease-free in February 2020. Sadly, in August, scans showed that Peter had relapsed with disease spreading throughout his body, classing his relapse as high-risk and reducing his chances of long-term survival. His parents reached out to Solving Kids' Cancer UK for support in understanding the treatment path ahead and the options available to Peter, as relapsed neuroblastoma is particularly difficult to treat. Peter was immediately enrolled on the BEACON study, part-funded by Solving Kids' Cancer UK. His response to this was mixed, however it did clear disease in his bone marrow. After receiving radiotherapy to his skull, there were no further treatment options available for Peter unless his disease worsened, so the family decided to 'wait and watch' until his next scans.

Scans showed further shrinkage of the skull tumour and no progression of the disease. With these results and the support of Solving Kids' Cancer UK, the family was able to enrol Peter on the DFMO study. They flew out to North Carolina to start a two-year treatment plan in early 2022. In July 2023, Peter's scans showed that he had no evidence of active disease, but he will continue receiving treatment until January 2024.

"Solving Kids' Cancer UK have been key in helping us navigate relapse treatment options, fundraising for treatment in the US, organising the US trips, supporting us all emotionally and practically. Honestly don't know where we'd be right now without their support!"
Mandy, mum to Peter

Solving Kids' Cancer UK

Awareness




Gail Jackson, Kim Leadbeater and Nick Bird at the Westminster Roundtable, June 2022

Alongside our work in research and support, we are committed to raising wider awareness of neuroblastoma and its devastating impact. We are striving to highlight the challenges in this complex landscape that are hindering efforts to improve the treatment and care for children. By working collaboratively across the paediatric cancer community and engaging with key decision-makers, we hope to deliver change at a national level for the benefit of children and families.

Back Britain to Beat Childhood Cancer campaign
In January 2023, we launched our campaign in partnership with the Daily Express, titled 'Back Britain to Beat Childhood Cancer'. To improve the treatment and outcome of neuroblastoma, clinical research must be accelerated, which is why we're urging the government to act by investing in childhood cancer research. In the ongoing campaign, parents, politicians, clinicians and industry experts have shared their knowledge and views on how and why the government must better prioritise the needs of children with cancer.

External affairs strategy
As a charity that has long advocated for children with cancer, we know that we have the knowledge and expertise to facilitate real change. However, policy and public affairs is a new and complex world to Solving Kids' Cancer UK. We were therefore thrilled to have partnered with OVID to develop our first formal external affairs strategy that sets out a five-year plan to push paediatric cancer and neuroblastoma up the policy agenda, while strengthening paediatric cancer research and access to clinical trials. The strategy will officially launch in September 2023.

Westminster Roundtable
In June 2022, Solving Kids' Cancer UK joined Kim Leadbeater MP and Tom Tugendhat MP, at a roundtable of experts in Westminster to advise on efforts to secure UK-led vaccine trials for children with cancer. Solving Kids' Cancer UK was joined by parents of children with neuroblastoma – Shirley Hepworth and Claire Scott, as well as medical experts in the field. As part of our Family Support Service, Solving Kids' Cancer UK has supported families to travel overseas to access clinical trials of potential new therapies that are not available in the UK. But this comes with an immense financial and emotional cost to families. With strong support from MPs, Kim Leadbeater and Tom Tugendhat, this roundtable opened the discussion of securing more government investment into ultra-rare children's cancers like neuroblastoma to make more clinical trials available for children here in the UK. The benefits to this would be multi-faceted – by not only better serving children and families affected by neuroblastoma now, but also developing lasting infrastructure that would establish the UK as a leader in the field, allowing children to benefit far into the future.

Research advocacy
Chair of the Board of Trustees, Nick Bird, and Head of Research, Leona Knox, were asked to participate in the Children's Oncology Group (COG) Spring meeting 2022 to discuss ways forward with determining the role of high-dose chemotherapy and stem-cell transplant in high-risk neuroblastoma. Leona helped open the half-day meeting by sharing a personal perspective and Nick helped close the meeting as the only advocate on the panel. COG leaders are now using the session to generate ideas for a future study in North America. Leona was also asked to present at the FDA Pediatric Subcommittee of the Oncologic Drugs Advisory Committee meeting in May 2022, to discuss the potential utility of an intermediate clinical endpoint (response to induction therapy) in high-risk neuroblastoma. We hope this will push for the acceleration of the evaluation of new therapies in high-risk neuroblastoma.



Beau was diagnosed with high-risk neuroblastoma in December 2020, aged four. She immediately began frontline treatment, enduring chemotherapy, surgery, stem cell transplant, radiotherapy and immunotherapy. Before completing her treatment, her family were told that she had relapsed and that the cancer had returned in multiple places.

Despite continued efforts to treat the relapsed neuroblastoma, Beau's disease spread. In May 2023, treatment was halted, and she and her family enjoyed life to the fullest for the time they could. Beau passed away one month later, at six years old.

Beau's mum, Shirley, became connected with Solving Kids' Cancer UK early on in their neuroblastoma journey. Shirley passionately advocates for change, not only for Beau's sake but for every child and family that endure this devastating disease. She was instrumental in enabling the Westminster Roundtable in June 2022, inspiring Solving Kids' Cancer UK to work at a new level to bring systemic change that will improve the lives of those affected by childhood cancer.




2023/24 Goals

- Launch and implement external affairs strategy.
- Consistent submissions to government consultations on health and cancer policy.
- Establish and grow SIOPEN advocate network.
- Continue to participate in clinical trial steering groups to accelerate progress.
- Initiate support programme for parents who are keen to become more involved in advocacy.

Your support

Over the last year, we have been humbled by the support we have received from our community and event fundraisers and the ongoing support we have received from our corporate supporters. Highlights from the year include:



ALENKA,
SKC FUNDRAISER



Royal Parks Half Marathon

The Royal Parks Half Marathon 2022 was the charity's biggest challenge event to date. Over 60 runners took part for #TeamSKC, all training and fundraising towards the same vision. Many were completely new to running but wanted to do something big to show their support.

Those participating took in some of the capital's world-famous landmarks, on closed roads and within four of London's eight Royal Parks – Hyde Park, The Green Park, St James's Park and Kensington Gardens. A team of Solving Kids' Cancer UK staff and volunteers were there at two points along the course to cheer on runners in our team as they went past. We proudly had some of the loudest cheers on the course!

Runners met us at our post-event celebration in the festival village once they had completed their half marathon. Here they celebrated their incredible achievement with other runners, alongside food, drinks and goody bags. It was truly a day to remember and £45,000 was raised for Solving Kids' Cancer UK.

GamesAid

We were delighted to continue our relationship and receive £20,000 from GamesAid – the UK video games industry-based charity.

This relationship means so much to us and the children and families we support. Children with neuroblastoma and their families are faced with immense challenges and as a small charity we are continually challenged to find the resources we need to ensure we can continue to be there to support them when they need us the most. We believe that GamesAid and its members truly understand this and help to make our families feel seen and heard.
Gail Jackson, CEO, Solving Kids' Cancer UK



CARL CAVERS
SKC UK PATRON &
SUMO GROUP CEO



Sumo Group

In 2022/23 we were able to launch our **Care & Connect Support Bags** thanks to Sumo Group's generous donation. Stacey Smith, Sumo Group's Head of IT Service Delivery, also sourced and gifted 100 tablets to include in the bags.

Sumo Group lent their video editing and production expertise to help us produce a charity film that will raise awareness of neuroblastoma and the support we provide. The filming took place in 2022/23 and was launched in May 2023.

Canoe challenge

In June 2022, a group of fundraisers went coast to coast across Scotland in canoes. Starting at Fort William and finishing at the end of Loch Ness, the five-day adventure was an 85km route that included man-made canals, three Scottish lochs, and secluded sections of river with rapids. They took on this challenge in memory of Kitty Warburton and raised over £5,800 for Solving Kids' Cancer UK.



Head shave

After volunteering abroad for three weeks across the summer of 2022, Connie came home and decided that she wanted to continue to give back. On the day of her return, she had her plaits cut off and her head shaved by her mum with dog clippers! She did all of this to raise funds of more than £1,200 for children with neuroblastoma.



















Events

Family Fun Day

Following the COVID-19 pandemic, we wanted to host a day in the summer that was as accessible as possible to all the families we support, where they could come together after a difficult couple of years of not being able to meet in-person. On 16 July 2022, we held our Family Fun Day which brought families together for a relaxed and child-inclusive event at the beautiful Knebworth House. Over 40 families attended and created connections while having a really good time. There was an array of activities for all ages and interests. Our friends at We Can Kick It, a US-based organisation dedicated to inspiring and empowering children and families affected by cancer, led football games and activities. There were plenty of activities for guests to enjoy together as a family, from giant lawn games to craft activities. There was also a wonderful BBQ lunch, fit for the glorious weather on the day!

Neuroblastoma Parent Global Symposium 2022

On 11 November 2022, we held our third Neuroblastoma Parent Global Symposium (NPGS) in partnership with Solving Kids' Cancer US. The award-winning global event aims to inform and empower families affected by neuroblastoma, connecting them with those who work to treat, help and support them.

The event welcomed over 400 participants who heard from world-leading scientific and clinical experts working to push boundaries in the treatment of neuroblastoma, as they provided updates on the latest cutting-edge research. It also included Q&A sessions with experts and virtual conversation rooms on specific topics where families could come together for peer support.

"This event highlights how well connected the oncology world is and that we are fortunate to have so many amazing experts around the global searching for better treatments/cures for this devasting disease."
Adam, Australia

Families can access all the content from the 2022 events on-demand at solvingkidscancer.org.uk
We are grateful for the support from Norgine, EUSA Pharma, United Therapeutics Oncology, Sanofi, Y-mAbs Therapeutics Inc and GRC World Forums in making this event possible.

Festive hope

Our Christmas Carol Concert, on 8 December 2022, was our first in-person festive get-together for three years and it did not disappoint.

We were joined by none other than the EastEnders cast who formed their own choir and gave a brilliant performance. They even stayed behind at the end to meet guests and take plenty of selfies.

We had some magical performances from the London Show Choir and the London Oratory School Chamber Choir, which left everyone feeling warm and festive. And we also celebrated some of our heroes of 2022 who had such a positive impact on the neuroblastoma community during the year, including a special scientific award to Dr Juliet Gray for her continued exceptional contribution to neuroblastoma research and dedicated patient care.





The EastEnders choir performing at our Christmas Carol Concert in December 2022.

Achievements & performance

The first year of our new strategy has been a busy and very successful one with significant progress made across each of our three key pillars – Research, Support and Awareness. This included a strong focus on maintaining and developing our lean infrastructure.

Solving Kids' Cancer UK

Research

- Formed the ACTION Consortium, a group of five charities across the US and Europe to launch the largest-ever research grant call dedicated to neuroblastoma at $2 million.
- Facilitated the opening of the UK's frontline high-risk neuroblastoma trial across multiple UK sites.
- Launched the ALADDIN educational programme alongside 13 multi-stakeholder partners, which aims to accelerate the pace of childhood cancer drug development by empowering current and future generations of researchers through education and knowledge.
- Sponsored and participated in the 2023 Advances in Neuroblastoma Research conference.
- Appointed two new members to our Scientific Advisory Board: Dr Julia Glade Bender, paediatric oncologist and Vice Chair of Paediatric Clinical Research at Memorial Sloan Kettering in New York; and Dr Meredith Irwin, Chief of Paediatrics at the Hospital for Sick Children in Toronto.
- Certified as a PIF TICK Trusted Information Creator.

Support

- Reached more families than ever before through direct support from our Family Support Service team, one-off support grants, Care & Connect Support Bags and attendance of our Neuroblastoma Parent Global Symposium.
- Developed a Solving Kids' Cancer UK family support post-treatment programme for families in post-treatment and bereavement.
- Provided 52 Care & Connect Support Bags to children diagnosed with neuroblastoma, containing toys, vouchers and equipment during active and long-term treatment.
- Supported 20 families from across the UK and Republic of Ireland, who raised over £1.6 million to enable them to access treatments and clinical trials not currently available within the NHS.
- Provided over £121,000 in pastoral grants to 58 families and launched the Big Love Fund in June 2022, providing 35 families with a financial support grant.

Awareness

- Worked with a range of stakeholders to develop our first ever external affairs strategy.
- Co-led the 'Back Britain to Beat Childhood Cancer' campaign launched in partnership with the Daily Express.
- Facilitated the first cross-party MP roundtable in Westminster, focussed on bringing more clinical trials to children with neuroblastoma in the UK.
- Advocated for the needs of children at an international level through contribution to the Children's Oncology Group (COG) Spring meeting 2022 and the FDA Pediatric Subcommittee of the Oncologic Drugs Advisory Committee meeting in May 2022.







Images above, from left to right:
Nick Bird, Charity Chair of the Year
Teddy and Jude.

Inspire public support for the Charity

- Raised £760k of unrestricted income in a very challenging economic climate.
- Had 60 runners in the Royal Parks Half Marathon, one of our largest ever challenge events.
- Strengthened our digital communications and social media infrastructure with the recruitment of a new role of Digital Campaigns and Marketing Officer.
- Welcomed many of our supporters and families to our in-person Christmas Carol Concert with tuneful support from the Eastenders Choir, London Show Choir and the London Oratory School Chamber Choir.
- Secured GamesAid funding for a seventh year running.

Strong governance and infrastructure

- After an extensive consultation process, designed and developed a new brand for the charity that more effectively and accurately represents the charity's growth and evolution.
- Contracted and procured a new website to support our brand and reach.
- Exceptional leadership from our Chair of Board of Trustees, Nick Bird, recognised by the Third Sector Awards, winning the award of Charity Chair of the Year 2022.
- Continued to effectively manage our costs to ensure we are a lean and agile organisation, responsive to the needs of our community.

Future plans

The charity has proven itself to be robust and resilient in the face of adversity and uncertainty as a result of the COVID-19 pandemic and resulting fragile economic climate, but we are not complacent. We will continue to find ways to adapt and evolve our operating model to ensure we can continue to provide services to children with neuroblastoma and their families for many years to come.

We have made significant progress in the first year of our new strategy and have achieved all of the ambitious objectives we set for ourselves in year one, which focussed on securing a strong foundation and platform from which to build.

Year two of our strategy will see the charity consolidating the many changes made within year one, with a focus on embedding and continually improving and adapting the services we offer to ensure we are meeting the expressed needs of our community.

Over the next year we will:

- Continue to effectively and passionately advocate for children and families affected by neuroblastoma and work in partnership with the global neuroblastoma clinical and research communities, to help facilitate more effective and less toxic treatment options for children in the UK.
- Progress our most ambitious international Request for Applications (RFA) to date, together with our international partners through the ACTION consortium. This focusses on refractory and relapse neuroblastoma, calling for innovative approaches to accelerating clinical trials and evaluation of novel therapies.
- Build on the success of our parental engagement model through expansion of our Parent Involvement Forum through wider recruitment of new members and establishing a dedicated research advocacy group.
- Host our annual Neuroblastoma Parent Global Symposium, together with our partner in the US, and based on feedback from the global community, include a psycho-social track alongside the scientific and research track, to provide a broader range of information to support carers of children with neuroblastoma.
- Following the completion of our pilot programmes, we will launch our Care & Connect Coaching programmes in 2023, which are a series of online sessions for parents of children diagnosed with neuroblastoma following the end of treatment, as well as for those in bereavement, focussing on parental wellbeing and life after cancer.
- Launch our first External Affairs Strategy, working collaboratively with a multi-stakeholder group, to proactively raise awareness of the barriers and challenges to progressing clinical trials in the UK and identify solutions that focus on accelerating progress towards bringing more effective and less toxic treatment options to children diagnosed with cancer, more quickly.
- Continue to grow and strengthen our fundraising pipeline through expansion of our corporate partnerships, development of an individual giving programme and further development of our named funds so that families have a supported way to raise funds in the name of their child that support the core activities of the charity.
- Recruit two additional Trustee Board members based on analysis of skills and experiences needed in accordance with the charity's five-year strategy.
- Focus on collaboration through both enhancing existing relationships with organisations who share our values and ambitions for children facing cancer and their families, as well as building new partnerships; seeking to minimise duplication and coordinating efforts across all of our three key pillars of research, support and awareness so that more children and families can benefit from our collective efforts.
- Build on our efforts to address equity, diversity and inclusion across our organisation both internally and externally, ensuring we are meeting the needs of staff and volunteers, as well as beneficiaries of the charity's services.
- Launch and embed our new brand and continue to develop our new CRM and website, ensuring we achieve maximum benefit from the investment which will include reaching more families in need and growing our database of supporters.

Structure, governance & management

Governing document

The Trustees, who are also Directors for the purposes of company law, present their report and the financial statements of the company for the year ended 31 March 2023.

The charity is controlled by its governing document, the Articles of Association, and constitutes an incorporated registered charity. The charity was incorporated on 30 March 2010 at Companies House, was entered in the Register of Charities on 20 April 2010 and is administered by the Trustees. At their discretion, the Trustees may spend all or part of the capital of the charity in furthering its Objects, in the following ways:

i) To raise funds. The Trustees must not undertake any substantial permanent trading activity and must comply with any relevant statutory regulations.

ii) To buy, take on lease or in exchange, hire or otherwise acquire property and to maintain and equip it for use.

iii) To sell, lease or otherwise dispose of all or any part of property belonging to the charity.

iv) To borrow money and to charge the whole or any part of the property belonging to the charity as security for repayment of the money borrowed.

Aims and objects

The charity's objects ("Objects") are specifically restricted to the following:

- To advance the understanding and treatment of cancer in children through the greater awareness, provision of equipment, access to treatment protocols in hospitals and medical centres and clinical research aimed at improved diagnosis and treatment anywhere in the world.
- To advance the education, relieve the sickness and the poverty of persons living anywhere in the world through the provision of equipment, financial assistance and by any other charitable means that the directors in their absolute discretion think fit.

Public benefit

The Trustees give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the Objects and due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the principal activities of the charity are to provide public benefit.

Board of Trustees

Solving Kids' Cancer UK is governed by the Board of Trustees, chaired by Nick Bird. The Trustees determine the charity's strategic direction and oversee progress against objectives. It is responsible for governance and for upholding the charity's values. The charity must have at least two Trustees. The day-to-day running of the charity is the responsibility of the Chief Executive Officer.

The Board of Trustees supports the principles of good governance set out in the new Charity Governance Code (see www.charitygovernancecode.org) and also the continuous improvement model which the Code promotes.

The Board receives ongoing training and development, including periodic technical briefings on neuroblastoma research, has joint sessions with the Chair of the Scientific Advisory Board and attends the annual Neuroblastoma Parent Global Symposium and other relevant conferences/meetings.

The Board of Trustees has formal board meetings six times during the year. In accordance with the charity's Articles of Association, Trustees must undertake to attend meetings regularly and any Trustee failing to do so may be duly removed from their position.

The quorum necessary for the transaction of Trustee business at an ordinary meeting is two Trustees. The nominated Chair has the casting vote for decisions where there is equal weighting.

The Board selects and appoints new Trustees based upon their empathy with the Objects of the charity, skills and experience to help provide the appropriate level of governance and oversight for the charity to be effective, coupled with their ability to commit the necessary time for Board meetings and other key events.

Structure, governance & management continued

During the year, the Board focussed on the launch of the new strategy and oversight of the first set of deliverables, including agreeing the new brand and agreeing new roles within the organisation. The Board also supported the expansion of the SAB to increase representation across North America. The Chair, Nick Bird, attended an MP roundtable with the CEO in June 2022 with a focus on Advocacy.

Trustee induction procedures include completing relevant training and working with staff and existing Trustees to understand the organisation and develop internal relationships, to include one-to-one meetings with the CEO, Chair of the Board, Trustees and members of the Leadership Team. The induction also covers governance processes, strategic planning and finance, so that new Trustees are equipped with relevant knowledge about the organisation and its priorities. New Trustees are provided with a Role Description and Person Specification and Board Code of Conduct.

Scientific Advisory Board

Solving Kids' Cancer UK's Scientific Advisory Board (SAB) is an independent body of experts who are responsible for providing expert guidance and support to help us achieve our research goals, as well as overseeing our robust, AMRC accredited grant award process. Their advice and recommendations are presented to the Board of Trustees via our research team.

Our SAB continues to play an active role in guiding the research-related work of Solving Kids' Cancer UK and provides valuable feedback on our ongoing initiatives. The Project Monitoring Process was reviewed this year with the SAB guiding the revised approach to processes such as project extensions. The SAB received letters of intent for our latest international Request for Applications (ACTION) and gave scientific feedback to guide the final application.

The SAB also appointed two additional new members – one with specific neuroblastoma expertise and one non-neuroblastoma specific expert – which will further expand the capacity of the SAB and help reduce scenarios where a conflict of interest may arise, and proudly welcomed Dr Julia Glade Bender and Dr Meredith Irwin to the SAB.

The Trustees would like to extend their wholehearted gratitude to every member of our Scientific Advisory Board, for their continued dedication to push the charity's research goals forward, for the benefit of children with neuroblastoma in the UK and internationally. A special thanks goes to the Chair of our Scientific Advisory Board, Professor Andy Pearson, for providing his expertise and continued tireless commitment to help children with neuroblastoma and for his incredible enthusiasm and support for the work of Solving Kids' Cancer UK.

Staff remuneration

All salaries, including that of the Chief Executive, are based upon an assessment of the employment market, the skill levels required, the size and financial performance of the charity and the salary levels required to obtain the services of the best staff.

Equity, diversity and inclusion

Solving Kids' Cancer UK has a strong, caring ethos and is firmly committed to equity, diversity, and inclusion (EDI), which is integral to our new five-year strategy and values.

We are committed to embedding principles of equity, diversity and inclusion, ensuring that our operations, activities and services are designed and open for everyone to be included and to fostering culture, behaviours and practices in support of social justice.

EDI is fundamental to achieving our charity objectives to reach and be there for all families affected by neuroblastoma and for the health and wellbeing of all those we work with and exist for. We want everyone to feel included and believe in the importance of reflecting different perspectives, experiences and skills, including from those with lived experience of neuroblastoma, within our staff, board and volunteer teams.

We are not EDI experts, we don't have all the answers, and we won't always get it right – but this can't and won't hold us back. We are committed to learning, to listening and to creating safe spaces for difficult conversations that will inspire and lead to positive and lasting change.

Safeguarding

Our work and practice is underpinned by safeguarding principles with the aim of protecting children and young people and enhancing their welfare. Solving Kids' Cancer UK always works in accordance with legislation, statutory guidance and best safeguarding practices. Solving Kids' Cancer UK has robust safeguarding policies and procedures in place and all staff and Trustees receive dedicated safeguarding training upon induction with regular updates as required.
All hiring managers are required to access Safer Recruitment training to ensure that our recruitment processes are robust with an emphasis on ensuring the safety and welfare of the children and families we support. All staff and Trustees are required to have a basic DBS check and clearance before commencing their role with Solving Kids' Cancer UK and this is extended to any volunteer or service provider that may have regular direct interaction with the children and families we support. The charity reviews and revises safeguarding policies and procedures at regular intervals, at least annually, and has a designated safeguarding lead within the leadership team and a Trustee with designated safeguarding oversight.



Volunteers

The Trustees are extremely grateful for the considerable contribution made by the charity's volunteers and fundraisers in support of children with high-risk neuroblastoma, including our Parent Involvement Forum members, our committed and generous Patrons Rob Brydon, Carl Cavers and, welcomed as a Patron just after the year end, Kellie Bright. We are grateful to all those who lend their time, expertise and resources in furtherance of our charitable objectives.

This extends to the significant contribution made by clinicians and researchers who advise the charity on the complex landscape of high-risk neuroblastoma treatment, as well as those individuals that assist the office team with administration activities necessary for us to achieve our aims and objectives. During the year, the charity was supported by a huge number of volunteers working virtually who collectively contributed over 2,000 hours and we are hugely grateful to them all.

We would particularly like to acknowledge the dedication and commitment of our Patron, Carl Cavers, Chief Executive Officer of the Sumo Group, for his unwavering support of our charity. Over the last year, Carl has raised wider awareness of the needs of children with neuroblastoma and their families through his participation in national and international racing championships and introduced our charity to his wider network, supporting the growth of our individual and corporate support.

Through Carl, the charity has benefitted from incredible support from the Sumo Group who alongside donating funds to support our Care & Connect Support Bags, lend the charity their varied skills and expertise and help raise wider awareness.

Our legal & administrative details





Registered charity name
Solving Kids' Cancer UK
(changed from Solving Kids' Cancer UK Ltd on 25 August 2023)

Charity registration number
1135601 (England and Wales)
SC045094 (Scotland)

Company registration number
07208648

Registered office
Unit 02-03 Salisbury House,
29 Finsbury Circus
London EC2M 5SQ

Previous address
(until 11 September 2023)
Coram Campus
41 Brunswick Square
London WC1N 1AZ

Trustees
Nick Bird (Chair of the Board of Trustees)
Joseph Tabone (Board Policy and Safeguarding Lead)
Matthew G White (Equality, Diversity and Inclusion Lead)
David Coulon (Treasurer)
Alexandra Lane
Dr Áine McCarthy

Company Secretary
Gemma Wadsley

Chief Executive
Gail Jackson

Leadership Team
Anne Denman (Head of Fundraising and Communications left December 2022)
Claire Hislop (Head of Operations)
Danielle Russell (Head of Fundraising and Engagement – joined February 2023)
Gemma Wadsley (Head of Strategic Finance)
Leona Knox (Head of Research)
Vicky Inglis (Head of Family Support Service)

Auditors
Shipleys LLP
Chartered Accountants & Statutory Auditor
10 Orange Street, Haymarket
London, WC2H 7DQ

Bankers
National Westminster Bank
Church Road Branch
London, NW4 4DS

Investment managers
CCLA Investment Management Limited
Senator House
85 Queen Victoria Street
London, EC4V 4ET

Solicitors
Withers
16 Old Bailey
London EC4M 7EG

Our finances

Overview

We showed strong resilience in our income and operations during the year, in the face of the challenging external economic environment and cost of living crisis. Our unrestricted income was 10% down on the prior year at £760,051. We invested as planned in our new strategy whilst ensuring spend remained lean and we reported an unrestricted deficit of £52,415 before transfers, in line with our plans to reduce our reserves back into the target range through planned investment.

Overall, we are reporting an organisational surplus of £965,677, which reflects the timing difference between families raising funds and spending funds and is also reflective of our Research Strategy with timing, meaning we had significant activity within 2022/23 with the resulting funding commitments occurring within 2023/24.

Income

Our total income for the year was £2,991,524 (2022: £3,579,609). This is made up of £760,051 of unrestricted funds (2022: £843,739), £1,614,036 of designated funds (2022: £2,413,207) and £617,437 of restricted funds (2022: £322,663).

Our unrestricted income is made up of voluntary and investment income, which supports all of our charity's internal activities. This includes our family support provision – offering pastoral care to support families and providing evidence-based, impartial information to support parents in their choice of treatment options for their child and to access treatments and clinical trials if they are not available in the UK. It also includes our internal research team and infrastructure, all our fundraising activities and our operational running and governance. The majority of the remainder of our income relates to designated family funds which the Board have designated in the name of a child to support treatment options for that individual child and Income restricted to our Research Activities.

Whilst overall income has reduced by £588,085, this is largely as a result of designated funds which relates to income designated to family appeals with less families fundraising to travel abroad for treatment compared to the previous year.

Expenditure

Expenditure decreased slightly for the year at £1,884,851 (2022: £2,105,215). This reduction relates to families accessing treatment abroad which happened to be lower in this financial year. Family Support costs were down overall at £1,112,536 (2022: £1,246,284) as a result although Pastoral support to families has increased within this number. The phasing of Research commitments means that they fluctuate from year to year, with 2023 including one commitment extension at £38,379 (2022: £263,522). As noted as part of our new strategy, we have invested in our Family Support Service and Research teams as well as wider infrastructure such as website and our unrestricted expenditure has increased as a result to £862,928 (2022: £726,352).
Our costs remain extremely lean.

Investments

Given the nature of the organisation, supporting very young children and their families, our investment objectives are primarily to invest in an ethically sound manner in order to protect the value of the charity's assets against inflation and provide modest returns through a combination of income distribution and capital growth.
In addition to being mindful of the nature of investments made on behalf of the charity, the Trustees' appetite for risk is also influenced by the significant amount of funds that are designated for future purposes. The COIF Charities Ethical Investment Fund aims to provide a long-term gross return of 5% per annum net of inflation. Within this, the fund aims to deliver a consistent annual distribution of income and operate with a level of volatility (risk) that is no greater than 75% of the volatility of the UK equity market.
The return performance for the year was -2% given the market decline in the year, however, over the last three years the figure is +10.63%, which is consistent with our aims. Investment income for the year was £107,438.

Following a volatile investment year, we are reporting an investment loss of £184,680 (2022: £289,123 gain). However, over the total period, since purchase the investment has given capital growth of £1,019,388.

Our finances

continued

Reserves policy

The Trustees have adopted a reserves policy which they consider appropriate to ensure the continued ability of the charity to meet its objectives.

General funds are set aside to meet future costs to support our families and deliver our strategy. At the financial year-end, general funds were £959,981 (2022: £984,377).

General free reserves (undesignated funds excluding fixed assets) were £951,005 and represent 10.5 months' undesignated expenditure.

Free reserves are calculated as follows:

	2023 £
Total funds of the charity	13,333,320
Less: Restricted funds	(2,012,688)
Less: Designated funds	(10,360,651)
Less: Fixed assets held for charity use	(8,976)
	£951,005

The Reserves policy currently states that six to nine months of essential running costs should be covered in order to meet its obligations in the short-term (£545,000-£817,000 based upon 2023/24 budget). This is based on an assessment of the organisational risk approach and funding model.

As part of our five-year strategy, we agreed Investment in service delivery and income generation ahead of income growth, with planned deficits across the first half of the strategy and this year's deficit is the result of this plan. We have another deficit forecast for the 2024 budget which will bring our reserves position closer to the target range with the focus on fundraising investment, bringing through long-term fundraising growth alongside expenditure growth going forward.

This robust financial plan, alongside the need for caution given the continued challenging nature of the external environment for all charities, means that the Trustees are comfortable with the current reserves level and longer-term policy.

Designated funds are set aside for the treatment of specific children with neuroblastoma and are not available for the general running of the charity or any projects which do not directly relate to the treatment of that child. At the financial year-end, the charity held designated reserves of £10,360,651 (2022: £9,739,522). In the event of a child's death, the funds will be available to the family to support funeral and related costs and then the balance will be released from designated children's funds after a period of a year. Following the end of a successful course of treatment and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of five years so that they are available for that child should they suffer a relapse and require further treatment, a situation which is sadly common for neuroblastoma patients. This policy resulted in £280,187 (2022: £632,742) transferring from designated children's funds within the year with 70% transferred to the designated Solving Kids' Cancer UK Research Fund, 10% to the designated Solving Kids' Cancer UK Children's Reserve Fund, 10% to the Pastoral Grant fund and 10% to undesignated reserves.

Restricted Reserves are funds which can only be used for particular restricted purposes within the objects of the charity and arise when specified by the donor, or when funds are raised for particular restricted purposes. At the financial year-end, the charity held restricted reserves of £2,012,688 (2022: £1,643,744), of which £1,228,877 (2022: £1,218,822) arose from funds being held on behalf of families who were previously supported by Families Against Neuroblastoma.

Supporters of the charity are asked to note that, although the charity appears to hold significant reserves, 78% of these funds are designated or restricted to fund the treatment or support of children and families and a further 15% is designated or restricted to Research.

Risk management

The charity's Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks. The Trustees have overall responsibility for ensuring that the charity has an appropriate system of controls, financial and otherwise. They are responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- Its assets are safeguarded against unauthorised use or disposition;
- Proper records are maintained and financial information used within the charity or for publication is reliable and reviewed at every Trustee meeting; and
- The charity complies with relevant laws and regulations.

The risk register is a live document which is reviewed in detail every six months by the Board and Leadership Team and we have a secondary shorter-term register, which specifically groups the key current risks and our mitigation.

Risk categories include:

Governance
Covers risk of non-delivery of strategy, Board Skills & Capabilities and effective decision making and reporting.

Controls in place to manage these risks include a clear strategy underpinned by annual plans, a balanced and involved Board who have clear terms of reference and who consider their effectiveness and undertake training as appropriate. The Board request and receive regular reporting from executive management.

People
Covers risk of loss of key staff and poor structure.

Controls in place to manage these risks include strong oversight by CEO and senior managers, clear roles and responsibilities and strong HR processes. As staff numbers are small, this is a key risk which is closely monitored.

Finance
Covers all financial risks around effectiveness of our business model, level of reserves, management of investments and effective insurance.

Controls in place to manage these risks include annual budgeting and forecasting processes with regular reporting of our financial position to Trustees.
We have a clear reserves policy and hold general reserves to manage any changes in cash flow. We have an investment policy and investment managers who report on performance regularly.

Compliance
Covers all risks relating to non-compliance of required regulations including data protection, health and safety, employment and financial.

Controls in place to manage these risks include effective policies, staff training and awareness and effective advisors.

Operational, legal and physical
Covers risk of not being able to meet demands for family support and quality of support provided, risk of lack of funds due to expenditure exceeding income, health and safety risks and other operational risks including employment risks and disaster recovery.

Controls in place to manage these risks include ensuring the team have appropriate support to deliver in their roles and we are continuously considering current and future demand. Budgets and reserves are effectively managed to ensure funding is maintained. We have policies in place which are well understood and adhered to around health and safety, disaster recovery, employment policies and other areas of compliance.

Environmental /external factors
Covers reputational risk and relevant external risks such as economic conditions and Brexit.

Controls in place to manage these risks include effective communications policies and resource and ongoing monitoring of relevant external plans with action plans as required.

Grant-making policy
The Board of Trustees makes two types of grants. Firstly, grants to assist children suffering from neuroblastoma. Families, who need help, either self-refer, hear about the charity from their child's oncologist, or make contact with the charity's Family Support Team. Grants are also offered in the form of a hardship fund for families struggling to meet their

Our finances

continued

necessary costs due to the effects of having a child in treatment for neuroblastoma.

The second type is Research Grants. We engage in two distinct research funding mechanisms; a regular competitive funding call, and also ad-hoc Exceptional Funding Requests. All research grants are awarded in line with the principles laid out by the Association of Medical Research Charities (AMRC). Each application will be subject to rigorous scientific review guided by the charity's Scientific Advisory Board (SAB) and the nature of any grant made will depend on funds available through Solving Kids' Cancer UK's own reserves, or those made available through strategic collaborative partnerships.

Investment policy and objectives

The Deed of Trust allows the charity to deposit or invest funds in any manner; but to do so only after obtaining such advice from financial experts as the Trustees deem necessary and having regard to the suitability of investments and need for diversification. The charity aims to follow the COIF Ethical Fund Policy; excluding investments in companies involved in, for example, nuclear weapons, landmines, production of abortifacients, and other disqualifying criteria where there is a significant involvement (>10% of turnover).

Fundraising approach and policy

As a cause-related charity, we recognise that the service we offer for children and families affected by neuroblastoma and the advances in research we invest in would not be possible without the generous support and passion our supporters and families' supporters provide. We receive very little public funding for our work, relying on the generous support of the neuroblastoma community and general public.

We are registered with the regulatory body for fundraising in the UK, the Fundraising Regulator. As members of the scheme, we follow their Code of Fundraising Practice and comply with the key principles embodied in The Code. Many of our families raise funds for us at a local level and we ensure that they have all the information they need to comply with our policies and procedures.

It is hugely important to us that our supporters trust us and are well looked after:

- We ensure that we never put undue pressure on members of the public when raising funds.
- We are open and honest and approach our fundraising activities respectfully and considerately.
- We ensure that we comply with the wishes of our donors and comply with all general data protection laws.
- We respect the rights, dignity and privacy of our supporters and beneficiaries.
- We are accountable to our supporters and take this responsibility seriously.

We review all of our fundraising campaigns to ensure they fully comply with The Code and our fundraising activities are discussed regularly at Board meetings, to help ensure that our fundraising practices reflect and reinforce our values. Whether we're fundraising ourselves or working with families, organisations or volunteers, it's just as important.

We currently raise funds in a variety of ways, including: direct email campaigns, regular and individual giving programmes, virtual and in-person challenge events, corporate partnerships and percentage profit partnerships, direct cash donations, raffles, sponsored events and Charity of the Year partnerships. We have agreed and begun the implementation of a five-year fundraising strategy, which will further build upon our strong stewardship approach to develop existing income streams and develop new ones.

Within the year we achieved an unrestricted income of £760,051 with 29% coming from Corporate, Trusts & Foundations and Major Gifts, 23% from Community and Events and 22% coming through our family campaigns. Our performance reflects the challenging fundraising environment.

We take the protection of the personal data of all our supporters and donors extremely seriously and constantly review and monitor our fundraising policies and procedures to ensure we deliver 'best practice'. We do not engage professional fundraisers to raise money on our behalf.

We have a CRM system to further protect and manage our supporter data.

We welcome feedback on our fundraising activities at any time and strive to listen and learn from this feedback. During the course of the year, we recorded no complaints. We have a robust complaints policy. If a complaint about our fundraising activities is unable to be resolved through our complaints procedure, members of the public are advised to raise it with the Fundraising Regulator.

Trustees responsibilities statement

The Trustees (who are also the Directors of Solving Kids' Cancer UK for the purposes of company law) are responsible for preparing the Trustees Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under that law, the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the income and expenditure of the company for that period.

In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgements and accounting estimates that are reasonable and prudent; and
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of the persons who is a Trustee at the date of approval of this report confirms that:

- So far as each Trustee is aware, there is no relevant audit information of which the company's auditor is unaware; and
- Each Trustee has taken all steps that they ought to have taken as a Trustee to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Registered office:
Signed on behalf of the Board of Trustees
Unit 02-03 Salisbury House,
29 Finsbury Circus
London EC2M 5SQ



David Coulon
Trustee and Treasurer
10th October 2023

Independent auditors report

to the Trustees and members of Solving Kids' Cancer UK

Independent Auditors Report to the Trustees and members of Solving Kids' Cancer UK

Opinion

We have audited the financial statements of Solving Kids' Cancer UK ("the charitable company") for the year ended 31 March 2023, which comprise the Statement of Financial Activities (incorporating the Income and Expenditure Account), the Balance Sheet, the Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- Give a true and fair view of the state of the charitable company's affairs as at 31 March 2023 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- Have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- Have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustees Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Solving Kids' Cancer UK's ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the companies act 2006

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the Trustees Annual Report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- The directors' report included within the Trustees Annual Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees Annual Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- Adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- The financial statements are not in agreement with the accounting records and returns; or
- Certain disclosures of Trustees' remuneration specified by law are not made; or
- We have not received all the information and explanations we require for our audit; or
- The Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditors under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- We obtained an understanding of the charitable company's activities, controls and laws and regulations and assessed the susceptibility of the charitable

Independent auditors report

to the Trustees and members of Solving Kids' Cancer UK

company's financial statements to material misstatement from irregularities, including fraud.

- We determined that the laws and regulations that are most significant to the charitable company are the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)), Companies Act 2006, Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, the Fundraising Regulations and the charitable company's Articles of Association.
- Based on this understanding we designed our audit procedures to detect irregularities, including fraud. Testing undertaken included making enquiries on the management and those charged with governance; journal entry testing; review of bank letters, investments reports, Trustee board minutes and the Articles of Association; review of transactions for any undisclosed related party transactions; reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations. These procedures were designed to provide reasonable assurance that the financial statements were free from fraud or error.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- Conclude on the appropriateness of the Trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's Trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's Trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Tim Hardy (Senior Statutory Auditor)
10th October 2023
For and on behalf of SHIPLEYS LLP
Chartered Accountants & Statutory Auditor
10 Orange Street, Haymarket, London WC2H 7DQ

Statement of financial activities

Incorporating the income and expenditure account, year ended 31 March 2023

	Note	General funds Undesignated £	General funds Designated £	Restricted funds £	Total funds 2023 £	Total funds 2022 £
INCOME						
Donations	2	**569,044**	**1,602,591**	**592,670**	**2,764,305**	3,446,438
Trading activities	3	**29,265**	**11,445**	**3,800**	**44,510**	25,606
Investment income	4	**161,742**	**-**	**20,967**	**182,709**	107,565
TOTAL INCOME		**760,051**	**1,614,036**	**617,437**	**2,991,524**	3,579,609
EXPENDITURE ON:						
Raising funds	5	**(301,347)**	**(17,978)**	**(1,781)**	**(321,106)**	(353,065)
Charitable activities	6	**(561,581)**	**(755,452)**	**(246,712)**	**(1,563,745)**	(1,752,150)
TOTAL EXPENDITURE		**(862,928)**	**(773,430)**	**(248,493)**	**(1,884,851)**	(2,105,215)
NET (EXPENDITURE) / INCOME BEFORE (LOSSES) / GAINS ON INVESTMENTS		**(102,877)**	**840,606**	**368,944**	**1,106,673**	1,474,394
Net (losses) gains on investments	13	**–**	**(184,680)**	**–**	**(184,680)**	289,123
Other gains / (losses)		**50,462**	**(6,778)**	**–**	**43,684**	13,369
NET (EXPENDITURE) / INCOME		**(52,415)**	**649,148**	**368,944**	**965,677**	1,776,886
Transfer between funds	20, 21, 22	**28,019**	**(28,019)**	**–**	**–**	–
NET MOVEMENT IN FUNDS		**(24,396)**	**621,129**	**368,944**	**965,677**	1,776,886
RECONCILIATION OF FUNDS						
Total funds brought forward		**984,377**	**9,739,522**	**1,643,744**	**12,367,643**	10,590,757
TOTAL FUNDS CARRIED FORWARD		**959,981**	**10,360,651**	**2,012,688**	**13,333,320**	12,367,643

The statement of financial activities includes all gains and losses in the year.
All of the above amounts relate to continuing activities.
The notes on pages 38-57 form part of these financial statements.

Balance sheet

Year ended 31 March 2023

	Note	2023 £	2023 £	2022 £	2022 £
FIXED ASSETS					
Tangible assets	12		**8,976**		9,250
Investments	13		**3,519,388**		3,704,068
			3,528,364		3,713,318
CURRENT ASSETS					
Debtors	14	**100,921**		215,759	
Cash at bank and in hand		**11,284,479**		10,120,041	
		11,385,400		10,335,800	
CREDITORS: Amounts falling due within one year	15	**(1,022,050)**		(1,084,513)	
NET CURRENT ASSETS			**10,363,350**		9,251,287
TOTAL ASSETS LESS CURRENT LIABILITIES			**13,891,714**		12,964,605
CREDITORS: Amounts falling due after one year	16		**(558,394)**		(596,962)
NET ASSETS			**13,333,320**		12,367,643
FUNDS OF THE CHARITY					
Restricted funds	20		**2,012,688**		1,643,744
Designated funds	21		**10,360,651**		9,739,522
Undesignated funds	22		**959,981**		984,377
Total funds carried forward			**13,333,320**		**12,367,643**

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
These financial statements were approved by the members of the committee and authorised for issue on 10th October 2023 and are signed on their behalf by:

David Coulon, Trustee
Company registration number: 07208648

The notes on pages 38-57 form part of these financial statements.

Statement of cash flows

Year ended 31 March 2023

	Note	2023 £	2022 £
CASH FLOWS FROM OPERATING ACTIVITIES			
Net income		**965,677**	1,776,886
Adjustments for:			
Depreciation		**5,508**	4,715
Losses / (gains) on investments		**184,680**	(289,123)
Dividends and interest from investments		**(161,742)**	(107,565)
Decrease / (increase) in debtors		**119,512**	(53,848)
(Decrease) / increase in creditors		**(101,031)**	138,271
Net cash provided by operating activities		**1,012,604**	1,469,336
CASH FLOWS FROM INVESTING ACTIVITIES			
Dividends and interest from investments		**157,068**	106,772
Purchase of property, plant and equipment		**(5,234)**	(923)
Net cash provided by investing activities		**151,834**	105,849
CHANGE IN CASH AND CASH EQUIVALENTS	28	**1,164,438**	1,575,185
CASH AT START OF YEAR	28	**10,120,041**	8,544,856
CASH AT END OF YEAR	28	**11,284,479**	10,120,041

The notes on pages 38-57 form part of these financial statements.

Notes to the financial statements

1. Accounting policies

General information
Solving Kids' Cancer UK Ltd is a private company limited by guarantee incorporated in England under the Companies Act. The address of the registered office is Unit 02-03 Salisbury House, 29 Finsbury Circus, London EC2M 5SQ. The objectives of the charity are set out on page 23.

On 25 August 2023, the charitable company changed its name from Solving Kids' Cancer UK Ltd to Solving Kids' Cancer UK.

On 11 September 2023, the charity moved its registered office from Coram Campus, 41 Brunswick Square, London WC1N 1AZ to Unit 02-03 Salisbury House, 29 Finsbury Circus, London EC2M 5SQ.

Basis of preparation
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Solving Kids' Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policies.

The functional currency of the charity is considered to be pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling.

The amounts in the financial statements are presented to the nearest £, unless otherwise stated.

Preparation of the financial statements on a going concern basis
The financial statements of the charity have been prepared on the going concern basis. There are no material uncertainties about the charity's ability to continue. The Trustees consider that the going concern basis is appropriate having considered a period of at least twelve months from approval of these financial statements. The Trustees have prepared budgets and cash flow forecasts for that period which support the going concern assumption.

Fund accounting
Undesignated funds are available to spend on activities that further any of the purposes of charity.

Designated funds are funds of the charity which the Trustees have decided at their discretion to set aside to use for a specific purpose.

Restricted funds are donations which the donor has specified are to be solely used for particular restricted purposes within the objects of the charity.

Income
Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that those conditions will be fulfilled in the reporting period.

90% of any donation made to an individual appeal or journey is designated for the particular purpose of funding treatment not freely available on the NHS. The remaining 10% is retained within undesignated general funds to cover costs associated with the administration and management of appeals and journeys; including support with fundraising, logistics, and development of relationships as intermediary between families and the medical institutions that provide access to treatments and clinical trials.

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income from Government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred. In respect of the Coronavirus Job Retention Scheme grant; all conditions, with respect to the eligible costs being claimed, need to be met.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due. This is normally upon notification by our investment advisor of the dividend yield of the investment portfolio.

Expenditure and irrecoverable VAT
Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis.

Expenditure is classified under the following activity headings:

- Costs of raising funds comprise the costs of attracting donations and fundraising.
- Expenditure on charitable activities includes the cost incurred by the charity in the delivery of activities and services for its beneficiaries.

Grants payable are payments made to third parties in the furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the grant. Grant awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include staff, premises, finance and governance costs. These costs have been allocated between cost of raising funds and expenditure on charitable activities on the basis of an estimate of the proportion of time spent by staff on those activities.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Tangible fixed assets
Fixed assets are capitalised at cost and are depreciated over their estimated useful economic lives on a straight line basis as follows:
Equipment – 25% on straight line basis.

Fixed asset investments
Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

Notes to the financial statements continued

Debtors
Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand
Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions
Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments
The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases
The charity classifies the lease of the office space as an operating lease as the title remains with the lessor. Rental charges are charged on a straight line basis over the term of the lease.

Pension costs
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Differences between contributions payable in the year and the contributions actually paid are shown as either accruals or prepayments on the balance sheet.

2. Donations

	Undesignated funds £	Designated funds £	Restricted funds £	Total funds 2023 £
Donations	533,973	1,602,591	493,919	2,630,483
Donated services	35,071	-	-	35,071
Government grants	-	-	98,751	98,751
	569,044	**1,602,591**	**592,670**	**2,764,305**

	Undesignated funds £	Designated funds £	Restricted funds £	Total funds 2022 £
Donations	683,140	2,412,441	257,355	3,352,936
Donated services	32,000	-	-	32,000
Government grants	-	-	61,502	61,502
	715,140	**2,412,441**	**318,857**	**3,446,438**

The charity benefits greatly from the involvement and enthusiastic support of its many volunteers. In accordance with FRS 102 and Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the financial statements.

During the year, the charity received donated services relating to legal services and support for the Neuroblastoma Parent Global Symposium. The value of these services to the charity is estimated at £25,071 and £10,000 respectively (2022: £12,000 and £20,000 respectively). The estimated value of these services is recognised within income as a donation with an equivalent expense through the Statement of Financial Activities.

Income from Government grants comprises grants received under the UK Government COVID Medical Research Charity Support Fund of £98,751 (2022: £58,522) to provide support to UK Research in funding and the Government Coronavirus Job Retention Scheme of £nil (2022: £2,980). This grant was provided to support the cost of furloughed charity staff. The charity has not benefited from any other kinds of government assistance during the current or prior year.

3. Other trading activities

	Undesignated funds £	Designated funds £	Restricted funds £	Total funds £
Fundraising events 2023	**29,265**	**11,445**	**3,800**	**44,510**
Fundraising events 2022	21,540	766	3,300	25,606

Notes to the financial statements continued

4. Investment income

	Undesignated funds £	Designated funds £	Restricted funds £	Total funds 2023 £
Income from investments	107,438	-	-	107,438
Deposit account interest	54,304	-	20,967	75,271
	161,742	**-**	**20,967**	**182,709**

	Undesignated funds £	Designated funds £	Restricted funds £	Total funds 2022 £
Income from investments	106,111	-	-	106,111
Deposit account interest	948	-	506	1,454
	107,059	**-**	**506**	**107,565**

5. Cost of raising funds

	Undesignated funds £	Designated funds £	Restricted funds £	Total funds 2023 £
Cost of raising funds	188,963	17,978	1,781	208,722
Support costs	112,384	-	-	112,384
	301,347	**17,978**	**1,781**	**321,106**

	Undesignated funds (restated) £	Designated funds (restated) £	Restricted funds (restated) £	Total funds 2022 (restated) £
Cost of raising funds	193,375	50,755	1,876	246,006
Support costs	107,059	-	-	107,059
	300,434	**50,755**	**1,876**	**353,065**

6. Costs of charitable activities

	Activities undertaken £	Grant funding activities £	Support costs £	Total funds 2023 £
Support	181,279	807,590	123,667	1,112,536
Research	135,806	38,765	88,152	262,723
Awareness	117,548	-	70,938	188,486
	434,633	**846,355**	**282,757**	**1,563,745**

	Activities undertaken (restated) £	Grant funding activities (restated) £	Support costs (restated) £	Total funds 2022 (restated) £
Support	145,339	988,307	112,638	1,246,284
Research	89,930	263,522	33,583	387,035
Awareness	69,480	-	49,351	118,831
	304,749	**1,251,829**	**195,572**	**1,752,150**

Expenditure on charitable activities was £1,563,745 (2022: £1,752,150) of which £561,581 was undesignated (2022: £425,918), £755,452 was designated (2022: £1,178,048) and £246,712 was restricted (2022: £148,184).

Notes to the financial statements continued

7. Analysis of support costs

Support costs are allocated based on the proportion of time spent by staff on those activities.

	Support	Research	Awareness	Fundraising activities	Total 2023
	£	£	£	£	£
Staff costs	54,224	38,652	31,104	49,277	173,257
Premises and systems	42,579	30,351	24,424	38,694	136,048
Legal and professional	9,931	7,079	5,697	9,025	31,732
Finance costs	812	579	466	739	2,596
Depreciation	1,724	1,229	989	1,566	5,508
Governance costs	14,397	10,262	8,258	13,083	46,000
	123,667	**88,152**	**70,938**	**112,384**	**395,141**

	Support (restated)	Research (restated)	Awareness (restated)	Fundraising activities (restated)	Total 2022 (restated)
	£	£	£	£	£
Staff costs	48,933	14,589	21,440	46,509	131,471
Premises and systems	34,143	10,180	14,959	32,451	91,733
Legal and professional	13,115	3,910	5,746	12,465	35,236
Finance costs	1,155	345	506	1,099	3,105
Depreciation	1,755	523	769	1,668	4,715
Governance costs	13,537	4,036	5,931	12,866	36,370
	112,638	**33,583**	**49,351**	**107,058**	**302,630**

8. Governance costs

	2023	2022
	£	£
Auditor's remuneration	**13,000**	12,780
Legal and professional	**26,437**	18,048
Staff costs	**6,563**	5,542
	46,000	36,370

9. Analysis of grants

	2023	2022
	£	£
Children's treatment	**685,390**	900,765
Family support	**122,200**	87,542
Research		
University of Birmingham	**38,378**	-
Stanford University	**-**	125,000
UCL Great Ormond St Institute of Child Health	**-**	125,000
Newcastle University	**(912)**	13,522
University College London	**(1,001)**	-
Travel bursary	**2,300**	-
	846,355	1,251,829

Children's treatment grants are made towards the medical costs of the children suffering from neuroblastoma. The grants are paid directly to the hospitals providing the treatment.

Grants are made towards medical research for potential future life-saving treatments made possible through the constantly evolving world of burgeoning laboratory, pre-clinical and clinical research. These grants are paid directly to the institutions and are institutions working internationally which reflects the specialist and global nature of the research we fund.

Family Support Grants are those made towards providing essential support services to families affected by high risk childhood cancers. These grants are paid directly to affected families and organisations as appropriate or as directed.

Notes to the financial statements continued

10. Staff costs and emoluments

	2023 £	2022 £
Wages and salaries	**581,282**	493,263
Social security costs	**55,767**	44,600
Pension costs – defined contribution	**19,280**	16,412
	656,329	554,275

Pension costs are allocated to activities in proportion to the related staffing costs and are allocated between undesignated, designated and restricted funds on the basis of each employee's activities.

Particulars of employees: The average head count of employees during the year was 18 (2022: 15). The average number of full-time equivalent employees during the year is analysed as follows:

	2023 No.	2022 No.
Charitable activities	**7**	6
Fundraising	**3**	3
Support	**4**	3
	14	12

The number of employees whose remuneration for the year fell within the following bands, were:

	2023 No.	2022 No.
£70,000 to £79,999	**-**	1
£80,000 to £89,999	**1**	-

No higher paid staff were accruing benefits under a pension scheme (2022: None).

11. Net income

Net income is stated after charging:

	2023 £	2022 £
Auditor's remuneration		
Audit	**13,000**	12,780
Taxation	**804**	780
Depreciation	**5,508**	4,715
Operating leases – offices	**8,593**	10,043

12. Tangible fixed assets

	Equipment £
COST	
At 1 April 2022	**23,338**
Additions	**5,234**
At 31 March 2023	**28,572**
DEPRECIATION	
At 1 April 2022	**14,088**
Charge for the year	**5,508**
At 31 March 2023	**19,596**
NET BOOK VALUE	
At 31 March 2023	**8,976**
At 31 March 2022	9,250

Notes to the financial statements continued

13. Investments

Movement in market value	2023 £	2022 £
Market Value at 1 April 2022	**3,704,068**	3,414,945
Net (loss) / gain on revaluations	**(184,680)**	289,123
Market value at 31 March 2023	**3,519,388**	3,704,068
Historical cost at 31 March 2023	**2,500,000**	2,500,000

Analysis of investments as at 31 March 2023	Designated funds 2023 £	Designated funds 2022 £
UK listed investments	**3,519,388**	3,704,068

All investments are carried at their fair value. Holdings in investment funds, unit trusts and open-ended investment companies are at the bid price. The basis of fair value for quoted investments is equivalent to the market value, using the bid price.

Asset sales and purchases are recognised at the date of trade at cost (that is their transaction value).

The following investments were material in the context of the investment portfolio:
COIF Charities Ethical Investment Fund – £3,519,388 (2022: £3,704,068).

The main form of financial risk faced by the charity is that of volatility in investment markets due to wider economic conditions and variability of investment returns. This risk is mitigated by obtaining advice from a financial expert on the charity's investment portfolio.

14. Debtors

	2023 £	2022 £
Other debtors	**10,869**	137,831
Prepayments and accrued income	**90,052**	77,928
	100,921	215,759

15. Creditors: Amounts falling due within one year

	2023 £	2022 £
Trade creditors	**247**	-
Other creditors	**8,183**	53,384
Accruals and deferred income	**149,465**	55,643
Grant commitments (note 17)	**242,613**	372,998
Funds held as agent (note 18)	**621,542**	602,488
	1,022,050	1,084,513

16. Creditors: Amounts falling due after more than one year

	2023 £	2022 £
Grant commitments (note 17)	**558,394**	596,962

Grant commitments of £153,976 are due in more than five years (2022 £153,976).

17. Grant commitments

	2023 £	2022 £
Grant commitments brought forward	**969,960**	931,149
New commitments during the year	**38,766**	275,866
Payments made in the year	**(207,719)**	(237,055)
Grant commitments carried forward	**801,007**	969,960
Commitments at 31 March 2023 are payable as follows:		
Within one year	**242,613**	372,998
After more than one year	**558,394**	596,962
Grant commitments carried forward	**801,007**	969,960

Payments made in the year relate to milestone payments against existing grant commitments.

Notes to the financial statements continued

18. Funds held as agent

	2023 £	2022 £
Funds held as agent brought forward	**602,488**	598,212
Funds received during the year	**90,000**	297,000
Payments made	**(70,946)**	(292,724)
Funds held as agent carried forward	**621,542**	602,488

The charity has received funds as agent in its role as administrator of the Request for Applications (RFA) process and also of the research project for the prospective identification of children with "ultra-high-risk" (UHR) neuroblastoma.

At the year end, the charity held £621,542 (2022: £602,488) and this has been included in creditors in Note 15. £392,604 was held on behalf of Zoe4Life (2022: £389,024), £174,198 on behalf of The Merryn Lacy Trust (2022: £200,617) and £54,740 on behalf of Joining Against Cancer in Kids (J-A-C-K) (2022: £12,847).

19. Commitments under operating leases

At 31 March 2023 the company had total minimum lease payments under non-cancellable operating leases as set out below.

Land and buildings	2023 £	2022 £
Operating leases which expire:		
Within 1 year	1,619	9,833
Within 2 to 5 years	1,484	-
	3,103	9,833

20. Restricted funds

	Balance at 1 April 2022 £	Income £	Expenditure £	Transfers £	Balance at 31 March 2023 £
Families Against Neuroblastoma (FAN)	932,614	16,488	(10,918)	-	938,184
FAN Emergency Relapse Fund	286,208	4,485	-	-	290,693
HK Fund	15,842	-	(9,923)	-	5,919
CE Discretionary Fund	3,782	-	(3,544)	-	238
Restricted research funds	45,534	1,078	(22)	-	46,590
Parent Conference Fund	834	28,979	(29,813)	-	-
Other funds	96,815	55,324	(1,505)	-	150,634
Joining Against Cancer in Kids	27,180	-	-	-	27,180
Sunni Mae Fund	84,365	-	-	-	84,365
Family Support Fund	25,000	-	(25,000)	-	-
Support bags	25,000	-	(25,000)	-	-
Merryn Lacey Fund	100,570	-	-	-	100,570
Lottery funding	-	9,660	(3,521)	-	6,139
Ruperts Revenge Trust Fund	-	248,191	(100,022)	-	148,169
ALADDIN	-	46,181	(39,021)	-	7,160
Isla Caton Fund	-	207,051	(204)	-	206,847
	1,643,744	**617,437**	**(248,493)**	**-**	**2,012,688**

	Balance at 1 April 2021 £	Income £	Expenditure £	Transfers £	Balance at 31 March 2022 £
Families Against Neuroblastoma (FAN)	937,188	399	(4,973)	-	932,614
FAN Emergency Relapse Fund	286,100	108	-	-	286,208
HK Fund	15,842	-	-	-	15,842
CE Discretionary Fund	3,782	-	-	-	3,782
Restricted research funds	-	59,060	(13,526)	-	45,534
Parent Conference Fund	-	52,542	(51,708)	-	834
Other funds	91,684	57,003	(51,872)	-	96,815
Joining Against Cancer in Kids	27,180	-	-	-	27,180
Sunni Mae Fund	84,365	-	-	-	84,365
Family Support fund	25,000	25,000	(25,000)	-	25,000
Furlough Fund	-	2,981	(2,981)	-	-
Support bags	-	25,000	-	-	25,000
Merryn Lacey Fund	-	100,570	-	-	100,570
	1,471,141	**322,663**	**(150,060)**	**-**	**1,643,744**

Notes to the financial statements continued

20. Restricted funds Continued

Restricted funds can only be used for particular restricted purposes within the objects of the charity as specified by the donor or when funds are raised for particular restricted purposes.

Families Against Neuroblastoma (FAN)/ FAN Emergency Relapse Fund
There are 10 funds transferred from Families Against Neuroblastoma (FAN) and held for the sole use of individual children for access to treatment and welfare/ pastoral issues. Treatments are limited to those that are consistent with Solving Kids' Cancer UK Clinical Trial Policy. A further two donations from FAN were received to be used solely to support children with relapsed neuroblastoma with no access to other funds to pay for treatment that is not freely available on the NHS.

HK Fund is restricted for the sole purposes of supporting an individual named child. In accordance with the wishes of the donor, the fund supports the long-term health and welfare related needs of the beneficiary and is not accessed on a regular basis.

CE Discretionary Fund was established through an individual donation made to the charity to provide the Chief Executive with a means to fund initiatives in support of the effective working of the organisation, but for which no other budget existed.

Restricted Research Funds is a restricted fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research.

Parent Conference Fund represents donations towards the annual parent conference.

Other Funds represent funds created by families in memoriam specifically for research and advocacy projects.

Joining Against Cancer in Kids is a restricted fund which has been provided by Joining Against Cancer in Kids to support the costs incurred by families when participating in neuroblastoma trials/treatment being conducted at The Memorial Sloan Kettering Cancer Centre, New York or Hospital Saint Joan de Déu Barcelona.

Sunni Mae Fund is restricted to support the development and operational running of a Solving Kids' Cancer UK's presence in Ireland and/or provide wider support to Irish families affected by neuroblastoma. Alternatively, the fund can be used to support a future research funding call in which the Sunni Mae Trust will be acknowledged as a named collaborative funding partner.

Family Support Fund is restricted to the activities of the family support team.

Furlough Fund represents a government grant provided to support the cost of furloughed charity staff.

Support Bags represents funds donated specifically to create Support bags for all children diagnosed with neuroblastoma.

Merryn Lacey Fund represents funds donated by the trust which are restricted to research.

Lottery Funding represents a National Lottery Award for all restricted to our family support Life after Cancer Programme.

Ruperts Revenge Trust Fund represents restricted funds of £100,000 towards the Anti-CD47 + anti-GD2 research and £148,191 restricted to research.

ALADDIN represents a European funding grant for the delivery of a multi-stakeholder educational programme on regulatory science in paediatric cancer drug development.

Isla Caton Fund represents funds transferred and raised for pioneering research in memory of beautiful Isla who loved to sing and dance.

21. Designated funds

	Balance at 1 April 2022	Income	Expenditure	Transfers	Net losses on investments	Other gains and losses	Balance at 31 March 2023
	£	£	£	£	£	£	£
Designated Funds	6,923,606	1,525,794	(783,716)	(280,187)	-	-	7,385,497
Solving Kids' Cancer Children's Reserve Fund	600,812	-	(9,400)	28,019	-	-	619,431
Solving Kids' Cancer Research Fund	959,004	101,466	61,150	196,130	-	(6,778)	1,310,972
Family Support Fund	29,123	3,000	(30,724)	-	-	-	1,399
COVID-19 Fund	143	-	-	-	-	-	143
Big Love and Pastoral Funds	5,927	615	(10,740)	28,019	-	-	23,821
Designated General	16,839	(16,839)	-	-	-	-	-
Investment Reserve	1,204,068	-	-	-	(184,680)	-	1,019,388
	9,739,522	**1,614,036**	**(773,430)**	**(28,019)**	**(184,680)**	**(6,778)**	**10,360,651**

	Balance at 1 April 2021	Income	Expenditure	Transfers	Net gains on investments	Other gains and losses	Balance at 31 March 2022
	£	£	£	£	£	£	£
Designated Funds	6,191,809	2,389,373	(1,024,834)	(632,742)	-	-	6,923,606
Solving Kids' Cancer Children's Reserve Fund	477,933	-	(3,669)	126,548	-	-	600,812
Solving Kids' Cancer Research Fund	728,385	45	(200,000)	442,919	-	(12,345)	959,004
Family Support Fund	28,423	1,000	(300)	-	-	-	29,123
COVID-19 Fund	120	23	-	-	-	-	143
Big Love Fund	-	5,927	-	-	-	-	5,927
Designated General	-	16,839	-	-	-	-	16,839
Investment Reserve	914,945	-	-	-	289,123	-	1,204,068
	8,341,615	**2,413,207**	**(1,228,803)**	**(63,275)**	**289,123**	**(12,345)**	**9,739,522**

Designated funds are funds which have been allocated by the Trustees out of undesignated general funds to specific appeals for the treatment of children with neuroblastoma. In the event of a child's death, the funds will be released from designated funds. Following the end of a successful course of treatment, and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of 5 years so that they are available for that child should they suffer a relapse and require further treatment, a situation which is

Notes to the financial statements continued

21. Designated funds Continued

common for neuroblastoma patients. During the year, this policy resulted in transfers of £280,187 (2022: £632,742) with 70% transferred to the designated Solving Kids' Cancer Research Fund, 10% to the designated Solving Kids' Cancer Children's Reserve Fund, 10% to designated pastoral funds and 10% to undesignated reserves.

Solving Kids' Cancer Children's Reserve Fund is money designated to;
(1) support families who are fundraising for treatment who may require additional financial support to be able to meet the deadlines for enrolment on a particular clinical trial, and
(2) support children who are receiving treatment abroad but for whom additional unanticipated medical expenses are incurred. During the year £28,019 was transferred from designated funds (2022: £126,548).

Solving Kids' Cancer Research Fund is a designated fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research. During the year, £196,130 was transferred from designated funds (2022: £442,919).

Family Support Fund is designated to the activities of the family support team.

COVID-19 Fund is designated to the granting of funds to families of children with Neuroblastoma who have suffered a loss of income or increase in costs as a result of the diagnosis. It is initially for those affected by the need to shield during COVID-19.

Big Love and Pastoral Funds is designated to the granting of pastoral funds to support a child or young person's physical or emotional welfare and to support families in bereavement. During the year £28,019 was transferred from designated funds (2022: £nil).

Designated General is a general fund to hold designated income prior to allocation against an individual fund for example whilst awaiting gift aid allocation.

Investment Reserve represents the movement in fair value on investments since acquisition.

22. Undesignated funds

	Balance at 1 April 2022	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2023
	£	£	£	£	£	£
Undesignated funds	**984,377**	**760,051**	**(862,928)**	**28,019**	**50,462**	**959,981**

	Balance at 1 April 2021	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2022
	£	£	£	£	£	£
Undesignated funds	778,001	843,739	(726,352)	63,275	25,714	984,377

23. Analysis of net assets between funds

Fund balances at 31 March 2023 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2023
	£	£	£	£
Tangible fixed assets	8,976	-	-	8,976
Investments	-	3,519,388	-	3,519,388
Cash at bank and in hand	1,523,780	7,555,004	2,205,695	11,284,479
Other net current (liabilities) / assets	(572,775)	(271,763)	(76,591)	(921,129)
Creditors falling due in more than one year	-	(441,978)	(116,416)	(558,394)
	959,981	**10,360,651**	**2,012,688**	**13,333,320**

Fund balances at 31 March 2022 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2022
	£	£	£	£
Tangible fixed assets	9,250	-	-	9,250
Investments	-	3,704,068	-	3,704,068
Cash at bank and in hand	1,470,884	6,842,983	1,806,174	10,120,041
Other net current (liabilities) / assets	(495,757)	(265,789)	(107,208)	(868,754)
Creditors falling due in more than one year	-	(541,740)	(55,222)	(596,962)
	984,377	**9,739,522**	**1,643,744**	**12,367,643**

24. Company limited by guarantee

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is £10.

25. Taxation

The charity is exempt from tax on income and gains to the extent that these are applied to its charitable objects.

26. Related party transactions

The key management personnel of the charity for the year comprised the Trustees, Chief Executive and the Heads of Departments. The total employee benefits of the key management personnel were £301,390 (2022: £286,020).

The Trustees did not receive any remuneration or other benefits during the year (2022: £nil). One Trustee received reimbursement of expenses during the year of £854 relating to memberships and subscriptions (2022: £655).

Notes to the financial statements continued

26. Related party transactions Continued

During the year the charity paid salaries of £nil (2022: £710) to a close family member of Nick Bird, a Trustee.

The total donations received from two Trustees (2022: 2) during the year amounted to £1,100 (2022: £280).

27. Financial instruments

Financial assets measured at fair value through statement of financial activities:

	2023 £	2022 £
Investments	**3,519,388**	3,704,068

The income, expense, gains and losses in respect of all financial instruments are summarised below:

	2023 £	2022 £
Net (loss) / gain on revaluation of investments	**(184,680)**	289,123
Investment income	**107,438**	106,111

For further details about risks arising from financial instruments and the measurement basis see note 13.

28. Analysis of changes in debt

	At 1 April 2022	Cash flows £	At March 2023 £
Net cash			
Cash at bank and in hand	**10,120,041**	**1,164,438**	**11,284,479**

	At 1 April 2021	Cash flows £	As at March 2022 £
Net cash			
Cash at bank and in hand	8,544,856	1,575,185	10,120,041

29. Comparatives for the statement of financial activities

	Undesignated funds (restated) £	Designated funds (restated) £	Restricted funds (restated) £	Total funds 2022 (restated) £
INCOME				
Donations	715,140	2,412,441	318,857	3,446,438
Trading activities	21,540	766	3,300	25,606
Investment income	107,059	-	506	107,565
TOTAL INCOME	**843,739**	**2,413,207**	**322,663**	**3,579,609**
EXPENDITURE				
Raising funds	(300,434)	(50,755)	(1,876)	(353,065)
Charitable activities	(425,918)	(1,178,048)	(148,184)	(1,752,150)
TOTAL EXPENDITURE	**(726,352)**	**(1,228,803)**	**(150,060)**	**(2,105,215)**
NET INCOME BEFORE GAINS ON INVESTMENTS	117,387	1,184,404	172,603	1,474,394
Net gains on investments	-	289,123	-	289,123
Other gains / (losses)	25,714	(12,345)	-	13,369
NET INCOME	143,101	1,461,182	172,603	1,776,886
Transfer between funds	63,275	(63,275)	-	-
NET MOVEMENT IN FUNDS	206,376	1,397,907	172,603	1,776,886
RECONCILIATION OF FUNDS				
Total funds brought forward	778,001	8,341,615	1,471,141	10,590,757
TOTAL FUNDS CARRIED FORWARD	**984,377**	**9,739,522**	**1,643,744**	**12,367,643**

30. Prior year adjustment

Following the implementation of our new five year organisational strategy we have amended how we group our charitable expenditure from 'Access to Medical', 'Medical Research' and 'Education, Awareness and Family Support' to our three Strategy Pillars of 'Support', 'Research' and 'Awareness'. In practice the change for the prior year figures is simply the movement of Family Support grants and other spend moving from 'Education, Awareness and Family Support' to the first pillar of 'Support'.



Thank you

We want to say a heartfelt thanks to the following companies, people, schools, charities, foundations and trusts for their wonderful support.

Companies

Allen & Overy LLP
Aqua Leak
Burnt Peach
CitrusHR
EUSA
Fusebox Games
GamesAid
Google
GRC World Forums
Harper Collins
Irish SBA
iTech Media
Marks Sattins
MiniClip
Norgine
Pipeline Technology Centre
Privacy Culture
PwC
Ritter Sport
Sanofi
Scamp and Dude
Sumo Digital
Sumo Group PLC
United Therapeutics
Y-mAbs Therapeutics Inc.

Patron & Champions

Kellie Bright
Rob Brydon
Carl Cavers
Demie Risby

Scientific Advisory Board

Professor Andy Pearson – Chair
Dr John Maris – Vice-Chair
Dr Juliet Gray
Dr Lucas Moreno
Professor Michel Zwaan
Dr Julie Park
Dr Steve DuBois
Dr Meredith Irwin
Dr Julia Glade Bender
Nick Bird – Lay Member

Ambassadors & individuals

Clare and Chris Andrew
Polly Arber
Delroy Atkinson
Bobby Brazier
Jamie Borthwick
Ashley Byam
Mary Boulin
Ed Cartledge
Natalie Cassidy
Navin Chowdhry
Tony Clay
Will Cocker
Pippa Collins
Graham Cooper
Ellie Dadd
Tom Donegan
Roger Griffiths
Liam Gurney
Shirley Hepworth
Harley Kisberg
Gurlaine Kur Garcha
Stewart and Cassie Leaver
Chris Lee
Emma and Jamie Mascaro
Shona McGarty
Darren Mills
Dan Moore
Matthew Morrison
Clair Norris
Robson O'Reardon
Adina Pascall
Heather Peace
Helen Pearson
Lara Polati
Juhaim RasulChoudhury
Reach Creative Branding Ltd
Stacey Smith
Balvinder Sopal
James Speakman
Lorraine Stanley
Nick Streeter
Gilly Taylforth
Aaron Thiara
Iulia and Padmesh Thuraisingham
Ioannis Topsakalidis
Lacey Turner
Jessie Wallace
Mark Ward

Charities, foundations & trusts

Anticancer Fund
Arnold Clark Community Fund
Band of Parents
Childrens Neuroblastoma Cancer Foundation
GamesAid
Joining Against Cancer in Kids (J-A-C-K)
Kindred Foundation
Neuroblastoma UK
Rupert's Revenge
Sir John Sumner's Trust
Solving Kids' Cancer US
Special Effect
St. George's Society of New York
St James' Place Charitable Foundation
The Blackwood Engineering Trust
The Evan Foundation
The Hospital Saturday Trust
The Merryn Lacy Trust
The Tula Trust
Zoe4Life

Hero Awards 2022 recipients

Jacqueline Barber
Dr Juliet Gray
Krystal Knight
Donna Ludwinski
Danny Maloney
Mariann Nagy
Rebecca Rodgers
Stacey Smith
Sam Green and Sharon Stanley
Julie and Mel Williams
Scholes Junior and Infant School, Holmfirth

Parent Involvement Forum

Naomi Bentham
Leeanne Brennan
Kate Dixon
Claire Donnelly
Garrett Fitzgerald
Stewart Leaver
Naomi Shefford-Thomas
Carrie Wright

Family & named funds

Alfie's Wishes
Hannah's Heroes
Oscar Knox Fund
Smiles for Stanley
The Isla Caton Fund

Schools

Kings's School Hove
London Oratory School Chamber Choir
Pakefield High School

Solving Kids' Cancer UK

Solving Kids' Cancer UK is a registered charity. We receive very little public funding for our work, relying completely on the generous support of the neuroblastoma community and general public.

The support you give will make the difference to the lives of children and families affected by childhood cancer. For more information on how you can support and to donate visit:
solvingkidscancer.org.uk

@SKC_UK
SolvingKidsCancer365
skc365
Solving Kids' Cancer UK

Solving Kids' Cancer UK is a registered charity in England and Wales (1135601) and in Scotland (SCO45094). It is a company limited by guarantee in England and Wales (7208648). The charity and company currently operate as Solving Kids' Cancer UK.

Solving Kids' Cancer UK
Unit 02-03, Salisbury House, 29 Finsbury Circus, London EC2M 5SQ
Email: info@solvingkidscancer.org.uk
Telephone: 020 7284 0800

FUNDRAISING REGULATOR

Solving Kids' Cancer UK

England & Wales - Charity number 1135601

Accounts



Solving Kids' Cancer

Solving Kids' Cancer UK

Annual Report

& Accounts 2021/22


Solving Kids' Cancer UK

Annual Report

& Accounts 2021/22

Contents

Page 4 Introduction from Our Chair and CEO
Page 8 Our Strategic Plan
Page 10 Research
Page 12 Support
Page 14 Awareness
Page 16 Your Support and Events
Page 20 Achievements and Performance
Page 22 Future Plans
Page 23 Structure, Governance and Management
Page 27 Finances
Page 32 Independent Auditor's Report
Page 35 Financial Statements and Notes



Who's on our cover?

Flora is an energetic, outdoor-loving three-year-old from East Lothian, Scotland. She loves playing at the beach, splashing in the sea, playing at the park and building puzzles. She is a huge Peppa Pig fan and enjoys playing Peppa games on her tablet.

In January 2021, Flora was diagnosed with autism spectrum disorder. In the months that followed, Flora wasn't herself and her parents were given the devastating news that at just two years old she had high-risk neuroblastoma.

We are currently supporting Flora's family and their fundraising campaign to access the Bivalent Vaccine in New York.

Our year

Solving Kids' Cancer UK's vision is a future where no child dies of the childhood cancer neuroblastoma or suffers due to the treatment they receive.


Neuroblastoma is a rare and complex childhood cancer; around 90% of neuroblastoma cases occur in children younger than five years of age. It is the most common cancer in infants. Devastatingly, survival rates for neuroblastoma are as low as 50% in cases of high-risk disease, with even less chance of survival if a child relapses. This is the reality we are fighting to change.

We are a small but mighty parent-led charity with children firmly at our heart. We are striving for a better outcome for children and families affected by neuroblastoma, both now and in the future. In every conversation, we amplify their voice and ensure children are at the heart of all we do.

We will not stop until children with neuroblastoma, in the UK and beyond, have access to the treatment they need, when they need it, as close to home as possible. We do this through three key pillars: **Research, Support** and **Awareness.**

Over the last year we have:

- Continued to drive innovative research and worked in collaboration with five partners to award collectively over £500,000 in research grants
- Supported over 400 families by providing emotional, practical and financial support
- Supported 21 families from across the UK and Republic of Ireland, who raised over £2.5 million to enable them to access treatments and clinical trials not currently available within the NHS
- Collectively saved families nearly £200,000 by negotiating treatment costs with institutions
- Welcomed over 500 participants from 45 countries to our second Neuroblastoma Parent Global Symposium
- Delivered our most ambitious and successful group fundraising event ever with over 230 people taking part in our Butterfly Relay, raising over £30,000 and covering 125,000km
- Worked with our supporters who raised over £250,000 through community, challenge and event fundraising
- Welcomed our second charity patron – Carl Cavers, CEO of SUMO Group PLC



Welcome

Introduction from our Chair of Trustees

Over the last twelve months we have worked tirelessly to deliver on our mission to help children and families affected by neuroblastoma, growing as an organisation, and cementing progress and achievements made since we launched our current five-year strategy in 2017. As we reach the end of that period we can look back with great pride and satisfaction at the transformational journey our charity has been on.

Built from nothing, we now have a research function that is the equal of any operating in children's cancers. Working in partnership with others to invest in innovative new research to find better and safer treatments for children with neuroblastoma while providing more options for those desperately in need right now. Driven by a deep knowledge and understanding of the neuroblastoma landscape that allows us to focus on unmet needs and prioritise areas that can deliver the greatest impact for children.

Our support for families with children going through treatment and beyond now blends the personal knowledge and experience that has always been an intrinsic part of who we are with a professional framework of skills and best practices. We have forged excellent relationships with the clinical community and other charities, and enhanced our reputation for delivering emotional, practical, and financial support with honesty and integrity while always putting the needs of children and families first in everything we do.

Operationally we have never been stronger, our processes and policies never more robust or comprehensive. We have made strategic investments in our systems infrastructure despite the ensuing uncertainty caused by the pandemic and are already starting to see the benefits in terms of greater automation, efficiency gains, and enhanced financial management and reporting. The commitment, dedication, and togetherness of our staff team, putting children and families at the heart of everything we do, is truly what makes us who we are as an organisation.

Our governance structures are strong and secure, board oversight of the organisation is robust, and all our Trustees are deeply engaged and invested in the charity's work. Each brings their own individual knowledge and expertise to the team, as we strive to maintain a balance of parent and non-parent Trustees to provide broad perspectives.

Of course, now is also time to remind ourselves that we cannot rest on our laurels. There is much more work to do. For all that has been achieved over the last five years, the reality is children and families affected by neuroblastoma still need us today just as much as they ever have done. As I look ahead to the next important chapter in our charity's history with anticipation, expectation, hope, and optimism, I know that we will not let them down.



Nick Bird
Chair of the Board of Trustees







Where there is heart, there is hope

Welcome from our CEO

This quote from a family really speaks to the very ethos of this special charity that I'm privileged to be part of. The SKC staff team, Board of Trustees, volunteers and supporters consistently inspire me through their dedication and unwavering commitment to supporting children with neuroblastoma and their families both now and into the future. Everything they do is with a heart full of hope. This Annual Review is full of both and I'm so very proud to be part of Team SKC.

Over the last year, our charity has grown significantly both in relation to the wider range of partners we work with to facilitate and fund research, and through the numbers of families of children diagnosed with neuroblastoma who we have offered our support to over the last year, which has been more than ever before in the charity's history. The team has consistently risen to the continued pandemic challenges and ensured that our important events, including our parent conference and our Christmas carol concert could be delivered virtually again this year. Our second Neuroblastoma Parent Global Symposium, delivered again with our partners and friends in the US, was shortlisted for an innovation award and reached an audience from across the world.

Our most ambitious and successful fundraising event to date was our Butterfly Relay, and my sincere thanks go to Clare Andrew, mum to Hannah, who led the charge - the event raised over £30,000. I am continually inspired by the families who support us in so many ways - by fundraising for the charity and connecting us to their networks or by lending us their skills and expertise. Like Clare, Stewart and Cassie Leaver are another shining example of the very heart of this charity, and through their fundraising efforts in memory of their beautiful daughter Jossie, they have raised in excess of £120,000 for SKC.

This year we welcomed Carl Cavers as our second charity Patron. Carl is not only a highly successful and accomplished businessperson and entrepreneur, he is also full of heart, and became involved with our charity following his support of a young man called Luke, who you will read about in this review. My heartfelt thanks to Carl, to the wonderful people at 2K and Firaxis and their friends from Marvel, and most especially to Luke's very special family and friends, who we are honoured to continue to support with their fundraising efforts in Luke's name. The charity is proud to be launching a fund inspired by Luke's story during 2022.





As we look back and celebrate all that's been achieved over the last five years, we look forward with hope as we launch our bold new five-year strategy in 2022. With existing and new partners, we will launch our most ambitious research funding award to-date with a focus on accelerating more effective treatments. We will aim to reach all families of children diagnosed with neuroblastoma in the UK, providing a broader range of practical, emotional and financial support at any point of the journey. And we will continue to advocate for children and their families, developing our first public affairs policy to more boldly champion the needs of all children diagnosed with neuroblastoma, and their families.

My final words are reserved for the children and families we support – it is you who motivate, inspire and drive us in everything we do - to be bolder and to never lose our focus on helping in the here and now whilst striving to make the future brighter. You are our heart and our hope.



Gail Jackson
Chief Executive Officer



Our strategic plan

Our next five-year strategy will be launched in 2022, with our core priorities and objectives set out within three pillars: Research, Support and Awareness. These will be underpinned by three key enablers – sustainability, good governance, and impact – and guided by our charity values:

Caring

We care passionately about children with neuroblastoma, their families, and all those who care for them, including our staff, volunteers, and supporters.

Transparent

We are open and honest about all that we do and how we do it.

Collaborative

Relationships are at the heart of our work – from the children and families we work with, to the individuals, organisations and networks that are involved in their care.

Inclusive

Our services are developed to ensure they meet need and we aim to make them accessible to all.

Determined

We lead with tenacity and are unfaltering in our drive to help, support and fight for children with cancer.

Hopeful

We have a strong sense of optimism and hope is at the heart of all that we do.

Over the last five years we have:

Research


- Mobilised 13 new projects spanning across the UK, Europe, and North America
- Facilitated the investment of over £3.5 million into pioneering research, with a focus on rapid clinical impact for children
- Enhanced our partnership approach by collaborating with 11 like-minded partners to bring maximum impact for children and their families
- Identified and prioritised areas of unmet need where children are most at risk, including a first ever funding call exclusively for primary refractory disease
- Received Association of Medical Research Charities (AMRC) accreditation for our robust grant review process, ensuring that we fund only the best and most influential research and in the fairest possible way
- Funded the Solving Kids' Cancer Senior Trials Coordinator for Neuroblastoma at University of Birmingham's Cancer Research UK Clinical Trials Unit (CRCTU), the first such position dedicated to a single childhood cancer

Support

- Provided vital practical, emotional and financial support to over 1,000 families
- Supported over 40 families to access treatments and clinical trials both within the UK and abroad
- Collectively saved families over £1million by negotiating treatment costs with institutions
- Introduced our Parent Involvement Forum, to ensure our service development meets families' needs
- Established and strengthened relationships across the clinical community e.g., through our partnership and part-funding of the National Neuroblastoma Nursing Group (NNNG), delivered in partnership with CCLG
- Strengthened capacity of our family support team to meet need and develop services
- Introduced our annual parent survey to encourage a regular dialogue with the neuroblastoma community
- Hosted three in-person parent education conferences welcoming over 400 participants
- Taken our parent conference online in the face of the pandemic and hosted the award-winning Neuroblastoma Parent Global Symposium in 2020 and 2021, welcoming over 1000 participants from over 50 countries

Awareness

- Embedded parent and research advocacy in our organisation, with team members positioned in key UK and international forums
- Formally challenged the decision by National Institute for Health and Care Excellence (NICE) not to approve anti-GD2 immunotherapy for children with neuroblastoma in the UK, paving the way for it to become part of frontline treatment
- Co-authored the first pediatric oncology advocate-only manuscript to be published in the Journal of Clinical Oncology, a leading scientific publication
- Participated in a debate on the role of stem cell transplantation and high-risk neuroblastoma at SIOP 2021 (International Society of Pediatric Oncology), and subsequently authored a special report that was accepted for publication in Pediatric Blood & Cancer



Research

We are dedicated to helping those facing a neuroblastoma diagnosis today, while also building a better future with better outcomes for children diagnosed in the future. We do this by driving and investing in pioneering clinical research, focused on finding treatments that are more effective and less toxic.

Our research mission is led by parents of children affected by neuroblastoma who have become experts in the field, allowing us to build a portfolio that has children and families at its heart. We are uniquely placed to use our influence, embedded position within the research community, and reputation alongside our AMRC- accredited research funding framework to make a difference for children.

"The charity has made outstanding progress in driving research, which is benefiting children with neuroblastoma in the UK." Andy Pearson (Prof), Chair of SKC UK Scientific Advisory Board (SAB)

We launched our formal Research Strategy in 2017. The ultimate goal of that strategy is to improve the outcome for children and adolescents with neuroblastoma, achieved by facilitating new clinical approaches evaluated through evidence-based clinical trials.

Clinical research brings the all-important hope that families need when facing a childhood cancer diagnosis. By investing in pioneering projects, we are working towards a future with improved outcomes for children with neuroblastoma, as well as bringing more options to the clinic for children who are in need of more and better options now.

Over the past five years

- Facilitated the investment of over £3.5 million into pioneering research, with a focus on immediate clinical impact for children
- Mobilised 13 new projects spanning across the UK, Europe, and North America
- Collaborated with 11 like-minded, patient-focused partners to bring maximum impact for children and their families
- Identified and prioritised areas of unmet need where children are most at risk, including the first ever funding call exclusively for primary refractory disease
- Received AMRC accreditation for our robust grant review process, ensuring that we fund only the best and most influential research, and in the fairest possible way

2021/22 Summary

Looking back to 2020, it was an unprecedented year in many ways, including in our research progress, as we launched three new international research studies and facilitated a £2.1 million investment in pioneering clinical research into neuroblastoma. Following this, as well as continuing to fund new projects, our focus for 2021/22 has been on long-term sustainability planning and strategy-building to ensure that we can continue to have impact of this scale.

Continuing momentum

In June 2021, we saw the launch of our latest funded project - Optimizing Immunotherapy for Primary Refractory Neuroblastoma. This project, led by Dr Robbie Majzner at Stanford University School of Medicine and Prof John Anderson at UCL Great Ormond Street Institute of Child Health will investigate a novel combination of two immunotherapy agents and low-dose chemotherapy in treating newly diagnosed refractory neuroblastoma as well as patients who have relapsed. It was funded following our 2019 International Neuroblastoma Research Initiative, which was the first of its kind to call specifically for proposals on primary refractory neuroblastoma, a sub-type of disease, which has incredibly poor outcomes and is in desperate need of change. This research work is currently translational in nature, with a built-in plan to move into clinical trials as soon as possible once necessary work to optimise the combination therapy is completed.

Planning for an ambitious 2022

In March this year, our Scientific Advisory Board met to discuss plans for our next international funding call. This was a very successful meeting that has been followed by an intense period of work by the research team to finalise the International Neuroblastoma Research Initiative 2022. This will mark our biggest funding call to date, and we are incredibly excited to see what the research community brings forward with such a huge potential for impact. We have, once again, used our collaborative approach to strengthen this award through partnership. Conversations with these like-minded organisations first began in 2021, and we are now excited to work closely with them as the funding call develops.

About MiNiVan

In 2015, we collaborated with Solving Kids' Cancer US, Joining Against Cancer in Kids (J-A-C-K) and Band of Parents to award $500,000 to bring this trial to both Europe and the USA. Founded on promising pre-clinical studies with a strong scientific rationale, it hopes to provide an innovative new treatment for relapsed and refractory neuroblastoma.

If successful, this therapy may offer an important alternative or complimentary treatment modality to chemotherapy-based regimens for children with neuroblastoma in the future.

Over the next five years

Accelerate Clinical Trial Development

We will focus on accelerating the development of new treatments by investing in clinical research and working with valued partners for maximum impact.

Prioritise the Needs of Children

We will engage with families to identify areas of unmet need, challenging experts to find solutions and work together to deliver maximum impact through the research we fund.

Foster Collaboration

We will build and strengthen international partnerships to share expertise, best practice and resources, whilst building knowledge.

Poppy

Poppy was diagnosed with high-risk neuroblastoma at just four years old, in the middle of the COVID-19 pandemic and just weeks after the arrival of her baby brother.

Initially, Mum, Claire, thought that Poppy's symptoms, including lack of appetite, complaints of leg pain and clinginess, were due to the huge changes brought on by the pandemic and having a new addition to the family.

However, after Poppy became more unwell, a consultation with the GP and blood tests at Bedford Hospital hinted at something more sinister. A chest X-ray finally revealed a tumour in Poppy's chest cavity, wrapping around her heart and pushing against her lung. This was later confirmed to be neuroblastoma.

After 13 rounds of chemotherapy in frontline treatment, Poppy enrolled onto the MiNivAn trial at the University of Southampton. The MiNivAn trial was co-funded by Solving Kids' Cancer UK in 2015.

The study is testing a new combination of radiation therapy and two different immunotherapy drugs in the hope that it will help to reduce a child's cancer, particularly where their disease is not responding well to standard chemotherapies.

For Poppy, the treatment helped reduce her 33 spots of disease to three. Since completing the trial, Poppy has gone back into frontline treatment, which includes surgery, high-dose chemo with stem-cell rescue and radiotherapy, and she has just completed her third round of immunotherapy.

"Clinical trials are so important to move cancer treatment forward. Chemotherapy is not always the answer for every child. The MiNivAn trial has helped Poppy move from 33 spots down to just 3, with no chemotherapy involved".

Claire, Poppy's Mum




Support

Our unique Family Support Service is dedicated to the neuroblastoma patient and parent community in the UK. The team blends personal experience and acquired knowledge, as parents of children affected by neuroblastoma, with professional skills and experience. They provide expert advice on practical, financial and emotional burdens, as well as helping to guide families through often difficult, complex and fraught decision-making processes.

Our service focuses on the here and now, easing the immediate burdens and pressures which a neuroblastoma diagnosis brings.

"My son was diagnosed at the age of 15 years, over 14 years ago. There was not much in the way of support for families in those days, and certainly no specialist input. Solving Kids' Cancer has been a godsend to so many. It's a guiding light when you feel lost and can't see a way forward and clarifies things amidst all the confusion." Parent in receipt of support from the charity



Luke

We have provided support to Luke and his wonderful family since he was diagnosed with neuroblastoma when he was 14 years old. In 2021, Luke and his family received the devastating news that there were no more curative options for him. Over the years, while facing aggressive and toxic cancer treatment, Luke found solace and comfort in the world of Marvel and gaming. Now he had one last special wish – to play a not yet released video game, Marvel's Midnight Suns from 2K and Firaxis Games.

His wish to play this game sparked a remarkable series of events and a groundswell of support across social media from the gaming community, which resulted in Luke's wish coming true. Incredibly, 2K – the game's publisher – reached out to us and a member of the 2K team visited Luke with a special in-development version of the game, making Luke among the first few people in the world to have the chance to play. He is now forever immortalised in the game with a special tribute: his name engraved on a tree and listed in the game's credits.

Luke sadly passed away in 2021 at the age of 23, but knowing him and his family and seeing his wish realised has had a profound effect on our charity, our work, and our supporters. Luke was committed and passionate about our work, the support we provide children and families and the future we are determined to see – a world without neuroblastoma and where the word holds no fear.

In Luke's own words,

Big love, only love, always love

Over the next five years

Reach all Families

Every family of a child diagnosed with neuroblastoma in the UK will have access to our support service from the point of diagnosis.

Broaden Range of Support

We will develop and expand our support offer in line with what families tell us they need.

Inform and Support Decision Making

We will ensure families have access to the most current and scientifically robust data from around the world and support their decision to access the best treatment possible.







Awareness

Both patient and research advocacy have been critical functions of the charity since its inception and have been key to many of the successes achieved. In research, this has led to many achievements, including the notable NICE appeal that helped lead to direct changes to standard therapy, and growth of a research portfolio that focuses on the unmet needs of children.

Our Family Support team is also fully immersed within the neuroblastoma community, which allows us to progress every aspect of our work with families at the very centre.

"The implementation of the Parent Involvement Forum is an excellent initiative and provides further opportunities for advocacy throughout the charity's work." Helen Pearson, Chair, National Neuroblastoma Nursing Group

There are several 'expert advocates' within our organisation who hold key positions within the international research landscape, many of which they have established themselves.

Head of Research - Leona Knox

- ACCELERATE Steering Committee
- ACCELERATE International Collaboration Working Group
- SIOPEN Advocate Committee Founding Chair (International Society of Paediatric Oncology European Neuroblastoma Group)
- American Association for Cancer Research (AACR) Affiliate Member and Paediatric Cancer Working Group (PCWG)
- Kids v Cancer Parent Council
- Innovative Therapies for Children with Cancer Advocate Committee Member

Research Advisor - Donna Ludwinski

- New Approaches to Neuroblastoma Therapy (NANT) Advisory Council
- Coalition Against Childhood Cancer (CAC2) Board
- National Cancer Institute (NCI) Paediatric Central Institutional Review Board
- American Association for Cancer Research (AACR) Affiliate Member and Paediatric Cancer Working Group (PCWG)
- Paediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC) for the US Food and Drug Administration (FDA)

Voluntary Research Director and Chair of Trustees – Nick Bird

- National Cancer Research Institute Neuroblastoma Group Member
- NHS England Clinical Reference Group for Children and Young People's Cancers Patient & Public Voice Representative
- Innovative Therapies for Children with Cancer Advocate Committee Founding Chair
- SIOPEN Advocate Committee Member
- National Institute for Health and Care Excellence (NICE) Patient Expert for anti-GD2 monoclonal antibody therapy
- Formerly National Cancer Research Institute Children's Group Member

Strengthening Research Advocacy

As we developed our new five-year strategy, our patient advocate experts within the research team continued their vital work in research advocacy. This year has seen several novel accomplishments by the team, including the first ever advocate-authored paper to be published in the Journal of Clinical Oncology (JCO). Nick Bird, Chair of Trustees and Research Director, led the authorship of this groundbreaking paper that discusses the issues at play in drug development for childhood cancer.

This was followed by a second landmark advocate-authored paper published in Pediatric Blood & Cancer (PBC), led again by Nick Bird, discussing the use of stem cell transplant in the treatment of high-risk neuroblastoma – a subject that has anguished parents over the last decade.

In addition, our research team has been heavily involved in breaking new ground by establishing formal advocate committees within the two major European collaborative research networks relevant to children with neuroblastoma, ITCC and SIOPEN. ITCC (Innovative Therapies for Children with Cancer) runs early phase clinical trials across all children's cancers, and SIOPEN (International Society of Paediatric Oncology European Neuroblastoma Group) is the multi-national group responsible for all major neuroblastoma clinical trials in Europe. Nick Bird and Leona Knox hold the two founding Chair positions of these Advocate Committees and as such represent the patient and parent voice within the Executive Committees of each respective organisation.

Their work will prove an invaluable foundation for the charity as we build our new Awareness pillar, which will encompass these important advocacy activities within the research community.

Over the next five years

Research Advocacy

We will amplify the voice of the children and parents, seeking to advance science and understanding of the disease alongside patient-centric research.

Patient Advocacy

We will champion the needs of individual children and their families, providing parent-led support around decision-making to improve treatment outcomes.

Awareness and Campaigning

We will raise the profile and support the treatment needs of children with neuroblastoma and other childhood cancers with the general public, government and public bodies.

Odile

Odile was diagnosed with low-risk neuroblastoma soon after she was born in 2019. Now three years old, Odile is a healthy, cheeky and loving toddler.

Odile's parents, Iulia and Padmesh, felt helpless in those early weeks and months after Odile was born. After spending hours searching for advice and information about low-risk neuroblastoma and being unable to find any, they both felt isolated and scared about Odile's future and totally unprepared to make potentially life-or-death decisions around their daughter's health. They finally came across information about our charity and were in regular contact with our dedicated Family Support Team, and through doing so were able to seek a second opinion, which helped inform their decision making.

In the summer of 2020, with Odile doing really well, Iulia signed up to be a Solving Kids' Cancer UK Ambassador. Iulia is dedicated to enabling the charity to reach more families from the point of diagnosis, including those families of children who are diagnosed with low and intermediate-risk neuroblastoma. This is largely shaped from experiencing the lack of information available about low-risk neuroblastoma and the conflicting opinions around treatment for children with this type of disease.

As part of her ambassador role, Iulia, who works for Google, introduced us to their incredible EMEA Business Strategy & Operations team, who gifted us a day of their time and expertise by hosting a focused strategy day. Over 14 amazing Googlers signed up to participate alongside members of our team and Board of Trustees. The Googlers reflected with us, informed and challenged us.

Despite our small size, we have huge ambitions on behalf of children with neuroblastoma and their families. Our day with Google helped us realise that our ambition and determination is far more important than our size and that we need to think beyond any limitations and be bold and unapologetic for children and families who deserve nothing less.



Your support

Over the last year, we have been humbled by the support we have received from our community and event fundraisers and the ongoing support we have received from our corporate supporters. Highlights from the year include:

Bents Garden and Home

It was an honour to be selected as Bents Garden & Home's Charity of the Year. It was wonderful working together on a variety of fundraising activities with the highlight being the Bents Butterfly Ball. The connection came through Stewart & Cassie Leaver and their beautiful daughter, Jossie.

Bents Butterfly Ball: The much-anticipated event was a magical night and huge success with so much warmth, enthusiasm, and compassion for the work of Solving Kids' Cancer. The night completely exceeded expectations with an incredible £42,000 raised. The emotion and depth of feeling for our cause and especially for little Jossie, taken far too soon by neuroblastoma, was clear for all to see. The raffle and auction had everyone spending generously, and the entertainment and atmosphere in the room provided a huge tonic as the country began to slowly emerge from the pandemic. We are extremely grateful to the team at Bents and all their customers for their incredible support and generosity.

"Solving Kids' Cancer is a cause very close to the hearts of everyone at Bents Garden & Home, following the loss of our Financial Director's great niece, six-year-old Jossie Leaver, who bravely battled with neuroblastoma. Through this family connection, we became very aware of the fantastic support provided by the charity to those whose lives are affected by this devastating condition, seeing first-hand how it helped Jossie and her family, and learning more about the incredible work it carries out. Whilst it is a relatively small charity, it has a huge heart and fantastic levels of support for the families it cares for. As a business, we are delighted to be able to help with our annual Charity of the Year fundraising and are looking forward to being able to present the charity with what we hope will be a sizable donation in April 2022." Bents Garden and Home.

Jossie also inspired a large group of friends and family to take part in the Thames Bridges Trek in September 2021, across Childhood Cancer Awareness Month. All those who knew, loved, or felt inspired by her were part of 'Jossie's Posse', and together, in her memory, they walked 25km across London.

Over the course of the year more than £120,000 was raised in Jossie's memory and honour by these amazing and dedicated supporters.







iTech Media:

We are delighted to have the support of our wonderful corporate partner, iTech Media, with members of their team completing two challenge events for us within a couple of days in October 2021. Firstly, Tough Mudder, a team of 11 competing for us in South London. Then came the Royal Parks Half Marathon on a sunny October morning. We are so grateful for their support and the amazing amount raised for us.

SUMO Group:

SUMO's connection came through Luke's story (page 12) on social media, and because of this, we are delighted their CEO, Carl Cavers, is now one of our Charity Patrons. SUMO's generosity and support has enabled SKC UK to grow and deliver projects that simply had not been possible previously. Their continued support never ceases to amaze us. Over the next year, we will be working closely with the SUMO team to launch the Care & Connect Family Support bag project: an idea that is now becoming a reality, all thanks to SUMO's generosity.

"I'm honoured and humbled to be part of the SKC UK team and join as Patron of this remarkable charity. The work SKC UK do around both researching the disease and around dealing with the impact of treatment is incredible. We are in a privileged position as games developers; not only can we help by donating financially, but we can help bring a measure of joy to these children's lives as they and their families navigate such a challenging time. SKC is accomplishing so much, and I'm determined to help raise awareness for this deserving charity." Carl Cavers, CEO, Sumo Group and SKC Charity Patron

Solving Kids' Cancer
BUTTERFLY RELAY 2021

Butterfly Relay

The wonderful Butterfly Relay took place from May to September 2021, inspired by and created in memory of Hannah for what would have been her 21st birthday. One of our ambassadors, Clare Andrew, Hannah's Mum, worked with SKC to launch this wonderful event, saying, **"Hannah fought for so long, I feel like she wouldn't want us to just give up and walk away. She'd say 'Well, what are you going to do now then? Come on, let's go!'".**

10,000 butterflies were knitted by volunteers across the country in support of this event and children with neuroblastoma. Each team member carried a knitted butterfly on their journey as a symbol of hope.

The event saw over 230 people taking part and raised over £30,000 for the charity. This incredible group walked, swam, ran, cycled, and skipped throughout the five months. The original target was 21,000km, but this target was soon smashed, and together participants collectively travelled over 125,000km!






Your support

A2B for Stanley

In October 2021, a special event took place in memory of a very special boy, Stanley. Starting from Addenbrooke's Hospital in Cambridgeshire (where Stanley spent six months with all the wide ranging, often brutal, treatments he received during his battle with neuroblastoma) a team of friends and family cycled 222 miles, crossing the border into Wales to end in Brecon, raising over £5,000 for the charity.

"We would like to acknowledge all the hard work, amazing charity contributions, warm hospitality from complete strangers, and superb riding efforts from the entire team on A2B for Stanley. Riding 222 miles from Addenbrooke's to Brecon was no mean feat in what at times was torrential rain, but everyone involved, riders and support crew, smiled throughout. A true testament to our amazing little hero, Stanley George Appleton, who continues to be an inspiration to all those that deliver each time in his honour." Sarah and Paul, Stanley's parents.



Ollie's Climb

The wonderful Ollie trained hard for months with his dad to prepare for climbing Pen y Fan. He completed his challenge and raised £1,300 to fight for a brighter future for other children.



Events

Taking our events online

To meet the challenge of COVID-19 we were, once again, faced with the difficult decision to take our in-person events online. Taking our events online has made them accessible to families across the world, enabling us to extend our reach and be more inclusive than ever before. Our enormous and sincere thanks to GRC World Forums and their team for continuing to make these events possible.

NEUROBLASTOMA PARENT GLOBAL SYMPOSIUM 2021
5th & 6th November

Neuroblastoma Parent Global Symposium 2021

On 5 and 6 November 2021, we held our second Neuroblastoma Parent Global Symposium in partnership with Solving Kids' Cancer US and Children's Neuroblastoma Cancer Foundation (CNCF). This event, which brings together the research and parent communities, was born from our in-person Parent Education Conference (2012–2019) which sadly had to be postponed in 2020 and 2021 due to the pandemic. While this was incredibly disappointing because we know the value of the in-person conference to families, it meant the evolution of a more accessible virtual gathering, which also has global reach.

The event welcomed over 500 participants and provided a range of information sessions led by international leaders in the neuroblastoma field. It included more opportunities for Q&A with the experts and introduced conversation rooms focused on specific topics where families could come together for peer support, something they previously hadn't had the opportunity to access. The event was highly valued by the parent community, which was reflected in the feedback we received after the event.

"One of the greatest benefits of these sessions is that us parents are gaining the confidence that we can make as many informative decisions as possible for our kids and their treatment paths. That's a huge thing. Keep up the good work."

"Just an amazing achievement by all involved. Thank you so much."

"Thank you so much for the time and effort put into making this such a great event! Very valuable information!"

We are proud that NPGS 2021 has been shortlisted in the Third Sector Awards 2022 in the category of Best Service Delivery Innovation, as well as being awarded Best Specialist Child Cancer Research and Parent Support NPO - UK in the Healthcare & Pharmaceutical Awards 2022.

This event has been a wonderful opportunity for the charity to grow and adapt and will continue to inform our educational activities moving forward.

Families can access all the content from our 2021 and 2020 events on-demand through the NPGS website - www.nbparentsymposium.com

We are grateful for the support from Y-mAbs Therapeutics, Jubilant Radiopharma and Sanofi in making this event possible.

Caroling Together

Our second virtual Carol Concert took place on 16 December 2021. We welcomed 180 households to the event and raised over £7,000 in support of our work. There were stunning performances from the likes of The Jupiter Singers, Astræa, London Oratory School Chamber Choir and the cast of TINA: The Tina Turner Musical. Our Patron, Rob Brydon, also performed exclusively alongside His Fabulous Band.

Five Solving Kids' Cancer UK Hero Awards were presented to some very special people in the neuroblastoma community. The winners were: Carol Benbow; Rainbow Ward, North Middlesex Hospital; 2K and Firaxis, Emma Rees and Michelle Collins.



Achievements and performance:

The post-pandemic world continued to present great challenges to both our charity and the children and families we exist for. Throughout this challenging year we have remained resolute and focused on the delivery of our six key strategic objectives, set out in our 2017–2022 strategic plan.

1. Strengthen governance to successfully deliver our charity's mission

- Strengthened and recruited to our Board with a view to succession processes and planning.
- Implemented a CRM system to improve donor journey, communications and impact measurement.
- Strengthened our risk register and added an addendum covering current risk factors such as COVID-19.
- Implemented our new finance system.
- Continued to streamline our costs to ensure we are a lean and agile organisation, responsive to the needs of our community.
- Undertook a comprehensive review of our 2017-2022 Strategic Plan and consulted the parent and clinical communities and charity partners to inform our 2022-2027 Strategic Plan.

2. Engage and inspire long-term public support for the charity and the fight against neuroblastoma

- Implemented our ambitious Fundraising and Comms Strategy.
- Hosted the Butterfly Relay, inspired by Hannah Edwards, and collectively travelled over 100km.
- Recruited for the new role of Relationship Manager, who works closely with our corporate supporters.
- Welcomed over 180 households to our second virtual Christmas Carol Concert, raising over £7,000.
- Secured GamesAid funding for a sixth year running.
- Raised over £250,000 through our dedicated community and challenge event supporters.
- Developed a relationship with Google, who provided their expertise and time to deliver a strategy day focusing on three key areas of development.
- Launched Solving Kids' Cancer Named Funds, enabling families to raise funds in their child's name to directly support key areas of our work.

3. Review and enhance the charity's support offerings

- Increased capacity within our Family Support Service team to ensure we can reach all children and their families.
- Provided hundreds of families with emotional and practical support and evidence-based and impartial information about neuroblastoma and its treatment.
- Delivered our second Neuroblastoma Parent Global Symposium, reaching over 500 participants across 45 countries.
- Provided over £75,000 in pastoral grants to 13 families.
- Enhanced our own understanding of the global clinical trial landscape and launched an internal learning programme via regular research drop-ins.
- Saved families collectively nearly £200,000 by negotiating treatment costs with institutions.

4. Facilitate access to the best available treatments and most promising clinical trials

- Supported families to raise £2.5 million to access treatments and clinical trials not currently available within the NHS.
- Facilitated access to treatment in the UK and overseas for 15 children.
- Organised flights and accommodation for ten families.
- Saved families collectively nearly £200,000 by negotiating the costs of their treatments with cancer institutions.
- Continued to provide patient advocacy, championing the needs of individual children and their families.

5. Support and enable best in class clinical research, accessible in the UK

- Produced the first ever advocate-only authored paper on paediatric cancer to be published in the Journal of Clinical Oncology (JCO).
- Saw a second landmark advocate-authored paper published in Pediatric Blood and Cancer (PBC), discussing the use of stem cell transplant in treatment for high-risk neuroblastoma.
- Helped to establish two new advocate committees within the Innovative Therapies for Children with Cancer research network (ITCC) and the leading European neuroblastoma research organisation, SIOPEN.
- Directly committed over £250,000 to innovative research and facilitated the commitment of over £500,000 alongside partners.
- Facilitated an initial roundtable meeting in Parliament to drive the development of a cross-party strategy, which will consider how to bring more innovative therapies to the UK.

6. Harness the combined power and resources of the neuroblastoma community to most effectively advocate for, and work in support of, children and their families.

- Partnered with three other charities to help deliver more and better treatment options for children with neuroblastoma.
- Surveyed our community and worked with our Parent Involvement Forum to inform our new strategy and service development.
- Worked in collaboration with Solving Kids' Cancer US and Children's Neuroblastoma Cancer Foundation to host the second Neuroblastoma Parent Global Symposium.

Future plans

Like many charities, the ongoing challenges presented by the pandemic will have an impact on our work and the community we serve for years to come, in addition to the challenges presented by the emerging cost of living crisis.

We will develop our services in line with our 2022–2027 strategic plan, informed by our three pillars – Research, Support and Awareness – and underpinned by our three enablers – sustainability, good governance and impact. We will remain focused on the needs of the neuroblastoma community and take an inclusive approach to raising our voice for the benefit of children and their families.

Through this, we will continue in our unswerving vision for a future where no child dies of neuroblastoma or suffers due to the treatment they receive.

Over the next year we will:

- Launch our 2022–2027 Strategic Plan, informed by our stakeholders and developed in line with our vision to build on the success and learning from our 2017 –2022 Strategic Plan; ensuring we have a blueprint for our growth, sustainability and stability into the future.
- Continue to build and enhance relationships and work in partnership with the global neuroblastoma family, as well as clinical and research communities, to support our vision and work to raise our collective voice. Ensuring we continue to advocate passionately and effectively for children and families affected by neuroblastoma.
- In September 2022, issue our most ambitious international Request for Applications (RFA) to date, inviting researchers to submit their ideas to us as part of our competitive Research Funding Award process.
- Provide additional pastoral support by launching a special fund for families across the UK and Ireland, inspired by Luke Wiltshire.
- Build on the success of the second Neuroblastoma Parent Global Symposium by working with Solving Kids' Cancer US and the neuroblastoma clinical community to host our third virtual global event for the benefit of families and all those who support them. Inspired by the success of the symposiums, we will also launch our SKC webinar series for families in the UK.
- Continue to develop our support service, informed by the neuroblastoma parent and clinical community. We will launch our bespoke Care & Connect Family Support bags and develop services for families affected by bereavement, and those navigating psychosocial and physical challenges following years of intensive treatment.
- Continue to develop our education and advocacy offer through developing project partnerships in Europe and transatlantically. We will take an active role in the ongoing debate around childhood cancer outcomes, through developing our own public affairs strategy; and continuing to build relationships with UK Principal Treatment Centres and other organisations providing direct and frontline services to families affected by neuroblastoma and other children's cancers.
- Enter the second year of our ambitious fundraising strategy, informed by our stakeholders and responsive to the current landscape, to ensure our long-term sustainability and growth.
- Invest in our team, in line with our new strategic plan, to strengthen our offer in family support, fundraising and comms.
- Undertake consultation with stakeholders to inform a brand refresh and further develop our website to ensure it meets the needs of those we are trying to reach and of the charity itself.
- Continue to enhance the functioning of our Board in line with strategic planning to ensure effective and robust succession planning is in place.
- Focus on strengthening our organisational effectiveness by further embedding our CRM and Finance database systems, enabling us to develop sophisticated mechanisms for reporting, gathering insight and demonstrating our impact.

Structure, governance and management:

Governing Document

The Trustees, who are also Directors for the purposes of company law, present their report and the financial statements of the company for the year ended 31 March 2022.

The charity is controlled by its governing document, the Articles of Association, and constitutes an incorporated registered charity. The charity was incorporated on 30 March 2010 at Companies House, was entered in the Register of Charities on 20 April 2010 and is administered by the Trustees. At their discretion, the Trustees may spend all or part of the capital of the charity in furthering its Objects, in the following ways:

i) to raise funds. The Trustees must not undertake any substantial permanent trading activity and must comply with any relevant statutory regulations.

ii) to buy, take on lease or in exchange, hire or otherwise acquire property and to maintain and equip it for use.

iii) to sell, lease or otherwise dispose of all or any part of property belonging to the charity.

iv) to borrow money and to charge the whole or any part of the property belonging to the charity as security for repayment of the money borrowed.

Aims and Objects

The charity's objects ("Objects") are specifically restricted to the following:

- To advance the understanding and treatment of cancer in children through the greater awareness, provision of equipment, access to treatment protocols in hospitals and medical centres and clinical research aimed at improved diagnosis and treatment anywhere in the world.
- To advance the education, relieve the sickness and the poverty of persons living anywhere in the world through the provision of equipment, financial assistance and by any other charitable means that the directors in their absolute discretion think fit.

Public Benefit

The Trustees give due regard to the public benefit provided by the Charity in relation to its charitable purpose as set out by the Objects and due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the principal activities of the Charity are to provide public benefit.

Board of Trustees

Solving Kids' Cancer UK is governed by the Board of Trustees, chaired by Nick Bird. The Trustees determine the Charity's strategic direction and oversee progress against objectives. It is responsible for governance and for upholding the Charity's values. The Charity must have at least two Trustees. The day-to-day running of the Charity is the responsibility of the Chief Executive.

The Board of Trustees supports the principles of good governance set out in the new Charity Governance Code (see www.charitygovernancecode.org) and also the continuous improvement model which the Code promotes.

The Board of Trustees, receive periodic technical briefings on neuroblastoma research, have joint sessions with the Chair of the Scientific Advisory Board and attend the annual Neuroblastoma Symposium and other relevant conferences/meetings. During the year, Trustees and the full staff team joined together for a strategy day to support the design of the new five-year strategy.



The Board of Trustees has formal board meetings six times during the year. Trustees initially commit to a three-year term and may hold office for a maximum of three, three yearly terms. Trustees who have undertaken their first three-year term of office could elect to extend their trusteeship by an additional one, two or three years. Trustees may resign from office by serving one month's written notice to the other Trustees. In accordance with the charity's Articles of Association, Trustees must undertake to attend meetings regularly and any Trustee failing to do so may be duly removed from their position.

The quorum necessary for the transaction of Trustee business at an ordinary meeting is two Trustees. The Trustees agree that the nominated Chair has the casting vote for decisions where there is equal weighting.

Trustees may be appointed by the members by an ordinary resolution or by the directors by a resolution of the directors.

The Board selects new Trustees based upon their empathy with the Objects of the charity, skills and experience to help provide the appropriate level of governance and oversight for the charity to be effective, coupled with their ability to commit the necessary time for Board meetings and other key events, to include the annual Neuroblastoma Symposium.

During the year, the Board focused on their succession planning and skills gaps. One new Trustee, Dr Aine McCarthy joined the Board on 20 July 2021 and Bronwyn Ellis stepped down on 6 February 2022. We would like to extend our sincerest thanks to Bronwyn for her unfaltering support of the work of the charity over the course of her tenure as Trustee. The Board is looking to undertake a further Board recruitment process during 2022/23 to increase the number of Board members. Alexandra Lane, Trustee, is also further developing her knowledge of research, and will be joining the Research Workgroup in 2022, which is tasked to work towards achieving the objectives of the Research pillar within the new five-year strategy.

Trustee induction procedures include completing relevant training and working with staff and existing Trustees to understand the organisation and develop internal relationships, to include one-to-one meetings with the CEO, Chair of the Board, Trustees and members of the Leadership Team. The induction also covers governance processes, strategic planning and finance, so that new Trustees are equipped with relevant knowledge about the organisation and its priorities. New Trustees are provided with a Role Description and Person Specification and Board Code of Conduct.

Scientific Advisory Board

Solving Kids' Cancer UK's Scientific Advisory Board (SAB) is an independent body of experts who are responsible for providing expert guidance and support to help us achieve our research goals, as well as overseeing our robust, AMRC accredited grant award process. Their advice and recommendations are presented to the Board of Trustees via our research team.

Our SAB continues to play an active role in guiding the research-related work of Solving Kids' Cancer UK and provides valuable feedback on our ongoing initiatives. The Annual Progress Reports submitted by the leader of each funded project were reviewed, with further interim reports requested to more closely monitor progress of some of the projects. The scope of our next international Request for Applications has been decided, which will call for more innovative clinical research and novel approaches to make best use of limited resources, focused on the unmet needs of children. The SAB also voted to appoint two additional new members – one with specific neuroblastoma expertise and one non-neuroblastoma specific expert– which will further expand the capacity of the SAB and help reduce scenarios where a conflict of interest may arise.

The Trustees would like to extend their wholehearted gratitude to every member of our Scientific Advisory Board, for their continued dedication to push the Charity's research goals forward, for the benefit of children with neuroblastoma in the UK and internationally. A special thanks goes to the Chair of our Scientific Advisory Board, Professor Andy Pearson, for providing his expertise and continued tireless commitment to help children with neuroblastoma, and for his incredible enthusiasm and support for the work of Solving Kids' Cancer UK.

Staff Remuneration

All salaries, including that of the Chief Executive, are based upon an assessment of the employment market, the performance of each member of staff, the skill levels required, the size and financial performance of the charity and the salary levels required to obtain the services of the best staff.

Equity, Diversity and Inclusion

Solving Kids' Cancer UK has a strong, caring ethos and is firmly committed to equity, diversity, and inclusion (EDI), recently enshrined in our two new charity values, caring and inclusive. With the launch of our new five-year charity strategy, we are addressing EDI with renewed focus and will shortly be convening a working group to determine our EDI vision and objectives – centred around those with lived experience – and to ensure we deliver our plan and continually monitor our performance.

We are committed to embedding principles of equity, diversity, and inclusion, ensuring that our operations, activities, and services are designed and open for everyone to be included, and fostering culture, behaviours, and practices in support of social justice.

EDI is fundamental to achieving our charity objectives to reach and be there for all families affected by neuroblastoma, and for the health and wellbeing of all those we work with and exist for. We want everyone to feel included and believe in the importance of reflecting different perspectives, experiences, and skills, including from those with lived experience of neuroblastoma, within our staff, Board, and volunteer teams.

We are not EDI experts, we don't have all the answers, and we won't always get it right - but this can't and won't hold us back. We are committed to learning, to listening and to creating safe spaces for difficult conversations that will inspire and lead to positive and lasting change.

Safeguarding

Our work and practice is underpinned by safeguarding principles with the aim of protecting children and young people and enhancing their welfare. SKC UK always works in accordance with legislation, statutory guidance, and best safeguarding practices. SKC UK has robust safeguarding policies and procedures in place and all staff and Trustees receive dedicated safeguarding training upon induction with regular updates as required.

All hiring managers are required to access Safer Recruitment training to ensure that our recruitment processes are robust with an emphasis on ensuring the safety and welfare of the children and families we support. All staff and Trustees are required to have a basic DBS check and clearance before commencing their role with SKC and this is extended to any volunteer or service provider that may have regular direct interaction with the children and families we support. The charity reviews and revises safeguarding policies and procedures at regular intervals, at least annually, and has a designated safeguarding lead within the leadership team and a Trustee with designated safeguarding oversight.

Volunteers

The Trustees are extremely grateful for the considerable contribution made by the charity's volunteers and fundraisers in support of children with neuroblastoma, including our Ambassadors, our Parent Involvement Forum members and all those who lend their time, expertise and resources in furtherance of our charitable objectives.

This extends to the significant contribution made by clinicians and researchers who advise the charity on the complex landscape of high-risk neuroblastoma treatment, as well as those individuals that assist the office team with administration activities necessary for us to achieve our aims and objectives. During the year, the charity was supported by a huge number of volunteers working virtually who collectively contributed over 3,500 hours and we are hugely grateful to them all.



Our legal and administrative details

Registered charity name

Solving Kids' Cancer UK Ltd

Charity registration number

1135601 (England and Wales)
SC045094 (Scotland)

Company registration number

07208648

Registered office
Coram Campus
41 Brunswick Square
London
WC1N 1AZ

Trustees

The Trustees who served the company during the period were as follows:

Nick Bird (Chair)
Joseph Tabone
Matthew G White
David Coulon (Treasurer)
Bronwyn Ellis stepped down as Trustee on 6 February 2022
Alexandra Lane
Dr Áine McCarthy joined the Board on 20 July 2021

Company Secretary
Gemma Wadsley

Chief Executive
Gail Jackson

Leadership Team

Claire Hislop (Head of Operations)
Gemma Wadsley (Head of Strategic Finance)
Anne Denman (Head of Fundraising and Comms)
Leona Knox (Head of Research)
Vicky Inglis (Head of Family Support)

Auditors

Shipleys LLP
Chartered Accountants & Statutory Auditor
10 Orange Street, Haymarket
London, WC2H 7DQ

Bankers

National Westminster Bank,
Church Road Branch,
London, NW4 4DS

Investment managers

CCLA Investment Management Limited
Senator House
85 Queen Victoria Street
London, EC4V 4ET

Solicitors
Withers
16 Old Bailey
London EC4M 7EG

Our finances

Overview

We have had a strong year financially with unrestricted income recovering to pre-pandemic levels and expenditure focused on supporting our beneficiaries with operating expenditure remaining extremely lean.

Whilst the external environment remains challenging with the global COVID-19 pandemic ongoing, cost of living costs increasing and Russia's invasion of Ukraine all impacting charities operationally and financially, we have remained strong and have invested in the implementation of our fundraising strategy and are already seeing the impact in our increased income position. We have seen a large number of families looking to access treatment with our support and this has also had an impact on our overall designated income going up.

We have agreed a revised five-year organisational strategy alongside a five-year budget, which will see us invest in organisational sustainability and growth with deficits across the earlier years, which will spend down the reserves.

Income

Our total income for the year was £3,579,609 (2021: £2,297,271). This is made up of £843,739 of unrestricted funds (2021: £703,597), £2,413,207 of designated funds (2021: £1,503,456) and £322,663 restricted funds (2021: £90,218).

Our unrestricted income is made up of voluntary and investment income, which supports all of our charity's internal activities. This includes our family support provision – offering pastoral care to support families, and providing evidence-based, impartial information to support parents in their choice of treatment options for their child and to access treatments and clinical trials if they are not available in the UK. It also includes our internal research team and infrastructure, all our fundraising activities and our operational running and governance. The majority of the remainder of our income relates to designated family funds, which the Board have designated in the name of a child to support treatment options for that individual child.

Total income has grown by £1,282,338 for the year, which is largely based on the number of families raising funds to access treatment this year. Our unrestricted income has grown as we are embedding our fundraising strategy, focusing on donor development and engagement and we have built some strong new partnerships and relationships.

Expenditure

Expenditure decreased slightly for the year at £2,105,215 (2021: £2,309,712). The make-up of our expenditure is dependent on our Family Funds being accessed for treatment and whilst income was up this year, this was very much towards the back end of the year so expenditure for these funds will occur within 2022/23. Access to treatment costs were up overall at £1,094,940 (2021: £1,011,301). The phasing of Research commitments means that they fluctuate from year to year with 2022 including two new commitments at £263,522 (2021: £704,181). As noted, we have endeavoured to reduce our operational costs including continuing to have low rental costs and running our Neuroblastoma Parent Global Symposium online.

Investments

Given the nature of the organisation, supporting very young children and their families, our investment objectives are primarily to invest in an ethically sound manner, in order to protect the value of the charity's assets against inflation, and provide modest returns through a combination of income distribution and capital growth. In addition to being mindful of the nature of investments made on behalf of the charity, the Trustees' appetite for risk is also influenced by the significant amount of funds that are designated for future purposes. The COIF Charities Ethical Investment Fund aims to provide a long-term gross return of 5% per annum net of inflation. Within this, the fund aims to deliver a consistent annual distribution of income and operate with a level of volatility (risk) that is no greater than 75% of the volatility of the UK equity market. The return performance for the year was 7.6% which is consistent with our aims.

Following an extremely volatile investment year, particularly in relation to the ongoing COVID-19 pandemic and Global instability as a result of the Russian Invasion of Ukraine and the cost of living crisis, we are pleased to report an investment gain of £289,123 (2021: £571,632). Over the total period since purchase the investment has given capital growth of £1,204,068. The market is extremely volatile in the current climate and as at 31st October 2022 our investment loss for the current year to date is £231,847.

Reserves Policy

The Trustees have adopted a Reserves Policy, which they consider appropriate to ensure the continued ability of the charity to meet its objectives.

General funds are set aside to meet research, education, family support and administration costs. At the financial year-end, general funds were £984,377 (2021: £778,001).

General free reserves (undesignated funds excluding fixed assets) were £975,127 and represent 11 months' undesignated expenditure.

Free reserves are calculated as follows:

	2022
	£
Total funds of the charity	12,367,643
Less: Restricted funds	(1,643,744)
Less: Designated funds	(9,739,522)
Less: Fixed assets held for charity use	(9,250)
	£975,127

The Reserves Policy currently states that six to nine months of essential running costs should be covered in order to meet its obligations in the short term (£520,000-£781,000 based upon 2022/23 budget). This is based on an assessment of the organisational risk approach and funding model.

Whilst we are currently above our reserves target at 11 months, Trustees have this year agreed their 2022-27 Five-Year Strategy, which has been developed alongside a Five-Year Financial Strategy, which provides investment in the organisational capacity and supports sustainable future income sustainability. The proposed budgets over the first three years would see the General Reserves level fall back to within the policy range.

This robust financial plan, alongside the need for caution given the continued challenging nature of the external environment for all charities, means that the Trustees are very comfortable with the current reserves level and longer-term policy.

Designated funds are set aside for the treatment of specific children with neuroblastoma, and are not available for the general running of the charity or any projects which do not directly relate to the treatment of that child. At the financial year-end, the charity held designated reserves of £9,739,522 (2021: £8,341,615). In the event of a child's death, the funds will be released from designated children's funds. Following the end of a successful course of treatment, and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of five years so that they are available for that child should they suffer a relapse and require further treatment, a situation which is common for neuroblastoma patients. This policy resulted in £632,742 (2021: £1,402,616) transferring from designated children's funds within the year with 70% transferred to the designated Solving Kids' Cancer Research Fund, 20% to the designated Solving Kids' Cancer Children's Reserve Fund and 10% to undesignated reserves.

Restricted Reserves are funds which can only be used for particular restricted purposes within the objects of the charity, and arise when specified by the donor or when funds are raised for particular restricted purposes. At the financial year-end, the charity held restricted reserves of £1,643,744 (2020: £1,471,141), of which £1,218,822 (2021: £1,223,288) arose from funds being held on behalf of families who were previously supported by Families Against Neuroblastoma.

Supporters of the charity are asked to note that, although the charity appears to hold significant reserves, 72% of these funds are designated or restricted to fund the treatment or support of children and families and a further 9% is designated or restricted to Research.

Impact of COVID-19 and Other External Factors

We continue to manage the ongoing risk of COVID-19 as part of our overall risk management, as well as the Russian Invasion of Ukraine and the cost of living crisis. These external factors create additional challenges for us across the organisation with impact on household incomes squeezed and fundraising still limited by the pandemic, operationally and financially. Controls in place include regular income and expenditure reforecasts and updates to the Board. We continue to support families to travel safely and within the COVID-19 rules. Financially we remain lean in our overheads with reduced office space and we held a virtual symposium rather than an in-person event in light of the ongoing risks and costs.

We also held another successful virtual Carol Concert. Our areas of investment all relate to income generation. Our staff have continued to work remotely throughout the year.

Risk Management

The charity's Trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks. The Trustees have overall responsibility for ensuring that the charity has an appropriate system of controls, financial and otherwise. They are responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the charity or for publication is reliable and reviewed at every trustee meeting; and
- the charity complies with relevant laws and regulations.

The risk register is a live document which is reviewed in detail every six months by the Board and Leadership Team and we have a secondary shorter-term register, which specifically groups the key current risks and our mitigation.

Risk categories include:

Governance

Covers risk of non-delivery of strategy, Board Skills & Capabilities and effective decision-making and reporting.

Controls in place to manage these risks include a clear strategy underpinned by annual plans, a balanced and involved Board who have clear terms of reference and who consider their effectiveness and undertake training as appropriate. The Board request and receive regular reporting from executive management.

People

Covers risk of loss of key staff and poor structure.

Controls in place to manage these risks include strong oversight by CEO and senior managers, clear roles and responsibilities and strong HR processes. As staff numbers are small, this is a key risk which is closely monitored.

Finance

Covers all financial risks around effectiveness of our business model, level of reserves, management of investments and effective insurance.

Controls in place to manage these risks include annual budgeting and forecasting processes with regular reporting of our financial position to Trustees. We have a clear reserves policy and hold general reserves to manage any changes in cash flow. We have an investment policy and investment managers who report on performance regularly.

Compliance

Covers all risks relating to non-compliance of required regulations including data protection, health and safety, employment and financial.

Controls in place to manage these risks include effective policies, staff training and awareness and effective advisors.

Operational, Legal and Physical

Covers risk of not being able to meet demands for family support and quality of support provided, risk of lack of funds due to expenditure exceeding income, health and safety risks and other operational risks including employment risks and disaster recovery.

Controls in place to manage these risks include ensuring the team has appropriate support to deliver in their roles and we are continuously considering current and future demand. Budgets and reserves are effectively managed to ensure funding is maintained. We have policies in place which are well understood and adhered to around health and safety, disaster recovery, employment policies and other areas of compliance.

Environmental / External Factors

Covers reputational risk and relevant external risks such as economic conditions and Brexit.

Controls in place to manage these risks include effective communications policies and resource and ongoing monitoring of relevant external plans with action plans as required.

Russian Invasion of Ukraine

We are currently also running a Russian Invasion of Ukraine specific risk register, which reflects the key risks this presents and the relevant mitigations. These include Financial risks and Income risk as fuel prices rise. Our strong financial controls support our management of these risks.

Grant-making Policy

The Board of Trustees makes two types of grants. Firstly, grants to assist children suffering from neuroblastoma. Families, who need help, either self-refer, hear about the charity from their child's oncologist, or make contact with the charity's Family Support Team. Grants are also offered in the form of a hardship fund for families struggling to meet their necessary costs due to the effects of having a child in treatment for neuroblastoma.

The second type is Research Grants. We engage in two distinct research funding mechanisms; a regular competitive funding call, and also ad-hoc Exceptional Funding Requests. All research grants are awarded in line with the principles laid out by the Association of Medical Research Charities (AMRC). Each application will be subject to rigorous scientific review guided by the Charity's Scientific Advisory Board (SAB) and the nature of any grant made will depend on funds available through Solving Kids' Cancer UK's own reserves, or those made available through strategic collaborative partnerships.

Investment Policy and Objectives

The Deed of Trust allows the charity to deposit or invest funds in any manner; but to do so only after obtaining such advice from financial experts as the Trustees deem necessary and having regard to the suitability of investments and need for diversification. The charity aims to follow the COIF Ethical Fund Policy; excluding investments in companies involved in, for example, nuclear weapons, landmines, production of abortifacients, and other disqualifying criteria where there is a significant involvement (>10% of turnover).

Fundraising Approach and Policy

As a cause-related charity, we recognise that the service we offer for children and families affected by neuroblastoma and the advances in research we invest in would not be possible without the generous support and passion our supporters, and families' supporters, provide.

We receive very little public funding for our work, relying on the generous support of the neuroblastoma community and general public.

We are registered with the regulatory body for fundraising in the UK, the Fundraising Regulator. As members of the scheme, we follow their Code of Fundraising Practice and comply with the key principles embodied in The Code. Many of our families raise funds for us at a local level and we ensure that they have all the information they need to comply with our policies and procedures.

It is hugely important to us that our supporters trust us and are well looked after:

- We ensure that we never put undue pressure on members of the public when raising funds.
- We are open and honest and approach our fundraising activities respectfully and considerately.
- We ensure that we comply with the wishes of our donors and comply with all general data protection laws.
- We respect the rights, dignity and privacy of our supporters and beneficiaries.
- We are accountable to our supporters and take this responsibility seriously.

We review all of our fundraising campaigns to ensure they fully comply with The Code and our fundraising activities are discussed regularly at Board meetings, to help ensure that our fundraising practices reflect and reinforce our values. That's just as important whether we're fundraising ourselves or working with families, organisations or volunteers.

We currently raise funds in a variety of ways, including: Direct email campaigns, regular and individual giving programmes, virtual and in person challenge events, corporate partnerships and percentage profit partnerships, direct cash donations, raffles, sponsored events and Charity of the Year partnerships. We have agreed and begun the implementation of a five-year fundraising strategy, which will further build upon our strong stewardship approach to develop existing income streams and develop new ones.

Within the year we achieved an unrestricted income of £844,000 with 31% coming through our family campaigns, 21% coming from Corporate, Trusts & Foundations and 18% from Challenge and Events. We outperformed our expectations in each of these areas.

We take the protection of the personal data of all our supporters and donors extremely seriously, and constantly review and monitor our fundraising policies and procedures to ensure we deliver 'best practice'. We do not engage professional fundraisers to raise money on our behalf. During the year we have implemented a new Customer Relationship Management system to further protect and manage our supporter data.

We welcome feedback on our fundraising activities at any time and strive to listen and learn from this feedback. During the course of the year we recorded no complaints. We have a robust complaints policy. If a complaint about our fundraising activities is unable to be resolved through our complaints procedure, members of the public are advised to raise it with the Fundraising Regulator.

Trustees Responsibilities Statement

The Trustees (who are also the Directors of Solving Kids' Cancer UK for the purposes of company law) are responsible for preparing the Trustees Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under that law the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the income and expenditure of the company for that period.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and accounting estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of the persons who is a Trustee at the date of approval of this report confirms that:

- so far as each Trustee is aware, there is no relevant audit information of which the company's auditor is unaware; and
- each Trustee has taken all steps that they ought to have taken as a trustee to make themselves aware of any relevant audit information and to establish that the company's auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Registered office:
Signed on behalf of the Board of Trustees
Coram Campus
41 Brunswick Square
London
WC1N 1AZ



David Coulon
Trustee and Treasurer
7th November 2022

Financial statements

31 March 2022

Independent Auditor's Report to the Trustees and members of Solving Kids' Cancer UK

Opinion

We have audited the financial statements of Solving Kids' Cancer UK Ltd ("the charitable company") for the year ended 31 March 2022 which comprise the Statement of Financial Activities (incorporating the Income and Expenditure Account), the Balance Sheet, the Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2022 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and trustees Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions Relating to Going Concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Solving Kids' Cancer UK Ltd's ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other Information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on Other Matters Prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees Annual Report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report included within the Trustees Annual Report has been prepared in accordance with applicable legal requirements.

Matters on Which We Are Required to Report By Exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees Annual Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements

We have been appointed as auditors under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

- We obtained an understanding of the charitable company's activities, controls and laws and regulations and assessed the susceptibility of the charitable company's financial statements to material misstatement from irregularities, including fraud.
- We determined that the laws and regulations that are most significant to the charitable company are the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)), Companies Act 2006, Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, the Fundraising Regulations and the charitable company's Articles of Association.

- Based on this understanding we designed our audit procedures to detecting irregularities, including fraud. Testing undertaken included making enquiries on the management and those charged with governance; journal entry testing; review of bank letters, investments reports, trustee Board minutes and the Articles of Association; review of transactions for any undisclosed related party transactions; reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations. These procedures were designed to provide reasonable assurance that the financial statements were free from fraud or error.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of Our Report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

10 Orange Street
Haymarket
London
WC2H 7DQ



Simon Robinson
(Senior Statutory Auditor)

For and on behalf of SHIPLEYS LLP
Chartered Accountants & Statutory Auditor
7th November 2022

Financial statements

Statement of financial activities (incorporating the income and expenditure account)
Year ended 31st March 2022

	Note	General Funds Undesignated	General Funds Designated	Restricted funds	Total Funds 2022	Total Funds 2021
		£	£	£	£	£
Income						
Donations	2	715,140	2,412,441	318,857	3,446,438	2,120,029
Trading activities	3	21,540	766	3,300	25,606	40,520
Investment income	4	107,059	-	506	107,565	136,722
Total Income		**843,739**	**2,413,207**	**322,663**	**3,579,609**	**2,297,271**
Expenditure On:						
Raising funds	5	(293,844)	(50,755)	(1,876)	(346,475)	(299,349)
Charitable activities	6	(432,508)	(1,178,048)	(148,184)	(1,758,740)	(2,010,363)
Total Expenditure		**(726,352)**	**(1,228,803)**	**(150,060)**	**(2,105,215)**	(2,309,712)
Net Income / (Expenditure) Before (Losses) / Gains On Investments		117,387	1,184,404	172,603	1,474,394	(12,441)
Net gains on investments	13	–	289,123	–	289,123	571,632
Other gains/(losses)		25,714	(12,345)	–	13,369	
Net Income / (Expenditure)		143,101	1,461,182	172,603	1,776,886	559,191
Transfer between funds	20,21,22	63,275	(63,275)	–	–	–
Net Movement In Funds		206,376	1,397,907	172,603	1,776,886	559,191
Reconciliation Of Funds						
Total funds brought forward		778,001	8,341,615	1,471,141	10,590,757	10,031,566
Total Funds Carried Forward		984,377	9,739,522	1,643,744	12,367,643	10,590,757

The statement of financial activities including all gains and losses in the year. All of the above amounts relate to continuing activities.

Balance sheet

Statement of financial activities (incorporating the income and expenditure account)
Year ended 31st March 2022

	Note	2022 £	2022 £	2021 £	2021 £
Fixed Assets					
Tangible assets	12		9,250		13,042
Investments	13		3,704,068		3,414,945
			3,713,318		3,427,987
Current Assets					
Debtors	14	215,759		161,118	
Cash at bank and in hand		10,120,041		8,544,856	
		10,335,800		8,705,974	
CREDITORS: Amounts falling due within one year	15	(1,084,513)		(986,042)	
NET CURRENT ASSETS			9,251,287		7,719,932
TOTAL ASSETS LESS CURRENT LIABILITIES			12,964,605		11,147,919
CREDITORS: Amounts falling due after one year	16		(596,962)		(557,162)
NET ASSETS		–	12,367,643	–	10,590,757
FUNDS OF THE CHARITY					
Restricted funds	20		1,643,744		1,471,141
Designated funds	21		9,739,522		8,341,615
Undesignated funds	22		984,377		778,001
Total Funds Carried Forward			**12,367,643**		**10,590,757**

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements were approved by the members of the committee and authorised for issue on 7th November 2022 and are signed on their behalf by:



David Coulon
Trustee
Company Registration Number: 07208648

Statement of cash flows

Year ended 31 March 2022

	Note	2022 £	2021 £
CASH FLOWS FROM OPERATING ACTIVITIES			
Net income		1,776,886	559,191
Adjustments for:			
Depreciation		4,715	5,519
Losses / (gains) on investments		(289,123)	(571,632)
Dividends and interest from investments		(107,565)	(136,722)
Loss on disposal of fixed assets		-	312
Decrease / (increase) in debtors		(53,848)	(51,628)
Increase in creditors		138,271	486,374
Net cash provided by operating activities		1,469,336	291,414
CASH FLOWS FROM INVESTING ACTIVITIES			
Dividends and interest from investments		106,772	110,517
Purchase of property, plant & equipment		(923)	(15,774)
Net cash provided by investing activities		105,849	94,743
CHANGE IN CASH AND CASH EQUIVALENTS	28	1,575,185	386,157
CASH AT START OF YEAR	28	8,544,856	8,158,699
CASH AT END OF YEAR	28	**10,120,041**	**8,544,856**

Notes to the Financial Statements

1. Accounting Policies

General information

Solving Kids' Cancer UK Ltd is a private company limited by guarantee incorporated in England under the Companies Act. The address of the registered office is Coram Campus, 41 Brunswick Square, London WC1N 1AZ. The objectives of the charity are set out on page 23.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Solving Kids' Cancer UK Ltd meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policies.

The functional currency of the charity is considered to be pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling.

The amounts in the financial statements are presented to the nearest £, unless otherwise stated.

Preparation of the financial statements on a going concern basis

The financial statements of the charity have been prepared on the going concern basis. There are no material uncertainties about the charity's ability to continue. The trustees consider that the going concern basis is appropriate having considered a period of at least twelve months from approval of these financial statements. The trustees have prepared budgets and cash flow forecasts for that period which support the going concern assumption.

Fund accounting

Undesignated funds are available to spend on activities that further any of the purposes of charity.

Designated funds are funds of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose.

Restricted funds are donations which the donor has specified are to be solely used for particular restricted purposes within the objects of the charity.

Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that those conditions will be fulfilled in the reporting period.

90% of any donation made to an individual appeal or journey is designated for the particular purpose of funding treatment not freely available on the NHS. The remaining 10% is retained within undesignated general funds to cover costs associated with the administration and management of appeals and journeys; including support with fundraising, logistics, and development of relationships as intermediary between families and the medical institutions that provide access to treatments and clinical trials.

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income from Government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred. In respect of the Coronavirus Job Retention Scheme grant; all conditions, with respect to the eligible costs being claimed, need to be met.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due. This is normally upon notification by our investment advisor of the dividend yield of the investment portfolio.

Expenditure and irrecoverable VAT

- Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis.

Expenditure is classified under the following activity headings:

- Costs of raising funds comprise the costs of attracting donations and fundraising.
- Expenditure on charitable activities includes the cost incurred by the charity in the delivery of activities and services for its beneficiaries

Grants payable are payments made to third parties in the furtherance of the charitable objects of the charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the grant.
Grant awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Support costs include staff, premises, finance and governance costs. These costs have been allocated between cost of raising funds and expenditure on charitable activities on the basis of an estimate of the proportion of time spent by staff on those activities.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Tangible fixed assets

Fixed assets are capitalised at cost and are depreciated over their estimated useful economic lives on a straight line basis as follows:

Equipment – 25% on straight line basis

Fixed asset investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

The charity classifies the lease of the office space as an operating lease as the title remains with the lessor. Rental charges are charged on a straight line basis over the term of the lease.

Pension costs

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Differences between contributions payable in the year and the contributions actually paid are shown as either accruals or prepayments on the balance sheet.

2. Donations

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2022
	£	£	£	£
Donations	683,140	2,412,441	257,355	3,352,936
Donated services	32,000	-	-	32,000
Government grants	-	-	61,502	61,502
	715,140	2,412,441	318,857	3,446,438

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2021
	£	£	£	£
Donations	497,829	1,494,139	71,358	2,063,326
Donated services	53,234	-	-	53,234
Government grants	-	-	3,469	3,469
	551,063	1,494,139	74,827	2,120,029

The charity benefits greatly from the involvement and enthusiastic support of its many volunteers. In accordance with FRS 102 and Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the financial statements.

During the year, the charity received donated services relating to legal services and support for both the Neuroblastoma Parent Global Symposium and Carol Concert. The value of these services to the charity is estimated at £12,000 and £20,000 respectively (2021: £13,234 and £40,000 respectively).

The estimated value of these services is recognised within income as a donation with an equivalent expense through the Statement of Financial Activities.

Income from Government grants comprises grants received under the UK Government COVID Medical Research Charity Support Fund of £58,522 (2021: £nil) to provide support to UK Research in funding and the Government Coronavirus Job Retention Scheme of £2,981 (2021: £3,469). This grant was provided to support the cost of furloughed charity staff. The charity has not benefited from any other kinds of government assistance during the current or prior year.

3. Other Trading Activities

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2022
	£	£	£	£
Fundraising events	**21,540**	**766**	**3,300**	**25,606**

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2021
	£	£	£	£
Fundraising events	**17,492**	**9,317**	**13,711**	**40,520**

4. Investment Income

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2022
	£	£	£	£
Income from investments	106,111	-	-	106,111
Deposit account interest	948	-	506	1,454
	107,059	**-**	**506**	**107,565**

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2021
	£	£	£	£
Income from investments	129,400	-	-	129,400
Deposit account interest	5,642	-	1,680	7,322
	135,042	**-**	**1,680**	**136,722**

5. Cost of Raising Funds

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2022
	£	£	£	£
Costs of raising funds	193,314	50,755	1,876	245,945
Support costs	100,530	-	-	100,530
	293,844	**50,755**	**1,876**	**346,475**

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2021
	£	£	£	£
Costs of raising funds	154,331	22,151	468	176,950
Support costs	122,399	-	-	122,399
	276,730	**22,151**	**468**	**299,349**

6. Costs of Charitable Activities

	Activities undertaken directly	Grant funding activities	Support costs	Total Funds 2022
	£	£	£	£
Access to treatment	125,772	900,765	68,403	1,094,940
Medical Research	90,010	263,522	42,328	395,860
Education, Awareness and Family Support	89,048	87,542	91,350	267,940
	304,830	**1,251,829**	**202,081**	**1,758,740**

	Activities undertaken directly	Grant funding activities	Support costs	Total Funds 2021
	£	£	£	£
Access to treatment	205,222	728,676	77,403	1,011,301
Medical Research	59,300	704,181	22,981	786,462
Education, Awareness and Family Support	5,353	115,265	91,982	212,600
	269,875	**1,548,122**	**192,366**	**2,010,363**

Expenditure on charitable activities was £1,758,740 (2021: £2,010,363) of which £432,508 was undesignated (2021: £417,556), £1,178,048 was designated (2021: £1,289,187) and £148,184 was restricted (2021: £303,620).

7. Analysis of Support Costs

Support costs are allocated based on the proportion of time spent by staff on those activities.

	Access to treatment	Medical Research	Education, Awareness and Family Support	Fundraising activities	Total 2022
	£	£	£	£	£
Staff costs	24,400	12,097	50,502	44,452	91,733
Premises	23,583	16,202	21,893	30,055	91,733
Legal and professional	9,059	6,223	8,409	11,544	35,235
Finance costs	799	549	741	1,018	3,107
Depreciation	1,212	833	1,125	1,545	4,715
Governance costs	9,350	6,424	8,680	11,916	36,370
	68,403	**42,328**	**91,350**	**100,530**	**302,611**

	Access to treatment	Medical Research	Education, Awareness and Family Support	Fundraising activities	Total 2021
	£	£	£	£	£
Staff costs	31,989	6,178	53,029	57,129	148,325
Premises	17,833	6,598	15,296	25,630	65,357
Legal and professional	3,857	1,427	3,308	5,543	14,135
Finance costs	13,406	4,960	11,499	19,268	49,133
Depreciation	1,506	557	1,292	2,164	5,519
Governance costs	8,812	3,261	7,558	12,665	32,296

8. Governance Costs

	2022	2021
	£	£
Auditor's remuneration	12,780	12,540
Legal and professional	18,048	14,795
Staff costs	5,542	4,961
	36,370	**32,296**

9. Analysis of Grants

	2022	2021
	£	£
Children's treatment	900,765	728,676
Medical Research		
Stanford University	125,000	-
UCL Great Ormond St Institute of Child Health	125,000	-
Newcastle University	13,522	-
University of Birmingham	-	434,762
Gustave Roussy Hospital, Paris	-	109,419
Children's Hospital of Philadelphia	-	68,750
The Royal Marsden Hospital	-	60,000
Institute of Cancer Research	-	31,250
Education and family support	87,542	115,265
	1,251,829	**1,548,122**

Children's treatment grants are made towards the medical costs of the children suffering from neuroblastoma. The grants are paid directly to the hospitals providing the treatment.

Grants are made towards medical research for potential future life-saving treatments made possible through the constantly evolving world of burgeoning laboratory, pre-clinical and clinical research. These grants are paid directly to the institutions and are institutions working internationally which reflects the specialist and global nature of the research we fund.

Grants for Education and family support are those made towards providing essential support services to families affected by high risk childhood cancers and relating to scientific information on developments in research on neuroblastoma and evolving treatment options. These grants are paid directly to affected families and organisations as appropriate or as directed.

10. Staff Costs and Emoluments

	2022	2021
	£	£
Wages and salaries	493,263	453,214
Social security costs	44,600	40,957
Pension costs – defined contribution	16,412	14,326
	554,275	**508,497**

Pension costs are allocated to activities in proportion to the related staffing costs and are allocated between undesignated, designated and restricted funds on the basis of each employee's activities.

Particulars of employees:

The average head count of employees during the year was 15 (2021: 14). The average number of full-time equivalent employees during the year is analysed as follows:

	2022	2021
	No.	No.
Charitable activities	6	5
Fundraising	3	4
Support	3	3
	12	**12**

The number of employees whose remuneration for the year fell within the following bands, were:

	2022	2021
	No.	No
£70,000 to £79,999	**1**	**1**

No higher paid staff were accruing benefits under a pension scheme (2021: None)

11. Net Income

Net income is stated after charging:

	2022	2021
	£	£
Auditor's remuneration		
Audit	12,780	12,540
Taxation	780	780
Depreciation	4,715	5,519
Operating leases – offices	10,043	26,107

12. Tangible Fixed Assets

	Equipment
	£
COST	
At 1 April 2021	24,162
Additions	923
Disposals	(1,747)
At 31 March 2022	**23,338**
DEPRECIATION	
At 1 April 2021	11,120
Charge for the year	4,715
Disposals	(1,747)
At 31 March 2022	**14,088**
NET BOOK VALUE	
At 31 March 2022	**9,250**
At 31 March 2021	13,042

13. Investments

Movement in market value		2022	2021
		£	£
Market Value at 1 April 2021		3,414,945	2,843,313
Net gain / (loss) on revaluations		289,123	571,632
Market value at 31 March 2022		**3,704,068**	**3,414,945**
Historical cost at 31 March 2022		2,500,000	2,500,000

Analysis of investments at 31 March 2022:		Designated Funds 2022	Designated Funds 2021
		£	£
UK Listed investments		3,704,068	3,414,945

All investments are carried at their fair value. Holdings in investment funds, unit trusts and open-ended investment companies are at the bid price. The basis of fair value for quoted investments is equivalent to the market value, using the bid price. Asset sales and purchases are recognised at the date of trade at cost (that is their transaction value).

The following investments were material in the context of the investment portfolio:

COIF Charities Ethical Investment Fund - £3,704,068 (2021: £3,414,945).

The main form of financial risk faced by the charity is that of volatility in investment markets due to wider economic conditions and variability of investment returns. This risk is mitigated by obtaining advice from a financial expert on the charity's investment portfolio.

14. Debtors

		2022	2021
		£	£
Trade debtors		-	499
Other debtors		137,831	117,496
Prepayments and accrued income		77,928	43,123
		215,759	**161,118**

15. Creditors

Amounts falling due within one year		2022	2021
		£	£
Other creditors		53,384	-
Accruals and deferred income		55,643	13,843
Grant commitments (note 17)		372,998	373,987
Funds held as agent (note 18)		602,488	598,212
		1,084,513	**986,042**

16. Creditors

Amounts falling due after more than one year		2022	2021
		£	£
Grant commitments (note 17)		**596,962**	**557,162**

Grant commitments of £153,976 are due in more than five years (2021: £153,976).

17. Grant Commitments

		2022	2021
		£	£
Grant commitments brought forward		931,149	673,137
New commitments during the year		275,866	704,181
Payments made in the year		(237,055)	(446,169)
Grant commitments carried forward		**969,960**	**931,149**
Commitments at 31 March 2022 are payable as follows:			
Within one year		372,998	373,987
After more than one year		596,962	557,162
Grant commitments carried forward		**969,960**	**931,149**

18. Funds Held as Agent

	2022	2021
	£	£
Funds held as agent brought forward	598,212	357,874
Funds received during the year	297,000	249,191
Payments made	(292,724)	(8,853)
Funds held as agent carried forward	**602,488**	**598,212**

The charity has received funds as agent in its role as administrator of the Request for Applications (RFA) process and also of the research project for the prospective identification of children with "ultra-high-risk" (UHR) neuroblastoma.

At the year end, the charity held £602,488 (2021: £598,212) and this has been included in creditors in Note 15. £389,024 was held on behalf of Zoe4life (2021: £349,176), £200,617 on behalf of The Merryn Lacy Trust (2021: £249,036) and £12,847 on behalf of Joining Against Cancer in Kids (J-A-C-K) (2021: £nil).

19. Commitments Under Operating Leases

At 31 March 2022 the company had total minimum lease payments under non-cancellable operating leases as set out below.

Land and buildings	2022	2021
	£	£
Operating leases which expire within 1 year	**9,833**	**9,833**

20. Restricted Funds

	Balance at 1 April 2021	Income	Expenditure	Transfers	Balance at 31 March 2022
	£	£	£	£	£
Families Against Neuroblastoma (FAN)	937,188	399	(4,973)	-	932,614
FAN Emergency Relapse Fund	286,100	108	-	-	286,208
HK Fund	15,842	-	-	-	15,842
CE Discretionary Fund	3,782	-	-	-	3,782
Restricted research funds	-	59,060	(13,526)	-	45,534
Parent Conference fund	-	52,542	(51,708)	-	834
Other funds	91,684	57,003	(51,872)	-	96,815
Joining Against Cancer in Kids	27,180	-	-	-	27,180
Sunni Mae Fund	84,365	-	-	-	84,365
Family Support fund	25,000	25,000	(25,000)	-	25,000
Furlough Fund	-	2,981	(2,981)	-	-
Support bags	-	25,000	-	-	25,000
Merryn Lacey Fund	-	100,570	-	-	100,570
	1,471,141	**322,663**	**(150,060)**	**-**	**1,643,744**

	Balance at 1 April 2020	Income	Expenditure	Transfers	Balance at 31 March 2021
	£	£	£	£	£
Families Against Neuroblastoma (FAN)	953,332	1,380	(12,973)	(4,551)	937,188
FAN Emergency Relapse Fund	289,653	300	(3,853)	-	286,100
HK Fund	15,842	-	-	-	15,842
CE Discretionary Fund	3,782	-	-	-	3,782
Restricted research funds	45,000	-	(45,000)	-	-
Parent Conference fund	-	16,301	(16,301)	-	-
Other funds	95,429	23,768	(138,209)	110,696	91,684
Joining Against Cancer in Kids	33,713	-	(6,533)	-	27,180
Sunni Mae Fund	84,365	-	-	-	84,365
Covid-19 fund	32,750	20,000	(52,750)	-	-
Family Support fund	25,000	25,000	(25,000)	-	25,000
Furlough Fund	-	3,469	(3,469)	-	-
	1,578,866	**90,218**	**(304,088)**	**106,145**	**1,471,141**

20. Restricted Funds

Restricted funds can only be used for particular restricted purposes within the objects of the charity as specified by the donor or when funds are raised for particular restricted purposes.

Families Against Neuroblastoma (FAN)/ FAN Emergency Relapse Fund

There are 10 funds transferred from Families Against Neuroblastoma (FAN) and held for the sole use of individual children for access to treatment and welfare / pastoral issues. Treatments are limited to those that are consistent with Solving Kids' Cancer UK Ltd Clinical Trial Policy. A further two donations from FAN were received to be used solely to support children with relapsed neuroblastoma with no access to other funds to pay for treatment that is not freely available on the NHS. During the year, £nil was transferred from this fund to unrestricted funds (2021: £4,551). In the prior year, this represented interest accumulated on a closed FAN fund which should have been credited to the unrestricted fund in prior years.

HK Fund is restricted for the sole purposes of supporting an individual named child. In accordance with the wishes of the donor, the fund supports the long-term health and welfare related needs of the beneficiary, and is not accessed on a regular basis.

CE Discretionary Fund was established through an individual donation made to the charity to provide the Chief Executive with a means to fund initiatives in support of the effective working of the organisation, but for which no other budget existed.

Restricted research funds is a restricted fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research.

Parent conference fund represents donations towards the annual parent conference.

Other Funds represent funds created by families in memoriam specifically for research and advocacy projects. During the year, £nil (2021: £110,696) was transferred from the designated Research Fund to support these research projects.

Joining Against Cancer in Kids is a restricted fund which has been provided by Joining Against Cancer in Kids to support the costs incurred by families when participating in neuroblastoma trials/treatment being conducted at The Memorial Sloan Kettering Cancer Centre, New York or Hospital Saint Joan de Déu Barcelona.

Sunni Mae Fund is restricted to support the development of a partnership with a UK medical institution to enable children from the Republic of Ireland to travel to the United Kingdom to enrol on early phase clinical trials that are not available at Our Lady Children's Hospital, Crumlin. Alternatively, if such a partnership cannot be formed, the fund can be used to support a future research funding call in which The Sunni Mae Trust will be acknowledged as a named collaborative funding partner. Explicit agreement will be sought for the latter at such time as the charity deems appropriate.

COVID-19 fund is restricted to the granting of funds to families of children with Neuroblastoma who have suffered a loss of income or increase in costs as a result of the diagnosis. It is initially for those affected by the need to shield during COVID-19.

Family support fund is restricted to the activities of the family support team.

Furlough Fund represents a government grant provided to support the cost of furloughed charity staff.

Support bags represents funds donated specifically to create Support bags for all children diagnosed with Neuroblastoma.

Merryn Lacey Fund represents funds donated by the trust which are restricted to Research.

21. Designated Funds

	Balance at 1 April 2021	Income	Expenditure	Transfers	Net losses on investments	Other gains and losses	Balance at 31 March 2022
	£	£	£	£	£	£	£
Designated Funds	6,191,809	2,389,373	(1,024,834)	(632,742)	-	-	6,923,606
Solving Kids' Cancer Children's Reserve Fund	477,933	-	(3,669)	126,548	-	-	600,812
Solving Kids' Cancer Research Fund	728,385	45	(200,000)	442,919	-	(12,345)	959,004
Family Support fund	28,423	1,000	(300)	-	-	-	29,123
Covid-19 fund	120	23	-	-	-	-	143
Big Love Fund	-	5,927	-	-	-	-	5,927
Designated general	-	16,839	-	-	-	-	16,839
Investment Reserve	914,945	-	-	-	289,123	-	1,204,068
	8,341,615	**2,413,207**	**(1,228,803)**	**(63,275)**	**289,123**	**(12,345)**	**9,739,522**

	Balance at 1 April 2020	Income	Expenditure	Transfers	Net losses on investments	Balance at 31 March 2021
	£	£	£	£	£	£
Designated Funds	7,182,484	1,328,542	(916,601)	(1,402,616)	-	6,191,809
Solving Kids' Cancer Children's Reserve Fund	197,410	-	-	280,523	-	477,933
Lorlatinib	60,000	-	(60,000)	-	-	-
Solving Kids' Cancer Reserve Fund	-	174,042	(316,793)	871,136	-	728,385
Family Support fund	45,615	-	(2,192)	(15,000)	-	28,423
Covid-19 fund	-	872	(15,752)	15,000	-	120
Investment Reserve	343,313	-	-	-	571,632	914,945
	7,828,822	**1,503,456**	**(1,311,338)**	**(250,957)**	**571,632**	**8,341,615**

Designated funds are funds which have been allocated by the trustees out of undesignated general funds to specific appeals for the treatment of children with neuroblastoma. In the event of a child's death, the funds will be released from designated funds. Following the end of a successful course of treatment, and a child exhibiting no evidence of disease (NED), funds will remain designated for a period of 5 years so that they are available for that child should they suffer a relapse and require further treatment, a situation which is common for neuroblastoma patients. During the year, this policy resulted in transfers of £632,742 (2021: £1,402,616) with 70% transferred to the designated Solving Kids' Cancer Research Fund, 20% to the designated Solving Kids' Cancer Children's Reserve Fund and 10% to undesignated reserves.

Solving Kids' Cancer Children's Reserve Fund is money designated to;

(1) support families who are fundraising for treatment who may require additional financial support to be able to meet the deadlines for enrolment on a particular clinical trial, and

(2) support children who are receiving treatment abroad but for whom additional unanticipated medical expenses are incurred. During the year £126,548 was transferred from Designated funds (2021: £280,523)

Solving Kids' Cancer Research Fund is a designated fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research. During the year, £442,919 was transferred from Designated Funds (2021: £981,832) and £nil was transferred to restricted other funds (2021: £110,696).

Family Support Fund is designated to the activities of the family support team. During the year £nil was transferred to the designated COVID-19 fund (2021: £15,000).

COVID-19 fund is designated to the granting of funds to families of children with Neuroblastoma who have suffered a loss of income or increase in costs as a result of the diagnosis. It is initially for those affected by the need to shield during COVID-19. During the year £nil (2021: £15,000) was transferred from the designated Family Support Fund.

Big Love Fund is designated to the granting of pastoral funds to support a child or young person's physical or emotional welfare and to support families in bereavement.

Designated general is a general fund to hold designated income prior to allocation against an individual fund for example whilst awaiting gift aid allocation.

Investment Reserve represents the movement in fair value on investments since acquisition.

22. Undesignated Funds

	Balance at 1 April 2021	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2022
	£	£	£	£	£	£
Undesignated funds	**778,001**	**843,739**	**(726,352)**	**63,275**	**25,714**	**984,377**

	Balance at 1 April 2020	Income	Expenditure	Transfers	Other gains and losses	Balance at 31 March 2021
	£	£	£	£	£	£
Undesignated funds	**623,878**	**703,597**	**(694,286)**	**144,812**	**-**	**778,001**

23. Analysis of Net Assets Between Funds

Fund balances at 31 March 2022 are represented by:

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2022
	£	£	£	£
Tangible fixed assets	9,250	-	-	9,250
Investments	-	3,704,068	-	3,704,068
Cash at bank and in hand	1,470,884	6,842,983	1,806,174	10,120,041
Other net current (liabilities)/assets	(495,757)	(265,789)	(107,208)	(868,754)
Creditors falling due in more than one year	-	(541,740)	(55,222)	(596,962)
	984,377	**9,739,522**	**1,643,744**	**12,367,643**

Fund balances at 31 March 2021 are represented by:

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2021
	£	£	£	£
Tangible fixed assets	13,042	-	-	13,042
Investments	-	3,414,945	-	3,414,945
Cash at bank and in hand	1,299,123	5,640,261	1,605,472	8,544,856
Other net current (liabilities)/assets	(534,164)	(156,429)	(134,331)	(824,924)
Creditors falling due in more than one year	-	(557,162)	-	(557,162)
	778,001	**8,341,615**	**1,471,141**	**10,590,757**

24. Company Limited by Guarantee

The charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is £10.

25. Taxation

The charity is exempt from tax on income and gains to the extent that these are applied to its charitable objects.

26. Related Party Transactions

The key management personnel of the charity for the period comprised the Trustees, Chief Executive and the Heads of Departments. The total employee benefits of the key management personnel were £286,020 (2021: £289,017).

The trustees did not receive any remuneration or other benefits during the year (2021: £nil). One trustee received reimbursement of expenses during the year of £655 relating to memberships and subscriptions (2021: £nil).

PricewaterhouseCoopers LLP, a firm in which a trustee, David Coulon, is a member, provided HR services to the charity for £nil (2021: £5,400). The supplier relationship ended in December 2020.

The Neuroblastoma Parent Global Symposium and the Carol Concert were supported by GRC World Forums (previously Data World Protection Forum), an organisation in which Nicholas James, the husband of a trustee, Bron Ellis, has a controlling interest. GRC World Forums provided all services free of charge. In the prior year, GRC World Forums provided the platform for £1,620, but provided all other services free of charge.

During the year the charity paid salaries of £710 (2021: £2,420) to a close family member of Nick Bird, a trustee. The total donations received from 2 trustees (2021: 4) during the year amounted to £280 (2021: £2,906).

27. Financial Instruments

Financial assets measured at fair value through statement of financial activities:

	2022	2021
	£	£
Investments	**3,704,068**	**3,414,945**

The income, expense, gains and losses in respect of all financial instruments are summarised below:

	2022	2021
	£	£
Net (loss) / gain on revaluation of investments	**289,123**	**571,632**
Investment income	**106,111**	**129,400**

For further details about risks arising from financial instruments and the measurement basis see note 13.

28 . Analysis of Changes in Debt

	At 1 April 2021	Cash flows	At 31 March 2022
	£	£	£
Net cash			
Cash at bank and in hand	**8,544,856**	**1,575,185**	**10,120,041**

	At 1 April 2020	Cash flows	At 31 March 2021
	£	£	£
Net cash			
Cash at bank and in hand	**8,158,699**	**386,157**	**8,544,856**

29. Comparatives for the Statement of Financial Activities

Fund balances at 31 March 2021 are represented by:

	Undesignated Funds	Designated Funds	Restricted Funds	Total Funds 2021
	£	£	£	£
INCOME			-	
Donations	551,063	1,494,139	74,827	2,120,029
Trading activities	17,492	9,317	13,711	40,520
Investment income	135,042	-	1,680	136,722
TOTAL INCOME	**703,597**	**1,503,456**	**90,218**	**2,297,271**
EXPENDITURE				
Raising funds	(276,730)	(22,151)	(468)	(299,349)
Charitable activities	(417,556)	(1,289,187)	(303,620)	(2,010,363)
TOTAL EXPENDITURE	**(694,286)**	**(1,311,338)**	**(304,088)**	**(2,309,712)**
NET INCOME / (EXPENDITURE) BEFORE LOSSES ON INVESTMENTS	9,311	192,118	(213,870)	(12,441)
Net losses on investments	-	571,632	-	571,632
NET INCOME/(EXPENDITURE)	9,311	763,750	(213,870)	559,191
Transfer between funds	144,812	(250,957)	106,145	
NET MOVEMENT IN FUNDS	154,123	512,793	(107,725)	559,191
RECONCILIATION OF FUNDS				
Total funds brought forward	623,878	7,828,822	1,578,866	10,031,566
TOTAL FUNDS CARRIED FORWARD	**778,001**	**8,341,615**	**1,471,141**	**10,590,757**

Thank you!

We want to say a heartfelt thanks to the following companies, people, schools, charities, foundations and trusts for their wonderful support.



Companies
2K
Allen & Overy LLP
Baxi Heating UK
Bents Garden and Home
Burnt Peach
Charity Travel
Fine Tubes Ltd
Firaxis Games
GamesAid
Google
GRC World Forums
Henley Shipping
ICECO Ltd
Intercontinental Exchange (ICE)
iTech Media
Jefferies
Jubilant
Mark Bushnell Ltd
Marks Sattin
Marlin - Smartsearch
Marvel Entertainment
Maurice Turnor Gardner
McClure Solicitors
Mishcon de Reya LLP
Moody's - BVD Publishing Limited
Pipeline Technology Centre
Privacy Culture
PWC Foundation
Sanofi
Scamp and Dude
Smart Tech
SmartCredit Ltd
SUMO Digital
SUMO Group PLC
The Makery
Walsingham Planning
Y-mAbs Therapeutics Inc.

Ambassadors and individuals
Adina Pascall (Google Volunteer)
Anna Kaye
Anna Riera (Google Volunteer)
Ben Doltis
Clare and Chris Andrew
Dan Moore
Dot Courtney
Graham Cooper
Helen Pearson
Ioannis Topsakalidis
Iulia and Padmesh Thuraisingham
Jake Billings
Jeremy Doltis
Lara Polati
Lee Hodson
Liam Gurney
Luke Wiltshire, Claire Riley and their family
Malcolm Raven
Mark Nicholson
Mark Ward
Mimoza Bag
Nick Streeter
Pam Sekhon
Pippa Collins
Rachel Moore
Rev Sue Pitkin
Rosie Brandreth
Steve Taylor
Stewart and Cassie Leaver
Tanya Branchflower
Team Ottie
Tom Grennan

Data Volunteers
Alex, Avery, Badr, Caira, Ellen, Gracie, Mae, Morag, Orla, Tara and Walid

Patron and Champions
Rob Brydon
Carl Cavers
Demie Risby

Parent Involvement Forum
Naomi Bentham
Leeanne Brennan
Kate Dixon
Claire Donnelly
Garrett Fitzgerald
Stewart Leaver
Naomi Shefford-Thomas
Carrie Wright

Schools
London Oratory School Chamber Choir
Pakefield High School
The Hurst Community College
The Read School, Selby
South Wilford Endowed CofE School
Prae Wood Primary School
Kesteven & Sleaford High School

Charities, foundations and trusts
Band of Parents
GamesAid
Joining Against Cancer in Kids (J-A-C-K)
Neuroblastoma Australia
Neuroblastoma UK
Solving Kids' Cancer US
Children's Neuroblastoma Cancer Foundation
Special Effect
St James' Place Charitable Foundation
St. George's Society of New York
The Merryn Lacy Trust
The Rose Foundation
Wade's Army
Zoe4life
Rupert's Revenge

Family and named funds
Alfie's Wishes
Oscar Knox Fund
Smiles for Stanley

Solving Kids' Cancer UK

Annual Report

& Accounts 2021/22

Solving Kids' Cancer UK is a registered charity. We receive very little public funding for our work, relying on the generous support of the neuroblastoma community and general public.


Solving Kids' Cancer UK is a registered charity in England and Wales (1135601) and in Scotland (SCO45094). It is a company limited by guarantee in England and Wales (7208648). The charity and company currently operates as Solving Kids' Cancer.

To support our work visit:

Solving Kids' Cancer UK
Coram Campus
41 Brunswick Square
London
WC1N 1AZ

020 7284 0800

info@solvingkidscancer.org.uk



@SKC_UK

SolvingKidsCancer365

skc365

Solving Kids' Cancer UK

www.solvingkidscancer.org.uk

NIHR | National Institute for Health Research
Non-commercial partners

Member of amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES

Registered with FUNDRAISING REGULATOR

Solving Kids' Cancer UK

England & Wales - Charity number 1135601

Accounts

Solving Kids' Cancer



Solving Kids' Cancer UK

Annual report and accounts 2020/21

Report contents

Our impact 3

About us 6

Supporting and enabling clinical research in the UK 7

Reviewing and enhancing our support 10

Accessing best available treatments and most promising clinical trials 12

Enhancing and inspiring public support 14

Harnessing the combined power of the neuroblastoma community 16

Strengthening governance 18

Neuroblastoma Parent Global Symposium 2020 20

Achievements and performance 22

Future plans 24

Structure, governance and management 25

- Objectives and activities 25
- Our legal and administrative details 27

Financial review 28

Independent auditors report to the Trustees and members of Solving Kids' Cancer UK 33

Financial statements 36

Notes to the financial statements 39

Thank you! 58



Who's on our cover?

Daya is 4 years old. She is a fun-loving, smiley, and resilient little girl and loves spending time with her twin sister Jasmine and older sister Anaya.

Daya was diagnosed with high-risk neuroblastoma in 2017 at just 11 months old. She began intense and aggressive frontline treatment but following chemotherapy doctors advised that Daya's primary tumour was inoperable due to its position. We supported the family to fundraise an incredible £362,000 for specialised life-saving surgery in New York which removed the remaining neuroblastoma tumour.

After enduring two and a half years of harsh treatment, including extensive surgery, chemotherapy, radiotherapy, and painful immunotherapy, Daya is now in remission and doing well.



Our impact

Solving Kids Cancer UK is fighting for a future where no child dies of neuroblastoma or suffers due to the treatment they receive.

Children with neuroblastoma simply do not have the time to wait. We are responsible to the children, their families and to those who support us, to demonstrate the impact of our work, and the progress we are making. This year, with your support and despite the challenges COVID-19 has presented, we have achieved more than ever before:

- **Increased our research funding by over 50%**
- **Worked with partners to award over £2.1million in research grants**
- **Ensured children in the UK have access to the same standard of care as those in Europe by funding the SIOPEN High-Risk Neuroblastoma 2 trial in the UK**
- **Provided support to more families than ever before in the charity's history**
- **Brought together over 700 registrants, from over 40 different countries to the inaugural Neuroblastoma Parent Global symposium**
- **Led an international partnership of parent charities, awarding $1.3milliion, to enable the first-ever transatlantic collaboration between North American and European paediatric cancer consortia – a landmark in paediatric oncology research**
- **Supported 16 families to access their choice of treatment in the most challenging of years.**
- **Launched our Parent Involvement Forum**
- **Raised over £100,000 via community and event fundraising**



An introduction from our Chair

It is so pleasing to see how Solving Kids' Cancer UK has stepped up once again this year, working tirelessly every day to put children with neuroblastoma first despite all the challenges of the pandemic. Fighting for all children by initiating and funding ground-breaking new research projects. Doing our best for each child by delivering a support service that looks after children and families with unrivalled care and commitment.

You will read in these pages how we have succeeded in bringing together the major research groups from Europe and North America for the first time in history. Under our leadership, seven parent-led charities came together to provide the funding power, drive, and determination to advance precision medicine for children with newly diagnosed neuroblastoma through a new transatlantic clinical trial (TITAN). The trial stands as a testament to the collective determination of all partners to cure more young children afflicted by this terrible disease.

TITAN will be integrated into the new pan-European trial for children diagnosed with high-risk neuroblastoma. Solving Kids' Cancer UK is also a major funder of that trial, underlining the critical role we now have at the heart of UK research. It is vital for us to get this message out far and wide, to help grow our support and allow us to do even more to help children.

Nobody knows better than our Family Support Team about the challenges of dealing with a neuroblastoma diagnosis. As a charity we are proud to have parents at the heart of everything we do, working alongside other members of our staff team who routinely go the extra mile to meet the needs of families facing their darkest hours. The additional burdens resulting from the pandemic; financial, practical, and emotional, have made our support provision over the last year more vital than ever. Ensuring that families have been able to access clinical trials abroad through travel restrictions and COVID-19 protocols may have stretched us to the limit, but our team has always managed to come through when required.



Whilst inevitably the pandemic prevented us from holding our annual parent conference in 2020, it did not stop our pioneering spirit from seizing a new opportunity to bring together the neuroblastoma community, this time globally. Partnering with our American friends at Solving Kids' Cancer and Children's Neuroblastoma Cancer Foundation (CNCF), we designed and delivered a two-day online symposium attended by over 700 delegates from more than 40 countries. It was incredible to witness how well this groundbreaking event was received.

I would like to send my sincere thanks to everyone who has supported Solving Kids' Cancer UK during this past year. From donations, to offers of assistance, to messages of support and encouragement, to simple words of appreciation. You have all helped us to deliver for children and families once again. Solving Kids' Cancer UK is not a large charity, and we don't aspire to be, but we do constantly strive to do more. I must pay tribute to Gail and our entire team for consistently going above and beyond despite the difficult circumstances we've all had to operate in this year. Finally, it would be remiss of me not to also mention the contribution of our Trustees, who have once again stepped up to help navigate the best course for the charity through this pandemic. It is a privilege to work alongside such dedicated people, each of whom generously volunteers their time in pursuit of the purpose at the heart of our charity and that drives us all – to help more children with neuroblastoma survive.



Nick Bird
Chair of Trustees

"From donations, to offers of assistance, to messages of support and encouragement, to simple words of appreciation. You have all helped us to deliver for children and families once again."

From our CEO



Of the many circumstances I had anticipated in readiness for becoming this charity's new CEO in April 2020, a global pandemic was certainly not one of them.

COVID-19 hit just a few weeks prior to my joining the charity and certainly in those early few months, it dominated just about everything. We began the year with a great deal of uncertainty about how we would raise the funds we needed given the cancellation of all planned fundraising events.

Of even greater concern to us was how this pandemic would affect our families – families who are already experiencing the unimaginable challenges of a neuroblastoma diagnosis, undergoing intensive treatment, at a time when lockdown and social distancing measures meant that they had to become even further isolated from friends and family due to restrictions and parents often having to support their child in treatment alone, because only one parent was permitted on the ward. Alongside this isolation, came the additional financial challenges which are already a burden experienced by so many families undergoing cancer treatment as often one parent will give up work to provide full-time care. The pandemic led to many job losses and sadly our families were not immune to this and so these financial and practical challenges intensified for so many. To meet this need we introduced our emergency fund with our charity partner Joining Against Cancer in Kids (J-A-C-K) for families affected by neuroblastoma who faced immediate financial burdens because of the pandemic.

I am tremendously proud of how the team at Solving Kids' Cancer UK has risen to the challenges and delivered more than I could have imagined possible in this most difficult time. They have tackled each challenge head-on with a renewed sense of determination and commitment, and the achievements have been significant, but they've only been possible through working with partners. We strongly believe in the power of partnership and collaboration and this year have worked with more than ever before.

Over the course of the year we awarded two major research funding grants together with the widest range of parent-led charity partners across Europe and the USA. We are hugely grateful to all of our partners for sharing our dedication and commitment to fund international clinical trials that bring the most innovative therapy options closer to frontline treatment. I'd like to extend my thanks and ongoing gratitude to our Scientific Advisory Board for their time, expertise and the invaluable contribution they make to ensuring we make robust science-based decisions about research investments.

We reached out to our wider parent community this year through our Parent Survey and gained valuable insights about how we could further develop and improve our services and incorporate the views of even more parents more robustly into our work. We were incredibly proud to introduce the charity's first Parent Involvement Forum this year, which you will see profiled on page 17.

Our partnership approach extends to the medical profession and we are proud funders of the National Neuroblastoma Nursing Group, a sub-group of the RCN/CCLG Children & Young People's Nursing Group. The group comprises cancer nurse specialists and research nurses involved in the care of children with neuroblastoma across the country and together they progress pieces of work over and above their day-to-day duties. This year the group supported us with input and advice on the development of our family support information which will be sent out to all treatment centres so that families hear more about our support service at the earliest possible opportunity.

We are so grateful for our corporate partners and individual supporters who have championed our charity this year, despite the ongoing challenges that have had an impact on us all. We will never take this support for granted and their continued passion and dedication to our shared cause has so often given us a much needed boost; from inspirational fundraising events to unexpected donations, these moments have meant so much to us all.

And so we look forward to the next year with anticipation, hope and continued determination to achieve even more on behalf of children with neuroblastoma and their families. As ever, my thanks go to our Board for their wisdom and guidance, our staff team for their incredible tenacity and resilience and to our volunteers and supporters for their time and generosity. Together, we are stronger.



Gail Jackson
Chief Executive Officer



About us

We are a parent-led charity fighting for a future where no child dies of the childhood cancer neuroblastoma or suffers due to its treatment.

Neuroblastoma is an aggressive and devastating cancer which affects the youngest of children; the majority of children affected by this disease are diagnosed before the age of 5.

Every year, approximately 100 children and their families receive a neuroblastoma diagnosis. Around half of these children are diagnosed with high-risk neuroblastoma. A diagnosis of high-risk neuroblastoma is devastating for families and presents complex challenges that will have an impact on every aspect of their lives. This has only been compounded by the COVID-19 pandemic. Despite the most intensive, toxic and painful treatment, 50% of children with high-risk neuroblastoma will not survive. Those who do survive often suffer lifelong health problems because of the harsh treatments they receive as young children.

Though progress is being made in the treatment and understanding of neuroblastoma too few children diagnosed with high-risk neuroblastoma are cured. We stand firm in our drive to bring even more innovative clinical trials to the UK for the benefit of all children diagnosed with neuroblastoma.

It is essential that promising developments in research are translated into effective treatment options for children fighting neuroblastoma now. Through this, we are determined to advance science and find a cure for future generations.

We help children and families affected by neuroblastoma by:

- Providing hope, information and support to families throughout their journeys
- Facilitating access to treatment in partnership with clinicians and researchers
- Advancing science through investment in clinical research
- Advocating for more effective and less toxic treatments

Supporting and enabling clinical research in the UK

We are committed to driving and investing in pioneering research, to advance the treatments that children can access to fight their disease.

A key part of this is advancing the treatments that children can access to fight their disease, which is why we are committed to driving and investing in pioneering clinical research.

2020 has brought many challenges for Solving Kids' Cancer UK in the face of the COVID-19 pandemic. Despite these adversities we have maintained our support for the research community and even increased our research funding, with the grants we have awarded totalling over £700,000. Funding UK research and international challenge grants that mandate transatlantic collaboration has ensured that the most promising new research is developed and progressed in both Europe and North America with a specific requirement for UK participation.

Our focus this year on strengthening partnerships and increased collaborative working meant an additional £2.1 million has been dedicated to research into neuroblastoma, helping children in the UK and beyond.



OVER THE LAST YEAR, WE HAVE...

- **Awarded four grants, committing over £700,000 to research**
- **Launched three groundbreaking projects which will help inform treatment for children with high-risk neuroblastoma globally**
- **Successfully passed the 2020 AMRC Audit – proving our commitment to fund research of the highest standard, in the fairest way**
- **Provided sponsorship for the biennial ANR conference, the leading international scientific research event for neuroblastoma**

Pursuing our mission in unprecedented times

The charity has seen many changes in the last year because of the pandemic, but our mission to help the children and families affected by neuroblastoma remains.

COVID-19 has been detrimental to the research landscape, with limits to funding and redeployment of staff away from clinics and onto the frontline. But despite this urgent health crisis, the fact remains that children with neuroblastoma simply do not have the time to wait, and so we are determined to accelerate the progress that is being made to find better treatments for those in desperate need.

This has meant not only increasing our funding into research in the past year, but also having close dialogue to support the researchers in our network by other means including timeline extensions, investigating delays and joining campaigns for extra government resource into medical research.

Funding trials in the UK

Progress has continued since we announced the funding of UK sites for the SIOPEN High-Risk Neuroblastoma 2 Trial, in partnership with Neuroblastoma UK. The project will follow on from the first SIOPEN High-Risk trial which saw an improvement to standard care protocols across Europe.

This latest trial will answer more questions related to chemotherapy and radiotherapy to ensure that high-risk patients are receiving the best care possible for their disease. Enabling this trial to open in the UK was incredibly important to ensure that children here have access to the same standard of care and more targeted therapies as those across Europe, where the study is already progressing.

As lead funders of this initiative, with generous contributions from the Charlie Hook Appeal Trust Fund and the Corey Ashcroft Fund, we look forward to seeing sites open in 2021 for all newly diagnosed children.

Giving more children a chance through international collaboration

Since the launch of our first International Neuroblastoma Research Initiative in 2018, we have been striving to expand our research impact by driving global collaboration.

This year, that culminated in the launch of two pioneering projects: the Transatlantic Integration Targeting ALK in Neuroblastoma (TITAN) study, and the Solving Indolent Neuroblastoma study. TITAN was awarded a total of $1.3 million from a group of seven parent-led research charities. It will see the introduction of a targeted therapy into frontline treatment for high-risk neuroblastoma, with the treatment of these children in Europe and North America being coordinated for the first time ever.

The Solving Indolent Neuroblastoma project being carried out by researchers across North America and Europe received £500,000 from a collective of charities brought together in Solving Kids' Cancer UK's second International Neuroblastoma Research Initiative. This landmark project is the first to focus solely on children with refractory disease, with hopes to give them a better chance at being treated in the most effective way, straight from diagnosis. We are incredibly proud to be the driving force behind both of these projects, which will set a precedent for our future international ambitions.

Building strong foundations to achieve our goals

The uncertainty surrounding the pandemic has allowed time for the charity to reflect on what has been achieved so far in our research work, which has grown dramatically in recent years, and to look ahead at how we can sustain this rate of progression.

This was a prominent topic of conversation at the most recent meeting of our Scientific Advisory Board (SAB), where it was made clear that the charity has had a very meaningful impact on the landscape since the SAB's establishment in 2017 and that this must continue. As such we are now looking at how we can build the infrastructure that will allow the growth of our international portfolio, and advance future collaborations.

With this in mind, we were thrilled to successfully pass the 2020 Association of Medical Research Charities' audit of our grant award process, which oversees the £2.1 million portfolio we have managed this year. This confirmed that the foundations of our research work are robust, fair, and transparent, and have impact; we now look forward to building upon this in the coming year, bringing meaningful benefit to children with neuroblastoma.

Member of amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES

VANESSA

Vanessa was a gutsy, happy young woman from Troon in Scotland who lost her decade-long battle with cancer just days before her 18th birthday. She was first diagnosed with high-risk neuroblastoma in 2009 at 8 years old and, after completing standard frontline treatment, was in remission.



Sadly, Vanessa relapsed in December 2011 and was given a less than 10% chance of survival. Her parents, Chris and Connie, immediately launched a fundraising appeal with Solving Kids' Cancer UK, known then as NCCA UK to raise funds needed to get Vanessa back into second remission.

Vanessa's campaign gathered national attention, in part thanks to her sister Olivia being a social media whizz and raised an incredible £800,000 which was used to fund Haploidentical Stem Cell transplant treatment in Tübingen, Germany, in August 2012. In January 2013, Vanessa's family were delighted to hear that she was once again in remission, and she was able to return to school and begin living a normal life again.

Just over a year later, the neuroblastoma returned. Due to the generosity of supporters from Vanessa's first appeal, significant funds had been raised which allowed the family to return to Germany for Vanessa to be enrolled onto an immunotherapy trial with Natural Killer(NK) cells to get her back into remission.

Devastatingly, whilst on a family holiday in America, Vanessa became symptomatic and new areas of disease were discovered.

The family were supported by Solving Kids' Cancer UK to identify other treatment options available for Vanessa. Vanessa was treated at her primary treating centre in Scotland which included radiotherapy and by the autumn of 2016, a slot was available for her to join the T Cell CAR trial at Great Ormond Street Hospital. As usual, Vanessa took everything in her stride and always with a smile. Vanessa sadly passed away on 1st June 2018, surrounded by her dear family.

Vanessa's legacy

Accelerating research into high-risk neuroblastoma is something that the family is passionate about, and 70% of the remaining funds are contributing to our research strategy and have enabled us to fund our research programme this year which has included SIOPEN High-Risk Neuroblastoma 2 trial, Titan and Solving Indolent Neuroblastoma project. Vanessa's remarkable legacy has been, and will continue to be, an integral part of sustaining our research goals during a year which has been so challenging.

"Connie and I would like to express a heartfelt thank you to everyone who so generously donated to give our precious Vanessa a chance at life. Vanessa loved life and would be delighted to know that some of the funds raised are now being used to help other kids with this terrible disease; giving them a fighting chance to love life too!"

Chris and Connie,
Vanessa's parents

Vanessa's parents, Chris and Connie, want her legacy to help as many children as possible and support families in desperate relapse/refractory situations where treatment options are limited, and funds are needed more urgently to access treatment. 20% of funds raised in Vanessa's name have been restricted to our reserves fund, which supports families in these situations who are facing a shortfall in funds and where time is not on their side.

Funds have also gone towards general reserves to ensure that we have the resources to continue supporting families. The importance of having adequate reserves in place has been highlighted by the COVID-19 pandemic and is crucial to continue the charity's operations on a secure and stable foundation, allowing us to concentrate our efforts towards helping children and families.

Reviewing and enhancing our support

In this year of great challenge, our Family Support Service has continued to provide unrivalled scope and quality of support for families affected by neuroblastoma.

The demand for this service grew exponentially over this last year. This has given families direct and one-to-one support as they negotiate complex challenges which have only been compounded by the pandemic.

The families within the neuroblastoma community are particularly vulnerable and have been deeply affected by the pandemic. We have experienced demand for our service increase by 258% throughout the year.

Lockdown led to entire families needing to shield and isolate themselves further to protect their vulnerable child, which had a disproportionate impact on their lives and wellbeing. In response to the crisis we partnered with Joining Against Cancer in Kids (J-A-C-K) and introduced our Emergency Fund for all families affected by neuroblastoma (low, intermediate or high-risk), who were facing additional burdens due to the pandemic.

During this time we also bolstered our team and welcomed Dan Ingle to the Family Support Service, Dan has been a member of team SKC for several years and has been there for all families throughout this difficult year, advocating on their behalf and providing dedicated support.



"Words cannot thank you enough for the help and support this has brought to our family. It was one fewer thing for us to have to think about. You will never know how much this fund meant to me and my husband and we will forever be grateful to your kind charity."

OVER THE LAST YEAR, WE HAVE...

- **Provided 304 pastoral grants to 57 families**
- **Provided 278 families with emotional and practical support, evidence-based and impartial information about neuroblastoma and its treatment**
- **Hosted our inaugural Neuroblastoma Parent Global Symposium online, reaching over 40 countries and welcoming over 700 participants**
- **Partnered with Joining Against Cancer in Kids (J-A-C-K) and introduced our Emergency Fund for families affected by neuroblastoma, in response to the COVID-19 pandemic, awarding £68,500 and supporting 49 families**

ELLEN

In January 2018, at just 2 years old, Ellen was diagnosed with high-risk neuroblastoma after several visits to the doctor with tummy pains.

Within days of being diagnosed, Ellen started eight cycles of chemotherapy. She had a difficult time struggling with infections after every chemotherapy cycle, so spent most of her time in hospital on antibiotics.

Thankfully the disease responded to the chemotherapy, and Ellen had a 13-hour surgery to remove as much of her tumour as possible. After surgery Ellen also had to endure high-dose chemotherapy, stem cell transplants, radiotherapy and five cycles of immunotherapy.

During Ellen's treatment, her parents Claire and Patrick were supported by Solving Kids' Cancer UK to access the Bivalent Vaccine clinical trial at the Memorial Sloan-Kettering Cancer Center in New York after deciding this would be the next treatment path for Ellen, in the hope the trial would reduce the chances of her cancer coming back. Despite involving the most intense treatment regime of all cancers, the disease returns in 40-50% of all children diagnosed with high-risk neuroblastoma. In 2019, the family raised nearly £550,000 exceeding their fundraising target.

In June 2020, Ellen and her family made the difficult decision to travel to New York during the pandemic to complete the vaccine trial. She remains free of disease and has since started Year 2.

Claire says, "Ellen is doing well now, thankfully, though we are now starting to deal with the long-term side effects that have been caused by the harsh treatment she went through. Even after all that she has been through, Ellen is such a happy little character. She gets such joy from the simple things that we can sometimes take for granted. She makes us laugh every single day. I feel such an overwhelming sense of gratitude that she is doing as well as she is and enjoying her life again. I am also acutely aware that some families have not been so fortunate."

Ellen's family has continued to support us, with Claire being appointed as a member of our Parent Involvement Forum in early 2021 (see page 17).

"I will never forget the moment the radiologist said that she wasn't happy with the scan. That was the moment when our lives changed forever. We were devastated."

Claire, Ellen's mum







Accessing best available treatments and most promising clinical trials

High-risk neuroblastoma is one of the most challenging childhood cancers to treat successfully and involves intense and aggressive multi-modal therapy.

Advancing science in this area requires both collaborative and complimentary international efforts and sometimes this means that advances in science through clinical trials initially take place in different parts of the world, including the UK.

Solving Kids' Cancer UK supports a parent's right to choose to enrol their child on a recognised clinical trial abroad as well as in the UK. Our frontline team blends lived experience with professional experience, has an in-depth knowledge of the current clinical trial landscape and provides evidence-based and impartial information to families; supporting them in their choice of treatment options for their child.

Over the course of the year, our Family Support Team assisted 16 children to travel abroad to access their family's chosen treatment despite the burden of travel restrictions. We have built a hugely supportive network of embassy officials, and we thank all those who have helped us advocate for children and their families in London, Barcelona and New York. We also thank our charity partner friends, St. George's Society, in New York.

OVER THE LAST YEAR, WE HAVE...

- **Supported families who raised £1.4 million to access their choice of treatment**
- **Facilitated access to treatment abroad for 16 children**
- **Organised 18 sets of flights and 18 accommodation stays**
- **Saved families collectively in excess of £114,000 by negotiating the costs of their treatments with cancer institutions**
- **In partnership with J-A-C-K, provided families accessing treatment outside of the UK with additional financial support towards associated travel/accommodation costs**

SERAPH

In 2017, just before Christmas, Seraph fell out of his cot and broke his arm. After experiencing more pain over Christmas, his parents took him back to hospital where an exploratory ultrasound revealed a tumour in his abdomen, and further investigation showed cancer in his skeleton and bone marrow.



Seraph's parents, Cass and Liam teamed up with Solving Kids' Cancer UK to fundraise an incredible £305,000 to access a clinical trial for Seraph, in the hope that it will prevent his cancer from returning in the future. After his end-of-treatment scans came back showing no evidence of disease, Seraph was accepted onto the Bivalent vaccine clinical trial in New York, and the family first travelled to America in June 2019.

Seraph's final trip was due in July 2020 in the midst of the pandemic. The family faced a very difficult decision as to whether to travel and if they felt it was safe to do.

Cass says, "We were advised to completely shield, and so we hadn't left the house for 10 weeks. Information was changing daily about visas, possible long quarantine times, and how the disease was transmitted. After breaking our isolation for a family trip to the US embassy to pitch our case to travel, and a nervous wait to see if we would be granted access to the States, we almost came unstuck over travel insurance. No one was insuring for COVID-19. All this and we were still unsure whether to travel. Eventually, we decided we'd work on the basis of what we knew. We knew Seraph had Neuroblastoma. We knew Neuroblastoma is a killer. We chose to throw everything at that. New York was a very different city when we got there, and we remained in our hotel room for the duration. Lucky for us, our final trip was sad but uneventful, and Seraph finished treatment in summer 2020".

"Gloriously noisy, messy, unidentifiably sticky, and wonderfully happy – the way any 6-year-old child deserves to be. There aren't words to describe the joy of this kind of normal."

Cass and Liam, Seraph's parents





Solving Kids' Cancer UK supported the family, along with 15 others during lockdown, in arranging travel and accommodation to ensure they felt safe and comfortable, both in the lead-up to their trip when travelling to London to pick up their visas and when travelling to and staying in New York.

Cass says, "Our lasting impression of the US portion of Seraph's treatment is of great fondness for a time when we got to be a family together, in a city which is now engraved upon our hearts. We thank Solving Kids' Cancer UK for helping us throughout this part in our journey. Hayley and Vicky, and Dan particularly (during one eventful flight) were our rocks."

"We feel extremely lucky that Seraph finished treatment when he did. I know how close to the edge we were during frontline. Thinking about the extra burden on families with recent diagnosis is a pain beyond. Whether getting through the long hospital days without extra support or attempting to fundraise during a time of scarcity, to the decision-making necessary in COVID times to navigate not one, but two deadly illnesses."

Seraph is now over two years with No Evidence of Disease. He has permanent hearing loss as a result of the harsh treatment but despite this is living his life to the full.

Enhancing and inspiring public support



2020 was a year like no other. Like many charities, the impact of COVID-19 was great and particularly impacted on our fundraising activities.

We responded swiftly to our fundraising challenges, taking events online and developing a series of bespoke virtual challenge events. We have been humbled by the commitment and generosity of our fundraisers, donors and corporate partners, who have met the challenges of the pandemic to continue to raise funds and awareness of our cause.

We launched our Ambassador programme early in lockdown to mobilise our supporters and identify new ones. Ambassadors have been responsible for some extraordinary fundraising and awareness activities, including an online raffle of a painting by Mark Owen of Take That, and Clare Andrew's Butterfly Relay – which has gone on to inspire 2021's virtual relay.

We were thrilled to welcome one of the UK's most celebrated performers, Rob Brydon, as our first charity Patron. Rob's support will help us continue to raise awareness of neuroblastoma and highlight our ambition to make a real difference for the children and families we support.

Our fundraising and communications team merged under new leadership and we have welcomed Emily Hall as our Research and Digital Communications Officer. Emily has been working closely with our research team to ensure our research achievements are embedded throughout our communications.

"I have had a personal connection to Solving Kids' Cancer UK for many years and their work is a cause that is very close to my heart. I am honoured to be the charity's first Patron."

Rob Brydon





OVER THE LAST YEAR, WE HAVE...

- **Developed an ambitious new fundraising and communications strategy**
- **Welcomed over 700 people to our first virtual Christmas Carol Concert**
- **Secured GamesAid funding for a fifth year running**
- **Raised over £106,000 through our dedicated community and challenge event supporters**
- **15,000+ butterflies created by #TeamButterflyKnitters for the 2021 Butterfly Relay**
- **Collaborated with other charities on fundraising initiatives, including the 20 for 20 initiative**

BEAUTY AND THE BEARD

"We are so proud to be supporting Solving Kids' Cancer UK once again. It is a truly special charity that does wonderful work." **Josh Brown**, Founder and Director of Henley Shipping

Between October and December 2020, our partners Henley Shipping got creative and started their own original campaign: Beauty and the Beard.

The challenge was to grow a beard or grow your hair for three months. Their energy, creativity, passion and social media presence inspired so many different people across their community to get involved. They also continued to develop new and exciting challenges to raise both funds and awareness across this time. They held game nights, sold t-shirts, ran competitions and key team members even dyed their hair peroxide blond!

Over £12,000 was raised across the three months and we are incredibly grateful for this corporate support.



WALKING 5KM A DAY

In January 2021, Hazel, aged 6, and Oscar, aged 8, from London, decided to raise funds for Solving Kids' Cancer UK.

They set themselves the fantastic challenge of walking 5km a day for five days. They updated their JustGiving page daily with details on where they walked and what they came across on their journeys. They ended up walking through both rain and shine, but the bad weather certainly didn't deter them! As a result of their dedication, Hazel and Oscar raised over £1,000 to support Solving Kids' Cancer UK.

They say: "We chose to do the walks for charity to remember our neighbour Noah and our brother Jasper. We chose to support Solving Kid's Cancer UK because we were impressed with what they have achieved to date and believed our fundraising could make a real difference. We really enjoyed the walks and exploring our local areas. The generous donations of our family and friends certainly helped motivate us when the challenge was tough or the weather wasn't great."



"We are proud of what we managed to achieve and very grateful for everyone's support." **Hazel and Oscar**



Harnessing the combined power of the neuroblastoma community

This year, collaboration and working in partnership has been key – harnessing the neuroblastoma community like never before to ensure we raise our collective voice and advocate for the children and families we serve.

Following our parent survey we launched our Parent Information Forum, who meet regularly to provide insight and expertise to help inform our service.

We have worked closely with the National Neuroblastoma Nurses Group, a sub-group of the RCN/CCLG Children & Young People's Nursing Group (NNNG), and through this partnership received their support with the development of our family support information, to ensure that families hear about our support service at the earliest possible point.

We also took the ambitious step to bring our annual conference online, collaborating with partner organisations across continents to host the Neuroblastoma Parent Global Symposium.

We have kept parent-led advocacy at the heart of our research strategy, with members of our research team holding 'patient expert' positions in national and international research groups, including the Innovative Therapies for Children with Cancer (ITCC) Consortium - Advocate Committee ACCELERATE Steering Committee, SIOPEN Association, National Cancer Research Institute (NCRI) Neuroblastoma Group, Coalition Against Childhood Cancer (CAC2) Board and New Approaches to Neuroblastoma Therapy (NANT) Advisory Council.

Our thanks to Solving Kids' Cancer US, Children's Neuroblastoma Cancer Foundation, Neuroblastoma UK, J-A-C-K, Zoe4Life, Merryn Lacy Trust, The Charlie Hook Appeal Trust Fund, Alfie's Wishes, The Corey Ashcroft Fund, Oscar Knox Fund, Smiles for Stanley Fund, Band of Parents, Wade's Army and the Ronan Thompson Foundation, for their generosity as our funding partners in 2020-21.

OVER THE LAST YEAR WE HAVE...

- **Launched our Parent Involvement Forum**
- **Worked in partnership with other parent-led organisations and awarded research grants, totalling £2.1million**
- **Launched our Emergency Fund at the outset of the pandemic in partnership with J-A-C-K**
- **Hosted and collaborated on the inaugural Neuroblastoma Parent Global Symposium**

INTRODUCING OUR PARENT INVOLVEMENT FORUM

We are a truly parent-led charity; parents with lived experience of neuroblastoma are represented across our Board of Trustees, our Leadership Team, operational team and volunteers. At every step we are a voice for children and their families. In every conversation we amplify their voice and ensure that children are at the heart of all we do.

At the height of the pandemic, we set out to understand what neuroblastoma parents needed from our charity, and we surveyed the wider neuroblastoma parent community. Insights from this survey were invaluable and directly informed our service development, the first step of which was to launch our Parent Involvement Forum in January 2021.

The forum is made up of parents who have all been supported by Solving Kids' Cancer UK at different stages through their child's neuroblastoma journey. They give their time voluntarily, providing a wealth of experience and insight which directly informs our service development and communications to ensure we have the greatest possible impact.

We continue to be inspired by their desire to support other families going through similar experiences and are so grateful for their generosity of spirit and dedication.



"I wanted to get involved as the help we received from Solving Kids' Cancer UK when Ellen was going through treatment was invaluable to us. It feels really important to me to now try to give something back. Hopefully, my input can help other families in the future who are going through the same traumatic experience as we did."

Claire, Ellen's mum

"Unfortunately, we're all members of an exclusive club that none of us wanted to join. We would do anything to make it any bit easier for the future members because we greatly appreciate what parents and all others have done in the past to improve our journeys"

Garrett, Lauren's dad

1 Anna Austin (to April 2021)
2 Naomi Bentham
3 Leeanne Brennan
4 Claire Donnelly
5 Kate Dixon
6 Garrett Fitzgerald
7 Stewart Leaver
8 Naomi Shefford-Thomas
9 Carrie Wright (from June 2021)

Strengthening governance

During the last year, we welcomed Gail Jackson as Chief Executive Officer, who joined at the peak of the pandemic in April 2020. Gail, with the support of our dedicated Board of Trustees, has guided the charity through the uncertainties of the pandemic.

We also recruited Alexandra Lane as a Trustee, welcoming her in September 2020. Alex is a lawyer specialising in health care regulatory work. Her eldest son, Archie, was diagnosed with Stage 4 high-risk neuroblastoma when he was just 2 years old. Despite intensive treatment, Archie sadly passed away in 2018.

The Board of Trustees, led by our Chair Nick Bird, have devoted so much of their time and energy to guiding the work of Solving Kids' Cancer UK this year, enabling us to reach more families than ever before, develop our services and extend our commitment to research.



"I hope that by collectively driving forward awareness, funding and research we can and will make a real difference in the future" **Alexandra**, Trustee



OVER THE LAST YEAR, WE HAVE...

- **Conducted a Board of Trustees skills audit and identified areas of recruitment**
- **Strengthened our risk register and added an addendum covering COVID-19**
- **Strengthened our recruitment and induction process for both Trustees and employees**
- **Begun implementation of a new CRM system to improve donor journey, communications and impact measurement**

CELEBRATING IN HOPE AND THANKS



In December, with the wonderful support of Data Protection World Forums, many generous performers and Stray Cat Productions, we welcomed over 700 people to our first virtual Christmas Carol Concert, celebrating together in hope and thanks.

We chose to use the evening to celebrate the work of the NHS, particularly those who had worked tirelessly to support the neuroblastoma community throughout the pandemic. As part of this, families we support were invited to nominate special people for our Solving Kids' Cancer UK NHS Hero Award. Five awards were given out on the night to extraordinary doctors, nurses, and hospital wards.

The event was presented live by our Trustee Bronwyn Ellis and featured a range of wonderful acts. Performers kindly gave their time to perform exclusively, including several household names.

We were thrilled to feature the London Oratory School Chamber Choir, singer Astræa, harpist Valeria Kurbatova, opera singer and 'Go Compare' star Wynne Evans, UK number one singer Newton Faulkner, and duo Tomos Lewis and Maddie Jones.

We were also privileged to welcome comedians Josh Widdicombe and Matt Richardson for warm and humorous festive messages. There were several delightful readings, too, including poems and messages from children the charity has supported, and Reverend Anne Doerr from the Royal Marsden led a blessing.

Attendees were invited to join us for virtual festive drinks before and after the concert. This was a lovely opportunity to mingle with friends, family, and colleagues at a time when we could not do so in person.

The event raised over £21,000 for the charity and, after what had been a very challenging year, the concert delivered an evening of joy, hope and some much-needed festive spirit.

"Congratulations on the Carol Concert, I was so moved by the personal stories and the NHS hero awards. It was wonderful to enjoy some festive spirit during this time when we're not able to celebrate together in person"

Ioan, Christmas Carol Concert attendee

Our thanks to everyone who helped make this event so special and the children who shared messages and readings on the night: Anya, Bibi, Daya, Ellen, Lucy, Eva, Lily-Mae, Oliver and Zakky.





Neuroblastoma Parent Global Symposium 2020

The cancellation of our annual in-person parent conference in 2020 was a very difficult but unavoidable decision for us in the face of the pandemic. However, this challenge provided the opportunity to think globally, extend our ambition and work with international partners to develop the virtual Neuroblastoma Parent Global Symposium, the first of its kind for the global neuroblastoma community.

On 6th and 7th November 2020, the inaugural Neuroblastoma Parent Global Symposium brought together families affected by neuroblastoma from around the world with those who work to treat, help and support them.

Presentations from 36 experts in Australia, North America, and Europe shared the latest information on biology, treatment, research, late effects and psychosocial challenges surrounding a childhood cancer diagnosis.

Over 700 parents, medical professionals, charity leaders, and industry representatives from 46 countries were able to view live presentations and panel sessions, and ask questions.

International experts delivered sessions providing credible and reliable information on treatment and clinical trials, including current treatment strategies in Europe, North America and Australia, and some of the impacts of a childhood cancer diagnosis on the whole family.

We collaborated with Children's Neuroblastoma Cancer Foundation and Solving Kids' Cancer (US), two charities with whom we have a history of collaboration, to deliver this worldwide event - the first of its kind for the international neuroblastoma community.

Families worldwide now have free access to information through 25 hours of recorded sessions which can all be viewed at **https://bit.ly/NPGS-2020**.

We are grateful to GRC World Forums and Y-mAbs Therapeutics for their support to help make this wonderful and inclusive event possible.

"It has been a real pleasure and privilege to discuss with friends and colleagues the most recent data and approaches to therapies for children with neuroblastoma." **Franco Locatelli**, Director of Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù

"This event highlighted how well connected the oncology world is and that we are fortunate to have so many amazing experts around the globe searching for better treatments/cures for this devastating disease." **Adam**, Australia

"An absolutely fantastic event, very informative and excellently run. As a family member of someone with neuroblastoma, it was great to hear of the newer treatment options and hear survivor stories." **Rosie**, UK

"What a phenomenal resource for families to connect, share information, and form community! Thank you for making this possible for families all over the world!" **Jessica**, USA

Solving Kids' Cancer® United Kingdom

Children's Neuroblastoma Cancer Foundation

Solving Kids' Cancer® United States

Online Event
6th & 7th November 2020
Join the conversation: #NPGS2020

NEUROBLASTOMA PARENT GLOBAL SYMPOSIUM 2020



Yael Mossé, MD

Director of the Neuroblastoma Development Therapeutics Program, Children's Hospital of Philadelphia

Targeting ALK - Discovery to Frontline Treatment

Moderated by Gavin Lindberg, Co-Founder & President, The EVAN Foundation

Online Event
6th & 7th November 2020
Join the conversation: #NPGS2020

NEUROBLASTOMA PARENT GLOBAL SYMPOSIUM 2020

Neuroblastoma Basics: Ask the Experts

Moderated by Leona Knox, Head of Research, SKC UK, NB Parent



Ami Desai, MD

Assistant Professor of Pediatrics, University of Chicago/Comer Children's Hospital



Cormac Owens, MD

Consultant Paediatric Oncologist, Children's Health Ireland at Crumlin



Steven DuBois, MD MS

Director, Experimental Therapeutics, Dana-Farber/Boston Children's Cancer and Blood Disorders Center



Thorsten Simon, MD, PhD

Clinical Director of the Department for Pediatric Oncology and Hematology, Children's Hospital of the University of Cologne

Online Event
6th & 7th November 2020
Join the conversation: #NPGS2020

NEUROBLASTOMA PARENT GLOBAL SYMPOSIUM 2020



Daniel Morgenstern, MD BChir PhD

Director, New Agent and Innovative Therapy Program (NAIT), The Hospital for Sick Children, Toronto

Opening Ceremony

Online Event
6th & 7th November 2020
Join the conversation: #NPGS2020

NEUROBLASTOMA PARENT GLOBAL SYMPOSIUM 2020



Jaume Mora, MD PhD

Scientific Director, Pediatric Cancer Center Barcelona

Naxitamab (hu3F8) Studies

Moderated by Gregory Sizikov, NB Parent

Online Event
6th & 7th November 2020
Join the conversation: #NPGS2020

NEUROBLASTOMA PARENT GLOBAL SYMPOSIUM 2020



Juliet Gray, MD, MA, MB BS, PhD

Clinical Lead Paediatric Oncology & Haematology, University Hospital Southampton

MiNivAn: MIBG and Antibody Combination Therapy

Moderated by Nick Bird, Chair of Trustees, SKC UK

Online Event
6th & 7th November 2020
Join the conversation: #NPGS2020

NEUROBLASTOMA PARENT GLOBAL SYMPOSIUM 2020

Cell Therapies in Neuroblastoma

Moderated by Nick Bird, Chair of Trustees, SKC UK



Navin Pinto, MD

Associate Professor of Pediatrics, University of Washington/Seattle Children's Hospital



Crystal Mackall, MD

Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine, Stanford Medicine



Franco Locatelli, MD, PhD

Full Professor of Pediatrics & Director of Department of Pediatric Hematology and Oncology, Sapienza University of Rome & IRCCS Ospedale Pediatrico Bambino Gesu



Andras Heczey, MD

Director, Cancer and Hematology Center, Texas Children's Hospital

40+ COUNTRIES REPRESENTED

30+ SPEAKERS PRESENTING ONLINE

30+ SESSIONS DURING THE SYMPOSIUM

25 HOURS OF RECORDED CONTENT TO VIEW

Achievements and performance

The last year has presented great challenges to both our charity and the children and families we serve. Throughout this challenge we have remained resolute and focused on the delivery of our six key strategic objectives.

1 Strengthen governance in order to successfully deliver our charity's mission

- Recruited a Secretary to the Board of Trustees to strengthen and manage board administrative processes
- Revised our core agreements to ensure consistency and improve the clarity of information for families
- Resourced and enabled our organisation to take an agile approach to service delivery at the onset of the pandemic
- Undertook a Trustees' skills audit, recruited to our board and carried out succession processes and planning
- Begun the implementation of a new CRM system in 2020/21 to improve donor journey, communications and impact measurement
- Strengthened our risk register and added an addendum covering COVID-19
- Begun the implementation of a new finance system
- Streamlined our costs to ensure we are a lean and agile organisation, responsive to the needs of our community

2 Engage and inspire long-term public support in the charity and in the fight against neuroblastoma

- Merged our fundraising and communications team under new leadership
- Undertook a review of our fundraising and communications activities, resulting in a new and ambitious fundraising and communications strategy
- Pivoted our fundraising efforts and adapted our activities to fit within the new online and virtual environment
- Recruited to the new role of Research and Digital Communications Officer
- Welcomed over 700 people to our first virtual Christmas Carol Concert, raising over £21,000
- Secured GamesAid funding for a fifth year running
- Launched our Ambassador programme to raise awareness and vital funds for our cause
- Raised over £106,000 through our dedicated community and challenge event supporters
- Partnered with other rare cancer charities on fundraising activities
- Welcomed our first charity patron – Rob Brydon

3 Review and enhance the charity's support offerings

- Provided 278 families with emotional and practical support, evidence-based and impartial information about neuroblastoma and its treatment, an increase of 258% compared to the previous year
- Partnered with Joining Against Cancer in Kids (J-A-C-K) and introduced our Emergency Fund for families affected by neuroblastoma, in response to the COVID-19 pandemic, awarding £68,500 and supporting 49 families
- Delivered our inaugural Neuroblastoma Parent Global Symposium, reaching over 700 participants across 46 countries
- Provided 304 pastoral grants to 57 families totaling £115,265
- Provided internal training at Eusa Pharma's conference on the high-risk neuroblastoma parent pathway
- Enhanced our own understanding of the global clinical trial landscape. Through active participation in specific neuroblastoma clinical trials update meetings we've ensured the Family Support Service best meets the ongoing needs of families

4 Facilitate access to the best available treatments and most promising clinical trials

- Supported families who raised £1.4 million to access treatment and trials not currently available on the NHS
- Facilitated access to treatment abroad for 16 children
- Organised 18 sets of flights and 18 accommodation stays
- Saved families collectively in excess of £114,000 by negotiating the costs of their treatments with cancer institutions
- In partnership with J-A-C-K, provided families accessing treatment that is outside of the UK with additional financial support toward associated travel/accommodation costs
- Advocated for children and families, working with international embassies to enable access to treatment during the global lockdown
- Lobbied institutions on behalf of children and families where clinical trials were put on hold as a result of the pandemic

5 Support and enable best in class clinical research, accessible in the UK

- Awarded four grants, committing over £700,000 to research
- Launched three groundbreaking projects that will help inform treatment for children with high-risk neuroblastoma globally:
  - A $1.3 million project spanning across Europe and North America which will see a targeted therapy introduced into frontline treatment for children with high-risk neuroblastoma
  - Opening the UK sites for a major European trial which will evaluate the current standard care for high-risk neuroblastoma and look to improve its effectiveness
  - A transatlantic collaborative translational study which will develop tools to detect chemo-resistant neuroblastoma at diagnosis
- Passed the first audit of our peer review process by the Association of Medical Research Charities, proving our robust approach to supporting and funding research of the highest standard
- Kept parent-led advocacy at the heart of our research strategy, with members of our research team holding 'patient expert' positions in national and international research groups

6 Harness the combined power and resources of the neuroblastoma community to most effectively advocate for, and work in support of, children and their families

- Partnered with 11 other charities, nationally and internationally, to help deliver more and better treatment options for children with neuroblastoma
- Surveyed our community and launched our Parent Involvement Forum
- Worked in partnership with other parent-led organisations and awarded research grants, totalling £2.1 million
- Worked closely with NNNG to raise awareness of our family support service in treatment centres
- Worked in collaboration with Solving Kids' Cancer US and Children's Neuroblastoma Cancer Foundation to host the first ever Neuroblastoma Global Parent Symposium

Future plans

Like many charities, the ongoing challenges presented by the pandemic will have an impact on our work and the community we serve for years to come. The children and families we support are particularly vulnerable and face additional challenges in the post-COVID-19 world.

We will remain focused on developing our services to meet the needs of our community by collaborating and working in partnership both nationally and internationally for the benefit of all those affected by neuroblastoma.

We will implement our new fundraising strategy to support our growth, service development and ambition to drive and fund innovative research for the benefit of children now and in the future, reach more families and further develop our support service.

We will take the first steps in reviewing our six-point strategic plan to inform our priorities for the future and will continue in our unswerving vision for a future where no child dies of neuroblastoma or suffers due to its treatment.

Over the next year we will:

- Retain our status as a principal funder of neuroblastoma clinical trials in the UK and continue to pursue our research strategy to deliver more effective and less toxic treatment options for children with neuroblastoma in the UK and beyond
- Review our 2017-2022 six-point strategic plan, build on success and create a blueprint for our growth, sustainability and stability into the future
- Continue to build and enhance relationships and work in partnership with the global neuroblastoma family, clinical and research communities to support our vision, and work to raise our collective voice to ensure we continue to advocate passionately and effectively for children and families affected by neuroblastoma
- Continue to develop and recruit to our board in line with our strategic planning and ensure effective succession planning is in place
- Build on the success of the inaugural Neuroblastoma Parent Global Symposium by working with our international partners and the neuroblastoma clinical community to host our second virtual global event for the benefit of families and all those who support them
- Launch our first bespoke virtual and inclusive fundraising and awareness-raising challenge event – the Butterfly Relay
- Implement our new ambitious fundraising strategy, informed by our stakeholders and responsive to the current landscape, to ensure our long-term sustainability and growth
- Continue to navigate beyond the uncertainty presented by the pandemic, and despite the challenges, focus on strengthening our organisational effectiveness by progressing our capital investment as identified in our strategic plan. We will protect and prioritise these investments and implement our new CRM and Finance database systems to ensure we remain focused on maximising the long-term charitable benefit we provide to children and families
- Continue to develop our support service and launch our regional support hubs and peer-to-peer support network across the UK. Consider ways we can support families further, which may include those facing bereavement and those navigating the complexities of parenting children who face psychosocial and physical challenges following years of intensive treatment and address the needs of young people in survivorship
- Continue to develop our education, advocacy and support offer through further developing our relationships with UK Principal Treatment Centres and other organisations providing direct and frontline services to families affected by neuroblastoma

Structure, governance and management

Governing document

The Trustees, who are also directors for the purposes of company law, present their report and the financial statements of the Company for the year ended 31 March 2021.

The Charity is controlled by its governing document, the Articles of Association, and constitutes an incorporated registered charity. The Charity was incorporated on 30 March 2010 at Companies House, was entered in the Register of Charities on 20 April 2010 and is administered by the Trustees.

At their discretion, the Trustees may spend all or part of the capital of the Charity in furthering its Objects, in the following ways:

i To raise funds. The Trustees must not undertake any substantial permanent trading activity and must comply with any relevant statutory regulations

ii To buy, take on lease or in exchange, hire or otherwise acquire property and to maintain and equip it for use

iii To sell, lease or otherwise dispose of all or any part of property belonging to the charity

iv To borrow money and to charge the whole or any part of the property belonging to the Charity as security for repayment of the money borrowed

Objectives and activities

The Charity's objectives ('Objects') are specifically restricted to the following:

- To advance the understanding and treatment of cancer in children through the greater awareness, provision of equipment, access to treatment protocols in hospitals and medical centres and clinical research aimed at improved diagnosis and treatment anywhere in the world
- To advance the education, relieve the sickness and the poverty of persons living anywhere in the world through the provision of equipment, financial assistance and by any other charitable means that the directors in their absolute discretion think fit

Public benefit

The Trustees give due regard to the public benefit provided by the Charity in relation to its charitable purpose as set out by the Objects and due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the principal activities of the Charity are to provide public benefit.

To meet the charity's objects, Solving Kid's Cancer UK currently provides a Family Support Service, a unique service dedicated to the neuroblastoma parent community, providing emotional and practical support to families affected by neuroblastoma, from point of diagnosis. The charity uses its knowledge, influence and reputation as passionate advocates to help shape, drive and fund research, identifying unmet needs and challenging experts to work with it to accelerate research and treatment options for children with neuroblastoma. It also supports parents right to choose to enrol their child on a recognised clinical trial abroad as well as in the UK.

Board of Trustees

Solving Kids' Cancer UK is governed by the Board of Trustees, chaired by Nick Bird. The trustees determine the Charity's strategic direction and oversee progress against objectives. It is responsible for governance and for upholding the Charity's values. The Charity must have at least two Trustees. The day-to-day running of the Charity is the responsibility of the Chief Executive.

The Board of Trustees supports the principles of good governance set out in the new Charity Governance Code (see **www.charitygovernancecode.org**) and also the continuous improvement model which the Code promotes.

The Board of Trustees receives periodic technical briefings on neuroblastoma research, ensuring there is appropriate knowledge and expertise held internally within the Board. It welcomes the Chair of Solving Kids' Cancer UK's Scientific Advisory Board to one of their formal Board Meetings as recommended by AMRC, and attends the annual neuroblastoma symposium and other relevant conferences/meetings.

The Board of Trustees has formal board meetings six times during the year. Trustees initially commit to a

three-year term and may hold office for a maximum of three, three yearly terms before being required to reapply to join. Trustees who have undertaken their first three-year term of office could elect to extend their trusteeship by an additional one, two or three years. Trustees may resign from office by serving one month's written notice to the other trustees. In accordance with the Charity's Articles of Association, Trustees must undertake to attend meetings regularly and any Trustee failing to do so may be duly removed from their position.

The quorum necessary for the transaction of Trustee business at an ordinary meeting is two Trustees. The Trustees agree that the nominated Chair has the casting vote for decisions where there is equal weighting.

Trustees may be appointed by the members by an ordinary resolution or by the directors by a resolution of the directors.

The Board appoints new Trustees based upon their empathy with the Objects of the Charity, skills and experience to help provide the appropriate level of governance and oversight for the Charity to be effective, coupled with their ability to commit the necessary time for Board meetings and other key events, to include the annual Neuroblastoma Parent Global Symposium.

During the year the Board conducted a Board Skills Audit to review its current composition, identify any skills gaps and consider arrangements for succession planning and has used this to build the future training and development plans. It also reviewed the Charity's operation and governance against the governance code and, as a result, implemented a project to consider our equality, diversity and inclusion policy and practice. It also appointed a Board safeguarding lead and ensured all staff and Board members undertook safeguarding training.

One new Trustee, Alexandra Lane, joined the Board in September 2020 and no Trustees stepped down during this period. A further new Trustee, Dr Áine McCarthy joined the Board in July 2021.

Trustee induction procedures include completing relevant training and working with staff and existing Trustees to understand the organisation and develop internal relationships, to include one-to-one meetings with the CEO, Chair of the Board, Trustees and members of the Leadership Team. The induction also covers governance processes, strategic planning and finance, so that new Trustees are equipped with relevant knowledge about the organisation and its priorities. New Trustees are provided with a Role Description and Person Specification and Board Code of Conduct.

Scientific Advisory Board

Solving Kids' Cancer UK's Scientific Advisory Board (SAB) is an independent body which is responsible for providing expert guidance and support to help us achieve our research goals, as well as overseeing our robust, AMRC-accredited grant award process. Their advice and recommendations are presented to the Board of Trustees via our research team.

The contribution of the SAB has been more valuable than ever in such a challenging year for the research community. Their work in governing our grant award process so rigorously and monitoring the progress of the Charity's ongoing projects contributed to our success in passing the 2020 AMRC Audit, our first since joining the association in 2018. They have also taken the opportunity to reflect on the accolades made since the SAB was established in 2017, and to think strategically about the future of our research endeavours as the landscape evolves in the wake of the pandemic. Professor Andy Pearson, Chair of the SAB was able to open these important conversations directly with the Board of Trustees at two of their meetings this year.

In 2020, to accommodate the very high degree of collaboration within the neuroblastoma research community in respect of our international challenge grants, a number of additional members of the scientific community kindly agreed to participate in two of our SAB meetings. This enabled the SAB to continue to function effectively and in accordance with its published conflict of interest policies.

The Trustees would like to extend their wholehearted gratitude to all members who participated in our SAB meetings over the past year, for their outstanding commitment to push the Charity's research goals forward, for the benefit of children with neuroblastoma in the UK and internationally. A special thanks goes to Chair of the Scientific Advisory Board, Professor Andy Pearson, for providing his continued dedication and expertise on the neuroblastoma landscape and his incredible enthusiasm and support for the work of Solving Kids' Cancer UK.

Staff remuneration

All salaries, including that of the Chief Executive, are based upon an assessment of the employment market, the performance of each member of staff, the skill levels required, the size and financial performance of the charity and the salary levels required to obtain the services of the best staff. Oversight of remuneration is a Board-reserved authority.

Diversity

Solving Kids' Cancer UK is very strongly committed to diversity in terms of equality gender, race, sexual orientation, religious beliefs and socio-economic status. Solving Kids' Cancer UK recognises its desire and responsibility to ensure our services are open and inclusive and meet the needs of all in society.

The Board, as part of its reviews and continuous improvement has implemented a project to further develop our equality, diversity and inclusive practices. Solving Kids' Cancer UK is committed to developing its staff and board recruitment and retention policies and processes to ensure we reflect the communities we serve and we support staff and volunteers to uphold equity in all of its activities. The Charity consistently interacts with a diverse cross-section of society and has mechanisms in place to ensure that respect and dignity are maintained.

Volunteers

The Trustees are extremely grateful for the considerable contribution made by the Charity's volunteers and fundraisers in support of children with high-risk neuroblastoma and who provide their valuable time to speak, share their work and provide expert information to our families as part of our Neuroblastoma Parent Global Symposium, as well as those that assist the office team with the administration necessary to achieve its aims and objectives. During the year, the charity was supported by a large number of volunteers including six Trustees, seven SAB members, eight Parent Involvement Forum members and over 36 expert speakers and facilitators at our Global Symposium.

Our legal and administrative details

Registered charity name

Solving Kids' Cancer UK Ltd
(from 14th September 2020)

Previously: Solving Kids' Cancer Europe

Charity registration number

1135601 (England and Wales)
SC045094 (Scotland)

Company registration number

07208648

Registered office

Coram Campus
41 Brunswick Square
London WC1N 1AZ
(from 11th September)

Trustees

The Trustees who served the Company during the period were as follows:

- Nicholas Bird (Chair)
- David Coulon (Treasurer)
- Bronwyn Ellis
- Alexandra Lane (from 14th September 2020)
- Joseph Tabone
- Matthew G White

Dr Áine McCarthy joined the Board on 20th July 2021.

Company Secretary

Gemma Wadsley

Chief Executive

Gail Jackson (from 14th April 2020)

Leadership Team

- Anne Denman (Head of Fundraising and Communications from 26th May 2020)
- Claire Hislop (Head of Operations)
- Vicky Inglis (Head of Family Support)
- Leona Knox (Head of Research)
- Tom Moore (Maternity cover - Head of Operations to 27th August 2020)
- Gemma Wadsley (Head of Strategic Finance)

Auditors

Shipleys LLP
Chartered Accountants & Statutory Auditor
10 Orange Street
Haymarket
London WC2H 7DQ

Bankers

National Westminster Bank
Church Road Branch
London NW4 4DS

Investment managers

CCLA Investment Management Limited
Senator House
85 Queen Victoria Street
London EC4V 4ET

Solicitors

Withers
16 Old Bailey
London EC4M 7EG

Financial review

Overview

It has been a challenging year for all charities financially in the face of a global pandemic with reductions to voluntary donations and increased need for and complexity of our services. We reacted quickly and worked hard to reduce our operational expenditure and amend our fundraising approach. This coupled with our reserves position has meant we have been able to continue providing all our services this year. We also provided an emergency grant in partnership with Joining Against Cancer in Kids (J-A-C-K) to support neuroblastoma families and believe we remain financially stable as we head into what is likely to be another challenging year.

Income

Our total income for the year was £2,297,271 (2020: £3,536,026). This is made up of £703,597 of unrestricted funds (2020: £750,437), £1,503,456 of designated funds (2020: £2,518,982) and £90,218 restricted funds (2020: £266,607).

Our unrestricted income is made up of voluntary and investment income which supports all of our Charity's internal activities including our family support provision – offering pastoral care to support families, and providing evidence-based, impartial information to support parents in their decision-making in respect of treatment options for their child and to access treatments and clinical trials if they are not available in the UK, our internal research team and infrastructure, all our fundraising activities and our operational running and governance. The majority of the remainder of our income relates to designated family funds which the Board has designated in the name of a child to support potential treatment options for that individual child.

Total income has reduced by £1,238,755 for the year which is largely due to the reduction in families seeking to access treatment this year. Our unrestricted income has also been impacted by the fact that we were unable to run any face-to-face challenge events or fundraisers within the year as a result of the COVID-19 pandemic, although we mitigated this through new fundraising streams and virtual events.

Expenditure

Expenditure decreased slightly for the year at £2,309,712 (2020: £2,557,610). The make up of our expenditure shifted this year with lower levels of children's treatment costs in line with the lower levels of families being supported at £728,676 (2020: £1,138.868) and an increase in research funding of trials in partnership, in line with our strategy at £704,181 (2020: £465,071). We have also increased our Pastoral grants to families this year at £115,265 (2020: £11,873). As noted we have worked hard to reduce our operational costs including reducing our rental costs and needing to move our Neuroblastoma Parent Global Symposium online. Support costs have reduced by 5% with property costs down 36% for the year.

Investments

Given the nature of the organisation, supporting very young children and their families, our investment objectives are primarily to invest in an ethically sound manner in order to protect the value of the Charity's assets against inflation, and provide modest returns through a combination of income distribution and capital growth. In addition to being mindful of the nature of investments made on behalf of the Charity, the Trustees' appetite for risk is also influenced by the significant amount of funds that are designated for future purposes. The COIF Charities Ethical Investment Fund aims to provide a long-term gross return of 5% per annum net of inflation. Within this, the fund aims to deliver a consistent annual distribution of income, and operate with a level of volatility (risk) that is no greater than 75% of the volatility of the UK equity market.

Following an extremely volatile investment year, particularly in relation to Brexit and the COVID-19 pandemic we are accounting for an investment gain of £571,632 (2020: £88,097 loss). Investment income however performed well at £135,042 for the year against £123,165 in the prior year. Since we started investing in the COIF Fund, our capital has increased by £914,945 and returned £641,552 thereby performing as per the Trustee's expectations.

Reserves policy

The Trustees have adopted a reserves policy which they consider appropriate to ensure the continued ability of the Charity to meet its objectives.

General funds are set aside to meet research, education, family support and administration costs. At the financial year-end general funds were £778,001 (2020: £623,878).

General free reserves (undesignated funds excluding fixed assets) were £764,959 and represent 11 months undesignated expenditure (based upon budget for the year April 2021 – March 2022).

Free reserves are calculated as follows:

	2021
	£
Total funds of the Charity	10,590,757
Less: Restricted funds	(1,471,141)
Less: Designated funds	(8,341,615)
Less: Fixed assets held for Charity use	(13,042)
	£764,959

The reserves policy currently states that six to nine months of essential running costs should be covered in order to meet its obligations in the short term (£350,000-£520,000). This is based on an assessment of the organisational risk approach and funding model.

Whilst we are currently above our reserves target at 11 months, Trustees are mindful of the ongoing COVID-19 pandemic and therefore are comfortable with the position at the year end. Whilst we are currently above our reserves target at 11 months trustees are mindful of the ongoing COVID-19 pandemic and therefore believe that the year-end free reserve balance is appropriate in the current circumstances.

We are currently reviewing our five-year strategy and as such will undertake a review of our reserves policy alongside the strategic implementation plan which will either articulate how we will reduce our reserves back in line with the target range or if required to support the new strategy will amend the policy as appropriate.

Designated funds are set aside for the treatment of specific children with neuroblastoma, and are not available for the general running of the Charity or any projects which do not directly relate to the treatment of that child. At the financial year-end, the Charity held designated reserves of £8,341,615 (2020: £7,828,822). In the event of a child's death, the funds will be released from the child's designated funds to support our wider charitable objectives. Following the end of a successful course of treatment, and a child exhibiting No Evidence of Disease (NED), funds will remain designated for a period of five years so that they are available for that child should they suffer a relapse and require further treatment, a situation which is common for neuroblastoma patients. This policy resulted in £1,402,616 (2020: nil) transferring from designated children's funds within the year with 70% transferred to the designated Solving Kids' Cancer Research Fund, 20% to the designated Solving Kids' Cancer Children's Reserve Fund and 10% to undesignated reserves.

Restricted reserves are funds which can only be used for particular restricted purposes within the objects of the Charity, and arise when specified by the donor or when funds are raised for particular restricted purposes. At the financial year-end, the Charity held restricted reserves of £1,471,141 (2020: £1,578,866), of which £1,223,288 (2020: £1,242,985) arose from funds being held on behalf of families who were previously supported by Families Against Neuroblastoma.

Supporters of the Charity are asked to note that, although the Charity appears to hold significant reserves, 76% of these funds are designated for specific children should they require treatment.

Impact of COVID-19

We continue to manage the ongoing risk of COVID-19 as part of our overall risk management. Controls in place include regular income and expenditure reforecasts and updates to the Board. We continue to support families to travel safely and within the COVID-19 rules, we have provided grants to families who have been shielding and we have worked with our research partners as they have had to adapt. Financially we have reduced our overheads by reducing our office space and rental costs, we held a virtual symposium rather than an in person event and held a very successful virtual Carol Concert. Whilst our income streams were affected to varying degrees we have been able to adapt and find some new sources of income to continue to be able to provide our services. Our staff have worked remotely throughout the year.

Risk management

The Charity's Trustees have considered the major risks to which the Charity is exposed and have reviewed those risks and established systems and procedures to manage those risks. The Trustees have overall responsibility for ensuring that the Charity has an appropriate system of controls, financial and otherwise. They are responsible for safeguarding the assets of the Charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the Charity or for publication is reliable and reviewed at every Trustee meeting; and

- the Charity complies with relevant laws and regulations.

The risk register was fully redesigned within the year and is a live document which is reviewed in detail every six months by the Board and Leadership Team.

Risk categories include:

Governance

Covers risk of non-delivery of strategy, Board skills and capabilities, and effective decision-making and reporting.

Controls in place to manage these risks include a clear strategy underpinned by annual plans, a balanced and involved Board who have clear terms of reference and who consider their effectiveness and undertake training as appropriate. The Board request and receive regular reporting from executive management.

People

Covers risk of loss of key staff and inadequate structure.

Controls in place to manage these risks include strong oversight by CEO and senior managers, clear roles and responsibilities and strong HR processes. As staff numbers are small this is a key risk which is closely monitored.

Finance

Covers all financial risks around effectiveness of our business model, level of reserves, management of investments and effective insurance.

Controls in place to manage these risks include annual budgeting and forecasting processes with regular reporting of our financial position to Trustees. We have a clear reserves policy and hold general reserves to manage any changes in cash flow. We have an investment policy and investment managers who report on performance regularly.

Compliance

Covers all risks relating to non-compliance of required regulations including data protection, health and safety, employment and financial.

Controls in place to manage these risks include effective policies, staff training and awareness and effective advisors.

Operational, legal and physical

Covers risk of not being able to meet demands for family support and quality of support provided, risk of lack of funds due to expenditure exceeding income, health and safety risks and other operational risks including employment risks and disaster recovery.

Controls in place to manage these risks include ensuring the team have appropriate support to delivery in their roles and we are continuously considering current and future demand. Budgets and reserves are effectively managed to ensure funding is maintained. We have policies in place which are well understood and adhered to around health and safety, disaster recovery, employment policies and other areas of compliance.

Environmental/external factors

Covers reputational risk and relevant external risks such as economic conditions and Brexit.

Controls in place to manage these risks include effective communications policies and resource and ongoing monitoring of relevant external plans with action plans as required.

COVID-19

We are currently also running a COVID-19 specific risk register which reflects the key risks that COVID-19 presents and the relevant mitigations. These include Financial risks, Infrastructure and Staff availability risks and we have strong mitigating controls in place to manage these risks.

Grant-making policy

The Board of Trustees make two types of grants. Firstly grants to assist children suffering from neuroblastoma. Families, who need help, either self-refer, hear about the Charity from their child's oncologist or make contact with the Charity's Family Support Team. Grants are also offered in the form of a hardship fund for families struggling to meet their necessary costs due to the effects of having a child in treatment for neuroblastoma.

The second type is research grants. We engage in two distinct research funding mechanisms; an annual competitive funding call, and also ad-hoc Exceptional Funding Requests. All research grants are awarded in line with the principles laid out by the Association of Medical Research Charities (AMRC). Each application will be subject to rigorous scientific review guided by the Charity's Scientific Advisory Board (SAB) and the nature of any grant made will depend on funds available through Solving Kids' Cancer UK's own reserves, or those made available through strategic collaborative partnerships.

Investment policy and objectives

The Deed of Trust allows the Charity to deposit or invest funds in any manner; but to do so only after obtaining such advice from financial experts as the Trustees deem necessary and having regard to the

suitability of investments and need for diversification. The Charity aims to follow the COIF Ethical Fund Policy; excluding investments in companies involved in, for example, nuclear weapons, landmines, production of abortifacients, and other disqualifying criteria where there is a significant involvement (>10% of turnover).

Fundraising approach and policy

As a cause-related Charity, we recognise that the service we offer for children and families affected by neuroblastoma and the advances in research we invest in would not be possible without the generous support and passion our supporters and families' supporters provide. We receive no public funding for our work, relying completely on the generous support of the neuroblastoma community and general public.

We are registered with the regulatory body for fundraising in the UK, the Fundraising Regulator. As members of the scheme, we follow its Code of Fundraising Practice and comply with the key principles embodied in it. Many of our families raise funds for us at a local level and we ensure that they have all the information they need to comply with our policies and procedures.

It is hugely important to us that our supporters trust us and are well looked after:

- We ensure that we never put undue pressure on members of the public when raising funds
- We are open and honest and approach our fundraising activities respectfully and considerately
- We ensure that we comply with the wishes of our donors and comply with all general data protection laws
- We respect the rights, dignities and privacy of our supporters and beneficiaries
- We are accountable

We review all of our fundraising campaigns to ensure they fully comply with the Code of Fundraising Practice and our fundraising activities are discussed regularly at Board meetings, to help ensure that our fundraising practices reflect and reinforce our values. That's just as important whether we're fundraising ourselves or working with families, organisations or volunteers.

We currently raise funds in a variety of ways, including: direct email campaigns; regular and individual giving programmes; virtual and in-person challenge events; corporate partnerships and percentage profit partnerships; direct cash donations; raffles; sponsored events; and Charity of the Year partnerships. The impact of COVID-19 has been felt throughout the charity, our services and the children and families we support; despite this we had a stable year with over £2m in donations. £1.5m of this related to our family funds which are raised via community fundraising and events, most of which were virtual. Our unrestricted fundraising approach pivoted to virtual challenge and community events, appeals and corporate support.

We take the protection of the personal data of all our supporters and donors extremely seriously, and constantly review and monitor our fundraising policies and procedures to ensure we deliver 'best practice'. We do not engage professional fundraisers to raise money on our behalf.

We welcome feedback on our fundraising activities at any time and strive to listen and learn from this feedback. During the course of the year we recorded four complaints which were managed in line with our complaints policy to a satisfactory conclusion. Our complaints log is subject to regular review by the Board of Trustees. If a complaint about our fundraising activities is unable to be resolved through our complaints procedure, members of the public are advised to raise it with the Fundraising Regulator.

Trustees responsibilities statement

The Trustees (who are also the directors of Solving Kids' Cancer UK for the purposes of company law) are responsible for preparing the Trustees Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under that law the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and the income and expenditure of the Company for that period.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and accounting estimates that are reasonable and prudent; and

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of the persons who is a Trustee at the date of approval of this report confirms that:

- so far as each Trustee is aware, there is no relevant audit information of which the Company's auditor is unaware; and
- each Trustee has taken all steps that they ought to have taken as a Trustee to make themselves aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

Registered office:
Coram Campus
41 Brunswick Square
London WC1N 1AZ

Signed on behalf of the Board of Trustees



David Coulon
Trustee and Treasurer

27th September 2021

Independent auditors report to the Trustees and members of Solving Kids' Cancer UK

Opinion

We have audited the financial statements of Solving Kids' Cancer UK Ltd ("the charitable company") for the year ended 31 March 2021 which comprise the Statement of Financial Activities (incorporating the Income and Expenditure Account), the Balance Sheet, the Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including The Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2021 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and trustees Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Solving Kids' Cancer UK Ltd's ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If,

based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees Annual Report, which includes the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report included within the Trustees Annual Report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the Trustees Annual Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the Trustees' report and from the requirement to prepare a strategic report.

Responsibilities of Trustees

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditors under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The extent to which the audit was considered capable of detecting irregularities including fraud

- We obtained an understanding of the charitable company's activities, controls and laws and regulations and assessed the susceptibility of

the charitable company's financial statements to material misstatement from irregularities, including fraud.

- We determined that the laws and regulations that are most significant to the charitable company are the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)), Companies Act 2006, Charities Act 2011, Charities and Trustee Investment (Scotland) Act 2005, the Fundraising Regulations and the charitable company's Articles of Association.
- Based on this understanding we designed our audit procedures to detecting irregularities, including fraud. Testing undertaken included making enquiries on the management and those charged with governance; journal entry testing; review of bank letters, investments reports, Trustee board minutes and the Articles of Association; review of transactions for any undisclosed related party transactions; reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations. These procedures were designed to provide reasonable assurance that the financial statements were free from fraud or error.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Trustees.
- Conclude on the appropriateness of the Trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's Trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's Trustees as a body, for our audit work, for this report, or for the opinions we have formed.



Simon Robinson
Senior Statutory Auditor
For and on behalf of Shipleys LLP
Chartered Accountants & Statutory Auditor

10 Orange Street
Haymarket
London WC2H 7DQ

27th September 2021

Financial statements

Statement of financial activities (incorporating the income and expenditure account)

Year ended 31 March 2021

	Note	General funds undesignated	General funds designated	Restricted funds	Total funds 2021	Total funds 2020
		£	£	£	£	£
Income						
Donations	2	551,063	1,494,139	74,827	2,120,029	3,277,381
Trading activities	3	17,492	9,317	13,711	40,520	126,832
Investment income	4	135,042	-	1,680	136,722	131,813
Total income		**703,597**	**1,503,456**	**90,218**	**2,297,271**	**3,536,026**
Expenditure						
Raising funds	5	(276,730)	(22,151)	(468)	(299,349)	(365,255)
Charitable activities	6	(417,556)	(1,289,187)	(303,620)	(2,010,363)	(2,192,355)
Total expenditure		**(694,286)**	**(1,311,338)**	**(304,088)**	**(2,309,712)**	**(2,557,610)**
Net income/ (expenditure) before (losses)/gains on investments		9,311	192,118	(213,870)	(12,441)	978,416
Net (losses) gains on investments	13	–	571,632	–	571,632	(88,097)
Net income/ (expenditure)		9,311	763,750	(213,870)	559,191	890,319
Transfer between funds	20, 21, 22	144,812	(250,957)	106,145	–	–
Net movement in funds		154,123	512,793	(107,725)	559,191	890,319
Reconciliation of funds						
Total funds brought forward		623,878	7,828,822	1,578,866	10,031,566	9,141,247
Total funds carried forward		778,001	8,341,615	1,471,141	10,590,757	10,031,566

The statement of financial activities includes all gains and losses in the year. All of the above amounts relate to continuing activities.

The notes on pages 39 to 57 form part of these financial statements.

Balance sheet

As at 31 March 2021

	Note	2021 £	2021 £	2020 £	2020 £
Fixed assets					
Tangible assets	12		13,042		3,099
Investments	13		3,414,945		2,843,313
			3,427,987		2,846,412
Current assets					
Debtors	14	161,118		83,285	
Cash at bank in and hand		8,544,856		8,158,699	
		8,075,974		8,241,984	
Creditors: amounts falling due within one year	15	(986,042)		(777,948)	
Net current assets			7,719,932		7,464,036
Total assets less current liabilities			11,147,919		10,310,448
Creditors: amounts falling due after one year	16		(557,162)		(278,882)
Net assets			10,590,757		10,031,566
Funds of the charity					
Restricted funds	20		1,471,141		1,578,866
Designated funds	21		8,341,615		7,828,822
Undesignated funds	22		778,001		623,878
Total charity funds			**10,590,757**		**10,031,566**

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements were approved by the members of the committee and authorised for issue on 27th September 2021 and are signed on their behalf by:



David Coulon
Trustee and Treasurer

Company registration number: 07208648

The notes on pages 39 to 57 form part of these financial statements.

Statement of cash flows

Year ended 31 March 2021

	Note	2021 £	2020 £
Cash flows from operating activities			
Net income		559,191	890,319
Adjustments for:			
Depreciation		5,519	1,575
Losses / (gains) on investments		(571,632)	88,097
Dividends and interest from investments		(136,722)	(131,813)
Loss on disposal of fixed assets		312	-
Decrease / (increase) in debtors		(51,628)	171,295
Increase in creditors		486,374	568,623
Net cash provided by operating activities		291,414	1,588,096
Cash flows from investing activities			
Dividends and interest from investments		110,517	131,813
Purchase of property, plant and equipment		(15,774)	(1,733)
Net cash provided by investing activities		94,743	130,080
Change in cash and cash equivalents	28	386,157	1,718,176
Cash at start of year	28	8,158,699	6,440,523
Cash at end of year	28	**8,544,856**	**8,158,699**

The notes on pages 39 to 57 form part of these financial statements.

Notes to the financial statements

1 Accounting policies

General information

Solving Kids' Cancer UK Ltd is a private Company limited by guarantee incorporated in England under the Companies Act. The address of the registered office is Coram Campus, 41 Brunswick Square, London WC1N 1AZ. The objectives of the Charity are set out on page 25.

On 18 September 2020, the charitable Company changed its name from Solving Kids' Cancer Europe to Solving Kids' Cancer UK Ltd.

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Solving Kids' Cancer UK Ltd meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policies.

The functional currency of the Charity is considered to be pounds sterling because that is the currency of the primary economic environment in which the Charity operates. The financial statements are also presented in pounds sterling.

The amounts in the financial statements are presented to the nearest £, unless otherwise stated.

Preparation of the financial statements on a going concern basis

The financial statements of the Charity have been prepared on the going concern basis. There are no material uncertainties about the Charity's ability to continue. The Trustees consider that the going concern basis is appropriate having considered a period of at least 12 months from approval of these financial statements. The Trustees have prepared budgets and cash flow forecasts for that period which support the going concern assumption.

Fund accounting

Undesignated funds are available to spend on activities that further any of the purposes of the Charity.

Designated funds are funds of the Charity which the Trustees have decided at their discretion to set aside to use for a specific purpose.

Restricted funds are donations which the donor has specified are to be solely used for particular restricted purposes within the objects of the Charity.

Income

Income is recognised when the Charity has entitlement to the funds, any performance conditions attached to the item of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Donations are recognised when the Charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance before the Charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the Charity and it is probable that those conditions will be fulfilled in the reporting period.

90% of any donation made to an individual appeal or journey is designated for the particular purpose of funding treatment not freely available on the NHS. The remaining 10% is retained within undesignated general funds to cover costs associated with the administration and management of appeals and journeys; including support with fundraising, logistics, and development of relationships as intermediary between families and the medical institutions that provide access to treatments and clinical trials.

Donated professional services and donated facilities are recognised as income when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the Charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the Charity which is the amount the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income from Government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the Charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred. In respect of the Coronavirus Job Retention Scheme grant; all conditions, with respect to the eligible costs being claimed, need to be met.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

Dividends are recognised once the dividend has been declared and notification has been received of the dividend due. This is normally upon notification by our investment advisor of the dividend yield of the investment portfolio.

Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis.

Expenditure is classified under the following activity headings:

- Costs of raising funds comprise the costs of attracting donations and fundraising
- Expenditure on charitable activities includes the cost incurred by the Charity in the delivery of activities and services for its beneficiaries

Grants payable are payments made to third parties in the furtherance of the charitable objects of the Charity. In the case of an unconditional grant offer this is accrued once the recipient has been notified of the grant award. The notification gives the recipient a reasonable expectation that they will receive the grant. Grant awards that are subject to the recipient fulfilling performance conditions are only accrued when the recipient has been notified of the grant and any remaining unfulfilled condition attaching to that grant is outside of the control of the Charity.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

Support costs are those functions that assist the work of the Charity but do not directly undertake charitable activities. Support costs include staff, premises, finance and governance costs. These costs have been allocated between cost of raising funds and expenditure on charitable activities on the basis of an estimate of the proportion of time spent by staff on those activities.

Governance costs comprise all costs involving the public accountability of the Charity and its compliance with regulation and good practice.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Tangible fixed assets

Fixed assets are capitalised at cost and are depreciated over their estimated useful economic lives on a straight-line basis as follows:

- Equipment – 25% on straight-line basis

Fixed asset investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Creditors and provisions

Creditors and provisions are recognised where the Charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

Operating leases

The Charity classifies the lease of the office space as an operating lease as the title remains with the lessor. Rental charges are charged on a straight-line basis over the term of the lease.

Pension costs

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Differences between contributions payable in the year and the contributions actually paid are shown as either accruals or prepayments on the balance sheet.

2 Donations

	Undesignated funds	Designated funds	Restricted funds	Total funds 2021
	£	£	£	£
Donations	497,829	1,494,139	71,358	2,063,326
Donated services	53,234	–	–	53,234
Government grants	–	–	3,469	3,469
	551,063	1,494,139	74,827	2,120,029

	Undesignated funds	Designated funds	Restricted funds	Total funds 2020
	£	£	£	£
Donations	570,104	2,449,318	257,959	3,277,381

The Charity benefits greatly from the involvement and enthusiastic support of its many volunteers. In accordance with FRS 102 and Charities SORP (FRS 102), the economic contribution of general volunteers is not recognised in the financial statements.

During the year, the Charity received donated services relating to legal services and support for the Neuroblastoma Parent Global Symposium. The value of these services to the Charity is estimated at £13,234 and £40,000 respectively (2020: £nil). The estimated value of these services is recognised within income as a donation with an equivalent expense through the Statement of Financial Activities.

Income from Government grants comprises grants received under the Government Coronavirus Job Retention Scheme of £3,469 (2020: £nil). This grant was provided to support the cost of furloughed Charity staff. The Charity has not benefited from any other kinds of government assistance during the current or prior year.

3 Other trading activities

	Undesignated funds	Designated funds	Restricted funds	Total funds 2021
	£	£	£	£
Fundraising events	17,492	9,317	13,711	40,520

	Undesignated funds	Designated funds	Restricted funds	Total funds 2020
	£	£	£	£
Fundraising events	43,792	69,664	-	113,456
Sponsorship income	13,376	-	-	13,376
	57,168	69,664	-	126,832

4 Investment income

	Undesignated funds	Designated funds	Restricted funds	Total funds 2021
	£	£	£	£
Income from investments	129,400	–	–	129,400
Deposit account interest	5,642	–	1,680	7,322
	135,042	–	1,680	136,722

	Undesignated funds	Designated funds	Restricted funds	Total funds 2020
	£	£	£	£
Income from investments	101,199	–	–	101,199
Deposit account interest	21,966	–	8,648	30,614
	123,165	–	8,648	131,813

5 Costs of raising funds

	Undesignated funds	Designated funds	Restricted funds	Total funds 2021
	£	£	£	£
Costs of raising funds	154,331	22,151	468	176,950
Support costs	122,399	–	–	122,399
	276,730	22,151	468	299,349

	Undesignated funds	Designated funds	Restricted funds	Total funds 2020
	£	£	£	£
Costs of raising funds	219,534	28,462	413	248,409
Support costs	116,846	–	–	116,846
	336,380	28,462	413	365,255

6 Costs of charitable activities

	Undesignated funds	Designated funds	Restricted funds	Total funds 2021
	£	£	£	£
Access to treatment	205,222	728,676	77,403	1,011,301
Medical research	59,300	704,181	22,981	786,462
Education, awareness and family support	5,353	115,265	91,982	212,600
	269,875	1,548,122	192,366	2,010,363

	Undesignated funds	Designated funds	Restricted funds	Total funds 2020
	£	£	£	£
Access to treatment	172,576	1,138,868	114,011	1,425,455
Medical research	42,314	465,071	33,783	541,168
Education, awareness and family support	147,359	11,873	66,500	225,732
	362,249	1,615,812	214,294	2,192,355

Expenditure on charitable activities was £2,010,363 (2020: £2,192,355) of which £417,556 was undesignated (2020: £404,201), £1,289,187 was designated (2020: £1,484,348) and £303,620 was restricted (2020: £303,806).

7 Analysis of support costs

Support costs are allocated based on the proportion of time spent by staff on those activities.

	Access to treatment	Medical research	Education, awareness and family support	Fundraising activities	Total 2021
	£	£	£	£	£
Staff costs	31,989	6,178	53,029	57,129	148,325
Premises	17,833	6,598	15,296	25,630	65,357
Legal and professional	3,857	1,427	3,308	5,543	14,135
Finance costs	13,406	4,960	11,499	19,268	49,133
Depreciation	1,506	557	1,292	2,164	5,519
Governance costs	8,812	3,261	7,558	12,665	32,296
	77,403	22,981	91,982	122,399	314,765

	Access to treatment	Medical research	Education, awareness and family support	Fundraising activities	Total 2020
	£	£	£	£	£
Staff costs	60,292	20,775	35,505	43,315	159,887
Premises	32,047	7,645	18,477	44,595	102,764
Legal and professional	2,359	563	1,360	3,282	7,564
Finance costs	8,852	2,112	5,104	12,319	28,387
Depreciation	491	117	283	684	1,575
Governance costs	9,970	2,571	5,771	12,651	30,963
	114,011	33,783	66,500	116,846	331,140

8 Governance costs

	2021	2020
	£	£
Auditor's remuneration	12,540	12,300
Legal and professional	14,795	13,850
Staff costs	4,961	4,813
	32,296	30,963

9 Analysis of grants

	2021	2020
	£	£
Children's treatment	728,676	1,138,868
Medical research		
University of Birmingham	434,762	150,000
Children's Cancer Institute, Australia	-	13,950
Princess Maxima Center, Utrecht	-	27,815
Leeds Institute of Medical Research	-	58,328
Newcastle University	-	54,120
Hospital Vall d'Hebron, Barcelona	-	160,858
The Royal Marsden Hospital	60,000	-
Children's Hospital of Philadelphia	68,750	-
ICR	31,250	-
Goustave Roussy Hospital, Paris	109,419	
Education and family support	115,265	11,873
	1,548,122	1,615,812

Children's treatment grants are made towards the medical costs of the children suffering from neuroblastoma. The grants are paid directly to the hospitals providing the treatment.

Grants are made towards medical research for potential future life-saving treatments made possible through the constantly evolving world of burgeoning laboratory, pre-clinical and clinical research. These grants are paid directly to the institutions and are largely international institutions which reflects the specialist and global nature of the research we fund.

Grants for education and family support are those made towards providing essential support services to families affected by high-risk childhood cancers and relating to scientific information on developments in research on neuroblastoma and evolving treatment options. These grants are paid directly to affected families and organisations as appropriate or as directed.

10 Staff costs and emoluments

	2021	2020
	£	£
Wages and salaries	453,214	444,074
Social security costs	40,957	43,784
Pension costs – defined contribution	14,326	12,031
	508,497	499,889

Pension costs are allocated to activities in proportion to the related staffing costs and are allocated between undesignated, designated and restricted funds on the basis of each employee's activities.

Particulars of employees

The average head count of employees during the year was 14 (2020: 14). The average number of full-time equivalent employees during the year is analysed as follows:

	2021	2020
	£	£
Charitable activities	5	6
Fundraising	4	4
Support	3	2
	12	12

The number of employees whose remuneration for the year fell within the following bands, were:

	2021	2020
	£	£
£60,000 to £69,999	–	1
£70,000 to £79,999	1	–

No higher-paid staff were accruing benefits under a pension scheme (2020: None).

11 Net income

Net income is stated after charging:

	2021	2020
	£	£
Auditor's remuneration		
Audit	12,540	12,300
Taxation	780	780
Depreciation	5,519	1,575
Operating leases – offices	26,107	52,338

12 Tangible fixed assets

	Equipment
	£
Cost	
At 1 April 2020	72,463
Additions	15,774
Disposals	(64,075)
At 31 March 2021	24,162
Depreciation	
At 1 April 2020	69,364
Charge for the year	5,519
Disposals	(63,763)
At 31 March 2021	11,120
Net book value	
At 31 March 2021	13,042
At 31 March 2020	3,099

13 Investments

Movement in market value	2021	2020
	£	£
Market value at 1 April 2020	2,843,313	2,931,410
Net gain/(loss) on revaluations	571,632	(88,097)
Market value at 31 March 2021	3,414,945	2,843,313
Historical cost at 31 March 2021	2,500,000	2,500,000

Analysis of investments at 31 March 2021	Designated funds 2021	Designated funds 2020
	£	£
UK listed investments	3,414,945	2,843,313

All investments are carried at their fair value. Holdings in investment funds, unit trusts and open-ended investment companies are at the bid price. The basis of fair value for quoted investments is equivalent to the market value, using the bid price. Asset sales and purchases are recognised at the date of trade at cost (that is their transaction value).

The following investments were material in the context of the investment portfolio:

- COIF Charities Ethical Investment Fund – £3,414,945 (2020: £2,843,313).

The main form of financial risk faced by the Charity is that of volatility in investment markets due to wider economic conditions and variability of investment returns. This risk is mitigated by obtaining advice from a financial expert on the Charity's investment portfolio.

14 Debtors

	2021	2020
	£	£
Trade debtors	499	1,120
Other debtors	117,496	57,882
Prepayments and accrued income	43,123	24,283
	161,118	83,285

15 Creditors: amounts falling due within one year

	2021	2020
	£	£
Taxation and social security	–	5,493
Accruals and deferred income	13,843	20,326
Grant commitments (note 17)	373,987	394,255
Funds held as agent (note 18)	598,212	357,874
	986,042	777,948

16 Creditors: amounts falling due after more than one year

	2021	2020
	£	£
Grant commitments (note 17)	557,162	278,882

Grant commitments of £153,976 are due in more than five years (2020: £nil).

17 Grant commitments

	2021	2020
	£	£
Grant commitments brought forward	673,137	449,830
New commitments during the year	704,181	465,071
Payments made in the year	(446,169)	(241,764)
Grant commitments carried forward	931,149	673,137
Commitments at 31 March 2021 are payable as follows		
Within one year	373,987	394,255
After more than one year	557,162	278,882
Grant commitments carried forward	931,149	673,137

18 Funds held as agent

	2021	2020
	£	£
Funds held as agent brought forward	357,874	–
Funds received during the year	249,191	357,874
Payments made	(8,853)	–
Funds held as agent carried forward	598,212	357,874

The charity has received funds as agent in its role as administrator of the Request for Applications (RFA) process and also of the research project for the prospective identification of children with 'ultra-high-risk' (UHR) neuroblastoma.

At the year end, the charity held £598,212 (2020: £357,874) and this has been included in creditors in Note 15. £349,176 was held on behalf of Zoe4Life (2020: £199,978) and £249,036 on behalf of The Merryn Lacy Trust (2020: £157,896).

19 Commitments under operating leases

At 31 March 2021 the company had total minimum lease payments under non-cancellable operating leases as set out below.

	2021	2020
	£	£
Operating leases which expire within one year	9,833	13,367

20 Restricted funds

	Balance at 1 April 2020	Income	Expenditure	Transfers	Balance at 31 March 2021
	£	£	£	£	£
Families Against Neuroblastoma (FAN)	953,332	1,380	(12,973)	(4,551)	937,188
FAN Emergency Relapse Fund	289,653	300	(3,853)	–	286,100
HK Fund	15,842	–	–	–	15,842
CE Discretionary Fund	3,782	–	–	–	3,782
Restricted Research Funds	45,000	–	(45,000)	–	–
Parent Conference Fund	–	16,301	(16,301)	–	–
Other funds	95,429	23,768	(138,209)	110,696	91,684
Joining Against Cancer in Kids	33,713	–	(6,533)	–	27,180
Sunni Mae Fund	84,365	–	–	–	84,365
COVID-19 Fund	32,750	20,000	(52,750)	–	–
Family Support Fund	25,000	25,000	(25,000)	–	25,000
Furlough Fund	–	3,469	(3,469)	–	–
	1,578,866	90,218	(304,088)	106,145	1,471,141

	Balance at 1 April 2019	Income	Expenditure	Transfers	Balance at 31 March 2020
	£	£	£	£	£
Families Against Neuroblastoma (FAN)	958,524	19,192	(24,384)	–	953,332
FAN Emergency Relapse Fund	354,263	1,539	(66,149)	–	289,653
HK Fund	18,581	17	(2,756)	–	15,842
CE Discretionary Fund	19,819	–	(1,037)	(15,000)	3,782
Restricted Research Funds	30,000	–	–	15,000	45,000
Parent Conference Fund	–	80,000	(80,000)	–	–
Other funds	115,835	41,244	(111,106)	49,456	95,429
Joining Against Cancer in Kids	50,000	–	(16,287)	–	33,713
Sunni Mae Fund	–	84,365	–	–	84,365
COVID-19 Fund	–	15,250	(2,500)	20,000	32,750
Family Support Fund	–	25,000	–	–	25,000
	1,547,022	266,607	(304,219)	69,456	1,578,866

Restricted funds can only be used for particular restricted purposes within the objects of the Charity as specified by the donor or when funds are raised for particular restricted purposes.

Families Against Neuroblastoma (FAN)/FAN Emergency Relapse Fund

There are 10 funds transferred from Families Against Neuroblastoma (FAN) and held for the sole use of individual children for access to treatment and welfare / pastoral issues. Treatments are limited to those that are consistent with Solving Kids' Cancer UK Ltd Clinical Trial Policy. A further two donations from FAN were received to be used solely to support children with relapsed neuroblastoma with no access to other funds to pay for treatment that is not freely available on the NHS. During the year, £4,551 was transferred from this fund to unrestricted funds (2020: £nil). This represented interest accumulated on a closed FAN fund which should have been credited to the unrestricted fund in prior years.

HK Fund

HK Fund is restricted for the sole purposes of supporting an individual named child. In accordance with the wishes of the donor, the fund supports the long-term health and welfare related needs of the beneficiary, and is not accessed on a regular basis.

CE Discretionary Fund

CE Discretionary Fund was established through an individual donation made to the Charity to provide the Chief Executive with a means to fund initiatives in support of the effective working of the organisation, but for which no other budget existed. During the year, £nil (2020: £15,000) was transferred to Restricted Research Funds at the request of the donor as this level of funds was no longer required in this fund.

Restricted Research Funds

Restricted Research Funds is a restricted fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research.

Parent Conference Fund

Parent Conference Fund represents donations towards the annual parent conference.

Other funds

Other funds represent funds created by families in memoriam specifically for research and advocacy projects. During the year £110,696 (2020: £nil) was transferred from the designated Research Fund to support these research projects. During the year £nil (2020: £49,456) was transferred from designated funds to other funds following the undesignation of the Special Events Fund. The original purpose to fund event places was no longer required.

Joining Against Cancer in Kids

Joining Against Cancer in Kids is a restricted fund which has been provided by Joining Against Cancer in Kids (J-A-C-K) to support the costs incurred by families when participating in neuroblastoma trials/treatment being conducted at The Memorial Sloan Kettering Cancer Centre, New York or Hospital Saint Joan de Déu Barcelona.

Sunni Mae Fund

Sunni Mae Fund is restricted to support the development of a partnership with a UK medical institution to enable children from the Republic of Ireland to travel to the United Kingdom to enrol on early phase clinical trials that are not available at Our Lady Children's Hospital, Crumlin. Alternatively, if such a partnership cannot be formed, the fund can be used to support a future research funding call in which The Sunni Mae Trust will be acknowledged as a named collaborative funding partner. Explicit agreement will be sought for the latter at such time as the Charity deems appropriate.

COVID-19 Fund

COVID-19 Fund is restricted to the granting of funds to families of children with Neuroblastoma who have suffered a loss of income or increase in costs as a result of the diagnosis. It is initially for those affected by the need to shield during COVID-19. During the year £nil (2020: £20,000) was transferred from designated funds which reflects the charity's initial 50% commitment to the fund alongside J-A-C-K.

Family Support Fund

Family Support Fund is restricted to the activities of the Family Support Team.

Furlough Fund

Furlough Fund represents a government grant provided to support the cost of furloughed Charity staff.

21 Designated funds

	Balance at 1 April 2020	Income	Expenditure	Transfers	Net losses on investments	Balance at 31 March 2021
	£	£	£	£	£	£
Designated funds	7,182,484	1,328,542	(916,601)	(1,402,616)	–	6,191,809
Solving Kids' Cancer Children's Reserve Fund	197,410	–	–	280,523	–	477,933
Lorlatinib	60,000	–	(60,000)	–	–	–
Solving Kids' Cancer Research Fund	–	174,042	(316,793)	871,136	–	728,385
Family Support Fund	45,615	–	(2,192)	(15,000)	–	28,423
COVID–19 Fund	–	872	(15,752)	15,000	–	120
Investment reserve	343,313	–	–	–	571,632	914,945
	7,828,822	1,503,456	(1,311,338)	(250,957)	571,632	8,341,615

	Balance at 1 April 2019	Income	Expenditure	Transfers	Net losses on investments	Balance at 31 March 2020
	£	£	£	£	£	£
Designated funds	5,836,898	2,518,982	(1,158,434)	(14,962)	–	7,182,484
Solving Kids' Cancer Children's Reserve Fund	197,410	–	–	–	–	197,410
Lorlatinib	60,000	–	–	–	–	60,000
Solving Kids' Cancer Research Fund	339,414	–	(354,376)	14,962	–	–
Family Support Fund	65,615	–	–	(20,000)	–	45,615
Investment reserve	431,410	–	–	–	(88,097)	343,313
Special Events Fund	49,456	–	–	(49,456)	–	–
	6,980,203	2,518,982	(1,512,810)	(69,456)	(88,097)	7,828,822

Designated funds are funds which have been allocated by the trustees out of undesignated general funds to specific appeals for the treatment of children with neuroblastoma. In the event of a child's death, the funds will be released from designated funds. Following the end of a successful course of treatment, and a child exhibiting No Evidence of Disease (NED), funds will remain designated for a period of five years so that they are

available for that child should they suffer a relapse and require further treatment, a situation which is common for neuroblastoma patients. During the year, this policy resulted in transfers of £1,402,616 (2020: £nil) with 70% transferred to the designated Solving Kids' Cancer Research Fund, 20% to the designated Solving Kids' Cancer Children's Reserve Fund and 10% to undesignated reserves. During the year, £nil (2020: £14,962) was transferred from in memoriam to designated research funds.

Solving Kids' Cancer Children's Reserve Fund

Solving Kids' Cancer Children's Reserve Fund is money designated to:

- Support families who are fundraising for treatment who may require additional financial support to be able to meet the deadlines for enrolment on a particular clinical trial
- Support children who are receiving treatment abroad but for whom additional unanticipated medical expenses are incurred. During the year £280,523 was transferred from designated funds (2020: £nil)

Lorlatinib

Lorlatinib is a designated fund set up to hold monies that have been awarded to The Royal Marsden Hospital for the Lorlatinib clinical trial.

Solving Kids' Cancer Research Fund

Solving Kids' Cancer Research Fund is a designated fund where monies are not currently awarded to any specific research project, but nonetheless earmarked to support research. During the year, £981,832 was transferred from designated funds (2020: £nil), £110,696 was transferred to restricted other funds (2020: £nil) and £nil (2020: £14,962) was transferred from designated in memoriam funds.

Family Support Fund

Family Support Fund is designated to the activities of the Family Support Team. During the year £15,000 was transferred to the designated COVID-19 Fund (2020: £20,000 to the restricted COVID-19 Fund)

COVID-19 Fund

COVID-19 Fund is designated to the granting of funds to families of children with Neuroblastoma who have suffered a loss of income or increase in costs as a result of the diagnosis. It is initially for those affected by the need to shield during COVID-19. During the year £15,000 (2020: £nil) was transferred from the designated Family Support Fund.

Investment reserve

Investment reserve represents the movement in fair value on investments since acquisition.

Special Event Fund

Special Event Fund is a designated fund where monies are not currently awarded to any specific event, but nonetheless earmarked to help fund events for fundraising.

22 Undesignated funds

	Balance at 1 April 2020	Income	Expenditure	Transfers	Balance at 31 March 2021
	£	£	£	£	£
Undesignated funds	623,878	703,597	(694,286)	144,812	778,001

	Balance at 1 April 2019	Income	Expenditure	Transfers	Balance at 31 March 2020
	£	£	£	£	£
Undesignated funds	614,022	750,437	(740,581)	–	623,878

23 Analysis of net assets between funds

Fund balances at 31 March 2021 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2021
	£	£	£	£
Tangible fixed assets	13,042	–	–	13,042
Investments	–	3,414,945	–	3,414,945
Cash at bank and in hand	1,299,123	5,640,261	1,605,472	8,544,856
Other net current (liabilities)/assets	(534,164)	(156,429)	(134,331)	(824,924)
Creditors falling due in more than one year	–	(557,162)	–	(557,162)
	778,001	8,341,615	1,471,141	10,590,757

Fund balances at 31 March 2020 are represented by:

	Undesignated funds	Designated funds	Restricted funds	Total funds 2020
	£	£	£	£
Tangible fixed assets	3,099	–	–	3,099
Investments	–	2,843,313	–	2,843,313
Cash at bank and in hand	840,173	5,274,644	2,043,882	8,158,699
Other net current (liabilities)/assets	(219,394)	(133,113)	(465,016)	(817,523)
Creditors falling due in more than one year	–	(156,022)	–	(156,022)
	623,878	7,828,822	1,578,866	10,031,566

24 Company limited by guarantee

The Charity is a company limited by guarantee and has no share capital. The liability of each member in the event of winding up is £10.

25 Taxation

The Charity is exempt from tax on income and gains to the extent that these are applied to its charitable objects.

26 Related party transactions

The key management personnel of the Charity for the period comprised the Trustees, Chief Executive and the Heads of Departments. The total employee benefits of the key management personnel were £289,017 (2020: £276,274).

The Trustees did not receive any remuneration or other benefits during the year (2020: £nil). The Trustees did not receive any reimbursement of expenses during the year (2020: £nil)

PricewaterhouseCoopers LLP, a firm in which a Trustee, David Coulon, is a member, provided HR services to the charity for £5,400 (2020: £3,600). The supplier relationship ended in December 2020.

The Neuroblastoma Parent Global Symposium and the Carol Concert were supported by GRC World Forums (previously Data World Protection Forum), an organisation in which Nicholas James, the husband of a Trustee,

Bron Ellis, has a controlling interest. GRC World Forums provided the platform for £1,620 (2020: £nil), but provided all other services free of charge. In the prior year, GRC World Forums supported the Carol Concert and purchased tickets at market value of £600 and were acknowledged as supporter in the concert programme.

During the year, the Charity paid salaries of £2,420 (2020: £nil) to a close family member of Nick Bird, a Trustee.

The total donations received from four Trustees (2020: two) during the year amounted to £2,906 (2020: £750).

27 Financial instruments

Financial assets measured at fair value through statement of financial activities:

	2021	2020
	£	£
Investments	3,414,945	2,843,313

The income, expense, gains and losses in respect of all financial instruments are summarised below:

	2021	2020
	£	£
Net (loss) / gain on revaluation of investments	571,632	(88,097)
Investment income	129,400	101,199

For further details about risks arising from financial instruments and the measurement basis see note 13.

28 Analysis of changes in debt

	At 1 April 2020	Cash flows	At 31 March 2021
	£	£	£
Net cash: cash at bank and in hand	8,158,699	386,157	8,544,856

	At 1 April 2019	Cash flows	At 31 March 2020
	£	£	£
Net cash: cash at bank and in hand	6,440,523	1,718,176	8,158,699

29 Comparatives for the statement of financial activities

	Undesignated funds	Designated funds	Restricted funds	Total funds 2020
	£	£	£	£
Income				
Donations	570,104	2,449,318	257,959	3,277,381
Trading activities	57,168	69,664	-	126,832
Investment income	123,165	-	8,648	131,813
Total income	750,437	2,518,982	266,607	3,536,026
Expenditure				
Raising funds	(336,380)	(28,462)	(413)	(365,255)
Charitable activities	(404,201)	(1,484,348)	(303,806)	(2,192,355)
Total expenditure	(740,581)	(1,512,810)	(304,219)	(2,557,610)
Net income/(expenditure) before losses on investments	9,856	1,006,172	(37,612)	978,416
Net losses on investments	-	(88,097)	-	(88,097)
Net income/(expenditure)	9,856	918,075	(37,612)	890,319
Transfer between funds	-	(69,456)	69,456	-
Net movement in funds	9,856	848,619	31,844	890,319
Reconciliation of funds				
Total funds brought forward	614,022	6,980,203	1,547,022	9,141,247
Total funds carried forward	623,878	7,828,822	1,578,866	10,031,566

Thank you!

We want to say a big thank you to the following companies, people, schools, charities, foundations and trusts for their support.

Companies

Allen & Overy LLP
Baxi Heating UK
Burnt Peach
Charity Travel
Data Protection World Forum
Fine Tubes Ltd
GamesAid
Google
GRC World Forum
Greenergy
Henley Shipping
ICECO Ltd
Intercontinental Exchange (ICE)
ITech Media
Jefferies
Lehane Rock School
Liberty London
Mark Bushnell Ltd
Marks Sattin
Marlin- Smartsearch
Maurice Turnor Gardner
McClure Solicitors
Moody's - BVD Publishing Limited
Pasta 'n' Play
Privacy Culture
PWC Foundation
Scamp and Dude
Skin I Care
Smart Tech
SmartCredit Ltd
Sparkle Child
Squire Patton Boggs
The Makery
Waitrose
Women in Motion
Y-mAbs Therapeutics Inc.

Ambassadors and individuals

Clare and Chris Andrew
Mimoza Bag
Avani Desha Bhalla
Jessica Bird (volunteer)
Jake Bird
Rosie Brandreth
Abby Burgin
Nandini Chatto
Maggie Cherry
Amy Coleman
Graham Cooper
Dot Courtney
Spencer Crossley
Clare Dawson
Rev Anne Doerr, Royal Marsden
Ben Doltis
Jeremy Doltis
Gemma Gould
Tom Grennan
Jo Hockton
Lee Hodson
Anna Kaye
Stewart and Cassie Leaver
Róisin McMullan
Dan Moore
Rachel Moore
Adam Murphy
Mark Nicholson
Jacinta Nuttall
Helen Pearson
Lara Polati
Malcolm Raven
Pam Sekhon
Steve Taylor
Iulia and Padmesh Thuraisingham
Ioannis Topsakalidis
Mark Ward

Patron and champions

Rob Brydon
Demie Risby

Parent Involvement Forum

Anna Austin
Naomi Bentham
Leeanne Brennan
Kate Dixon
Claire Donnelly
Garrett Fitzgerald
Stewart Leaver
Naomi Shefford-Thomas
Carrie Wright

Schools

Bramley Church of England Primary School
London Oratory School Chamber Choir
St. Vincent Primary School
The Hurst Community College
The Read School, Selby

Charities, foundations and trusts

Band of Parents
Children's Neuroblastoma Cancer Foundation
Ecclesiastical
Joining Against Cancer in Kids (J-A-C-K)
Kids Out
Neuroblastoma Australia
Neuroblastoma UK
Ronan Thompson Foundation
Solving Kids' Cancer US
St James' Place Charitable Foundation
St. George's Society of New York
The Merryn Lacy Trust
The Rose Foundation
Wade's Army
Zoe4Life

Family and named funds

Alfie's Wishes
Oscar Knox Fund
Smiles for Stanley
The Charlie Hook Appeal Trust Fund

Solving Kids' Cancer

Solving Kids' Cancer UK is a registered charity

We receive no public funding for our work, relying completely on the generous support of the neuroblastoma community and general public. To support our work, please visit **www.solvingkidscancer.org.uk/donate** or scan the QR code:

Solving Kids' Cancer UK
Coram Campus, 41 Brunswick Square, London WC1N 1AZ
Telephone **020 7284 0800**

SolvingKidsCancer365
SKC_UK skc365
Solving Kids' Cancer UK

www.solvingkidscancer.org.uk

Solving Kids' Cancer UK Ltd is a registered charity in England and Wales (1135601), and in Scotland (SCO45094). It is a company limited by guarantee in England and Wales (7208648). The charity and company is currently operating as Solving Kids' Cancer UK.

NIHR | National Institute for Health Research
Non-commercial partners

Member of amrc
ASSOCIATION OF MEDICAL RESEARCH CHARITIES

Registered with FUNDRAISING REGULATOR